Thermo Fisher Scientific (TMO)

Company ID: 47 | CIK: 0000097745
10-Q view:
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data
No 10-Q data

Business Unit / Product Segments

Major Customers (% of Revenue)

No 10-Q data

Operational KPIs

Backlog (backlog)

Recycling facility capacity (capacity)

No 10-Q data

Common Stockholders of Record (customers)

No 10-Q data

Customers Served (customers_served)

No 10-Q data

Employee survey participation (engagement)

No 10-Q data

Power Generation Capacity (generation_capacity)

No 10-Q data

R&D Employees (headcount)

Backlog (order_book)

Orders booked net of shipments (orders_received)

No 10-K data

Accrued acquisition expenses (other)

No 10-K data

Accrued restructuring costs (other)

No 10-K data

Acquisition impact on revenue (other)

No 10-K data

Acquisition revenue contribution (other)

No 10-K data

Acquisition spend (other)

No 10-K data

Additional restructuring charges (other)

No 10-K data

Additional restructuring charges expected (other)

No 10-K data

Additional restructuring charges identified (other)

No 10-K data

Adjusted earnings per share (other)

No 10-K data

Adjusted operating income (other)

No 10-K data

Adjusted operating income margin (other)

No 10-K data

Annual cost reductions (other)

No 10-K data

Annual cost savings (other)

No 10-K data

Annual cost savings from restructuring (other)

Available revolving credit (other)

No 10-K data

Available revolving credit capacity (other)

No 10-K data

Biomass power facilities (other)

No 10-Q data

Biomass power facilities operated (other)

No 10-Q data

Board meetings held (other)

No 10-Q data

Bottling lines installed (other)

No 10-Q data

Buyback authorization (other)

No 10-K data

COVID-19 product sales (other)

No 10-Q data

COVID-19 related revenue (other)

No 10-Q data

COVID-19 related sales (other)

No 10-K data

COVID-19 response revenue (other)

No 10-K data

COVID-19 response sales (other)

No 10-Q data

COVID-19 testing product sales (other)

COVID-19 testing revenue (other)

COVID-19 testing sales (other)

No 10-K data

Call option shares purchasable (other)

No 10-Q data

Call options purchased (other)

No 10-Q data

Capex guidance (other)

No 10-K data

Capital expenditure guidance (other)

No 10-K data

Capital expenditures (other)

No 10-K data

Capital expenditures guidance (other)

No 10-K data

Cash and investments (other)

No 10-K data

Cash and short-term investments (other)

No 10-K data

Cash dividends per share (other)

No 10-K data

Cash flow from operations (other)

No 10-K data

Cash from operating activities (other)

No 10-K data

Cash from operations (other)

No 10-K data

Cash income tax payments guidance (other)

No 10-K data

Cash proceeds from business sales (other)

No 10-K data

Cash provided by operating activities (other)

No 10-K data

Coal processors (other)

No 10-K data

Commercial paper outstanding (other)

No 10-K data

Commercial paper weighted average interest rate (other)

No 10-K data

Commercial paper weighted average maturity (other)

No 10-K data

Committee meetings held (other)

No 10-Q data

Common Stock Outstanding (other)

No 10-Q data

Common Stock outstanding (other)

No 10-Q data

Common shares issued (other)

No 10-Q data

Common shares outstanding (other)

Consolidated operating margin (other)

No 10-K data

Consolidated working capital (other)

No 10-K data

Convertible debt outstanding (other)

No 10-K data

Countries of operation (other)

Countries with operations (other)

No 10-K data

Currency exchange contract notional (other)

No 10-K data

Currency translation impact on revenue (other)

No 10-K data

Current contract assets (other)

No 10-K data

Derivative notional (other)

No 10-K data

Derivative notional amount (other)

No 10-K data

Derivative notional outstanding (other)

No 10-K data

Dionex purchase price (other)

No 10-K data

ERG Chapters (other)

No 10-Q data

Effective tax rate (other)

No 10-K data

Employee Involvement Survey Participation (other)

No 10-Q data

Employee Resource Groups (other)

No 10-Q data

Employee Survey Participation (other)

No 10-Q data

Employee survey participation (other)

No 10-Q data

Employees affected by restructuring (other)

No 10-K data

Employees planned for termination (other)

No 10-K data

Employees terminated (other)

No 10-K data

Employees with severance obligations (other)

No 10-K data

Environmental liability (other)

No 10-K data

Environmental remediation reserve (other)

No 10-K data

Equity-based compensation expense (other)

No 10-K data

Expected annual cost savings (other)

No 10-K data

Expected cost savings (other)

No 10-K data

Expected medical device excise tax (other)

No 10-K data

Expected restructuring charges (other)

No 10-K data

Expected severance charge (other)

No 10-K data

Export sales (other)

No 10-Q data

FEI operating income (other)

No 10-K data

FEI revenue (other)

No 10-K data

Fair value of debt (other)

No 10-K data

Free cash flow (other)

No 10-K data

Goodwill (other)

No 10-K data

Goodwill fair value cushion (other)

No 10-Q data

Holders of record (other)

No 10-Q data

Identified additional restructuring charges (other)

No 10-K data

Identified restructuring charges (other)

No 10-K data

Indefinite-lived intangible assets (other)

No 10-K data

Indefinite-lived intangibles (other)

No 10-K data

Interest rate swap notional (other)

No 10-K data

Lease discount rate (other)

No 10-K data

Majority-owned public subsidiaries (other)

No 10-K data

Majority-owned subsidiaries (other)

No 10-K data

Market value held by nonaffiliates (other)

No 10-Q data

Minority-equity subsidiaries (other)

No 10-Q data

Minority-interest subsidiaries (other)

No 10-Q data

Number of Reportable Segments (other)

Online product catalog (other)

No 10-Q data

Operating countries (other)

No 10-Q data

Operating income margin (other)

No 10-K data

Operating margin (other)

No 10-K data

Organic revenue growth (other)

No 10-K data

Organic revenue increase (other)

No 10-K data

Outstanding debt (other)

No 10-K data

PPD acquisition revenue contribution (other)

No 10-K data

PPD revenue contribution (other)

Percentage-of-completion revenue (other)

No 10-Q data

Percentage-of-completion revenues (other)

No 10-Q data

Planned position eliminations (other)

No 10-K data

Planned restructuring charges (other)

No 10-K data

Planned terminations remaining (other)

No 10-K data

Power plants in operation (other)

No 10-Q data

Power plants operated (other)

No 10-Q data

Pro forma revenue growth (other)

No 10-K data

Pro forma shares outstanding (other)

No 10-K data

Proposed acquisitions (other)

No 10-K data

Publicly traded subsidiaries (other)

No 10-K data

Put option obligation outstanding (other)

No 10-Q data

Put option shares (other)

No 10-K data

Put options expired (other)

No 10-Q data

Put options outstanding (other)

No 10-K data

Put options sold (other)

No 10-Q data

Remaining repurchase authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Remaining terminations (other)

No 10-K data

Remediation land acreage (other)

No 10-Q data

Reportable segment operating margin (other)

No 10-K data

Reportable segments operating margin (other)

No 10-K data

Research and Development Expense (other)

No 10-Q data

Research and development expenditures (other)

No 10-Q data

Research and development expense (other)

No 10-Q data

Research and development expenses (other)

No 10-Q data

Restricted share awards (other)

No 10-K data

Restructuring accrual (other)

No 10-K data

Restructuring cash expenditures (other)

No 10-K data

Restructuring cash payments (other)

No 10-K data

Restructuring charges (other)

No 10-K data

Restructuring charges identified (other)

No 10-K data

Restructuring cost savings (other)

No 10-K data

Restructuring terminations (other)

No 10-K data

Restructuring terminations announced (other)

No 10-K data

Restructuring terminations occurring (other)

No 10-K data

Restructuring terminations remaining (other)

No 10-K data

Revenue growth (other)

No 10-K data

Revenue growth vs pro forma (other)

No 10-K data

Revolver availability (other)

No 10-K data

Revolving credit availability (other)

No 10-K data

Revolving credit capacity (other)

No 10-K data

Revolving credit capacity available (other)

No 10-K data

Revolving credit facility availability (other)

No 10-K data

Sales and service professionals (other)

No 10-Q data

Securities lending borrowings outstanding (other)

No 10-K data

Segment operating margin (other)

No 10-K data

Share repurchase authorization remaining (other)

No 10-K data

Shareholders of Record (other)

No 10-Q data

Shares Outstanding (other)

No 10-K data

Shares held in Thoratec (other)

No 10-K data

Shares of common stock issued (other)

No 10-Q data

Shares of common stock outstanding (other)

No 10-K data

Shares outstanding (other)

Shares purchased under put options (other)

No 10-Q data

Shares reserved for issuance (other)

No 10-Q data

Shares reserved under directors plans (other)

No 10-Q data

Short-term debt (other)

No 10-K data

Spa locations remaining (other)

No 10-K data

Stock options outstanding (other)

Tax rate guidance (other)

No 10-K data

Terminations completed (other)

No 10-K data

Thoratec shares owned (other)

No 10-K data

Total debt (other)

No 10-K data

Total debt outstanding (other)

No 10-K data

Total indebtedness (other)

No 10-K data

Total outstanding debt (other)

No 10-K data

Unissued shares reserved (other)

No 10-Q data

Unrecognized compensation cost (other)

No 10-K data

Unrecognized equity compensation (other)

No 10-K data

Unrecognized equity compensation cost (other)

No 10-K data

Unrecognized stock compensation (other)

No 10-K data

Unrecognized tax benefits (other)

No 10-K data

Unused lines of credit (other)

No 10-Q data

Vested stock options (other)

No 10-K data

Warranty accrual (other)

No 10-K data

Warranty accrual balance (other)

No 10-K data

Warranty liability (other)

No 10-K data

Warranty obligation balance (other)

No 10-K data

Weighted average diluted shares (other)

No 10-K data

Weighted average lease discount rate (other)

No 10-K data

Weighted-average lease term (other)

No 10-K data

Weighted-average remaining operating lease term (other)

No 10-K data

Workforce affected by restructuring (other)

Workforce affected by severance (other)

No 10-K data

Workforce reduction (other)

No 10-K data

Working capital (other)

No 10-K data

Year 2000 external costs (other)

No 10-K data

Year 2000 external costs expected (other)

No 10-K data

Year 2000 external costs incurred (other)

No 10-K data

Year 2000 remediation costs (other)

No 10-K data

us-gaap:NumberOfReportableSegments (other)

Power plants operated (properties)

Revenue, Remaining Performance Obligation, Amount (rpo)

Leased Property (square_footage)

No 10-Q data

Spa Thira locations (stores)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

Demographics

No demographic data found.

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No 10-Q data

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-27restructuringin_progress1%2026-12-31Primarily Laboratory Products and Biopharma ServicesUSD 220 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of July 31, 2026, identified restructuring actions expected to result in additional charges of approximately $220 million, primarily in 2026; additional actions may be identified in future periods. Severance actions in 2026 affected approximately 1% of the workforce.
2026-06-27restructuringin_progress1%GlobalPrimarily facility consolidations and cost reduction measures across all segments; YTD charges by segment: Laboratory Products and Biopharma Services $95M, Life Sciences Solutions $23M, Analytical Instruments $21M, Specialty Diagnostics $3M, Corporate $7MUSD 147 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions in 2026 affected approximately 1% of the workforce; YTD charge of $147M includes $72M net restructuring charges (severance/facility) and $76M of other items including ~$60M long-lived asset impairment in Laboratory Products and Biopharma Services. Accrued restructuring balance was $72M at period end, expected to be paid primarily through 2026. Employee count not disclosed.
2026-06-27restructuringannounced2026-07-31GlobalPrimarily Laboratory Products and Biopharma ServicesUSD 220 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of July 31, 2026 (post-quarter), company identified additional restructuring actions expected to result in charges of approximately $220 million, primarily in 2026, with further actions expected in future periods. Employee count not disclosed.
2026-06-27acquisition_additioncompleted2026-03-242026-03-24United StatesLaboratory Products and Biopharma Services (clinical research / endpoint data solutions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Clario Holdings, Inc. for $9,098M purchase price; headcount added not disclosed. Two smaller proteomics software acquisitions also completed in 2026 within Analytical Instruments; headcount not disclosed.
2026-06-27divestiture_reductionannounced2026-04-272026-09-30GlobalSpecialty Diagnostics — microbiology businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell microbiology business to Astorg for approximately $1.075 billion (cash plus $50M seller note); expected to close in Q3 2026 subject to regulatory approvals. Headcount removed not disclosed; held-for-sale assets/liabilities disclosed but no employee figures.
2026-06-27restructuringin_progress1%GlobalLaboratory Products and Biopharma ServicesUSD 147 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in 2026. YTD charges of $147M include headcount reductions, facility consolidations, and impairment of long-lived assets.
2026-06-27acquisition_additioncompleted2026-03-24United StatesLaboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Clario Holdings, Inc. on March 24, 2026. Headcount not explicitly disclosed.
2026-06-27restructuringin_progressUSD 72,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-28restructuringin_progress1%Primarily Laboratory Products and Biopharma ServicesUSD 49 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2026 restructuring and other costs of $49 million, principally severance from headcount reductions and facility consolidations; severance actions affected less than 1% of workforce. Accrued restructuring balance of $65 million at March 28, 2026; expected to be paid primarily through 2026.
2026-03-28restructuringannounced2026-05-012026-12-31Primarily Laboratory Products and Biopharma ServicesUSD 290 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 1, 2026, company identified additional restructuring actions expected to result in approximately $290 million of additional charges, primarily in 2026, and expects to identify further actions in future periods.
2026-03-28restructuringin_progressPrimarily Laboratory Products and Biopharma Services; charges also in Life Sciences Solutions, Analytical Instruments, and CorporateUSD 49 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2026 restructuring and other costs of $49M (LSS $9M, AI $4M, LPBS $33M, Corporate $3M) for headcount reductions and facility consolidations; severance actions affected less than 1% of workforce; includes ~$15M of other charges such as long-lived asset impairment. Accrued restructuring balance moved from $70M to $65M.
2026-03-28restructuringannounced2026-05-01Primarily Laboratory Products and Biopharma ServicesUSD 290 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 1, 2026 the company identified additional restructuring actions expected to result in approximately $290M of charges, primarily in 2026, with further actions expected to be identified in future periods; no employee count disclosed
2026-03-28acquisition_additioncompleted2026-03-242026-03-24United StatesLaboratory Products and Biopharma Services (clinical research)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials; purchase price $9,099M; no headcount added disclosed
2026-03-28acquisition_additioncompletedUnited States and GermanyAnalytical Instruments (proteomics software)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Two proteomics software companies acquired in 2026 to strengthen mass spectrometry and proteomics software capabilities; no headcount or dates disclosed
2026-03-28divestiture_reductionannounced2026-04-27Specialty Diagnostics (microbiology business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell microbiology business to Astorg for approximately $1.075B (cash plus $50M seller note); expected to close in H2 2026 subject to regulatory approvals; no headcount disclosed. Assets of business at March 28, 2026: current assets $231M, long-term assets $758M
2026-03-28restructuringin_progress1%2026-01-012026-12-31GlobalLaboratory Products and Biopharma ServicesUSD 49 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce. Charges include headcount reductions, facility consolidations, and impairment of long-lived assets.
2026-03-28restructuringannounced2026-05-012026-12-31GlobalLaboratory Products and Biopharma ServicesUSD 290 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company identified additional restructuring actions expected to result in charges of approximately $290 million, primarily in 2026.
2026-03-28acquisition_additioncompleted2026-03-242026-03-24United StatesLaboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials. Headcount not explicitly disclosed.
2026-03-28acquisition_additioncompleted2026-03-282026-03-28United States, GermanyAnalytical Instrumentsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired two proteomics software companies, one in the U.S. and one in Germany. Headcount not explicitly disclosed.
2026-03-28restructuringin_progressUSD 34,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-31restructuringcompleted5%Company-wide (facility consolidations and cost reduction measures); restructuring charges recorded across Life Sciences Solutions ($154M), Analytical Instruments ($81M), Specialty Diagnostics ($10M), Laboratory Products and Biopharma Services ($147M), Corporate ($(29)M)USD 300 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		MD&A cites approximately $0.3B of 2025 charges for headcount reductions and facility consolidations with ~$0.5B expected annual savings; footnote accrual rollforward shows $197M net severance/facility charges in 2025, with $70M accrued at year-end payable primarily through 2026.
2025-12-31restructuringannounced2026-02-26Primarily Laboratory Products and Biopharma Services, Life Sciences Solutions, and Analytical InstrumentsUSD 250 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Additional restructuring actions identified as of the filing date; charges expected primarily in 2026, with further actions anticipated in future periods.
2025-12-31acquisition_additioncompleted2025-09-012025-09-01Life Sciences Solutionsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired filtration and separation business from Solventum Corporation; cash paid $3,944M. Headcount added not disclosed.
2025-12-31acquisition_additioncompletedLaboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired a sterile fill finishing and packaging facility during 2025 to meet U.S. manufacturing capacity demand; headcount not disclosed.
2025-12-31divestiture_reductioncompletedUSD 51 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Disposition of a consolidated joint venture during 2025; net charges of $51M. Associated workforce impact not quantified.
2025-12-31acquisition_additionannounced2026-06Laboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Agreement to acquire Clario Holdings, Inc. for approximately $8,875M cash plus deferred and contingent consideration; expected close mid-2026 pending regulatory approvals. Headcount addition not disclosed.
2025-12-31restructuringin_progress5%GlobalPrimarily Laboratory Products and Biopharma Services; also Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and CorporateUSD 362 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 restructuring and other costs of $362M; severance actions tied to facility consolidations and cost reduction affected approximately 5% of the workforce. Includes $165M of other net charges (principally $94M long-lived asset impairments and $51M for disposition of a consolidated joint venture). Accrued restructuring balance was $70M at year-end; costs expected to be paid primarily through 2026. Headcount count not disclosed.
2025-12-31restructuringannounced2026-02-26GlobalLaboratory Products and Biopharma Services, Life Sciences Solutions, and Analytical InstrumentsUSD 250 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Actions identified as of February 26, 2026 expected to result in additional charges of approximately $250 million, primarily in 2026; further actions expected to be identified in future periods. Headcount not disclosed.
2025-12-31acquisition_additioncompleted2025-09-01GlobalLife Sciences Solutions (filtration and separation business acquired from Solventum Corporation)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed September 1, 2025 for $3,944M cash paid ($3,870M net purchase price); $2,101M goodwill recorded. Acquired headcount not disclosed. Excluded from management's and the auditor's ICFR assessment (approximately 1% of total assets and revenues).
2025-12-31acquisition_additionannounced2026-06-30GlobalLaboratory Products and Biopharma Services (Clario Holdings, Inc.)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Clario for approximately $8.875B cash plus $125M deferred and up to $400M contingent consideration; expected to close by mid-2026, subject to closing conditions and regulatory approvals. Expected completion date is the filer's stated 'middle of 2026' placeholder.
2025-12-31divestiture_reductioncompletedNot disclosedConsolidated joint venture dispositionUSD 51 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 restructuring and other costs included $51M of net charges for disposition of a consolidated joint venture; associated headcount not disclosed.
2025-12-31restructuringcompleted5%GlobalVariousUSD 362 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the workforce. Total restructuring and other costs were $362 million.
2025-12-31restructuringin_progressUSD 197,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-27restructuringin_progress4%Company-wideUSD 161 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions tied to facility consolidations and cost-reduction measures affected roughly 4% of the workforce in 2025; $161 million of net restructuring charges incurred in the first nine months of 2025, with $127 million paid, leaving an accrued balance of $85 million at quarter-end.
2025-09-27restructuringannounced2026-12-31Laboratory Products and Biopharma Services (primarily)USD 140 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of October 31, 2025, identified restructuring actions expected to result in approximately $140 million of additional charges, primarily in 2025 and 2026; company expects to identify further actions in future periods.
2025-09-27restructuringin_progressLife Sciences SolutionsUSD 78 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2025 restructuring and other costs for the segment; nine-month total was $132 million.
2025-09-27restructuringin_progressAnalytical InstrumentsUSD 54 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2025 restructuring and other costs for the segment; nine-month total was $68 million.
2025-09-27restructuringin_progressLaboratory Products and Biopharma ServicesUSD 39 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2025 restructuring and other costs for the segment; nine-month total was $139 million.
2025-09-27divestiture_reductioncompletedUSD 51 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Net charges for disposition of a consolidated joint venture excluded from the accrued restructuring balance; headcount impact not quantified.
2025-09-27restructuringin_progress4%All segments; charges reported by segment (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Biopharma Services, Corporate)USD 316 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2025 program of severance actions from headcount reductions and facility consolidations affected approximately 4% of the company's workforce (nine months ended 2025-09-27). Nine-month charges by segment: Life Sciences Solutions $132M, Analytical Instruments $68M, Specialty Diagnostics $5M, Laboratory Products and Biopharma Services $139M, Corporate $(29)M. Accrued restructuring balance rose from $50M to $85M; company expects to pay accrued costs primarily through 2025. Charges exclude $155M of net charges (incl. $91M long-lived asset impairments) and $51M net charges for disposition of a consolidated joint venture. No absolute employee count or announcement date disclosed.
2025-09-27restructuringannounced2025-10-31Primarily Laboratory Products and Biopharma ServicesUSD 140 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event disclosure: as of 2025-10-31 the company identified additional restructuring actions expected to result in roughly $140M of further charges, primarily in 2025 and 2026, with more actions expected to be identified in future periods. No employee count disclosed.
2025-09-27acquisition_additioncompleted2025-09-012025-09-01Life Sciences Solutions (filtration and separation business)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Solventum Corporation's Purification and Filtration business closed 2025-09-01; purchase price $3,944M cash. Headcount added through the acquisition is not disclosed in this filing.
2025-09-27restructuringin_progress4%GlobalLaboratory Products and Biopharma ServicesUSD 316 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 4% of the company's workforce in 2025. Charges include headcount reductions, facility consolidations, and impairment of long-lived assets.
2025-09-27acquisition_additioncompleted2025-09-01GlobalLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Solventum Corporation's Purification and Filtration business on September 1, 2025. Headcount not explicitly disclosed.
2025-09-27restructuringin_progressUSD 161,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-28restructuringin_progress2%Company-wide; primarily Laboratory Products and Biopharma ServicesUSD 180 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First-half 2025 restructuring and other costs of $180 million, primarily headcount reductions and facility consolidations; severance actions affected approximately 2% of the workforce. Additional charges of approximately $140 million expected, primarily in 2025, mainly in the Laboratory Products and Biopharma Services segment.
2025-06-28restructuringin_progress2%All segmentsUSD 99 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2025 severance actions for facility consolidations and cost reduction affected approximately 2% of the workforce; absolute headcount not disclosed. Six-month restructuring and other costs by segment: Life Sciences Solutions $54M, Analytical Instruments $14M, Specialty Diagnostics $5M, Laboratory Products and Biopharma Services $100M, Corporate $7M (total $180M, including $67M long-lived asset impairment). Accrued restructuring balance $74M at 2025-06-28; payments expected primarily through 2025.
2025-06-28restructuringannounced2025-08-01Laboratory Products and Biopharma ServicesUSD 140 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Identified as of 2025-08-01, after quarter end; additional actions expected to be identified in future periods; charges expected primarily in 2025. Employee count not disclosed.
2025-06-28acquisition_additionannounced2025-12-31Life Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Solventum Corporation's Purification and Filtration business (drinking water filtration excluded) for approximately $4.0 billion cash at closing; expected to complete by end of 2025, subject to customary closing conditions. Headcount added not disclosed.
2025-06-28restructuringin_progress2%USD 180 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company's workforce in the first six months of 2025. Total restructuring and other costs were $180 million.
2025-06-28restructuringannounced2025-08-012025-12-31Laboratory Products and Biopharma ServicesUSD 140 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		As of August 1, 2025, the company identified additional restructuring actions primarily in the Laboratory Products and Biopharma Services segment, expecting additional charges of approximately $140 million, primarily in 2025.
2025-06-28restructuringin_progressUSD 99,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-29restructuringin_progress1%Primarily Laboratory Products and Biopharma Services; also Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, CorporateUSD 98 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2025 severance actions tied to facility consolidations and cost reduction affected roughly 1% of the workforce; charges include headcount reductions, facility consolidations, and long-lived asset impairments.
2025-03-29restructuringannounced2025-12-31Primarily Laboratory Products and Biopharma ServicesUSD 120 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 2, 2025, company identified additional restructuring actions expected to result in roughly $120 million of further charges, primarily in 2025, with more actions possible later.
2025-03-29restructuringin_progress1%2025-12-31USD 43 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states severance actions for facility consolidations and cost reduction in 2025 affected approximately 1% of the workforce; no absolute count or announcement date given. Q1 2025 restructuring and other costs by segment: Life Sciences Solutions $42M, Analytical Instruments $4M, Specialty Diagnostics $2M, Laboratory Products and Biopharma Services $45M, Corporate $5M (total $98M, including about $68M long-lived asset impairment and other items). Charge value shown is net restructuring charges accrued in Q1 2025; accrued restructuring balance $59M at 2025-03-29, payments expected primarily through 2025.
2025-03-29restructuringannounced2025-05-022025-12-31Laboratory Products and Biopharma ServicesUSD 120 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Actions identified as of 2025-05-02, after quarter end; charges expected primarily in 2025, with further actions expected to be identified in future periods. No employee count disclosed.
2025-03-29acquisition_additionannounced2025-12-31Life Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Solventum Corporation's Purification & Filtration business for approximately $4.1 billion cash; expected to close by end of 2025 subject to regulatory approvals. Headcount to be added is not disclosed.
2025-03-29restructuringin_progress1%GlobalVariousUSD 98 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in the first three months of 2025.
2025-03-29restructuringannounced2025-05-022025-12-31GlobalLaboratory Products and Biopharma ServicesUSD 120 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions primarily in the Laboratory Products and Biopharma Services segment expected to result in additional charges of approximately $120 million, primarily in 2025.
2025-03-29restructuringin_progressUSD 43,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31restructuringcompleted2%All segments; largest component in Laboratory Products and Biopharma ServicesUSD 379 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2024 severance actions tied to facility consolidations and cost reductions affected roughly 2% of the workforce; charges of about $0.3 billion related to headcount and facility actions, with the $379 million line item also including long-lived asset impairments and other items. Restructuring costs by segment (millions): Life Sciences Solutions $69, Analytical Instruments $4, Specialty Diagnostics $17, Laboratory Products and Biopharma Services $280, Corporate $9. Accrued restructuring severance/facility charges incurred in 2024 were $97 million; the company expects to pay accrued restructuring costs primarily through 2025, and the broader program continues (see subsequent-event record).
2024-12-31restructuringannounced2025-02-20Primarily Laboratory Products and Biopharma ServicesUSD 200 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		As of February 20, 2025, restructuring actions identified with approximately $200 million of additional charges expected, primarily in 2025; further actions may be identified in future periods. No completion date or employee count disclosed.
2024-12-31restructuringin_progress2%2025-12-31GlobalPrimarily Laboratory Products and Biopharma Services; also Life Sciences Solutions, Specialty Diagnostics, Analytical Instruments, CorporateUSD 379 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2024 activity only. Severance actions affected approximately 2% of the company's workforce; net severance/accrual charges were $97M, with the $379M total including long-lived asset impairments and other charges. Accrued restructuring costs expected to be paid primarily through 2025.
2024-12-31restructuringannounced2025-02-202025-12-31GlobalPrimarily Laboratory Products and Biopharma ServicesUSD 200 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-fiscal-year-end disclosure: additional restructuring actions identified as of the filing date, expected to result in approximately $200M of additional charges, primarily in 2025; further actions expected in future periods. Headcount impact not disclosed.
2024-12-31acquisition_additioncompleted2024-07-102024-07-10Sweden / GlobalLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of proteomics provider completed July 10, 2024 for $3,146M; acquired headcount not disclosed in the filing.
2024-12-31restructuringcompleted2%GlobalVariousUSD 300 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the workforce. Charges of approximately $0.3 billion incurred in 2024.
2024-12-31restructuringin_progressUSD 97,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-28restructuringin_progress2%Company-wide; largest charges in Laboratory Products and Biopharma ServicesUSD 151 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month restructuring and other costs of $151 million; severance actions tied to facility consolidations and cost reductions affected roughly 2% of the workforce in 2024. Accrued restructuring balance of $53 million at quarter-end; company expects to pay accrued costs primarily through 2024.
2024-09-28restructuringannounced2024-11-012024-12-31USD 310 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 1, 2024, identified restructuring actions expected to result in approximately $310 million of additional charges, primarily in 2024; further actions may be identified in future periods.
2024-09-28restructuringin_progress2%GlobalCompany-wide; restructuring costs by segment for nine months 2024: Life Sciences Solutions $26M, Analytical Instruments $2M, Specialty Diagnostics $12M, Laboratory Products and Biopharma Services $107M, Corporate $4MUSD 151 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2024 severance actions from facility consolidations and cost reductions affected about 2% of workforce; nine-month restructuring and other costs were $151M ($45M in Q3). Severance accrual rolled from $60M at 2023-12-31 to $53M at 2024-09-28 ($77M charges, $84M payments). Actions affected about 2% of workforce; absolute headcount not disclosed and total workforce not disclosed, so implied headcount cannot be validated.
2024-09-28restructuringannounced2024-11-01GlobalNot specifiedUSD 310 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of 2024-11-01 (post-quarter), company identified restructuring actions expected to generate about $310M of additional charges, primarily in 2024; further actions expected in future periods. Employee count not disclosed.
2024-09-28acquisition_additioncompleted2024-07-102024-07-10Sweden (global operations)Life Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of proteomics provider Olink closed 2024-07-10; purchase price $3,146M net of cash acquired. Headcount added through the acquisition is not disclosed in this filing.
2024-09-28restructuringin_progress2%GlobalVariousUSD 151 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company's workforce in 2024. Total restructuring and other costs for the nine months ended Sept 28, 2024 were $151 million.
2024-09-28restructuringannounced2024-11-01GlobalVariousUSD 310 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of Nov 1, 2024, the company identified restructuring actions expected to result in additional charges of approximately $310 million, primarily in 2024.
2024-09-28restructuringin_progressUSD 77,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-29restructuringin_progress1%2024-12-31Company-wide (severance actions across segments)USD 106 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2024 severance actions tied to facility consolidations and cost reduction measures affected approximately 1% of the workforce; six-month restructuring and other costs were $106 million. Accrued restructuring balance of $49 million at June 29, 2024, expected to be paid primarily through 2024.
2024-06-29restructuringannounced2024-08-022024-12-31USD 80 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 2, 2024, identified restructuring actions expected to result in approximately $80 million of additional charges, primarily in 2024; further actions may be identified in future periods.
2024-06-29restructuringin_progress1%2024-12-31All segments; charges concentrated in Laboratory Products and Biopharma ServicesUSD 106 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states 2024 severance actions for facility consolidations and cost reduction affected about 1% of the workforce; no absolute headcount given. Charge is six-month restructuring and other costs (Q2: $77M), including ~$55M of other items such as $47M long-lived asset impairment; severance accrual moved from $60M to $49M. Six-month charges by segment: Life Sciences Solutions $16M, Analytical Instruments $10M, Specialty Diagnostics $5M, Laboratory Products and Biopharma Services $71M, Corporate $4M. Accrued costs expected to be paid primarily through 2024.
2024-06-29restructuringannounced2024-08-02USD 80 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter disclosure: actions identified as of August 2, 2024 expected to drive roughly $80M of additional charges, mostly in 2024; further actions anticipated in future periods. No employee count disclosed.
2024-06-29acquisition_additioncompleted2024-07-10SwedenLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Olink Holding AB (publ) acquired July 10, 2024 (subsequent event); purchase price ~$3.21B. No headcount added disclosed in the filing.
2024-06-29restructuringin_progress1%GlobalVariousUSD 106 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in the first six months of 2024. Charges include headcount reductions, facility consolidations, and impairment of long-lived assets.
2024-06-29acquisition_additioncompleted2024-07-10SwedenLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Olink Holding AB (publ) on July 10, 2024. Headcount not explicitly disclosed.
2024-06-29restructuringin_progressUSD 51,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-30restructuringin_progress2024-12-31Company-wideUSD 29 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2024 charges primarily for headcount reductions and facility consolidations to streamline operations; severance actions affected less than 1% of the workforce. Accrued restructuring balance of $51 million at quarter-end; payments of $32 million during the quarter.
2024-03-30restructuringannounced2024-12-31Company-wideUSD 75 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 3, 2024, identified restructuring actions expected to result in approximately $75 million of additional charges, primarily in 2024; further actions may be identified in future periods.
2024-03-30restructuringin_progress2024-12-31All segments (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Biopharma Services, Corporate)USD 29 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Continuing charges for headcount reductions and facility consolidations; 2024 severance actions affected less than 1% of workforce (no count disclosed). Q1 charge of $29M split by segment: Life Sciences Solutions $2M, Analytical Instruments $7M, Specialty Diagnostics $5M, Laboratory Products and Biopharma Services $14M, Corporate $1M. Accrued restructuring balance moved from $60M at 2023-12-31 to $51M at 2024-03-30 (net charges $25M excluding $4M non-cash, payments $32M, FX $(2)M). Company expects to pay accrued restructuring costs primarily through 2024.
2024-03-30restructuringannounced2024-05-032024-12-31USD 75 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter disclosure: as of 2024-05-03 the company identified restructuring actions expected to result in approximately $75M of additional charges, primarily in 2024; further actions expected to be identified in future periods. No employee count disclosed.
2024-03-30restructuringin_progress1%GlobalVariousUSD 29 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce.
2024-03-30restructuringannounced2024-05-03GlobalVariousUSD 75 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $75 million, primarily in 2024.
2024-03-30restructuringin_progressUSD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progress5%Company-wide (global)All four segments plus corporate; severance actions tied to facility consolidations and cost reduction measuresUSD 194 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance actions during 2023 affected roughly 5% of the workforce (percentage as disclosed, no absolute count given). $194M is net restructuring charges incurred in 2023 per the liability rollforward, principally severance and facility consolidation costs; total restructuring and other costs were $459M including impairments and other items. MD&A cites ~$0.2B of charges expected to yield ~$0.5B annual savings, mainly from lower employee expense. No explicit announcement or completion date disclosed.
2023-12-31restructuringannounced2024-02-222024Company-wide (global)USD 70 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		As of February 22, 2024, additional restructuring actions identified expected to generate ~$70M of charges primarily in 2024; headcount impact not disclosed. Further actions may be identified in future periods. Date in expected_completion_date reflects the filing's statement that charges will be primarily recorded in 2024.
2023-12-31restructuringin_progress5%GlobalAll segments; charges concentrated in Laboratory Products and Biopharma Services ($295M) and Life Sciences Solutions ($105M)USD 459 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2023 severance actions from facility consolidations and cost reduction affected about 5% of the workforce; $459M income-statement charge includes severance, long-lived asset impairments, contract terminations and litigation items; accrued restructuring balance $60M at year-end, payable primarily through 2024. MD&A separately indicates roughly $0.2B of 2023 restructuring charges are expected to yield about $0.5B of annual savings.
2023-12-31restructuringannounced2024-02-22Not disclosedNot disclosedUSD 70 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of the February 22, 2024 filing date, identified actions expected to generate about $70M of additional charges, primarily in 2024; further actions expected in future periods
2023-12-31acquisition_additioncompleted2023-01-032023-01-03United KingdomSpecialty Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price $2,699M; acquired headcount not disclosed
2023-12-31acquisition_additioncompleted2023-08-142023-08-14United StatesLaboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price $910M; acquired headcount not disclosed
2023-12-31acquisition_additionannounced2023-10-172024-06-30SwedenLife Sciences Solutions (upon closing)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tender offer at $26.00 per share, approximately $3.1B; expected to close by mid-year 2024 subject to regulatory approvals; acquired headcount not disclosed
2023-12-31restructuringcompleted5%2023-01-012023-12-31GlobalVariousUSD 459 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the company's workforce. Total restructuring and other costs were $459 million.
2023-12-31restructuringin_progressUSD 194,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progress4%Company-wide; severance actions tied to facility consolidations and cost reduction measuresUSD 379 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine months ended 2023-09-30 restructuring and other costs of $379M (three months: $84M) primarily for headcount reductions and facility consolidations to streamline operations; severance actions affected approximately 4% of the workforce. Accrued restructuring balance rose from $41M at 2022-12-31 to $73M at 2023-09-30 (net charges $175M, payments $142M). Excluded from the accrual roll-forward: $165M of net charges (principally $127M long-lived asset impairments in Laboratory Products and Biopharma Services and Life Sciences Solutions, $26M contract termination costs, $18M pre-acquisition litigation and other) and $39M impairment of a disposal group held for sale beginning Q3 2023. Company expects to pay accrued restructuring costs primarily through 2023.
2023-09-30restructuringannounced2023-11-032023-12-31USD 65 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 3, 2023, company identified additional restructuring actions expected to result in charges of approximately $65 million, primarily in 2023; additional actions may be identified in future periods when specified criteria are met.
2023-09-30divestiture_reductionin_progressUSD 39 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Impairment charge of $39 million for a disposal group held for sale beginning in the third quarter of 2023; loss attributable to Thermo Fisher reduced by $19 million attributable to a noncontrolling interest. No employee count disclosed.
2023-09-30acquisition_additionannounced2023-10-172024-06-30Global (Sweden-based target)Life Sciences Solutions (upon completion)USD 3,100 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Proposed acquisition of Olink Holding AB (publ) at $26.00 per share, approximately $3.1 billion; tender offer commenced, expected to close by mid-year 2024 subject to regulatory approvals. No headcount figures disclosed.
2023-09-30restructuringin_progress4%GlobalCompany-wide; charges by segment: Life Sciences Solutions $100M, Analytical Instruments $31M, Specialty Diagnostics $9M, Laboratory Products and Biopharma Services $228M, Corporate $11M (nine months ended September 30, 2023)USD 175 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2023 severance actions from facility consolidations and cost reductions affected about 4% of the workforce; $175M net restructuring charges incurred in 2023 through September 30 (principally severance and facility-consolidation costs), excluding $165M of other charges (impairments, contract termination, pre-acquisition litigation) and $39M held-for-sale disposal-group impairment. Accrued restructuring balance was $73M at September 30, 2023. No absolute employee count or announcement date disclosed; total workforce not disclosed, so implied headcount cannot be validated.
2023-09-30restructuringannounced2023-11-03GlobalNot specifiedUSD 65 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of November 3, 2023 the company identified restructuring actions expected to generate additional charges of about $65M, primarily in 2023, with further actions expected in future periods. Post-quarter disclosure; employee count not stated.
2023-09-30restructuringin_progress4%2023-01-012023-12-31GlobalVariousUSD 379 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 4% of the company's workforce in 2023. Charges include headcount reductions, facility consolidations, and impairment of long-lived assets.
2023-09-30acquisition_additioncompleted2023-01-032023-01-03United KingdomSpecialty Diagnosticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired The Binding Site Group, a U.K.-based provider of specialty diagnostic assays and instruments.
2023-09-30acquisition_additioncompleted2023-08-142023-08-14United StatesLaboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence.
2023-09-30acquisition_additioncompleted2023-01-012023-09-30United StatesAnalytical Instrumentsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired a U.S.-based developer of Raman-based spectroscopy solutions.
2023-09-30restructuringin_progressUSD 175,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-07-01restructuringin_progress3%Company-wide; severance actions tied to facility consolidations and cost reduction measuresUSD 295 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six months ended July 1, 2023 restructuring and other costs; severance actions affected approximately 3% of the workforce. Accrued restructuring balance of $98 million at July 1, 2023; $137 million of net restructuring charges incurred in 2023 with $80 million paid.
2023-07-01restructuringannounced2023-08-042023-12-31USD 85 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 4, 2023, additional restructuring actions identified expected to result in approximately $85 million of additional charges, primarily in 2023; further actions may be identified in future periods.
2023-07-01restructuringin_progress3%GlobalAll segments (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Biopharma Services, Corporate)USD 295 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2023 program of headcount reductions and facility consolidations; severance actions affected about 3% of workforce (no absolute count given). Six-month charge of $295M includes severance, $99M long-lived asset impairments, $26M contract termination costs and $18M net pre-acquisition litigation charges. Accrued restructuring balance $98M at quarter-end; further actions expected in future periods.
2023-07-01restructuringannounced2023-08-04GlobalNot specifiedUSD 85 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of August 4, 2023 the company identified restructuring actions expected to result in additional charges of about $85 million, primarily in 2023; employee counts not disclosed.
2023-07-01acquisition_additioncompleted2023-01-032023-01-03United KingdomSpecialty Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of The Binding Site Group completed January 3, 2023 (purchase price $2,699M including debt settled); acquired headcount not disclosed.
2023-07-01acquisition_additionannounced2023-12-31United StatesLaboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire CorEvitas, LLC for approximately $0.91 billion in cash, expected to close by end of 2023 subject to regulatory approvals; announcement date and acquired headcount not disclosed.
2023-07-01restructuringin_progress3%GlobalVariousUSD 295 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 3% of the company's workforce in the first six months of 2023. Charges include headcount reductions, facility consolidations, and impairment of long-lived assets.
2023-07-01acquisition_additioncompleted2023-01-03United KingdomSpecialty Diagnosticsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired The Binding Site Group on January 3, 2023. Headcount added not explicitly disclosed.
2023-07-01restructuringin_progressUSD 137,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-04-01restructuringin_progressCompany-wide; severance actions affected less than 2% of the workforceUSD 112 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2023 restructuring and other costs of $112 million included impairment of long-lived assets, pre-acquisition litigation charges, and headcount reductions and facility consolidations. Segment split of the $112M: Life Sciences Solutions $60M, Specialty Diagnostics $8M, Laboratory Products and Biopharma Services $43M, Corporate $1M, Analytical Instruments $0M. Accrued restructuring balance rose from $41M to $55M; $50M of net severance-type charges incurred, $36M paid.
2023-04-01restructuringannounced2023-12-31USD 125 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 5, 2023, identified restructuring actions expected to result in approximately $125 million of additional charges, primarily in 2023; additional actions may be identified in future periods.
2023-04-01restructuringin_progress2023-12-31Company-wideUSD 112 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions for facility consolidations and cost reduction affected 'less than 2% of the company's workforce'; no absolute headcount given. Q1 charge of $112M comprises ~$50M net severance-related restructuring charges plus ~$62M of long-lived asset impairments and pre-acquisition litigation charges. Segment charge split: Life Sciences Solutions $60M, Laboratory Products and Biopharma Services $43M, Specialty Diagnostics $8M, Corporate $1M. Accrued restructuring balance $55M at quarter-end; company expects to pay accrued costs primarily through 2023.
2023-04-01restructuringannounced2023-05-052023-12-31Company-wideUSD 125 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional restructuring actions identified after quarter-end, expected to generate approximately $125M of charges, primarily in 2023; further actions expected to be identified in future periods. No employee count disclosed.
2023-04-01acquisition_additioncompleted2023-01-03United KingdomSpecialty Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of The Binding Site Group (specialty diagnostic assays and instruments); purchase price $2,704M net of cash acquired. Headcount added through the acquisition is not disclosed in this filing.
2023-04-01restructuringin_progress2%2023-01-01GlobalVariousUSD 112 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company's workforce. Charges include impairment of long-lived assets and pre-acquisition litigation.
2023-04-01restructuringannounced2023-05-05GlobalVariousUSD 125 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $125 million, primarily in 2023.
2023-04-01restructuringin_progressUSD 50,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringcompleted2%GlobalUSD 114 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2022 severance actions tied to facility consolidations and cost reduction; value shown is an upper bound (<2% of workforce). Restructuring and other costs of $114M by segment: Life Sciences Solutions $30M, Analytical Instruments $1M, Specialty Diagnostics $68M, Laboratory Products and Biopharma Services $12M, Corporate $3M. Includes $68M net restructuring charges recorded to the accrual (severance, relocation and similar) plus $46M net charges, primarily long-lived asset impairments in Specialty Diagnostics. Remaining accrued restructuring balance of $41M expected to be paid primarily through 2023.
2022-12-31restructuringannounced2023-02-232023USD 60 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Identified restructuring actions as of the filing date, with charges expected primarily in 2023; no employee count disclosed. Company expects to identify additional actions in future periods as criteria are met.
2022-12-31restructuringin_progressGlobalMultiple segments including Specialty Diagnostics, Life Sciences Solutions, Laboratory Products and Biopharma Services, and CorporateUSD 114 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 restructuring and other costs of $114M, comprising severance, long-lived asset impairments and facility consolidation charges. Filer states 2022 severance actions affected less than 2% of the company's workforce; no absolute headcount given. Accrued restructuring balance was $41M at year-end, with payments expected primarily through 2023.
2022-12-31restructuringannounced2023-02-23GlobalNot specifiedUSD 60 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring actions identified as of the filing date, expected to result in approximately $60M of additional charges, primarily in 2023; further actions expected to be identified in future periods.
2022-12-31acquisition_additioncompleted2023-01-032023-01-03United KingdomSpecialty Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-fiscal-year acquisition closed 2023-01-03; purchase price $2.71 billion. No acquired headcount disclosed.
2022-12-31restructuringcompleted2%2022-01-012022-12-31GlobalVariousUSD 114 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company's workforce. Total restructuring and other costs were $114 million.
2022-12-31restructuringannounced2023-02-232023-12-31GlobalVariousUSD 60 (millions)subsequent_events
f5-10k / Qwen3.6-27B-Q8_0		As of February 23, 2023, identified restructuring actions expected to result in additional charges of approximately $60 million, primarily in 2023.
2022-12-31restructuringin_progressUSD 68,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-10-01restructuringin_progress0.5%Multiple segmentsUSD 33 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions tied to facility consolidations and cost reductions affected roughly 0.5% of the workforce in 2022; Q3 restructuring and other costs were $33 million.
2022-10-01restructuringin_progressMultiple segmentsUSD 59 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2022 restructuring and other costs of $59 million, primarily long-lived asset impairments, headcount reductions and facility consolidations.
2022-10-01restructuringannounced2022-11-042023-12-31USD 85 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 4, 2022, identified restructuring actions expected to generate approximately $85 million of additional charges, primarily in 2022 and 2023, with further actions possible.
2022-10-01restructuringin_progress0.5%GlobalMultiple segments (facility consolidations and cost reduction measures)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions in 2022 tied to facility consolidations and cost reductions affected about 0.5% of workforce; total headcount not disclosed in this filing. YTD 2022 restructuring charge $59M, including $28M non-cash impairment.
2022-10-01restructuringannounced2022-11-04GlobalNot specifiedUSD 85 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of 2022-11-04, identified actions expected to drive roughly $85M of additional charges, mainly in 2022 and 2023; further actions anticipated. Employee count not disclosed.
2022-10-01restructuringin_progress0.5%2022-01-012022-12-31GlobalVariousUSD 59 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 0.5% of the company's workforce in 2022. Total restructuring and other costs for the nine months ended Oct 1, 2022 were $59 million, including $28 million of non-cash impairment charges.
2022-10-01restructuringannounced2022-11-042023-12-31GlobalVariousUSD 85 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of Nov 4, 2022, the company identified restructuring actions resulting in additional charges of approximately $85 million, primarily in 2022 and 2023.
2022-10-01restructuringin_progressUSD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-07-02restructuringin_progress2022-12-31All segments; primarily Laboratory Products and Biopharma ServicesUSD 20 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 5, 2022, identified restructuring actions expected to result in additional charges of approximately $20 million, primarily in 2022; severance actions in H1 2022 affected less than 0.5% of the workforce. Segment-level H1 2022 restructuring charges: Life Sciences Solutions $6M, Analytical Instruments $4M, Specialty Diagnostics $3M, Laboratory Products and Biopharma Services $13M.
2022-07-02restructuringin_progressNot specifiedLife Sciences Solutions; Analytical Instruments; Specialty Diagnostics; Laboratory Products and Biopharma Services (charges allocated across all four segments)USD 20 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing 2022 program of headcount reductions and facility consolidations; severance actions affected less than 0.5% of workforce (no absolute count given). Net restructuring charges of $22M incurred in first six months of 2022 (excludes $4M non-cash); accrued balance $15M at quarter-end. As of 2022-08-05, additional actions identified implying roughly $20M of further charges, primarily in 2022, with more actions expected in future periods.
2022-07-02restructuringin_progress0.5%GlobalVariousUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 0.5% of the company's workforce in the first six months of 2022. Total restructuring and other costs were $26 million.
2022-07-02restructuringannounced2022-08-05GlobalVariousUSD 20 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of August 5, 2022, the company identified restructuring actions resulting in additional charges of approximately $20 million, primarily in 2022.
2022-07-02restructuringin_progressUSD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-04-02restructuringin_progress2022-12-31Multiple segmentsUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2022 severance actions tied to facility consolidations and cost reductions affected less than 0.1% of workforce; as of May 6, 2022, additional identified actions expected to generate roughly $15 million of charges, primarily in 2022. Accrued restructuring balance was $12 million at quarter-end.
2022-04-02restructuringin_progressGlobalMultiple segments (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Biopharma Services)USD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Continuing headcount reductions and facility consolidations; severance actions in 2022 affected less than 0.1% of the workforce (no absolute count given). Accrual roll-forward shows $6M net charges incurred in 2022, excluding $4M of net gains; income statement line 'Restructuring and other costs' was $2M (LSS $1M, Analytical Instruments $2M, Specialty Diagnostics $1M, LPBS $(2M)). Accrued restructuring balance went from $17M to $12M. No announcement date or completion date disclosed.
2022-04-02restructuringannounced2022-05-06GlobalNot specifiedUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter disclosure: as of May 6, 2022 the company identified restructuring actions expected to result in additional charges of approximately $15 million, primarily in 2022; further actions expected to be identified in future periods. No employee count disclosed.
2022-04-02acquisition_additioncompletedUnited StatesAnalytical Instrumentsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In 2022 the company acquired a U.S.-based developer of Fourier-transform infrared gas analysis technologies within the Analytical Instruments segment; no headcount or consideration detail disclosed. Note 2 also records Q1 2022 measurement-period adjustments to the 2021 PPD and PeproTech purchase price allocations (goodwill +$59M), with no headcount impact disclosed.
2022-04-02restructuringin_progress0.1%GlobalVariousUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 0.1% of the company's workforce.
2022-04-02restructuringannounced2022-05-06GlobalVariousUSD 15 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $15 million, primarily in 2022.
2022-04-02restructuringin_progressUSD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-31restructuringcompleted2022Company-wide (facility consolidations and cost-reduction measures)USD 37 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2021 severance actions affected less than 1% of workforce; $37M net severance/facility-consolidation charges accrued in 2021, $40M paid, $17M accrued at year-end payable primarily in 2022. Broader $197M restructuring and other costs line also included $122M intangible impairments and $35M compensation contractually due to employees of acquired businesses.
2021-12-31restructuringannounced2022-02-242022USD 20 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Disclosed as of the February 24, 2022 filing date: additional restructuring actions identified, roughly $20M of charges expected primarily in 2022; further actions may be identified in future periods.
2021-12-31acquisition_additioncompleted2021-01-15BelgiumLaboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired the European viral vector manufacturing business of Groupe Novasep SAS for $830M net cash; expands cell and gene vaccine/therapy manufacturing. Headcount not disclosed.
2021-12-31acquisition_additioncompleted2021-02-25United StatesLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Mesa Biotech, Inc., a molecular diagnostics (PCR point-of-care) company, for $407M net cash plus contingent consideration initially valued at $65M. Headcount not disclosed.
2021-12-31acquisition_additioncompleted2021-09-30Lengnau, SwitzerlandLaboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Assumed operating responsibility of a biologics manufacturing facility from CSL Limited (business combination, $18M net purchase price); fixed lease payments of $555M from 2021 to 2041. Headcount not disclosed.
2021-12-31acquisition_additioncompleted2021-12-08United States (global operations)Laboratory Products and Biopharma Servicesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired PPD, Inc., a global clinical research services provider, for $15.99B net cash plus $43M equity awards; $4.3B assumed debt repaid; PPD had 2020 revenues of $4.68B. Headcount not disclosed.
2021-12-31acquisition_additioncompleted2021-12-30United StatesLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired PeproTech, Inc., a developer and manufacturer of recombinant proteins, for $1.86B net cash consideration. Headcount not disclosed.
2021-12-31restructuringin_progress2022-12-31United States; EuropeMultiple businesses (facility consolidations and cost reduction measures)USD 37 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2021 severance actions from facility consolidations and cost reductions affected less than 1% of the workforce. Net restructuring charges incurred in 2021 were $37M; total restructuring and other costs of $197M also include $122M of acquired technology/tradename impairments and $35M of acquisition-date compensation. Accrued restructuring balance was $17M at year-end, payable primarily through 2022.
2021-12-31restructuringannounced2022-02-242022-12-31Not specifiedNot specifiedUSD 20 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of the February 24, 2022 filing date, additional restructuring actions identified that will result in approximately $20M of charges, primarily in 2022; further actions expected to be identified in future periods.
2021-12-31acquisition_additioncompleted2021-12-082021-12-08United StatesLaboratory Products and Biopharma Services (clinical research services)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount added not disclosed. PPD generated revenues of $4.68 billion in 2020; contributed $378 million of revenues post-acquisition in 2021.
2021-12-31acquisition_additioncompleted2021-12-302021-12-30United StatesLife Sciences Solutions (recombinant proteins)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount added not disclosed.
2021-12-31acquisition_additioncompleted2021-01-152021-01-15Belgium / EuropeLaboratory Products and Biopharma Services (viral vector manufacturing)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount added not disclosed.
2021-12-31acquisition_additioncompleted2021-02-252021-02-25United StatesLife Sciences Solutions (molecular diagnostics)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount added not disclosed.
2021-12-31acquisition_additioncompleted2021-09-302021-09-30Lengnau, SwitzerlandLaboratory Products and Biopharma Services (biologics manufacturing)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Headcount added not disclosed; fixed lease payments of $555 million expected 2021-2041.
2021-12-31acquisition_additioncompleted2021-12-31Ireland; Belgium; United StatesLife Sciences Solutions, Analytical Instruments, Specialty Diagnostics (smaller tuck-in acquisitions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Consolidated record for smaller 2021 acquisitions (cell sorting technology assets, Ireland-based life sciences distributor, digital PCR platform developer, micro-chip liquid chromatography technology, transplant diagnostics information system provider). Headcount added not disclosed; aggregate 'Other' purchase price of $402 million.
2021-12-31restructuringcompleted1%2021-01-012021-12-31GlobalVariousUSD 197 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce in 2021. Total restructuring and other costs were $197 million, including impairments and acquisition-related compensation.
2021-12-31restructuringin_progressUSD 37,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-10-02restructuringin_progressLife Sciences SolutionsUSD 20 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2021 net restructuring and other costs; includes SG&A charges of $23M offset by $3M credit in restructuring and other costs
2021-10-02restructuringin_progressAnalytical InstrumentsUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2021 net restructuring and other costs
2021-10-02restructuringin_progressEuropeSpecialty DiagnosticsUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2021 net charges; nine-month charges of $17M primarily for severance and fixed-asset write-downs tied to discontinuing a European product line
2021-10-02restructuringin_progressLaboratory Products and ServicesUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2021 net restructuring and other costs; nine-month charges of $44M primarily third-party transaction/integration costs for recent acquisitions
2021-10-02restructuringin_progressCorporateUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2021 net restructuring and other costs; nine-month charges of $18M primarily product liability litigation and pre-acquisition matters
2021-10-02restructuringannounced2021-11-042022-12-31USD 25 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 4, 2021, identified restructuring actions expected to result in approximately $25 million of additional charges, primarily in 2021 and 2022
2021-10-02restructuringin_progressUSD 192 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions tied to facility consolidations and cost reduction measures affected less than 1% of the workforce in the first nine months of 2021; no exact headcount given. The $192M charge spans cost of revenues, SG&A and the restructuring line, and includes non-severance items (acquired-technology impairment, transaction/integration costs, fixed-asset write-downs) partly offset by contingent-consideration credits. Severance actions affected less than 1% of the workforce.
2021-10-02restructuringannounced2021-11-04USD 25 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Actions identified as of November 4, 2021 (post-quarter); additional charges expected primarily in 2021 and 2022, with further actions expected in future periods. No employee count disclosed.
2021-10-02acquisition_additionannounced2021-04-152021-12-31Laboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of PPD, Inc. at $47.50 per share ($17.4B cash plus ~$3.5B net debt assumed); company expects completion by end of 2021 subject to regulatory clearance. Headcount to be added not disclosed.
2021-10-02acquisition_additioncompleted2021-01-15BelgiumLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the European viral vector manufacturing business of Groupe Novasep SAS for $834M net cash consideration; headcount added not disclosed.
2021-10-02acquisition_additioncompleted2021-02-25United StatesLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Mesa Biotech, Inc. for $409M net cash plus $65M initial fair value contingent consideration; headcount added not disclosed.
2021-10-02acquisition_additioncompleted2021-09-30SwitzerlandLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Assumed operating responsibility for the Lengnau biologics manufacturing facility from CSL Limited; fixed lease payments of $555M from 2021 to 2041. Headcount transferred not disclosed.
2021-10-02acquisition_additioncompletedbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Other first-nine-month 2021 acquisitions: cell sorting technology assets, an Ireland-based life sciences distributor and a digital PCR platform developer (Life Sciences Solutions), plus a Belgium-based micro-chip liquid chromatography column developer (Analytical Instruments). Headcounts not disclosed.
2021-10-02restructuringin_progress1%2021-01-01GlobalVariousUSD 151 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce in the first nine months of 2021. Total restructuring and other costs recorded were $151 million.
2021-10-02restructuringannounced2021-11-042022-12-31GlobalVariousUSD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		As of November 4, 2021, the company identified restructuring actions resulting in additional charges of approximately $25 million, primarily in 2021 and 2022.
2021-10-02restructuringin_progressUSD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-07-03restructuringin_progress2021-12-31Company-wide; severance actions affected less than 0.5% of workforceUSD 77 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2021 net restructuring and other costs of $77 million, primarily impairment of acquired technology and third-party transaction/integration costs; severance actions in H1 2021 affected less than 0.5% of workforce (no employee count disclosed).
2021-07-03restructuringannounced2021-08-062021-12-31USD 45 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 6, 2021, identified restructuring actions expected to result in approximately $45 million of additional charges, primarily in 2021; further actions may be identified during 2021.
2021-07-03restructuringin_progress2021-12-31GlobalMultiple segments (facility consolidations and cost reduction measures)USD 12 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions in first six months of 2021 affected less than 0.5% of the company's workforce; exact count not disclosed. $12M is net restructuring charges incurred in 2021 excluding $121M of other net charges (principally acquired-technology impairment and acquisition-related employee compensation). Accrued restructuring balance was $13M at 2021-07-03; company expects to pay accrued costs primarily through 2021.
2021-07-03restructuringannounced2021-08-062021-12-31GlobalNot specifiedUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of 2021-08-06 (filing date), company identified restructuring actions expected to result in additional charges of approximately $45M, primarily in 2021; further actions expected to be identified during 2021. Employee counts not disclosed.
2021-07-03acquisition_additioncompleted2021-01-152021-01-15Belgium / EuropeLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired European viral vector manufacturing business of Groupe Novasep SAS for approximately $834M net cash consideration; headcount added not disclosed.
2021-07-03acquisition_additioncompleted2021-02-252021-02-25United StatesLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Mesa Biotech, Inc. for approximately $406M net cash plus $65M initial fair value contingent consideration; headcount added not disclosed.
2021-07-03acquisition_additionannounced2021-04-152021-12-31United StatesLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of PPD, Inc. at $47.50/share ($17.4B cash plus ~$3.5B assumed net debt); FTC Second Request received 2021-07-16; company continues to expect completion by end of 2021. Headcount to be added not disclosed.
2021-07-03restructuringin_progress0.5%2021-07-03GlobalVariousUSD 119 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 0.5% of the company's workforce in the first six months of 2021. Q2 specific headcount not disclosed, only total charge of $119M.
2021-07-03restructuringannounced2021-08-062021-12-31GlobalVariousUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		As of August 6, 2021, company identified restructuring actions resulting in additional charges of approximately $45 million, primarily in 2021.
2021-07-03restructuringin_progressUSD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-04-03restructuringin_progress0.1%Company-wideUSD 38 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2021 net restructuring and other costs of $38 million; severance actions tied to facility consolidations and cost reductions affected less than 0.1% of the workforce. Charges also include compensation contractually due to employees of acquired businesses, third-party transaction/integration costs, and inventory revaluation step-up.
2021-04-03restructuringannounced2021-05-072021-12-31USD 40 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 7, 2021, company identified restructuring actions expected to result in approximately $40 million of additional charges, primarily in 2021; further actions may be identified during 2021.
2021-04-03acquisition_additioncompleted2021-01-152021-01-15BelgiumLaboratory Products and ServicesUSD 834 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired the European viral vector manufacturing business of Groupe Novasep SAS for approximately $834 million net cash consideration; headcount added not disclosed.
2021-04-03acquisition_additioncompleted2021-02-252021-02-25United StatesLife Sciences SolutionsUSD 406 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Mesa Biotech, Inc. for approximately $406 million net cash plus contingent consideration with initial fair value of $65 million; headcount added not disclosed.
2021-04-03restructuringin_progress0.1%GlobalMultiple segments; facility consolidations and cost reduction measuresUSD 38 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions at facility consolidations and cost reduction measures affected less than 0.1% of workforce (value shown is the disclosed upper bound); no absolute headcount given. Charge is total restructuring and other costs per MD&A ($38M), which the footnote breaks out as $3M net charges to the severance accrual plus $11M acquisition-related employee compensation and other items. Severance actions affected less than 0.1% of workforce; severance accrual balance was $15M at quarter-end.
2021-04-03restructuringannounced2021-05-07GlobalNot specifiedUSD 40 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter disclosure: restructuring actions identified as of May 7, 2021 expected to result in approximately $40M of additional charges, primarily in 2021; further actions expected to be identified during 2021. No employee count disclosed.
2021-04-03acquisition_additioncompleted2021-01-152021-01-15Belgium / EuropeLaboratory Products and Services — European viral vector manufacturing business of Groupe Novasep SASbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired for approximately $834M net cash consideration; no headcount of acquired employees disclosed.
2021-04-03acquisition_additioncompleted2021-02-252021-02-25United StatesLife Sciences Solutions — Mesa Biotech, Inc.business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired for approximately $406M net cash plus $65M initial fair value contingent consideration; no headcount of acquired employees disclosed.
2021-04-03acquisition_additionannounced2021-04-152021-12-31United StatesLaboratory Products and Services — PPD, Inc.subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire PPD at $47.50/share ($17.4B cash plus ~$3.5B assumed net debt), expected to close by end of 2021; no headcount disclosed. PPD 2020 revenue was $4.7B.
2021-04-03restructuringin_progress0.1%2021-01-03GlobalVariousUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 0.1% of the company's workforce. Charges primarily for compensation contractually due to employees of acquired businesses, third-party transaction/integration costs, and inventory revaluation.
2021-04-03acquisition_additioncompleted2021-01-15BelgiumLaboratory Products and ServicesUSD 834 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired European viral vector manufacturing business of Groupe Novasep SAS. Headcount not explicitly disclosed.
2021-04-03acquisition_additioncompleted2021-02-25United StatesLife Sciences SolutionsUSD 406 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired Mesa Biotech, Inc. Headcount not explicitly disclosed.
2021-04-03acquisition_additionannounced2021-04-152021-12-31GlobalLaboratory Products and ServicesUSD 17,400 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Entered into definitive agreement to acquire PPD, Inc. for $17.4 billion. Transaction expected to close by end of 2021. Headcount not explicitly disclosed.
2021-04-03restructuringin_progressUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringcompleted1%United States, Europe, and ChinaAll segments and corporate; severance charges concentrated in Analytical Instruments (headcount reductions in Europe, China, U.S.), Laboratory Products and Services, and CorporateUSD 51 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance actions for facility consolidations and cost reduction measures during 2020 affected approximately 1% of the workforce. $51M is net restructuring charges incurred in 2020 per the severance accrual rollforward; total 2020 net restructuring and other costs were $95M, excluding $48M of other net charges (acquired-technology write-offs, fixed-asset writedowns, environmental remediation). Program expected to yield ~$55M annual cost savings, partly in 2020 and to a greater extent in 2021. Accrued restructuring balance of $21M at 2020-12-31 payable primarily through 2021.
2020-12-31restructuringannounced2021-02-24USD 50 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		As of the filing date (February 24, 2021), company identified restructuring actions expected to result in approximately $50M of additional charges, primarily in 2021, with further actions expected to be identified during 2021. Employee headcount impact not quantified.
2020-12-31acquisition_additioncompletedUnited StatesLife Sciences SolutionsUSD 63 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		2020 acquisition of a U.S.-based provider of a spectral dye platform for high-resolution biology applications; $63M is the total purchase price including fair value of contingent consideration, not a severance charge. Employee headcount acquired not disclosed.
2020-12-31acquisition_additioncompleted2021-01-152021-01-15Belgium / EuropeLaboratory Products and ServicesUSD 853 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Acquired the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS for approximately $853M in cash on January 15, 2021 (after fiscal year-end). Purchase-price allocation pending; employee headcount acquired not disclosed.
2020-12-31acquisition_additionannounced2021-01-152021-03United StatesLife Sciences Solutions (upon completion)USD 450 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Definitive agreement signed January 15, 2021 to acquire Mesa Biotech, Inc. for approximately $450M in cash plus up to $100M upon milestones; disclosed as expected to close in Q1 2021 (date reflects quarter-end month), subject to customary closing conditions. Employee headcount not disclosed.
2020-12-31restructuringin_progress1%United States and EuropeCompany-wide (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, Corporate)USD 95 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2020 program comprised headcount reductions and facility consolidations (closure/consolidation of several U.S. and European facilities) plus write-off of acquired technology and transaction/integration costs. Severance actions affected approximately 1% of the workforce (implied ~800 of the >80,000 total). MD&A reports net restructuring and other costs of $95M for 2020; the accrual rollforward shows $51M of net restructuring charges incurred in 2020 (excluding $48M of other charges), with a $21M balance at year-end. Expected annual cost savings of approximately $55M beginning partly in 2020 and to a greater extent in 2021. Footnote allocates net charges by segment: Life Sciences Solutions $26M, Analytical Instruments $26M, Specialty Diagnostics $(3)M, Laboratory Products and Services $34M, Corporate $12M; employee counts are not broken out by segment, so a single consolidated record is used.
2020-12-31restructuringannounced2021-02-24Not specifiedNot specifiedUSD 50 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of the 2021-02-24 filing date the company had identified restructuring actions expected to generate approximately $50M of additional charges, primarily in 2021, and expected to identify further actions during 2021. No employee counts disclosed.
2020-12-31acquisition_additioncompletedUnited StatesLife Sciences SolutionsUSD 63 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of a U.S.-based provider of a spectral dye platform for high-resolution biology applications; $63M total purchase price including fair value of contingent consideration. Acquired headcount not disclosed; acquisition date not specified.
2020-12-31acquisition_additioncompleted2021-01-152021-01-15Belgium / EuropeLaboratory Products and ServicesUSD 853 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition of the European viral vector manufacturing business of Groupe Novasep SAS for approximately $853M in cash. Acquired headcount not disclosed.
2020-12-31acquisition_additionannounced2021-01-152021-03-31United StatesLife Sciences Solutions (upon completion)USD 450 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Mesa Biotech, Inc. for approximately $450M in cash plus up to $100M of milestone payments; expected to close in Q1 2021 subject to closing conditions. Acquired headcount not disclosed.
2020-12-31restructuringcompleted1%2020-01-012020-12-31GlobalVariousUSD 95 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in 2020. Net restructuring and other costs were $95 million.
2020-12-31restructuringin_progressUSD 51,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-26restructuringin_progress2021-12-31Europe, China, United StatesAnalytical InstrumentsUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month charges primarily for employee severance from headcount reductions in Europe, China and the U.S., plus abandoned facility costs.
2020-09-26restructuringin_progress2021-12-31United StatesLaboratory Products and ServicesUSD 27 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month charges primarily for employee severance at businesses streamlining operations and fixed-asset writedowns tied to consolidating U.S. commercial production.
2020-09-26restructuringin_progress2021-12-31Life Sciences SolutionsUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month net charges, primarily impairment of acquired technology in development.
2020-09-26restructuringin_progress2021-12-31Specialty DiagnosticsUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month net charges, principally third-party transaction costs including reimbursement for a terminated acquisition.
2020-09-26restructuringin_progress2021-12-31CorporateUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month costs for corporate severance and, to a lesser extent, product liability litigation charges in SG&A.
2020-09-26restructuringannounced2020-10-302021-12-31USD 45 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of October 30, 2020, identified restructuring actions expected to add roughly $45 million of charges, primarily in 2020 and 2021; more actions anticipated.
2020-09-26restructuringin_progress2021-12-31Global (facility consolidations and cost reduction measures in Europe, China and the U.S.)Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; Laboratory Products and Services; CorporateUSD 43 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states severance actions in the first nine months of 2020 affected less than 1% of the workforce; no absolute headcount given. Net restructuring charges incurred in 2020 through Sept 26 were $43M (excludes $24M of impairment/writedown charges); accrued restructuring balance was $32M at period end.
2020-09-26restructuringannounced2020-10-302021-12-31Not specifiedNot specifiedUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of October 30, 2020 the company identified restructuring actions expected to result in additional charges of approximately $45 million, primarily in 2020 and 2021, with further actions expected to be identified during 2020.
2020-09-26restructuringin_progress1%2020-09-26GlobalVarious (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, Corporate)USD 67 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce in the first nine months of 2020. Total net restructuring and other costs were $67 million.
2020-09-26restructuringannounced2020-10-302021-12-31GlobalVariousUSD 45 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		As of October 30, 2020, the company identified restructuring actions resulting in additional charges of approximately $45 million, primarily in 2020 and 2021.
2020-09-26restructuringin_progressUSD 43,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-27restructuringin_progressEurope, China, United StatesAnalytical InstrumentsUSD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six months ended 2020-06-27 charges, primarily employee severance from headcount reductions in Europe, China and the U.S., plus abandoned facility costs; $5 million of the total was recorded in Q2. Additional charges of approximately $60 million expected, primarily in 2020 and 2021.
2020-06-27restructuringin_progressSpecialty DiagnosticsUSD 52 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six months ended 2020-06-27 charges, principally third-party transaction/acquisition-related costs; $46 million recorded in Q2.
2020-06-27restructuringin_progressUnited StatesLaboratory Products and ServicesUSD 25 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six months ended 2020-06-27 charges, primarily employee severance at businesses streamlining operations and fixed-asset writedowns tied to consolidating U.S. commercial production operations; $3 million recorded in Q2.
2020-06-27restructuringin_progressCorporateUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six months ended 2020-06-27 charges for severance at corporate operations and, to a lesser extent, abandoned facility costs; $2 million recorded in Q2.
2020-06-27restructuringin_progressLife Sciences SolutionsUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six months ended 2020-06-27 charges; no charges recorded in Q2.
2020-06-27restructuringin_progressCompany-wide severance and facility consolidation programUSD 29 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance costs incurred in 2020 (six months); severance accrual balance of $22 million at 2020-06-27. Filer states severance actions affected less than 1% of workforce; no absolute headcount disclosed.
2020-06-27restructuringin_progressGlobalMultiple segments including Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, and CorporateUSD 102 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2020-06-27: severance actions from facility consolidations and cost reduction measures affected less than 1% of workforce (count not disclosed). Charge comprises $4M cost of revenues, $48M SG&A, $50M restructuring line; includes $13M fixed-asset writedowns and environmental remediation costs. Severance actions affected less than 1% of workforce.
2020-06-27restructuringannounced2020-07-31GlobalNot specifiedUSD 60 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of 2020-07-31, identified restructuring actions expected to result in approximately $60M of additional charges, primarily in 2020 and 2021; further actions expected to be identified during 2020. Employee counts not disclosed.
2020-06-27restructuringin_progressUnited States, Europe, ChinaAnalytical InstrumentsUSD 19 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2020-06-27 charges, primarily employee severance for headcount reductions in Europe, China and the U.S., plus abandoned facility costs. Headcount affected not disclosed.
2020-06-27restructuringin_progressGlobalSpecialty DiagnosticsUSD 52 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2020-06-27 charges, principally third-party transaction and acquisition-related costs. Headcount affected not disclosed.
2020-06-27restructuringin_progressUnited States, EuropeLaboratory Products and ServicesUSD 25 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2020-06-27 charges, primarily employee severance at businesses streamlining operations and fixed-asset writedowns tied to consolidation of U.S. commercial production operations. Headcount affected not disclosed.
2020-06-27restructuringin_progressGlobalCorporateUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2020-06-27 charges for severance at corporate operations and, to a lesser extent, abandoned facility costs. Headcount affected not disclosed.
2020-06-27restructuringin_progress1%2020-06-27GlobalMultiple segmentsUSD 56 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce in Q2 2020. Total net restructuring and other costs recorded were $56 million.
2020-06-27restructuringin_progress2020-06-27GlobalMultiple segmentsUSD 102 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		In the first six months of 2020, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce. Total net restructuring and other costs recorded were $102 million.
2020-06-27restructuringin_progressEmployee Severance [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-27restructuringin_progressFacility Closing [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-27restructuringin_progressOther Restructuring [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-27restructuringin_progressUSD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-28restructuringin_progress0.5%United States and EuropeAnalytical InstrumentsUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily employee severance from headcount reductions in the U.S. and Europe, plus abandoned facility costs
2020-03-28restructuringin_progressEurope and United StatesSpecialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cash restructuring charges for severance and other costs associated with headcount reductions; segment also recorded $4M of acquisition-related SG&A charges
2020-03-28restructuringin_progressUnited StatesLaboratory Products and ServicesUSD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cash charges for employee severance at businesses streamlining operations; segment also recorded $8M non-cash fixed asset writedowns tied to consolidation of commercial production operations in the U.S.
2020-03-28restructuringin_progressCorporateUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance at corporate operations and, to a lesser extent, abandoned facility costs
2020-03-28restructuringannounced2020-05-012020-12-31USD 65 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 1, 2020, identified restructuring actions expected to result in additional charges of approximately $65 million, primarily in 2020; additional actions expected to be identified during 2020
2020-03-28restructuringin_progressUnited States and EuropeMultiple segments including Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, and CorporateUSD 46 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2020 charges of $46M total ($38M restructuring and other costs, net, plus $2M cost of revenues and $6M SG&A). Severance actions from facility consolidations and cost reductions affected less than 0.5% of workforce; no absolute headcount disclosed. Severance actions affected less than 0.5% of workforce.
2020-03-28restructuringannounced2020-05-01Not specifiedNot specifiedUSD 65 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 1, 2020, identified restructuring actions expected to result in approximately $65M of additional charges, primarily in 2020; further actions expected to be identified during 2020.
2020-03-28acquisition_additionannounced2020-03-032021-06-30GlobalLife Sciences and molecular diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of QIAGEN N.V. at €39.00 per share (~$11.5B including ~$1.4B net debt); expected to close in first half of 2021. No headcount addition disclosed.
2020-03-28divestiture_reductioncompleted2019-06-282019-06-28GlobalSpecialty Diagnostics — Anatomical Pathology businessMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Anatomical Pathology business sold to PHC Holdings for $1.13B net of cash divested; referenced in Q1 2020 MD&A for revenue dilution context. No headcount reduction disclosed.
2020-03-28restructuringin_progress0.5%2020-03-28GlobalVariousUSD 38 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 0.5% of the company's workforce. Total net restructuring and other costs recorded were $38 million.
2020-03-28restructuringin_progressEmployee Severance [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-28restructuringin_progressFacility Closing [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-28restructuringin_progressOther Restructuring [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-28restructuringin_progressUSD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringcompleted1%United States and EuropeAll segments (facility consolidations and cost reduction measures)USD 52 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance actions tied to facility consolidations and cost reductions affected about 1% of the workforce in 2019. $52M cash charges, net, primarily severance and abandoned facility costs (gross costs incurred per roll-forward: $66M — severance $45M, facility abandonment $7M, other $14M; reserves reversed $14M). Accrued costs expected to be paid primarily through 2020; expected annual cost savings of ~$60M beginning in 2019.
2019-12-31restructuringannounced2020-02-26Life Sciences Solutions ~25%, Analytical Instruments ~30%, Laboratory Products and Services ~35%, Specialty Diagnostics ~10% of chargesUSD 65 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Additional restructuring actions identified after fiscal year-end, expected to result in charges of approximately $65 million primarily in 2020; segment split given as percentage of charges, not headcount. Company also expects to identify further actions during 2020.
2019-12-31restructuringin_progress1%2020-12-31United States and EuropeConsolidated (all segments)USD 66 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2019 severance actions from facility consolidations and cost-reduction measures affected approximately 1% of the workforce; $66M is total 2019 costs incurred (severance $45M, facility abandonment $7M, other $14M), excluding $482M divestiture gain and $17M other charges. Accrued restructuring costs expected to be paid primarily through 2020.
2019-12-31restructuringannounced2020-02-262020-12-31United States and EuropeConsolidated (allocated ~25% Life Sciences Solutions, ~30% Analytical Instruments, ~35% Laboratory Products and Services, ~10% Specialty Diagnostics of charges)USD 65 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Additional restructuring actions identified as of February 26, 2020 (after fiscal year-end), expected to result in charges of approximately $65M, primarily in 2020; further actions expected to be identified during 2020. Segment allocation is of charges, not headcount.
2019-12-31acquisition_additioncompleted2019-04-302019-04-30Not disclosedLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Brammer Bio for approximately $1.67 billion in cash (viral vector contract development and manufacturing); acquired headcount not disclosed. Brammer Bio reported revenues of approximately $140 million in 2018.
2019-12-31divestiture_reductioncompleted2019-06-282019-06-28Not disclosedSpecialty Diagnosticsdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Anatomical Pathology business to PHC Holdings Corporation for $1.13 billion, net of cash divested; pre-tax gain of approximately $478 million. Divested headcount not disclosed; business contributed approximately $115 million of revenues in 2019 through the date of sale.
2019-12-31restructuringcompleted1%2019United States and EuropeAll segmentsUSD 52 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce. Cash restructuring charges were $52 million, primarily for employee severance and abandoned facilities costs.
2019-12-31acquisition_additioncompleted2019-04-30GlobalLaboratory Products and ServicesMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquired Brammer Bio for approximately $1.67 billion in cash. Headcount not explicitly disclosed.
2019-12-31divestiture_reductioncompleted2019-06-28GlobalSpecialty DiagnosticsMD&A
f5-10k / Qwen3.6-27B-Q8_0		Sold Anatomical Pathology business to PHC Holdings Corporation for $1.13 billion. Headcount not explicitly disclosed.
2019-12-31restructuringin_progressEmployee Severance [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressFacility Closing [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressOther Restructuring [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-12-31restructuringin_progressUSD 66,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-28restructuringin_progress1%U.S. and EuropeCompany-wide facility consolidations and cost reduction measuresUSD 25 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions in the first nine months of 2019 affected approximately 1% of the workforce; $25 million of severance costs incurred in the nine months, with $29 million paid and a $26 million severance accrual remaining at September 28, 2019.
2019-09-28restructuringannounced2019-11-012020-12-31USD 80 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 1, 2019, identified restructuring actions expected to result in approximately $80 million of additional charges, primarily in 2019 and 2020; further actions may be identified during 2019.
2019-09-28divestiture_reductioncompleted2019-06-282019-06-28Specialty Diagnostics — Anatomical Pathology businessUSD 482 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Sold Anatomical Pathology business to PHC Holdings Corporation for $1.13 billion net of cash divested; pre-tax gain of approximately $482 million. No employee count disclosed.
2019-09-28acquisition_additioncompleted2019-04-302019-04-30Laboratory Products and Services — Brammer BioUSD 1,670 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Brammer Bio, a viral vector contract development and manufacturing organization, for approximately $1.67 billion in cash. No headcount disclosed.
2019-09-28restructuringin_progress1%United States; EuropeCompany-wide (facility consolidations and cost reduction measures)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions tied to facility consolidations and cost reduction measures affected roughly 1% of the workforce during the first nine months of 2019; includes closure and consolidation of several U.S. and European facilities. Cash restructuring charges of $33M recorded YTD 2019 (excludes non-cash items and divestiture gain).
2019-09-28restructuringannounced2019-11-012020-12-31Not specifiedCompany-wideUSD 80 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of November 1, 2019 the company identified restructuring actions expected to generate additional charges of about $80 million, primarily in 2019 and 2020; further actions expected to be identified during 2019.
2019-09-28acquisition_additioncompleted2019-04-302019-04-30Laboratory Products and ServicesUSD 1,674 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired viral vector CDMO Brammer Bio for approximately $1.67 billion in cash; no headcount disclosed. 2018 revenues of acquired business were about $140 million.
2019-09-28acquisition_additioncompletedSlovakiaAnalytical InstrumentsUSD 14 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of a Slovakia-based provider of mass spectrometry software for an aggregate purchase price of $14 million during the first nine months of 2019; no headcount disclosed.
2019-09-28divestiture_reductioncompleted2019-06-282019-06-28Specialty Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sold Anatomical Pathology business to PHC Holdings for $1.13 billion net of cash divested, generating a pre-tax gain of about $482 million; no headcount transferred disclosed. Divested business had roughly $115M of 2019 revenue through the sale date.
2019-09-28acquisition_additioncompleted2019-09-302019-09-30IrelandMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired an active pharmaceutical ingredient manufacturing site in Cork, Ireland for approximately €90 million in cash on September 30, 2019 (one day after quarter end); no headcount disclosed.
2019-09-28restructuringin_progress1%United States and EuropeVariousUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in the first nine months of 2019. Cash restructuring charges were $33 million.
2019-09-28restructuringannounced2019-11-012020-12-31GlobalVariousUSD 80 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		As of November 1, 2019, the company identified restructuring actions resulting in additional charges of approximately $80 million, primarily in 2019 and 2020.
2019-09-28restructuringin_progressEmployee Severance [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-28restructuringin_progressFacility Closing [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-28restructuringin_progressOther Restructuring [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-28restructuringin_progressUSD 37,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-29restructuringin_progressUnited States and EuropeMultiple segmentsUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions tied to facility consolidations and cost reduction affected less than 1% of the workforce in the first six months of 2019; $23 million of restructuring costs incurred in 2019 per severance roll-forward.
2019-06-29restructuringannounced2019-08-022020-12-31USD 75 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 2, 2019, identified restructuring actions expected to result in approximately $75 million of additional charges, primarily in 2019 and 2020; further actions may be identified during 2019.
2019-06-29restructuringin_progressUnited States and EuropeMultiple segments and corporate; facility consolidations and cost reduction measuresUSD 23 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions tied to facility consolidations and cost reductions affected less than 1% of the workforce in the first six months of 2019; exact headcount not disclosed. Cash costs incurred in 2019 totaled $23M (severance $13M, facility abandonment $3M, other $7M); accrued restructuring balance was $39M at June 29, 2019, expected to be paid primarily through 2019.
2019-06-29restructuringannounced2019-08-02USD 75 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of August 2, 2019 (post-quarter, filing date), the company identified restructuring actions expected to generate additional charges of approximately $75M, primarily in 2019 and 2020; further actions expected to be identified during 2019. Headcount affected not disclosed.
2019-06-29acquisition_additioncompleted2019-04-302019-04-30United StatesLaboratory Products and Services (viral vector contract development and manufacturing for gene and cell therapies)USD 1,673 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Brammer Bio for approximately $1.67B in cash (purchase price net of cash acquired $1,673M); 2018 revenue of the acquired business was approximately $140M. Headcount added not disclosed. Includes $3M of employee compensation due at closing recorded in restructuring and other costs.
2019-06-29divestiture_reductioncompleted2019-06-282019-06-28Specialty Diagnostics — Anatomical Pathology businessUSD 505 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sold Anatomical Pathology business to PHC Holdings for $1.13B net of cash divested, generating a pre-tax gain of approximately $505M. Employees removed through the sale not disclosed; divested business had approximately $115M of 2019 revenue through the sale date and $238M in full-year 2018.
2019-06-29restructuringin_progress1%2019-06-29United States and EuropeMultiple segmentsUSD 23 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce in the first six months of 2019. Cash components of restructuring plans totaled $23 million incurred in 2019.
2019-06-29restructuringannounced2019-08-022020-12-31GlobalCorporate and SegmentsUSD 75 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of August 2, 2019, the company identified restructuring actions resulting in additional charges of approximately $75 million, primarily in 2019 and 2020.
2019-06-29restructuringin_progressEmployee Severance [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-29restructuringin_progressFacility Closing [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-29restructuringin_progressOther Restructuring [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-29restructuringin_progressUSD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-30restructuringin_progressUnited States and EuropeAll segments and corporateUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2019 restructuring and other costs, net of $11 million, primarily employee severance and abandoned facility costs from closure and consolidation of U.S. and Europe facilities. Severance actions affected less than 1% of the workforce. As of May 3, 2019, additional charges of approximately $65 million identified, primarily in 2019 and 2020.
2019-03-30acquisition_additionannounced2019-04-30Laboratory Products and ServicesUSD 1,700 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Brammer Bio, a viral vector CDMO for gene and cell therapies, for approximately $1.7 billion in cash; completed April 30, 2019 (subsequent event). No headcount disclosed.
2019-03-30divestiture_reductionannounced2019-01-282019-06-30Specialty Diagnostics — Anatomical Pathology businessUSD 1,140 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement to sell Anatomical Pathology business to PHC Holdings Corporation for approximately $1.14 billion; expected to close in Q2 2019. No headcount disclosed.
2019-03-30restructuringin_progressUnited States and EuropeConsolidated (facility consolidations and cost reduction measures across all segments)USD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions from facility consolidations and cost reduction measures affected less than 1% of the workforce; no absolute headcount given. $28M total comprises $6M inventory revaluation in cost of revenues, $11M third-party transaction/integration costs in SG&A, and $11M severance and abandoned-facility costs.
2019-03-30restructuringannounced2019-05-03USD 65 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of the filing date, identified restructuring actions expected to result in approximately $65M of additional charges, primarily in 2019 and 2020; further actions expected to be identified during 2019. No employee count disclosed.
2019-03-30acquisition_additioncompleted2019-04-302019-04-30Laboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Brammer Bio acquired for approximately $1.7 billion in cash; viral vector CDMO for gene and cell therapies with 2018 revenues of approximately $140 million. No headcount disclosed.
2019-03-30acquisition_additionannouncedAnalytical Instrumentsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Gatan, Inc. from Roper Technologies for approximately $925 million in cash, subject to regulatory approvals. No announcement date or headcount disclosed.
2019-03-30divestiture_reductionannounced2019-01-282019-06-30Specialty Diagnostics — Anatomical Pathology businessbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell Anatomical Pathology business to PHC Holdings Corporation for approximately $1.14 billion; expected to close in Q2 2019. Business had approximately $85M of Q1 2019 revenues and $344M in full-year 2018. No headcount disclosed.
2019-03-30restructuringin_progress1%2019-03-30United States and EuropeMultiple segments (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, Corporate)USD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce. Total restructuring and other costs were $28 million, including $11 million for severance and abandoned facilities.
2019-03-30acquisition_additioncompleted2019-04-30Laboratory Products and ServicesUSD 1,700 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquired Brammer Bio for approximately $1.7 billion in cash. Headcount not disclosed.
2019-03-30divestiture_reductionannounced2019-01-282019-06-30Specialty DiagnosticsUSD 1,140 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Agreement to sell Anatomical Pathology business for approximately $1.14 billion. Expected to close in Q2 2019. Headcount not disclosed.
2019-03-30restructuringin_progressUSD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-30restructuringin_progressEmployee Severance [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-30restructuringin_progressOther Restructuring [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progress1%2018United States and EuropeAll reportable segments (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services) and CorporateUSD 88 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance actions tied to facility consolidations and cost-reduction measures affected roughly 1% of the workforce. Net recorded cash restructuring costs of $88M; Note 15 roll-forward shows gross 2018 costs incurred of $102M (severance $51M, abandonment of excess facilities $33M, other $18M) less $14M of reserve reversals. Accrued restructuring liability of $80M at Dec 31, 2018; severance payments expected primarily through 2019 and abandoned-facility payments over lease terms through 2027.
2018-12-31restructuringannounced2019-02-27Life Sciences Solutions (~40% of charges), Laboratory Products and Services (~30%), Analytical Instruments (~25%), Specialty Diagnostics (~5%)USD 65 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Disclosed as of the February 27, 2019 filing date: additional restructuring actions identified that will result in approximately $65M of charges expected primarily in 2019, with the company expecting to identify further actions during 2019. Charges to be recognized when criteria such as communication of benefit arrangements and abandonment of leased facilities are met. No employee count disclosed for these actions.
2018-12-31restructuringin_progress1%United States and EuropeMultiple segmentsUSD 91 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2018 net restructuring and other costs of $91M, including $88M of cash restructuring costs for severance and facility consolidation; severance actions affected approximately 1% of the workforce
2018-12-31restructuringannounced2019-02-27United States and EuropeMultiple segmentsUSD 65 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Additional restructuring actions identified as of the filing date, expected to result in charges primarily in 2019; headcount not disclosed
2018-12-31acquisition_additioncompleted2018-10-252018-10-25North AmericaLife Sciences SolutionsUSD 477 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Becton Dickinson's Advanced Bioprocessing business; purchase price shown, headcount added not disclosed
2018-12-31acquisition_additioncompletedNorth AmericaLife Sciences SolutionsUSD 65 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2018 acquisition of IntegenX Inc.; purchase price shown, headcount added not disclosed
2018-12-31acquisition_additionannouncedNorth AmericaAnalytical InstrumentsUSD 925 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Gatan, Inc. for approximately $925M cash, pending customary closing conditions and regulatory approvals; headcount not disclosed
2018-12-31divestiture_reductionannounced2019-01-28GlobalSpecialty DiagnosticsUSD 1,140 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell the Anatomical Pathology business to PHC Holdings for approximately $1.14B; 2018 revenues of the business were approximately $344M; headcount not disclosed
2018-12-31restructuringcompleted1%2018-01-012018-12-31GlobalVariousUSD 88 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce. Cash restructuring costs totaled $88 million.
2018-12-31acquisition_additioncompleted2018-10-252018-10-25North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquired Becton Dickinson and Company's Advanced Bioprocessing business for $477 million. Headcount not explicitly disclosed.
2018-12-31acquisition_additioncompleted2018-01-012018-12-31North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquired IntegenX Inc. for $65 million. Headcount not explicitly disclosed.
2018-12-31restructuringin_progressUSD 102,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressEmployee Severance [Member]USD 51,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressFacility Closing [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-12-31restructuringin_progressOther Restructuring [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-29restructuringin_progress1%United States and EuropeAll segmentsUSD 89 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First nine months of 2018: severance actions tied to facility consolidations and cost reduction affected roughly 1% of workforce. Costs incurred comprised $47M severance, $29M facility abandonment, $13M other; $75M was cash restructuring cost. Accrued restructuring balance of $88M at quarter-end; severance and retention costs payable primarily through 2019, abandoned-facility payments through 2027.
2018-09-29restructuringannounced2018-11-022019-12-31USD 95 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 2, 2018, identified restructuring actions expected to result in approximately $95 million of additional charges, primarily in 2018 and 2019, recorded when criteria such as communication of benefit arrangements and lease abandonment are met.
2018-09-29acquisition_additioncompleted2018-01-01North AmericaLife Sciences SolutionsUSD 65 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired rapid DNA platform provider for forensics and law enforcement applications; headcount added not disclosed.
2018-09-29acquisition_additioncompleted2018-10-25North AmericaLife Sciences SolutionsUSD 477 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Post-quarter acquisition of BD's Advanced Bioprocessing business for $477 million cash; business had 2017 revenues of $100 million. Headcount added not disclosed.
2018-09-29acquisition_additionannounced2018-01-012018-12-31Analytical InstrumentsUSD 925 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement to acquire Gatan, a maker of electron-microscope instrumentation and software, from Roper Technologies for approximately $925 million cash; expected to close by end of 2018. Headcount not disclosed.
2018-09-29restructuringin_progress1%United States and EuropeMultiple segments; facility consolidations and cost reduction measuresUSD 89 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions in first nine months of 2018 affected approximately 1% of the workforce; $89M of 2018 costs incurred (severance $47M, facility abandonment $29M, other $13M), excluding $40M of net income items. Accrued restructuring balance was $88M at 2018-09-29.
2018-09-29restructuringannounced2018-11-02Not specifiedNot specifiedUSD 95 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of 2018-11-02 the company identified restructuring actions expected to result in additional charges of approximately $95 million, primarily in 2018 and 2019, to be recorded when specified criteria are met.
2018-09-29acquisition_additioncompleted2018-10-25North AmericaLife Sciences SolutionsUSD 477 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Becton Dickinson's Advanced Bioprocessing business completed 2018-10-25 for $477M cash; 2017 revenues of the business were $100M. No headcount disclosed.
2018-09-29acquisition_additionannounced2018-12-31Not specifiedAnalytical InstrumentsUSD 925 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Gatan, Inc. (Roper Technologies subsidiary) for approximately $925M cash, expected to close by end of 2018 subject to regulatory approvals. No headcount disclosed.
2018-09-29acquisition_additioncompletedNorth AmericaLife Sciences SolutionsUSD 65 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2018 acquisition of IntegenX Inc., a rapid DNA platform provider, for an aggregate purchase price of $65M. No headcount disclosed.
2018-09-29restructuringin_progress1%United States and EuropeVarious (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services)USD 75 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in the first nine months of 2018. Cash restructuring costs totaled $75 million.
2018-09-29restructuringannounced2018-11-022019-12-31GlobalVariousUSD 95 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of November 2, 2018, the company identified restructuring actions resulting in additional charges of approximately $95 million, primarily in 2018 and 2019.
2018-09-29restructuringin_progressUSD 89,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-29restructuringin_progressEmployee Severance [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-29restructuringin_progressFacility Closing [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-29restructuringin_progressOther Restructuring [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progress1%United States and EuropeCompany-wideUSD 57 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions tied to facility consolidations and cost reduction affected roughly 1% of workforce in first six months of 2018; $57 million of costs incurred in 2018 per accrued restructuring rollforward (severance $29M, facility abandonment $20M, other $8M). Absolute headcount not disclosed.
2018-06-30restructuringin_progressUnited StatesLife Sciences SolutionsUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Net charges principally for severance, litigation-related matters, and facility consolidations in the U.S.
2018-06-30restructuringin_progressUnited StatesAnalytical InstrumentsUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily abandoned facilities costs for remediation and closure of a U.S. manufacturing facility; includes $2M inventory revaluation charges and $1M contingent-consideration income.
2018-06-30plant_closurein_progressUnited StatesAnalytical Instrumentsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Remediation and closure of a manufacturing facility in the U.S.; headcount impact not disclosed.
2018-06-30restructuringin_progressUnited States and EuropeSpecialty DiagnosticsUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance and other costs associated with facility consolidations in the U.S. and Europe.
2018-06-30restructuringin_progressLaboratory Products and ServicesUSD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $6M inventory revaluation charges, $11M Patheon transaction/integration costs, and $13M restructuring costs primarily for employee severance and hurricane response.
2018-06-30restructuringin_progressCorporateUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily severance.
2018-06-30restructuringannounced2018-08-032019-12-31USD 100 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Identified restructuring actions expected to result in approximately $100 million of additional charges, primarily in 2018 and 2019, recorded when criteria such as communication of benefit arrangements and lease abandonment are met.
2018-06-30acquisition_additioncompletedNorth AmericaLife Sciences SolutionsUSD 65 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired rapid DNA platform provider for forensics and law enforcement applications in 2018; headcount added not disclosed.
2018-06-30acquisition_additionannounced2018-08-032018-12-31Life Sciences SolutionsUSD 925 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement to acquire Gatan, Inc. from Roper Technologies for approximately $925 million in cash; expected to close by end of 2018 subject to regulatory approvals; headcount not disclosed.
2018-06-30restructuringin_progress1%Global (facility consolidations in U.S. and Europe)Multiple segments (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, Corporate)USD 81 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six-month total of $81M spans cost of revenues ($8M), SG&A ($11M) and the restructuring line ($62M); includes $57M of cash restructuring plan costs plus $11M litigation/hurricane/non-cash items. Severance actions tied to facility consolidations and cost reduction affected about 1% of workforce; no absolute headcount given.
2018-06-30restructuringannounced2018-08-03Not specifiedNot specifiedUSD 100 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Actions identified as of the filing date, expected to result in additional charges of approximately $100M primarily in 2018 and 2019, recorded when criteria such as communication of benefit arrangements and facility abandonment are met; no employee count disclosed.
2018-06-30acquisition_additioncompletedNorth AmericaLife Sciences SolutionsUSD 65 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of IntegenX Inc., a rapid DNA platform provider for forensics and law enforcement; aggregate purchase price $65M. No headcount added disclosed.
2018-06-30acquisition_additionannounced2018-12-31Not specifiedAnalytical Instruments (electron microscopy instrumentation and software)USD 925 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Gatan, Inc. from Roper Technologies for approximately $925M in cash; expected to close by end of 2018 subject to regulatory approvals. To be funded with new debt and cash; no headcount disclosed.
2018-06-30restructuringin_progress1%2018-06-30GlobalVariousUSD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in the first six months of 2018. Q2 specific headcount not disclosed, only aggregate YTD percentage.
2018-06-30restructuringannounced2018-08-032019-12-31GlobalVariousUSD 100 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $100 million, primarily in 2018 and 2019. Includes severance and abandoned lease expense.
2018-06-30restructuringin_progressUSD 57,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressEmployee Severance [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressFacility Closing [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressOther Restructuring [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressUnited States and EuropeLife Sciences SolutionsUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2018 net charges principally for litigation-related matters and severance for employees of an acquired business at the acquisition date; no employee count disclosed.
2018-03-31restructuringin_progressUnited StatesAnalytical InstrumentsUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily abandoned facilities costs for remediation and closure of a U.S. manufacturing facility; no employee count disclosed.
2018-03-31restructuringin_progressUnited States and EuropeSpecialty DiagnosticsUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance and other costs associated with facility consolidations; no employee count disclosed.
2018-03-31restructuringin_progressLaboratory Products and ServicesUSD 20 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $3M cost-of-revenues charges for sale of acquired-inventory revaluation, $7M SG&A Patheon transaction/integration costs, and $10M restructuring costs primarily for employee severance and hurricane response.
2018-03-31restructuringin_progressCorporateUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily severance.
2018-03-31restructuringannounced2018-05-042019-12-31USD 105 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 4, 2018, company identified restructuring actions expected to result in approximately $105 million of additional charges, primarily in 2018 and 2019; charges recorded when criteria such as communication of benefit arrangements and abandonment of leased facilities are met. Q1 severance actions affected less than 1% of the workforce, but total workforce size is not disclosed in this filing.
2018-03-31restructuringin_progressUnited States and EuropeMultiple segments including Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, and CorporateUSD 56 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2018 charges of $56M total: $3M cost of revenues (inventory revaluation), $8M SG&A (Patheon integration), $45M restructuring line. Severance actions affected less than 1% of workforce. Includes facility consolidations in U.S. and Europe, Patheon transaction/integration costs, and $10M other charges (litigation, hurricane response).
2018-03-31restructuringannounced2018-05-04Not specifiedNot specifiedUSD 105 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 4, 2018, identified restructuring actions expected to result in approximately $105M additional charges primarily in 2018 and 2019, recorded when criteria met (communication of benefit arrangements, facility abandonment).
2018-03-31acquisition_additioncompletedNorth AmericaLife Sciences SolutionsUSD 65 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2018 acquisition of IntegenX Inc., a rapid DNA platform provider for forensics and law enforcement, for aggregate purchase price of $65M. Headcount added not disclosed.
2018-03-31restructuringin_progress1%2018-03-31United States and EuropeCompany-wideUSD 35 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Severance and abandoned facilities costs associated with closure and consolidation of facilities. Affected less than 1% of workforce.
2018-03-31restructuringannounced2018-05-042019-12-31GlobalCompany-wideUSD 105 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Identified restructuring actions resulting in additional charges primarily in 2018 and 2019.
2018-03-31restructuringin_progressUSD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressEmployee Severance [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressFacility Closing [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressOther Restructuring [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringcompleted2017United States, Europe, AsiaAll reportable segments and CorporateUSD 62 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance costs incurred during 2017 for facility consolidations, cost-reduction measures and acquisition synergies; filing states these severance actions affected less than 2% of the workforce (exact headcount not disclosed, implied roughly under 1,400 of ~70,000). Segment detail: ~$23M severance in Life Sciences Solutions primarily for synergies; severance in Analytical Instruments for synergies; severance in Specialty Diagnostics for U.S./Europe headcount reductions; $41M in Laboratory Products and Services primarily severance plus Patheon acquisition-date compensation. $30M severance accrued at year-end payable primarily through 2018.
2017-12-31plant_closurecompleted2017United States, Europe, AsiaUSD 27 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Abandonment-of-excess-facilities charges incurred in 2017 from closure and consolidation of facilities; $19M paid in 2017 and $40M accrued at year-end payable over lease terms expiring through 2027. Headcount impact not separately quantified.
2017-12-31restructuringannounced2018-02-28Charge allocation: approx. 35% Life Sciences Solutions, 25% Analytical Instruments, 30% Laboratory Products and Services, 10% Specialty DiagnosticsUSD 105 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Subsequent-event disclosure: as of February 28, 2018 the company had identified restructuring actions expected to result in approximately $105 million of additional charges, primarily in 2018, with further actions to be identified during 2018. Headcount impact not disclosed.
2017-12-31acquisition_additioncompleted2017-08-292017-08-29Laboratory Products and ServicesUSD 7 (billions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Patheon N.V., a pharmaceutical contract development and manufacturing organization, for $7.36 billion including assumed net debt ($35.00 per share cash); $3.26 billion allocated to goodwill. Employee headcount added not disclosed. Acquisition-date compensation due to Patheon employees was recorded within LP&S restructuring costs per Note 14. Note: associated_charge fields carry the purchase price, not a severance charge.
2017-12-31acquisition_additioncompleted2017-02-142017-02-14Life Sciences SolutionsUSD 221 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Finesse Solutions, Inc. (scalable control automation systems and software for bioproduction) for $221 million net of cash. Employee headcount added not disclosed. Associated_charge fields carry purchase price.
2017-12-31acquisition_additioncompleted2017-03-022017-03-02Analytical InstrumentsUSD 94 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Core Informatics (cloud-based platforms supporting scientific data management) for $94 million net of cash. Employee headcount added not disclosed. Associated_charge fields carry purchase price.
2017-12-31acquisition_additioncompleted2017Specialty Diagnostics; Analytical InstrumentsUSD 110 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Aggregate $110 million for three small 2017 acquisitions: a North America-based molecular diagnostics company offering qPCR transplant tests (Specialty Diagnostics), and within Analytical Instruments a provider of desktop scanning electron microscopy solutions and a manufacturer of volatile organic compound monitoring instruments and integrated systems. Employee headcount added not disclosed. Associated_charge fields carry aggregate purchase price.
2017-12-31restructuringin_progress2%United States, Europe and AsiaCompany-wideUSD 298 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2017 pre-tax restructuring and other costs, net; severance actions disclosed as affecting less than 2% of workforce; includes $97M cash restructuring costs plus acquisition-related and other charges
2017-12-31restructuringannounced2018-02-28United States and EuropeLife Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and ServicesUSD 105 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Additional charges identified as of 2018-02-28, primarily expected in 2018; split approximately 35% Life Sciences Solutions, 25% Analytical Instruments, 30% Laboratory Products and Services, 10% Specialty Diagnostics; no employee count disclosed
2017-12-31acquisition_additioncompleted2017-08-292017-08-29GlobalLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Patheon N.V. acquired for $7.36 billion including assumed net debt; acquired headcount not disclosed
2017-12-31acquisition_additioncompleted2017-02-142017-02-14North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Finesse Solutions, Inc. acquired for $221 million net of cash; acquired headcount not disclosed
2017-12-31acquisition_additioncompleted2017-03-022017-03-02North AmericaAnalytical Instrumentsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Core Informatics acquired for $94 million net of cash; acquired headcount not disclosed
2017-12-31restructuringcompleted2%2017-01-012017-12-31GlobalVariousUSD 97 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 2% of the company's workforce. Cash restructuring costs totaled $97 million.
2017-12-31acquisition_additioncompleted2017-08-292017-08-29GlobalLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Patheon N.V. added headcount to the Laboratory Products and Services segment. Specific employee count not disclosed.
2017-12-31acquisition_additioncompleted2017-02-142017-02-14North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Finesse Solutions, Inc. added headcount to the Life Sciences Solutions segment. Specific employee count not disclosed.
2017-12-31acquisition_additioncompleted2017-03-022017-03-02North AmericaAnalytical Instrumentsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Core Informatics added headcount to the Analytical Instruments segment. Specific employee count not disclosed.
2017-12-31restructuringin_progressUSD 106,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressFacility Closing [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressOther Restructuring [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-12-31restructuringin_progressLife Sciences Solutions [Member]USD 48,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progress1%U.S., Europe and AsiaAll segmentsUSD 74 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First nine months of 2017: severance actions tied to facility consolidations and cost reductions affected roughly 1% of the workforce. Severance costs incurred of $49.3 million, abandonment of excess facilities $15.8 million, other $9.3 million; accrued restructuring balance of $68.6 million at September 30, 2017. As of November 3, 2017, additional charges of approximately $85 million identified, primarily to be recorded in 2017 and 2018.
2017-09-30acquisition_additioncompleted2017-08-282017-08-28GlobalLaboratory Products and ServicesUSD 7,358 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Patheon N.V. for $7.36 billion including assumption of net debt; no employee headcount added through the acquisition was disclosed. Restructuring charges related to synergy planning and employee severance/compensation due at Patheon on the acquisition date were recorded in the Laboratory Products and Services segment.
2017-09-30restructuringin_progress1%United States, Europe and AsiaCompany-wide; facility consolidations and cost reduction measures across all four segmentsUSD 49 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states severance actions in the first nine months of 2017 affected approximately 1% of the workforce; no absolute headcount given. Charge shown is cash severance costs incurred in 2017 (excludes $30M of other charges). Cash payments for severance/retention expected primarily through 2017; abandoned-facility payments run through lease terms expiring by 2027.
2017-09-30restructuringannounced2017-11-03Not specifiedNot specifiedUSD 85 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of November 3, 2017 the company identified restructuring actions expected to result in additional charges of approximately $85 million, primarily in 2017 and 2018, to be recorded when criteria such as communication of benefit arrangements and facility abandonment are met. Incremental to the ongoing program above; also referenced in MD&A.
2017-09-30acquisition_additioncompleted2017-08-282017-08-28GlobalLaboratory Products and Services (contract development and manufacturing organization services)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Patheon N.V. for $7.36 billion including assumed net debt; headcount added not disclosed. Related workforce items noted: unvested Patheon equity awards converted into 0.2M company RSUs and options over 0.3M shares; $21M of severance and compensation due at Patheon at acquisition date recorded within Laboratory Products and Services restructuring costs.
2017-09-30restructuringin_progress1%2017-09-30GlobalVariousUSD 95 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in the first nine months of 2017.
2017-09-30restructuringannounced2017-11-032018-12-31GlobalVariousUSD 85 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of November 3, 2017, the company identified restructuring actions resulting in additional charges of approximately $85 million, primarily in 2017 and 2018.
2017-09-30restructuringin_progressUSD 74,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressEmployee Severance [Member]USD 49,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressFacility Closing [Member]USD 15,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30restructuringin_progressOther Restructuring [Member]USD 9,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-01restructuringin_progress1%United States, Europe and AsiaCompany-wide (facility consolidations and cost reduction measures)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions associated with facility consolidations and cost reduction measures during the first six months of 2017 affected approximately 1% of the company's workforce; no absolute headcount disclosed.
2017-07-01restructuringannounced2017-08-042018-12-31USD 80 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 4, 2017, identified restructuring actions expected to result in additional charges of approximately $80 million, primarily in 2017 and 2018, recorded when criteria such as communication of benefit arrangements and abandonment of leased facilities are met.
2017-07-01restructuringin_progress1%United States, Europe and AsiaCompany-wide (multiple segments and corporate)USD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		No specific announcement date or completion date disclosed; actions occurred during the six months ended July 1, 2017. Charge shown is cash severance costs incurred in 2017 per the restructuring roll-forward (excludes $7M of other charges, net). Filer states severance and retention obligations are expected to be paid primarily through 2017, with abandoned-facility payments over lease terms expiring through 2027. Total headcount not disclosed, so absolute affected count cannot be derived.
2017-07-01restructuringannounced2017-08-04Company-wideUSD 80 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter disclosure: additional restructuring actions identified as of August 4, 2017, expected to result in charges of approximately $80 million, primarily in 2017 and 2018, recorded when specified criteria are met (e.g., communication of benefit arrangements, abandonment of leased facilities). Filer expects to identify further actions during 2017. No employee counts or geography breakdown disclosed.
2017-07-01acquisition_additionannounced2017-05-152017-12-31GlobalLaboratory Products and Servicesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition announced May 2017 (purchase agreement dated May 15, 2017); approximately $5.2 billion equity value plus assumption of about $2.0 billion net debt, expected to close by end of 2017 subject to regulatory approvals. No headcount for Patheon disclosed in this filing; Patheon revenues were approximately $1.9 billion for the year ended October 31, 2016.
2017-07-01restructuringin_progress1%2017-07-01GlobalVariousUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in the first six months of 2017. Total restructuring and other costs were $46.0 million YTD, including $31.6 million in cost of revenues and $38.3 million in SG&A.
2017-07-01restructuringannounced2017-08-042018-12-31GlobalVariousUSD 80 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of August 4, 2017, the company identified restructuring actions resulting in additional charges of approximately $80 million, primarily in 2017 and 2018.
2017-07-01restructuringin_progressUSD 43,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-01restructuringin_progressEmployee Severance [Member]USD 28,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-01restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-01restructuringin_progressFacility Closing [Member]USD 9,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-01restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-07-01restructuringin_progressOther Restructuring [Member]USD 5,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-01restructuringin_progressU.S., Europe and AsiaCompany-wide (facility consolidations and headcount reductions)USD 21 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2017 severance costs incurred of $14.9M plus abandonment of excess facilities $4.8M and other $1.6M; severance actions affected less than 1% of workforce. Accrued severance balance $29.1M at 2017-04-01; payments of $21.1M made in the quarter.
2017-04-01restructuringannounced2017-05-052018-12-31USD 95 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 5, 2017, company identified restructuring actions expected to result in approximately $95 million of additional charges, primarily in 2017 and 2018, recorded when criteria such as communication of benefit arrangements and lease abandonment are met.
2017-04-01acquisition_additioncompleted2017-02-14North AmericaLife Sciences SolutionsUSD 220 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Finesse Solutions, developer of control automation systems for bioproduction, for $220 million net of cash; no employee headcount disclosed.
2017-04-01acquisition_additioncompleted2017-03-02North AmericaAnalytical InstrumentsUSD 94 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Core Informatics, cloud-based scientific data management provider, for $94 million net of cash; no employee headcount disclosed.
2017-04-01restructuringin_progressUnited States, Europe and AsiaMultiple segments; facility consolidations and cost reduction measuresUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states severance actions in Q1 2017 affected less than 1% of the workforce; no absolute headcount given. Charge shown is severance costs incurred in 2017 per the cash restructuring roll-forward (excludes $5M net litigation-related charges). Total restructuring and other costs, net, recorded in Q1 2017 were $85.9M across all components.
2017-04-01restructuringannounced2017-05-05Not specifiedNot specifiedUSD 95 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of the May 5, 2017 filing date, the company identified restructuring actions expected to result in additional charges of approximately $95 million, primarily in 2017 and 2018, to be recorded when specified criteria are met (e.g., communication of benefit arrangements, abandonment of leased facilities). No employee counts disclosed.
2017-04-01acquisition_additioncompleted2017-02-14North AmericaLife Sciences SolutionsUSD 220 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of bioproduction control automation developer for $220M net of cash acquired; target 2016 revenues approximately $50M. Headcount added not disclosed; charge shown is total purchase price, not a workforce charge.
2017-04-01acquisition_additioncompleted2017-03-02North AmericaAnalytical InstrumentsUSD 94 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of cloud-based scientific data management platform provider for $94M net of cash acquired; target 2016 revenues approximately $10M. Headcount added not disclosed; charge shown is total purchase price, not a workforce charge.
2017-04-01restructuringin_progress1%2017-01-01U.S., Europe, AsiaVariousUSD 24 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce in the first three months of 2017.
2017-04-01restructuringannounced2017-05-052018-12-31GlobalVariousUSD 95 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $95 million, primarily in 2017 and 2018.
2017-04-01restructuringin_progressUSD 21,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-01restructuringin_progressEmployee Severance [Member]USD 14,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-01restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-01restructuringin_progressFacility Closing [Member]USD 4,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-01restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-04-01restructuringin_progressOther Restructuring [Member]USD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringin_progress3%2017-12-31United States, Europe and AsiaAll segmentsUSD 109 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2016 severance costs incurred per the restructuring reserve roll-forward; $83.2M of severance was paid during 2016, leaving $38.2M accrued at year-end. Company-wide, severance actions were disclosed as affecting less than 3% of the ~55,000-person workforce. Segment components included $60.2M in Life Sciences Solutions (primarily Affymetrix/FEI synergies) and severance for former FEI executives in Analytical Instruments, with the remainder across Specialty Diagnostics, Laboratory Products and Services and Corporate. The 2016 restructuring projects were expected to generate roughly $100M of annual cost savings ($60M LSS, $25M AI, $5M SD, $10M LPS). Severance payments expected primarily through 2017; no charges recorded yet for additional actions identified as of the filing date. MD&A separately cites $164M of total 2016 cash restructuring costs (severance, abandoned facilities and other).
2016-12-31plant_closurein_progress2027-12-31United States, Europe and AsiaAll segmentsUSD 46 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2016 costs incurred for abandonment of excess facilities from site closures and consolidations, including remediation and closure of a U.S. manufacturing facility (Analytical Instruments, FEI-related) and $17.9M of abandoned-facility costs in Life Sciences Solutions; headcount impact not quantified. Payments of $26.6M were made during 2016; $31.9M remained accrued at year-end. Abandoned-facility payments expected over lease terms expiring through 2027.
2016-12-31restructuringannounced2017-02-282017-12-31Life Sciences Solutions (~45% of charges), Analytical Instruments (~35% of charges), remainder across remaining segmentsUSD 85 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		As of February 28, 2017, the company had identified restructuring actions expected to result in approximately $85M of additional charges, primarily in 2017, to be recorded when specified criteria are met (e.g., communication of benefit arrangements, abandonment of leased facilities); additional actions expected to be identified during 2017. No employee count disclosed. Disclosed after fiscal year-end; disclosed in the restructuring footnote rather than the Note 16 subsequent-events note.
2016-12-31restructuringin_progressUnited States, Europe and AsiaConsolidated (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, Corporate)USD 395 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2016 net restructuring and other costs of $394.6M (MD&A rounds to $395M pre-tax), of which $166.9M was cash costs including $109.1M severance, $45.9M facility abandonment and $11.9M other. Severance actions from facility consolidations and cost reduction affected less than 3% of the workforce (no absolute count given). Cash payments for restructuring were $122.0M in 2016; accrued restructuring balance at year-end was $72.3M. Severance actions affected less than 3% of the company's workforce.
2016-12-31acquisition_additioncompleted2016-03-312016-03-31North AmericaLife Sciences SolutionsUSD 1,342 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price of $1.34B net of cash acquired; acquired headcount not disclosed. Affymetrix contributed $251M of revenue post-acquisition in 2016.
2016-12-31acquisition_additioncompleted2016-09-192016-09-19North AmericaAnalytical InstrumentsUSD 4,082 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price of $4.08B net of cash acquired; acquired headcount not disclosed. FEI contributed $385M of revenue post-acquisition in 2016 and created a new reporting unit (Materials and Structural Analysis).
2016-12-31restructuringannounced2017-02-28Primarily Life Sciences Solutions and Analytical Instruments segmentsLife Sciences Solutions (~45%), Analytical Instruments (~35%), remainder across other segmentsUSD 85 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring actions identified as of the filing date that will result in additional charges of approximately $85M, primarily in 2017, to be recorded when criteria such as communication of benefit arrangements and facility abandonment are met. Additional actions expected to be identified during 2017. No employee count disclosed.
2016-12-31acquisition_additionannounced2017-02-012017-02-28North AmericaLife Sciences SolutionsUSD 225 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Completed in February 2017 (after fiscal year-end, before filing); approximately $225M cash; Finesse revenues were approximately $50M in 2016. Acquired headcount not disclosed; purchase price allocation not yet available.
2016-12-31restructuringcompleted3%2016-01-012016-12-31GlobalAll segmentsUSD 164 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 3% of the company's workforce. Cash restructuring costs were $164 million.
2016-12-31acquisition_additioncompleted2016-09-192016-09-19North AmericaAnalytical Instrumentsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of FEI Company. Headcount not explicitly disclosed.
2016-12-31acquisition_additioncompleted2016-03-312016-03-31North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Affymetrix, Inc. Headcount not explicitly disclosed.
2016-12-31restructuringin_progressUSD 166,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member]USD 109,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 60,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressFacility Closing [Member]USD 45,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 17,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressOther Restructuring [Member]USD 11,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressAnalytical Instruments [Member]USD 67,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressLaboratory Products and Services [Member]USD 10,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressLife Sciences Solutions [Member]USD 78,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressSpecialty Diagnostics [Member]USD 6,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-12-31restructuringin_progressCorporate Segment [Member]USD 1,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-10-01restructuringin_progress2%United States, Europe and AsiaCompany-wideUSD 85 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First nine months of 2016: severance actions tied to facility consolidations and cost-reduction measures affected roughly 2% of the workforce; total costs incurred in 2016 were $136.8 million across severance, facility abandonment and other categories.
2016-10-01restructuringin_progressUnited StatesAnalytical InstrumentsUSD 31 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Third-quarter 2016 cash restructuring costs primarily for severance obligations payable to former FEI executives; part of $91.6 million total segment charges.
2016-10-01restructuringin_progressEuropeSpecialty DiagnosticsUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2016 net charges including $10.0 million for litigation-related matters, remainder principally severance for headcount reductions in Europe.
2016-10-01restructuringin_progressUnited StatesLaboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2016 cash restructuring costs for employee severance and facility consolidations in the U.S., partially offset by $0.7 million of litigation-related gains.
2016-10-01restructuringannounced2016-11-042017-12-31USD 70 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 4, 2016, identified restructuring actions expected to result in approximately $70 million of additional charges, primarily in 2016 and 2017, recorded when criteria such as communication of benefit arrangements and lease abandonment are met.
2016-10-01acquisition_additioncompleted2016-09-19North AmericaAnalytical InstrumentsUSD 4,080 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired FEI Company for $4.08 billion net of cash; no employee headcount added was disclosed.
2016-10-01acquisition_additioncompleted2016-03-31North AmericaLife Sciences SolutionsUSD 1,340 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Affymetrix for $1.34 billion net of cash including $254 million assumed debt; no employee headcount added was disclosed.
2016-10-01restructuringin_progress2%United States, Europe and AsiaMultiple segments and corporateUSD 141 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions tied to facility consolidations and cost-reduction measures affected about 2% of workforce over 9M 2016; cash restructuring costs incurred of $136.8M (severance $84.9M, facility abandonment $43.4M, other $8.5M). Severance/retention obligations primarily payable through 2016; abandoned-facility payments run over lease terms expiring through 2027. Total restructuring and other costs, net of $296.5M recorded in 9M 2016 across cost of revenues, SG&A and restructuring lines.
2016-10-01restructuringannounced2016-11-04United States, Europe and AsiaMultiple segments and corporateUSD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter disclosure: additional restructuring actions identified as of Nov 4, 2016, expected to result in roughly $70M of further charges primarily in 2016 and 2017, recorded once criteria such as benefit-communication and lease abandonment are met. No employee count disclosed.
2016-10-01acquisition_additioncompleted2016-09-19North AmericaAnalytical Instrumentsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FEI Company acquired for $4.08B net of cash; 2015 revenues $930M; $2.06B allocated to goodwill. Headcount added not disclosed. Post-acquisition severance obligations to former FEI executives drove $58.1M of cash restructuring costs in Analytical Instruments for 9M 2016.
2016-10-01acquisition_additioncompleted2016-03-31North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Affymetrix, Inc. acquired for $1.34B net of cash including $254M assumed debt; 2015 revenues $360M; $702M allocated to goodwill. Headcount added not disclosed.
2016-10-01restructuringin_progress2%2016-10-01U.S., Europe, AsiaCompany-wideUSD 141 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company's workforce in the first nine months of 2016. Includes headcount reductions and facility consolidations in U.S., Europe, and Asia.
2016-10-01restructuringannounced2016-11-042017-12-31GlobalCompany-wideUSD 70 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of November 4, 2016, the company identified restructuring actions resulting in additional charges of approximately $70 million, primarily in 2016 and 2017.
2016-10-01restructuringin_progressAnalytical Instruments [Member]USD 30,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressLaboratory Products and Services [Member]USD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressCorporate Segment [Member]USD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressUSD 136,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressEmployee Severance [Member]USD 84,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 44,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressFacility Closing [Member]USD 43,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 17,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressOther Restructuring [Member]USD 8,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressLife Sciences Solutions [Member]USD 62,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-10-01restructuringin_progressSpecialty Diagnostics [Member]USD 3,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progress1%United States, Europe and AsiaCompany-wide (facility consolidations and cost reduction measures)USD 92 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First six months of 2016: severance actions tied to facility consolidations and cost reductions affected roughly 1% of the workforce. Costs incurred of $91.5 million comprise severance $47.9M, abandonment of excess facilities $36.8M and other $6.8M; excludes $4.5M of net income items. Restructuring accrual balance of $78.9M at 2016-07-02.
2016-07-02restructuringannounced2016-08-052016-12-31USD 40 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 5, 2016, additional restructuring actions identified expected to result in charges of approximately $40 million, primarily in 2016, recorded when criteria such as communication of benefit arrangements and lease abandonment are met.
2016-07-02acquisition_additioncompleted2016-03-312016-03-31North AmericaLife Sciences SolutionsUSD 1,342 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Affymetrix, Inc. completed March 31, 2016 for total purchase price of $1.34 billion net of cash acquired; no employee headcount added was disclosed.
2016-07-02restructuringin_progress1%United States, Europe and AsiaMultiple segments and corporateUSD 86 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six-month program: severance actions at facility consolidations and cost-reduction measures affected approximately 1% of workforce (no absolute count given). Income-statement charge $86.0M; total across captions $146.7M (cost of revenues $28.0M, SG&A $32.7M). Cash severance costs incurred $47.9M; facility abandonment $36.8M. Segment charges: Life Sciences Solutions $93.7M, Analytical Instruments $26.3M, Specialty Diagnostics $(0.1)M, Laboratory Products and Services $22.3M, Corporate $4.5M. Includes closure/consolidation of several U.S., Europe and Asia facilities and closure costs for a U.S. manufacturing facility. Severance accrual rose from $31.3M to $78.9M; severance payments expected primarily through 2016, abandoned-facility payments through 2027.
2016-07-02restructuringannounced2016-08-05United States, Europe and AsiaMultiple segments and corporateUSD 40 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter disclosure: additional restructuring actions identified as of August 5, 2016, expected primarily in 2016; charges recorded when criteria such as employee communication and lease abandonment are met. No employee count disclosed.
2016-07-02acquisition_additioncompleted2016-03-31North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Affymetrix, Inc. acquired for $1.34B net of cash (2015 revenues $360M); $702M allocated to goodwill. No headcount added disclosed.
2016-07-02acquisition_additionannounced2016-052016-12-31North AmericaAnalytical Instrumentsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		FEI Company agreement signed in May 2016 for approximately $4.2B cash (2015 revenues $930M); expected to close by end of 2016, subject to FEI shareholder and regulatory approval. No headcount added disclosed; $2.0B bridge and $2.0B term loan committed.
2016-07-02restructuringin_progress1%2016-07-02Global (U.S., Europe, Asia)Various (Life Sciences Solutions, Analytical Instruments, Laboratory Products and Services, Corporate)USD 86 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company's workforce in the first six months of 2016. Includes headcount reductions, facility consolidations, and acquisition synergies.
2016-07-02restructuringannounced2016-08-05GlobalVariousUSD 40 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of August 5, 2016, the company identified restructuring actions resulting in additional charges of approximately $40 million, primarily in 2016. Includes severance and abandoned facility costs.
2016-07-02restructuringin_progressEmployee Severance [Member] / Corporate Segment [Member]USD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressAnalytical Instruments [Member]USD 5,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressLaboratory Products and Services [Member]USD 5,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressLife Sciences Solutions [Member]USD 10,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressSpecialty Diagnostics [Member]USD 1,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressUSD 91,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressEmployee Severance [Member]USD 47,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 34,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressFacility Closing [Member]USD 36,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 17,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-07-02restructuringin_progressOther Restructuring [Member]USD 6,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressU.S., Europe and AsiaLife Sciences SolutionsUSD 60 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $4.4M cost of revenues charges to conform Affymetrix accounting policies, $26.5M SG&A charges (incl. $23.6M Affymetrix transaction costs), and $28.8M restructuring costs net of litigation settlement gains; cash costs included $24.7M severance and $16.7M abandoned facility costs.
2016-04-02restructuringin_progressUnited StatesAnalytical InstrumentsUSD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $21.8M cash costs primarily for abandoned facilities, including remediation and closure of a U.S. manufacturing facility, partially offset by $2.7M gains on real estate sales.
2016-04-02restructuringin_progressSpecialty DiagnosticsUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cash costs of $1.1M for severance and headcount reductions/facility consolidations, substantially offset by non-cash gains.
2016-04-02restructuringin_progressLaboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $6.2M cost of revenues for inventories revalued at acquisition date, $2.8M cash restructuring costs primarily for employee severance, and $1.3M litigation settlement gain.
2016-04-02restructuringin_progressCorporateUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $2.0M SG&A charges for accelerated depreciation on information systems abandoned due to acquisition synergies and $0.3M severance at corporate operations.
2016-04-02restructuringannounced2016-05-062016-12-31USD 45 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 6, 2016, identified restructuring actions expected to result in approximately $45 million of additional charges, primarily in 2016, recorded when criteria such as lease abandonment are met.
2016-04-02acquisition_additioncompleted2016-03-312016-03-31North AmericaLife Sciences SolutionsUSD 1,342 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Affymetrix, Inc. for $1.34 billion net of cash acquired including $254 million assumed debt; no employee headcount added disclosed.
2016-04-02restructuringin_progressUnited States, Europe, AsiaMultiple segments including Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, CorporateUSD 90 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2016 net restructuring and other costs of $90.1M across segments. Severance actions affected less than 1% of workforce; no absolute headcount disclosed. Includes $67.8M cash costs (severance $29.7M, facility abandonment $35.1M, other $3.0M) offset by $16.8M income net. Accrued restructuring balance rose from $31.3M to $77.2M.
2016-04-02restructuringannounced2016-05-06Not specifiedNot specifiedUSD 45 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 6, 2016, company identified restructuring actions expected to result in additional charges of approximately $45M, primarily in 2016, to be recorded when specified criteria are met such as abandonment of leased facilities. No employee count disclosed.
2016-04-02acquisition_additioncompleted2016-03-312016-03-31North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Affymetrix, Inc. for $1.34B net of cash acquired, including $254M assumed debt. Affymetrix 2015 revenues were $360M. No headcount added disclosed.
2016-04-02acquisition_additioncompleted2016-01-012016-04-02Not specifiedAnalytical Instruments; Life Sciences SolutionsUSD 5 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		During 2016, acquired a provider of X-ray diffraction solutions (Analytical Instruments) and selected assets of a channel partner (Life Sciences Solutions) for aggregate purchase price of $5M. No headcount disclosed.
2016-04-02restructuringin_progress1%2016-01-03GlobalVariousUSD 90 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company's workforce. Charges include severance, abandoned facilities, and acquisition synergies.
2016-04-02restructuringannounced2016-05-06GlobalVariousUSD 45 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $45 million, primarily in 2016, to be recorded when specified criteria are met.
2016-04-02restructuringin_progressUSD 67,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressEmployee Severance [Member]USD 29,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 24,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressEmployee Severance [Member] / Corporate Segment [Member]USD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressFacility Closing [Member]USD 35,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 16,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressOther Restructuring [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressAnalytical Instruments [Member]USD 21,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressLaboratory Products and Services [Member]USD 2,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressLife Sciences Solutions [Member]USD 41,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-04-02restructuringin_progressSpecialty Diagnostics [Member]USD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringcompleted2%2016-12-31United States, Europe, and Asia (several facilities)All segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, CorporateUSD 91 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2015 severance actions tied to facility consolidations and cost-reduction measures affected approximately 2% of the workforce (no absolute employee count disclosed). Cash restructuring costs incurred in 2015 totaled $90.7 million per the restructuring rollforward (severance $57.0 million; abandonment of excess facilities $19.1 million; other $14.6 million). Total restructuring and other costs, net, across segments: Life Sciences Solutions $80.0M, Analytical Instruments $26.4M, Specialty Diagnostics $10.1M, Laboratory Products and Services $24.9M, Corporate $29.3M (aggregate $170.7M, including non-workforce items such as litigation and acquisition costs). Actions expected to generate ~$100M annual cost savings ($50M LSS, $25M AI, $10M SD, $15M LPS). Severance/retention payments expected primarily through 2016; abandoned-facility payments extend over lease terms through 2020. Actions occurred throughout 2015; no single announcement date disclosed.
2015-12-31acquisition_additioncompleted2015-02-042015-02-04North America (U.S.-based global provider)Life Sciences SolutionsUSD 289 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Advanced Scientifics, Inc., provider of single-use technologies for customized bioprocessing solutions; purchase price approximately $289 million (charge field reflects purchase price, not a workforce charge). Date given is the completion date per MD&A; employee headcount acquired was not disclosed. 2014 revenues approximately $80 million.
2015-12-31acquisition_additioncompleted2015-09-302015-09-30United Kingdom (global manufacturer of research chemicals)Laboratory Products and ServicesUSD 392 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Alfa Aesar from Johnson Matthey Plc for £257 million ($392 million) in cash (charge field reflects purchase price, not a workforce charge). Date given is the completion date; employee headcount acquired was not disclosed. 2014 revenues approximately £78 million.
2015-12-31restructuringannounced2016-02-25Approximately 70% of charges in Life Sciences Solutions; remainder across other segmentsUSD 55 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Subsequent-event disclosure: as of February 25, 2016 the company had identified restructuring actions expected to result in approximately $55 million of additional charges in 2016, to be recorded when specified criteria are met (e.g., abandonment of leased facilities). Company also expects to identify additional actions during 2016. No employee count disclosed.
2015-12-31restructuringin_progress2%United States, Europe and AsiaCompany-wide facility consolidations and headcount reductions across all four segments plus CorporateUSD 171 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2015 activity only; severance actions affected approximately 2% of the workforce (percent as disclosed, headcount not disclosed). Total pre-tax restructuring and other costs of $171M per MD&A, of which $90.7M was cash restructuring cost incurred in 2015 (severance $57.0M, facility abandonment $19.1M, other $14.6M) and $96.6M was paid in cash during 2015. Actions expected to yield about $100M of annual cost savings, largely from 2016.
2015-12-31restructuringannounced2016-02-25Not specifiedApproximately 70% in Life Sciences Solutions; remainder across other segmentsUSD 55 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-year-end identification of additional restructuring actions; charges primarily expected in 2016 and to be recorded when criteria are met (e.g., lease abandonment). Additional actions expected to be identified during 2016.
2015-12-31acquisition_additioncompleted2015-09-302015-09-30United KingdomLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired from Johnson Matthey Plc for £257M ($392M) cash; acquired headcount not disclosed.
2015-12-31acquisition_additioncompleted2015-02-042015-02-04North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Single-use bioprocess technologies provider acquired for approximately $289M; acquired headcount not disclosed.
2015-12-31acquisition_additioncompletedNot specifiedAnalytical Instruments and Specialty Diagnostics (channel partner tuck-ins)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Selected assets of chromatography/mass spectrometry channel partners and a transplant diagnostics channel partner acquired for an aggregate $19M; headcount not disclosed.
2015-12-31divestiture_reductioncompletedNot specifiedNot specified (small product line)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2015 sale of a small product line generated a $7.6M gain; associated workforce reduction not quantified.
2015-12-31acquisition_additionannounced2016-012016-06-30North AmericaLife Sciences Solutionssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement signed January 2016 to acquire Affymetrix for approximately $1.3B cash (Affymetrix 2015 revenues $360M); expected to close by end of Q2 2016, subject to shareholder and regulatory approvals; debt to be issued to partially fund. Acquired headcount not disclosed.
2015-12-31restructuringcompleted2%2015-01-012015-12-31GlobalVarious segmentsUSD 171 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company's workforce. Total pre-tax charges for restructuring and other costs were $171 million.
2015-12-31acquisition_additioncompleted2015-02-042015-02-04North AmericaLife Sciences SolutionsMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquired Advanced Scientifics, Inc. for approximately $289 million. Headcount not explicitly disclosed.
2015-12-31acquisition_additioncompleted2015-09-302015-09-30United KingdomLaboratory Products and ServicesMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquired Alfa Aesar from Johnson Matthey Plc for £257 million ($392 million). Headcount not explicitly disclosed.
2015-12-31restructuringin_progressUSD 90,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressCash Costs For Severance And Abandoned Facilities [Member] / Life Sciences Solutions [Member]USD 34,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressCharges For Cash Compensation Contractually Due To Employees Of Acquired Business [Member] / Life Sciences Solutions [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressTransaction Costs Related to Divestiture [Member] / Life Sciences Solutions [Member]USD 900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member]USD 57,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member] / Life Sciences Solutions [Member]USD 23,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member] / Corporate Segment [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressFacility Closing [Member]USD 19,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressFacility Closing [Member] / Life Sciences Solutions [Member]USD 4,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressOther Restructuring [Member]USD 14,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressOther Restructuring [Member] / Life Sciences Solutions [Member]USD 6,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressAnalytical Instruments [Member]USD 22,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressLaboratory Products and Services [Member]USD 7,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-12-31restructuringin_progressLife Sciences Solutions [Member]USD 40,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-26restructuringin_progress2%United States, Europe and AsiaCompany-wideUSD 53 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions tied to facility consolidations and cost-reduction measures affected approximately 2% of the workforce in the first nine months of 2015; 2015 restructuring plans incurred $36.0M severance, $11.9M abandonment of excess facilities, and $4.6M other costs.
2015-09-26restructuringin_progressUnited States and EuropeLife Sciences SolutionsUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2015 net charges include accelerated depreciation from facility closures, headcount reductions, and contingent-consideration income offset.
2015-09-26plant_closurein_progressUnited StatesAnalytical InstrumentsUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2015 charges primarily for remediation and closure of a U.S. manufacturing facility, plus employee severance and other headcount-reduction costs.
2015-09-26restructuringin_progressUnited States and EuropeSpecialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2015 net charges primarily cash costs for headcount reductions and facility consolidation.
2015-09-26restructuringin_progressLaboratory Products and ServicesUSD 6 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2015 net charges include severance, accelerated depreciation, Alfa Aesar transaction costs, and litigation-related charges of a divested business.
2015-09-26restructuringannounced2015-10-302016-06-30Company-wideUSD 65 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of October 30, 2015, identified restructuring actions expected to result in additional charges primarily in remainder of 2015 and first half of 2016, recorded when criteria such as facility abandonment are met.
2015-09-26restructuringin_progress2%United States, Europe and AsiaMultiple segments and corporateUSD 106 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions tied to facility consolidations and cost-reduction measures affected about 2% of the workforce over the first nine months of 2015; no absolute headcount given. Charge shown is total net restructuring and other costs recorded YTD 2015.
2015-09-26restructuringannounced2015-10-302016-06-30Not specifiedNot specifiedUSD 65 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Actions identified as of 2015-10-30, expected primarily in remainder of 2015 and first half of 2016; charges recorded when criteria such as facility abandonment are met. Filer also expects to identify further actions during remainder of 2015.
2015-09-26acquisition_additioncompleted2015-09-302015-09-30United KingdomLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Alfa Aesar acquired from Johnson Matthey Plc for £257 million ($389 million) cash; purchase price allocation not yet available and no headcount disclosed. Post-quarter event (closed 4 days after period end).
2015-09-26restructuringin_progress2%2015-09-26GlobalAll SegmentsUSD 106 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company’s workforce in the first nine months of 2015. Total net restructuring and other costs were $105.8 million.
2015-09-26restructuringannounced2015-10-302016-06-30GlobalAll SegmentsUSD 65 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of October 30, 2015, the company identified restructuring actions resulting in additional charges of approximately $65 million, primarily in the remainder of 2015 and the first half of 2016.
2015-09-26restructuringin_progress Laboratory Products And ServicesUSD 4,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Employee Severance / Pre2014 Restructuring PlansUSD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Facility Closing / Pre2014 Restructuring PlansUSD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Other Restructuring / Pre2014 Restructuring PlansUSD 2,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Pre2014 Restructuring PlansUSD 3,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Life Sciences SolutionsUSD 36,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Employee Severance / Life Sciences SolutionsUSD 22,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Other Restructuring / Life Sciences SolutionsUSD 5,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Analytical TechnologiesUSD 17,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Corporate / Employee SeveranceUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Life Sciences Solutions / Facility ClosingUSD 2,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Life Sciences Solutions / Transaction Costs Related To DivestitureUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Employee Severance / Restructuring Plans2014USD 8,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Restructuring Plans2014 / Facility ClosingUSD 1,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Restructuring Plans2014 / Other RestructuringUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Restructuring Plans2014USD 15,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Restructuring Plans2015 / Employee SeveranceUSD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Restructuring Plans2015 / Facility ClosingUSD 11,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Restructuring Plans2015 / Other RestructuringUSD 4,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Restructuring Plans2015USD 52,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Transaction Costs Related To DivestitureUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Life Sciences Solutions / Charges For Cash Compensation Contractually Due To Employees Of Acquired BusinessUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Charges For Cash Compensation Contractually Due To Employees Of Acquired BusinessUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-26restructuringin_progress Life Sciences Solutions / Cash Costs For Severance And Abandoned FacilitiesUSD 30,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress1%U.S., Europe and AsiaLife Sciences SolutionsUSD 34 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six-month net charges include severance ($20.1M), abandoned facility costs, transaction/integration costs for Life Technologies and Advanced Scientifics, and a $3.5M pre-acquisition litigation settlement provision; partially offset by $7.6M gain on sale of a product line and $1.9M gain on sale of real estate. Company-wide, severance actions affected approximately 1% of the workforce in the first six months of 2015.
2015-06-27restructuringin_progressUnited StatesAnalytical InstrumentsUSD 18 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily abandoned facility costs including remediation and closure of a U.S. manufacturing facility, plus headcount reductions; $18.3M of the charges were cash costs.
2015-06-27restructuringin_progressU.S. and EuropeSpecialty DiagnosticsUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes accelerated depreciation at facilities closing due to real estate consolidation and cash costs for employee severance and headcount reductions.
2015-06-27restructuringin_progressLaboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes Alfa Aesar transaction costs, cash restructuring for employee severance, and charges for a litigation-related matter of a divested business.
2015-06-27restructuringin_progressCorporateUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily accelerated depreciation on information systems to be abandoned due to integration synergies, plus severance at corporate operations.
2015-06-27restructuringannounced2015-07-312016-06-30USD 85 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of July 31, 2015, identified restructuring actions expected to result in approximately $85 million of additional charges, primarily in the remainder of 2015 and the first half of 2016, recorded when criteria such as facility abandonment are met.
2015-06-27restructuringin_progress1%United States, Europe and AsiaAll segments and corporateUSD 65 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions tied to facility consolidations and cost-reduction measures affected approximately 1% of the workforce in the first six months of 2015; absolute headcount not disclosed. Charge shown is the total net restructuring and other costs recorded across all segments for the six-month period, including charges to cost of revenues and SG&A. Program includes closure and remediation of a U.S. manufacturing facility in Analytical Instruments, headcount reduction at a corporate information-systems abandonment, and divestiture-related litigation charges.
2015-06-27restructuringannounced2015-07-312016-06-30USD 85 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter, restructuring actions identified as of July 31, 2015 expected to generate additional charges of about $85 million, primarily in the remainder of 2015 and the first half of 2016, to be recorded when criteria such as facility abandonment are met. Employee counts not disclosed; also referenced in MD&A.
2015-06-27acquisition_additioncompleted2015-02North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Advanced Scientifics, Inc. for approximately $289 million; 2014 revenues of the acquired business were about $80 million. Headcount added through the acquisition not disclosed.
2015-06-27acquisition_additionannounced2015-062015-12-31United KingdomLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement signed in June 2015 to acquire Alfa Aesar from Johnson Matthey Plc for £256 million (about $400 million) in cash; expected to close by end of 2015 subject to regulatory approvals. Headcount added not disclosed.
2015-06-27restructuringin_progress1%2015-06-27GlobalVariousUSD 52 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce in the first six months of 2015.
2015-06-27restructuringannounced2015-07-312016-06-30GlobalVariousUSD 85 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $85 million, primarily in the remainder of 2015 and the first half of 2016.
2015-06-27restructuringin_progress Laboratory Products And ServicesUSD 2,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Employee Severance / Pre2014 Restructuring PlansUSD 1,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Facility Closing / Pre2014 Restructuring PlansUSD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Other Restructuring / Pre2014 Restructuring PlansUSD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Pre2014 Restructuring PlansUSD 1,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Life Sciences SolutionsUSD 31,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Specialty DiagnosticsUSD 4,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Employee Severance / Life Sciences SolutionsUSD 20,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Other Restructuring / Life Sciences SolutionsUSD 4,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Analytical TechnologiesUSD 18,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Corporate / Employee SeveranceUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Life Sciences Solutions / Facility ClosingUSD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Life Sciences Solutions / Transaction Costs Related To DivestitureUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Employee Severance / Restructuring Plans2014USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Restructuring Plans2014 / Facility ClosingUSD 1,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Restructuring Plans2014 / Other RestructuringUSD 4,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Restructuring Plans2014USD 13,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Restructuring Plans2015 / Employee SeveranceUSD 29,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Restructuring Plans2015 / Facility ClosingUSD 13,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Restructuring Plans2015 / Other RestructuringUSD 4,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Restructuring Plans2015USD 46,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Transaction Costs Related To DivestitureUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Life Sciences Solutions / Charges For Cash Compensation Contractually Due To Employees Of Acquired BusinessUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Charges For Cash Compensation Contractually Due To Employees Of Acquired BusinessUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-27restructuringin_progress Life Sciences Solutions / Cash Costs For Severance And Abandoned FacilitiesUSD 25,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress1%U.S., Europe and AsiaCompany-wide (facility consolidations and cost reduction measures)USD 32 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2015 severance actions tied to facility consolidations and cost reductions affected approximately 1% of the workforce; $32.0 million of net restructuring and other costs recorded in the quarter, of which $22.5 million were cash costs.
2015-03-28restructuringannounced2015-05-012015-12-31USD 70 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 1, 2015, identified restructuring actions expected to result in approximately $70 million of additional charges, primarily in the remainder of 2015, recorded when criteria such as facility abandonment are met.
2015-03-28restructuringin_progress1%United States, Europe and AsiaMultiple segments; facility consolidations and cost reduction measuresUSD 40 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions tied to facility consolidations and cost reductions affected about 1% of workforce in Q1 2015; charge includes $0.6M cost of revenues, $7.6M SG&A and $32.0M restructuring line. Absolute headcount not disclosed.
2015-03-28restructuringannounced2015-05-01Not specifiedPrimarily facility abandonment actionsUSD 70 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 1, 2015, identified actions expected to generate roughly $70M of additional charges, mostly in remainder of 2015, recorded when criteria such as facility abandonment are met; further actions expected.
2015-03-28acquisition_additioncompleted2015-02-01North AmericaLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Advanced Scientifics, Inc. acquired for ~$289M in Feb 2015; acquired business had ~$80M of 2014 revenues. Headcount added not disclosed.
2015-03-28restructuringin_progress1%2015-03-28GlobalAll SegmentsUSD 40 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce. Total charges of $40.2 million include $32.0 million in restructuring costs, $7.6 million in SG&A charges, and $0.6 million in cost of revenues.
2015-03-28restructuringannounced2015-05-01GlobalAll SegmentsUSD 70 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of May 1, 2015, the company identified restructuring actions resulting in additional charges of approximately $70 million, primarily in the remainder of 2015.
2015-03-28restructuringin_progress Employee Severance / Pre2014 Restructuring PlansUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Facility Closing / Pre2014 Restructuring PlansUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Other Restructuring / Pre2014 Restructuring PlansUSD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Pre2014 Restructuring PlansUSD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Life Sciences SolutionsUSD 22,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Specialty DiagnosticsUSD 2,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Employee Severance / Life Sciences SolutionsUSD 14,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Other Restructuring / Life Sciences SolutionsUSD 1,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Analytical TechnologiesUSD 5,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Life Sciences Solutions / Facility ClosingUSD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Life Sciences Solutions / Transaction Costs Related To DivestitureUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Employee Severance / Restructuring Plans2014USD 4,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Facility Closing / Restructuring Plans2014USD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Other Restructuring / Restructuring Plans2014USD 3,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Restructuring Plans2014USD 8,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Employee Severance / Restructuring Plans2015USD 21,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Facility Closing / Restructuring Plans2015USD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Other Restructuring / Restructuring Plans2015USD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Restructuring Plans2015USD 22,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Transaction Costs Related To DivestitureUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Life Sciences Solutions / Charges For Cash Compensation Contractually Due To Employees Of Acquired BusinessUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Charges For Cash Compensation Contractually Due To Employees Of Acquired BusinessUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-28restructuringin_progress Life Sciences Solutions / Cash Costs For Severance And Abandoned FacilitiesUSD 16,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-31restructuringin_progress3%Global (US, Europe and Asia facilities)Company-wide; charges concentrated in Life Sciences SolutionsUSD 134 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2014 severance actions tied to facility consolidations and cost-reduction measures affected about 3% of the ~51,000-person workforce. Cash restructuring costs under the 2014 plans totaled $232.0M (severance $133.6M, facility abandonment $6.4M, other $92.0M, including $91.7M to monetize Life Technologies equity awards); further cash costs of $18.8M and $2.9M were incurred in 2014 under the 2013 and pre-2013 plans. MD&A separately cites ~$268M of total cash restructuring costs. Charges recorded in fiscal 2014; severance payments continue primarily through 2015 and facility payments through 2020. Expected annual cost savings ~$120M ($80M Life Sciences Solutions, $10M Analytical Instruments, $10M Specialty Diagnostics, $20M Laboratory Products and Services).
2014-12-31restructuringannounced2015-02-26Approximately half in Life Sciences Solutions segment; remainder across other segmentsUSD 70 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		As of the February 26, 2015 report date, identified actions expected to generate roughly $70 million of additional charges in 2015, with further actions possible during the year; charges recorded when specified criteria are met (e.g., abandonment of leased facilities). No employee count disclosed.
2014-12-31acquisition_additioncompleted2013-04-142014-02-03Life Sciences Solutionsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Merger agreement dated April 14, 2013; acquisition of Life Technologies Corporation completed February 3, 2014 for $15.30 billion net of cash acquired, including assumption of $2.28 billion of debt, and integrated into the Life Sciences Solutions segment. Life Technologies' 2013 revenues were $3.87 billion. Headcount added through the acquisition is not disclosed. Integration drove the bulk of 2014 severance and equity-award monetization costs (see 2014 restructuring action).
2014-12-31divestiture_reductioncompleted2014-03-212014-03-21Life Sciences Solutions (principally)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Sold legacy sera and media, gene modulation and magnetic beads businesses to GE Healthcare for $1.06 billion net of cash divested; pre-tax gain of ~$761 million recorded in restructuring and other costs (income), net. Divestiture was a condition to obtaining antitrust approval for the Life Technologies acquisition. Divested businesses had 2013 revenues of ~$250 million and 2013 operating income of ~$64 million. Employee headcount divested not disclosed.
2014-12-31divestiture_reductioncompleted2014-08-152014-08-15Laboratory Products and Servicesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Sold Cole-Parmer specialty channel business for $480 million in cash, net of cash divested; pre-tax gain of ~$134 million recorded in restructuring and other costs (income), net. Business had 2013 revenues of ~$232 million and 2013 operating income of ~$43 million. Employee headcount divested not disclosed.
2014-12-31acquisition_additioncompleted2014-02-032014-02-03GlobalLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Life Technologies Corporation completed for $15.30 billion purchase price; acquired headcount not disclosed in filing.
2014-12-31divestiture_reductioncompleted2014-03-212014-03-21GlobalLife Sciences Solutionsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of legacy sera and media, gene modulation and magnetic beads businesses to GE Healthcare for $1.06 billion; divestiture was a condition of antitrust approval for Life Technologies. Headcount removed not disclosed.
2014-12-31divestiture_reductioncompleted2014-08-152014-08-15GlobalLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Cole-Parmer specialty channel business for $480 million cash; headcount removed not disclosed.
2014-12-31restructuringin_progress3%2014-01-012015-12-31United States, Europe, AsiaCompany-wide; approximately half of additional 2015 charges expected in Life Sciences SolutionsUSD 232 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2014 Restructuring Plans cash costs of $232.0 million; severance actions for facility consolidations and cost reductions affected approximately 3% of workforce. MD&A reports $268 million total cash restructuring costs for 2014 including prior-year plans. Announcement date approximate (program activity during fiscal year; no specific date given).
2014-12-31restructuringannounced2015-02-262015-12-31GlobalApproximately half in Life Sciences Solutions; remainder across other segmentsUSD 70 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Additional restructuring actions identified as of filing date, to be recorded in 2015 when criteria met (e.g., facility abandonment); further actions expected during 2015.
2014-12-31acquisition_additionannounced2015-02-012015-02-28North AmericaLife Sciences Solutionssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Advanced Scientifics, Inc. (single-use bioprocessing technologies) for approximately $300 million completed February 2015; acquired headcount not disclosed. Announcement date approximate (month only disclosed).
2014-12-31restructuringcompleted3%2014-01-012014-12-31GlobalAll segmentsUSD 268 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 3% of the company’s workforce. Cash restructuring costs were $268 million, primarily associated with the Life Technologies acquisition including severance obligations and monetizing equity awards.
2014-12-31acquisition_additioncompleted2014-02-032014-02-03GlobalLife Sciences SolutionsMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Life Technologies Corporation completed on February 3, 2014. Specific headcount added not disclosed.
2014-12-31divestiture_reductioncompleted2014-03-212014-03-21GlobalLife Sciences SolutionsMD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of legacy sera and media, gene modulation and magnetic beads businesses to GE Healthcare. Specific headcount removed not disclosed.
2014-12-31divestiture_reductioncompleted2014-08-152014-08-15GlobalLaboratory Products and ServicesMD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of Cole-Parmer specialty channel business. Specific headcount removed not disclosed.
2014-12-31restructuringin_progress Laboratory Products And ServicesUSD 7,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Employee Severance / Pre2013 Restructuring PlansUSD 500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Facility Closing / Pre2013 Restructuring PlansUSD 2,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Other Restructuring / Pre2013 Restructuring PlansUSD 0 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Pre2013 Restructuring PlansUSD 2,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Employee Severance / Restructuring Plans2013USD 6,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Facility Closing / Restructuring Plans2013USD 1,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Other Restructuring / Restructuring Plans2013USD 10,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Restructuring Plans2013USD 18,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Life Sciences SolutionsUSD 232,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Specialty DiagnosticsUSD 18,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Life Sciences Solutions / Monetized Equity AwardsUSD 91,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Employee Severance / Specialty DiagnosticsUSD 9,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Corporate / Employee SeveranceUSD 1,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Employee Severance / Restructuring Plans2014USD 133,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Facility Closing / Restructuring Plans2014USD 6,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Other Restructuring / Restructuring Plans2014USD 92,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Restructuring Plans2014USD 232,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31restructuringin_progress Facility Closing / Life Sciences SolutionsUSD 5,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2014-12-31acquisition_additioncompleted2014-02-032014-02-03GlobalLife Sciences SolutionsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Life Technologies acquired for $15.30 billion net of cash acquired, including $2.28 billion assumed debt; headcount added not disclosed. $450 million of acquisition-related charges recorded in 2014.
2014-12-31divestiture_reductioncompleted2014-03-212014-03-21GlobalLife Sciences SolutionsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sera and media, gene modulation and magnetic beads businesses sold to GE Healthcare for $1.06 billion; pre-tax gain of approximately $761 million. Headcount removed not disclosed; divestiture was a condition of antitrust approval for Life Technologies.
2014-12-31divestiture_reductioncompleted2014-08-152014-08-15GlobalLaboratory Products and ServicesMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cole-Parmer specialty channel business sold for $480 million in cash; pre-tax gain of approximately $134 million. Headcount removed not disclosed.
2014-12-31restructuringin_progressGlobalPrimarily Life Sciences Solutions; remainder across other segmentsUSD 268 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2014 cash restructuring costs of $268 million, primarily tied to the Life Technologies acquisition (equity award monetization, executive and employee severance) plus headcount reductions and facility consolidations across other businesses. Employees affected not disclosed. Expected annual cost savings of approximately $120 million, including $80 million in Life Sciences Solutions.
2014-12-31restructuringannounced2015-02-26GlobalApproximately half in Life Sciences Solutions; remainder across other segmentsUSD 70 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring actions identified as of the original 10-K filing date (2015-02-26) expected to result in additional charges of approximately $70 million in 2015; further actions expected to be identified during 2015. Employees affected not disclosed.
2014-12-31restructuringcompleted2014GlobalLife Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and ServicesUSD 268 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cash restructuring costs primarily associated with Life Technologies acquisition including severance and equity monetization. Expected annual cost savings of $120 million.
2014-12-31acquisition_additioncompleted2014-02-03GlobalLife Sciences SolutionsMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Life Technologies Corporation completed February 3, 2014. Employee count not disclosed.
2014-12-31divestiture_reductioncompleted2014-03-21GlobalLife Sciences SolutionsMD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of legacy sera and media, gene modulation and magnetic beads businesses to GE Healthcare. Employee count not disclosed.
2014-12-31divestiture_reductioncompleted2014-08-15GlobalLaboratory Products and ServicesMD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of Cole-Parmer specialty channel business. Employee count not disclosed.
2014-09-27restructuringin_progress2%U.S., Europe and AsiaAll segments (Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Services, Corporate)USD 217 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions tied to facility consolidations and cost reductions affected roughly 2% of the workforce in the first nine months of 2014. The $216.7 million figure is costs incurred in 2014 under 2014 restructuring plans (severance $124.2M, abandonment of excess facilities $3.2M, other $89.3M). Company also identified additional charges of approximately $50 million, primarily in the remainder of 2014, as of October 31, 2014. No absolute employee count disclosed.
2014-09-27restructuringin_progress2%United States, Europe and AsiaCompany-wide; headcount reductions and facility consolidationsUSD 124 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions in first nine months of 2014 affected about 2% of workforce; charge shown is severance costs incurred under 2014 restructuring plans (total 2014 plan costs $216.7M). Absolute headcount not disclosed; accrued restructuring payments expected primarily through first half of 2015.
2014-09-27restructuringannounced2014-10-31Not specifiedCompany-wideUSD 50 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of October 31, 2014 the company identified actions expected to result in about $50M of additional charges, primarily in the remainder of 2014, recorded when criteria such as facility abandonment are met; further actions expected to be identified.
2014-09-27acquisition_additioncompleted2014-02-032014-02-03GlobalLife Sciences Solutions segmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Life Technologies Corporation for $15.30 billion net of cash acquired; acquired headcount not disclosed. Integration began immediately, with shared SG&A functions and severance obligations to former Life Technologies executives and employees recorded in restructuring.
2014-09-27divestiture_reductioncompleted2014-03-212014-03-21GlobalLife Sciences Solutionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of sera and media, gene modulation and magnetic beads businesses to GE Healthcare for $1.06 billion net of cash divested; divestiture was a condition of antitrust approval for Life Technologies. Employees removed not disclosed.
2014-09-27divestiture_reductioncompleted2014-08-152014-08-15GlobalLaboratory Products and Servicesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Cole-Parmer specialty channel business for $480 million cash net of cash divested, generating a pre-tax gain of about $133 million. Employees removed not disclosed.
2014-09-27restructuringin_progress2%2014-01-01GlobalAll Segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company’s workforce in the first nine months of 2014.
2014-09-27restructuringannounced2014-10-31GlobalAll SegmentsUSD 50 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		As of October 31, 2014, the company has identified restructuring actions that will result in additional charges of approximately $50 million, primarily in the remainder of 2014.
2014-09-27restructuringin_progress Laboratory Products And ServicesUSD 5,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Employee Severance / Pre2013 Restructuring PlansUSD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Facility Closing / Pre2013 Restructuring PlansUSD 2,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Other Restructuring / Pre2013 Restructuring PlansUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Pre2013 Restructuring PlansUSD 4,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Employee Severance / Restructuring Plans2013USD 5,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Facility Closing / Restructuring Plans2013USD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Other Restructuring / Restructuring Plans2013USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Restructuring Plans2013USD 12,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Life Sciences SolutionsUSD 221,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Specialty DiagnosticsUSD 13,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Employee Severance / Life Sciences SolutionsUSD 8,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Facility Closing / Life Sciences SolutionsUSD 2,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Other Restructuring / Life Sciences SolutionsUSD 2,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Analytical TechnologiesUSD 1,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Employee Severance / Analytical TechnologiesUSD 1,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Employee Severance / Specialty DiagnosticsUSD 2,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Life Sciences Solutions / Monetized Equity AwardsUSD 91,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Corporate / Employee SeveranceUSD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Employee Severance / Restructuring Plans2014USD 124,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Facility Closing / Restructuring Plans2014USD 3,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Other Restructuring / Restructuring Plans2014USD 89,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Restructuring Plans2014USD 216,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress CorporateUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-09-27restructuringin_progress Employee Severance / CorporateUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28acquisition_additioncompleted2014-02-032014-02-03Life Sciences SolutionsUSD 15,304 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Life Technologies Corporation completed February 3, 2014; total purchase price $15.30 billion net of cash acquired including $2.28 billion assumed debt. No employee headcount added was disclosed.
2014-06-28divestiture_reductioncompleted2014-03-212014-03-21Life Sciences SolutionsUSD 761 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sold sera and media, gene modulation and magnetic beads businesses to GE Healthcare for $1.05 billion net of cash divested; pre-tax gain of approximately $761 million. Divestiture was a condition to antitrust approval of the Life Technologies acquisition. No headcount removed was disclosed.
2014-06-28divestiture_reductionannounced2014-07-172014-09-30Laboratory Products and ServicesUSD 480 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement to sell Cole-Parmer specialty channel business for $480 million in cash; expected to close in Q3 2014 subject to regulatory approvals; after-tax proceeds to be used primarily to pay down debt. No headcount removed was disclosed.
2014-06-28restructuringin_progress1%U.S., Europe and AsiaAll segmentsUSD 232 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Second quarter 2014 net restructuring and other costs of $231.9 million across segments (Life Sciences Solutions $215.5M, Analytical Instruments $4.2M, Specialty Diagnostics $6.6M, Laboratory Products and Services $4.1M, Corporate $1.5M), including $156.1M cost-of-revenues charges for inventories revalued at acquisition and $14.9M SG&A charges. Headcount reductions and facility consolidations affected less than 1% of workforce in the first six months of 2014; exact employee counts not disclosed.
2014-06-28restructuringin_progress2014-12-31All segmentsUSD 70 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 1, 2014, identified restructuring actions expected to result in approximately $70 million of additional charges, primarily in the remainder of 2014, recorded when criteria such as facility abandonment are met.
2014-06-28restructuringin_progressUnited States, Europe, AsiaMultiple segments and corporaterestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions from facility consolidations and cost reductions affected less than 1% of workforce in H1 2014; no absolute headcount disclosed. Cash restructuring costs of $228M incurred in H1 2014.
2014-06-28restructuringannounced2014-08-01USD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of August 1, 2014, identified restructuring actions expected to result in additional charges of approximately $70 million, primarily in remainder of 2014; no employee count disclosed.
2014-06-28acquisition_additioncompleted2014-02-032014-02-03GlobalLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Life Technologies Corporation acquired for $15.30 billion; no headcount added disclosed. Life Technologies 2013 revenues were $3.87 billion.
2014-06-28divestiture_reductioncompleted2014-03-212014-03-21GlobalLife Sciences Solutionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sera and media, gene modulation and magnetic beads businesses sold to GE Healthcare for $1.05 billion; no headcount reduction disclosed.
2014-06-28divestiture_reductionannounced2014-07-172014-09-30GlobalLaboratory Products and Servicessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cole-Parmer specialty channel business agreed to be sold for $480 million cash; expected to close Q3 2014. No headcount reduction disclosed.
2014-06-28restructuringin_progress1%2014-06-28GlobalVariousUSD 61 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce in the first six months of 2014.
2014-06-28restructuringannounced2014-08-01GlobalVariousUSD 70 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $70 million, primarily in the remainder of 2014.
2014-06-28restructuringin_progress Laboratory Products And ServicesUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Employee Severance / Pre2013 Restructuring PlansUSD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Facility Closing / Pre2013 Restructuring PlansUSD 1,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Other Restructuring / Pre2013 Restructuring PlansUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Pre2013 Restructuring PlansUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Employee Severance / Restructuring Plans2013USD 4,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Facility Closing / Restructuring Plans2013USD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Other Restructuring / Restructuring Plans2013USD 5,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Restructuring Plans2013USD 11,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Employee Severance / Restructuring Plans2014USD 111,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Facility Closing / Restructuring Plans2014USD 1,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Restructuring Plans2014USD 197,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Other Restructuring / Restructuring Plans2014USD 84,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Life Sciences SolutionsUSD 208,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Specialty DiagnosticsUSD 8,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Employee Severance / Life Sciences SolutionsUSD 34,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Facility Closing / Life Sciences SolutionsUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Other Restructuring / Life Sciences SolutionsUSD 4,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Analytical TechnologiesUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Employee Severance / Analytical TechnologiesUSD 1,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Facility Closing / Analytical TechnologiesUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Other Restructuring / Analytical TechnologiesUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Employee Severance / Specialty DiagnosticsUSD 2,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Employee Severance / Laboratory Products And ServicesUSD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 1,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Life Sciences Solutions / Monetized Equity AwardsUSD 91,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-06-28restructuringin_progress Corporate / Employee SeveranceUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29acquisition_additioncompleted2014-02-03Life Sciences SolutionsUSD 15,304 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Life Technologies Corporation; total purchase price $15.30 billion net of cash acquired including $2.28 billion assumed debt. No employee headcount added disclosed.
2014-03-29divestiture_reductioncompleted2014-03-21Life Sciences SolutionsUSD 757 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sold sera and media, gene modulation and magnetic beads businesses to GE Healthcare for $1.05 billion net of cash divested; pre-tax gain approximately $757 million. Divestiture was a condition to antitrust approval for the Life Technologies acquisition. No employee headcount removed disclosed.
2014-03-29restructuringin_progressEurope and AsiaUSD 152 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2014 restructuring plans: severance $72.8 million, other (equity award monetization and retention) $78.7 million. Severance actions affected less than 1% of the company's workforce; exact headcount not disclosed.
2014-03-29restructuringannounced2014-05-022014-12-31USD 65 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 2, 2014, identified restructuring actions expected to result in additional charges of approximately $65 million, primarily in the remainder of 2014.
2014-03-29restructuringin_progressMultiple (U.S., Europe, Asia)Multiple segmentsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance actions from facility consolidations and cost reductions affected less than 1% of workforce in Q1 2014. No absolute headcount disclosed. Includes closure/consolidation of operations in several facilities in Europe and Asia.
2014-03-29restructuringannounced2014-05-02Not specifiedNot specifiedUSD 65 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 2, 2014, identified restructuring actions expected to result in additional charges of approximately $65 million, primarily in remainder of 2014. No employee count disclosed.
2014-03-29acquisition_additioncompleted2014-02-032014-02-03GlobalLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Life Technologies Corporation acquired for $15.30 billion. No headcount added disclosed. Life Technologies had $3.87 billion in 2013 revenues.
2014-03-29divestiture_reductioncompleted2014-03-212014-03-21Not specifiedLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sera and media, gene modulation, and magnetic beads businesses sold to GE Healthcare for $1.05 billion. No headcount reduction disclosed. Divestiture was a condition for antitrust approval of Life Technologies acquisition.
2014-03-29restructuringin_progress1%2014-03-29GlobalVariousUSD 152 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce. Cash restructuring costs of $151.5 million recorded in 2014 plans, primarily for severance and abandoned facility costs.
2014-03-29acquisition_additioncompleted2014-02-03GlobalLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Life Technologies Corporation completed on February 3, 2014. Headcount added not explicitly quantified in this filing.
2014-03-29divestiture_reductioncompleted2014-03-21GlobalLife Sciences Solutionsbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of sera and media, gene modulation and magnetic beads businesses to GE Healthcare completed on March 21, 2014. Headcount removed not explicitly quantified in this filing.
2014-03-29restructuringin_progress Analytical TechnologiesUSD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Laboratory Products And ServicesUSD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Employee Severance / Pre2013 Restructuring PlansUSD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Facility Closing / Pre2013 Restructuring PlansUSD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Other Restructuring / Pre2013 Restructuring PlansUSD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Pre2013 Restructuring PlansUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Employee Severance / Restructuring Plans2013USD 2,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Facility Closing / Restructuring Plans2013USD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Other Restructuring / Restructuring Plans2013USD 2,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Restructuring Plans2013USD 6,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Employee Severance / Restructuring Plans2014USD 72,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Facility Closing / Restructuring Plans2014USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Restructuring Plans2014USD 151,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Other Restructuring / Restructuring Plans2014USD 78,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Life Sciences SolutionsUSD 168,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress Specialty DiagnosticsUSD 3,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-03-29restructuringin_progress CorporateUSD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-12-31restructuringin_progressUnited States and EuropeAnalytical TechnologiesUSD 19 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2013 cash severance for headcount reductions and facility consolidations and closures in the U.S. and Europe; segment also incurred $3.3M abandoned-facility and $6.7M other cash costs including outplacement. Part of company-wide 2013 severance actions affecting roughly 3% of the workforce.
2013-12-31restructuringin_progressEurope and the United StatesSpecialty DiagnosticsUSD 18 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2013 cash severance from headcount reductions and facility consolidations, plus $2.8M abandoned-facility costs primarily for facilities in Europe and the U.S. and $3.5M other cash costs. Part of company-wide 2013 severance actions affecting roughly 3% of the workforce.
2013-12-31restructuringin_progressLaboratory Products and ServicesUSD 16 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2013 cash severance from headcount reductions and facility consolidations, plus $3.7M abandoned-facility and $2.4M other cash costs and $1.3M non-cash pension charges tied to the headcount reductions. Part of company-wide 2013 severance actions affecting roughly 3% of the workforce.
2013-12-31restructuringin_progressCorporateUSD 3 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance at corporate operations. Part of company-wide 2013 severance actions affecting roughly 3% of the workforce.
2013-12-31divestiture_reductionannounced2013-12Sera and media, gene modulation and magnetic beads businesses (principally Analytical Technologies segment)USD 4 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Agreement to sell to GE Healthcare for approximately $1.06B, a condition to antitrust approval of the Life Technologies acquisition; designated held for sale in January 2014. Businesses had 2013 revenues of about $250M and operating income of about $80M. Charge reflects transaction expenses for the sale agreement per Note 14. Headcount affected not disclosed.
2013-12-31acquisition_additioncompleted2013-04-142014-02-03Life Sciences Solutions (new reporting segment effective January 1, 2014)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Merger agreement dated April 14, 2013; completed February 3, 2014 for about $13.6B cash plus assumed net debt. Life Technologies had 2013 revenues of $3.9B. Headcount added through the acquisition is not disclosed in this filing.
2013-12-31restructuringannounced2014-02-27Company-wide, including Life TechnologiesUSD 50 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		As of the filing date, identified actions expected to generate roughly $50M of additional charges in 2014, with further actions expected during the year. First-quarter 2014 charges include acceleration of equity awards held by Life Technologies employees and severance for former Life Technologies executives.
2013-12-31restructuringin_progress3%United States, Europe and AsiaConsolidated (charges by segment: Analytical Technologies $82.0M; Specialty Diagnostics $62.0M; Laboratory Products and Services $24.5M; Corporate $11.3M)USD 180 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2013 activity only. Severance actions tied to facility consolidations and cost reduction affected approximately 3% of workforce; cash restructuring costs were $78M within the $179.8M total. Programs expected to deliver ~$80M annual savings, largely from 2014.
2013-12-31acquisition_additioncompleted2013-04-142014-02-03Global (headquartered in United States)New Life Sciences Solutions segmentsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Life Technologies Acquisition closed 2014-02-03, after fiscal year-end and before the 2014-02-27 filing date; purchase price ~$13.6B cash plus ~$1.5B assumed net debt. Life Technologies 2013 revenues were $3.9B; acquired headcount not disclosed. Purchase price allocation and pro forma information not yet available.
2013-12-31divestiture_reductionannounced2013-12GlobalAnalytical Technologies (sera and media, gene modulation, magnetic beads businesses)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to sell three businesses to GE Healthcare for ~$1.06B, a condition of antitrust approval for the Life Technologies Acquisition; approval obtained January 2014, at which point businesses were designated held for sale. Divested businesses had 2013 revenues ~$250M and operating income ~$80M; headcount not disclosed.
2013-12-31restructuringannounced2014-02-27Not specifiedConsolidated, including Life Technologies integrationUSD 50 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Actions identified as of 2014-02-27 expected to result in ~$50M of additional charges in 2014, primarily in the first half, with further actions expected. Includes significant Q1 2014 charges for accelerating Life Technologies employee equity awards and severance to former Life Technologies executives; those amounts not separately quantified.
2013-12-31restructuringcompleted3%2013-01-012013-12-31GlobalVariousUSD 78 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Cash restructuring costs primarily for headcount reductions and facility consolidations. Affected approximately 3% of workforce.
2013-12-31acquisition_additioncompleted2012-09-012012-09-01GlobalSpecialty Diagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of One Lambda in September 2012.
2013-12-31acquisition_additioncompleted2012-05-012012-05-01North AmericaLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Doe & Ingalls in May 2012.
2013-12-31restructuringin_progress Analytical TechnologiesUSD 28,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Employee Severance / Analytical TechnologiesUSD 18,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Facility Closing / Analytical TechnologiesUSD 3,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Other Restructuring / Analytical TechnologiesUSD 6,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Employee Severance / Specialty DiagnosticsUSD 17,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Facility Closing / Specialty DiagnosticsUSD 2,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Other Restructuring / Specialty DiagnosticsUSD 3,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Employee Severance / Laboratory Products And ServicesUSD 16,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Laboratory Products And ServicesUSD 22,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 3,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Other Restructuring / Laboratory Products And ServicesUSD 2,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Transaction Costs Related To Divestiture / Analytical TechnologiesUSD 4,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Employee Severance / Pre2012 Restructuring PlansUSD 500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Facility Closing / Pre2012 Restructuring PlansUSD 4,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Other Restructuring / Pre2012 Restructuring PlansUSD 100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Pre2012 Restructuring PlansUSD 4,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Employee Severance / Restructuring Plans2012USD 8,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Facility Closing / Restructuring Plans2012USD 2,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Other Restructuring / Restructuring Plans2012USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Restructuring Plans2012USD 14,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Employee Severance / Restructuring Plans2013USD 48,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Facility Closing / Restructuring Plans2013USD 3,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Restructuring Plans2013USD 61,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-12-31restructuringin_progress Other Restructuring / Restructuring Plans2013USD 9,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2013-09-28restructuringin_progress2%United States and EuropeAll segmentsUSD 54 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Year-to-date severance actions tied to facility consolidations and cost reductions affected roughly 2% of the workforce; $54.4M of net restructuring and other costs recorded in the nine months ended September 28, 2013.
2013-09-28restructuringannounced2013-12-31USD 60 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 1, 2013, identified restructuring actions expected to generate additional charges of approximately $60 million, primarily in the remainder of 2013.
2013-09-28restructuringin_progressAnalytical TechnologiesUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month other restructuring costs, net, of $15.0M for headcount reductions and facility consolidations, including $12.4M severance; segment total charges $43.6M including Life Technologies transaction costs.
2013-09-28restructuringin_progressSpecialty DiagnosticsUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month other restructuring costs, net, of $14.9M, primarily cash costs including $13.0M severance; segment total charges $52.5M including inventory revaluation and contingent consideration revisions.
2013-09-28restructuringin_progressLaboratory Products and ServicesUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month other restructuring costs of $22.5M, $21.1M cash, including $15.2M severance and $3.4M abandoned facility costs; segment total charges $23.1M.
2013-09-28restructuringin_progress2%2014-12-31United States and EuropeMultiple segments (Analytical Technologies, Specialty Diagnostics, Laboratory Products and Services, Corporate)USD 54 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Year-to-date severance actions from facility consolidations and cost reductions affected about 2% of the workforce; absolute headcount not disclosed. Charge shown is nine-month restructuring and other costs, net (cash restructuring costs were $55 million). Severance and retention obligations expected to be paid primarily through 2014; abandoned-facility payments through 2018.
2013-09-28restructuringannounced2013-11-012013-12-31Not specifiedNot specifiedUSD 60 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of November 1, 2013 the company identified restructuring actions expected to generate additional charges of about $60 million, primarily in the remainder of 2013; further actions expected to be identified. Employee counts not disclosed.
2013-09-28acquisition_additionannounced2013-04-142014-03-31GlobalLife Technologies Corporation (research, genetic analysis, applied markets)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Life Technologies for approximately $13.6 billion in cash plus assumed net debt, expected to close in early 2014; no headcount added or disclosed. Life Technologies 2012 revenues were $3.8 billion.
2013-09-28restructuringin_progress2%GlobalVariousUSD 54 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Year-to-date severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company's workforce. Includes headcount reductions and facility consolidations in the U.S. and Europe.
2013-09-28restructuringannounced2013-11-012013-12-31GlobalVariousUSD 60 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of November 1, 2013, the company identified restructuring actions resulting in additional charges of approximately $60 million, primarily in the remainder of 2013.
2013-09-28restructuringin_progress Analytical TechnologiesUSD 3,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Laboratory Products And ServicesUSD 3,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Employee Severance / Analytical TechnologiesUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Employee Severance / Specialty DiagnosticsUSD 4,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Employee Severance / Laboratory Products And ServicesUSD 2,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Facility Closing / Analytical TechnologiesUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 1,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Other Restructuring / Analytical TechnologiesUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Other Restructuring / Specialty DiagnosticsUSD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress CorporateUSD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Employee Severance / CorporateUSD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Other Restructuring / Laboratory Products And ServicesUSD 2,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Pre2012 Restructuring PlansUSD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Restructuring Plans2012USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Restructuring Plans2013USD 45,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Employee Severance / Pre2012 Restructuring PlansUSD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Employee Severance / Restructuring Plans2012USD 4,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Employee Severance / Restructuring Plans2013USD 39,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Facility Closing / Pre2012 Restructuring PlansUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Facility Closing / Restructuring Plans2012USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Facility Closing / Restructuring Plans2013USD 2,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Other Restructuring / Pre2012 Restructuring PlansUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Other Restructuring / Restructuring Plans2012USD 2,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-09-28restructuringin_progress Other Restructuring / Restructuring Plans2013USD 3,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress250U.S. and EuropeAnalytical TechnologiesUSD 25 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six-month cumulative: $9.4M severance for ~250 employees, $2.2M abandoned facility costs, $1.6M other cash costs; also $10.3M SG&A transaction costs for pending Life Technologies acquisition and $1.5M accelerated depreciation.
2013-06-29restructuringin_progress185Specialty DiagnosticsUSD 48 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six-month cumulative: $8.8M severance for ~185 employees and $0.9M other cash costs; also $24.2M cost-of-revenues charges for revalued inventories and $13.6M SG&A for contingent consideration revision.
2013-06-29restructuringin_progress220Laboratory Products and ServicesUSD 18 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Six-month cumulative: $12.8M severance for ~220 employees, $2.1M abandoned facility costs, $2.6M other cash costs including retention, relocation and outplacement.
2013-06-29restructuringin_progressCorporateUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		All cash costs, primarily severance at corporate operations and abandoned facility costs for a corporate facility; no employee count disclosed.
2013-06-29restructuringannounced2013-12-31USD 60 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Company identified additional restructuring actions expected to result in roughly $60 million of charges, primarily in the remainder of 2013; no headcount figure disclosed.
2013-06-29restructuringin_progress250United States and EuropeAnalytical TechnologiesUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 250 employees severed in first six months of 2013 from headcount reductions and facility consolidations; segment recorded $25.4M total net restructuring and other charges in the period, of which $13.6M was other restructuring costs ($13.2M cash).
2013-06-29restructuringin_progress185not specifiedSpecialty DiagnosticsUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 185 employees severed in first six months of 2013, primarily headcount reductions; segment recorded $47.5M total net restructuring and other charges, including $24.2M in cost of revenues (inventory revaluation) and $13.6M contingent consideration revision.
2013-06-29restructuringin_progress220not specifiedLaboratory Products and ServicesUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 220 employees severed in first six months of 2013 from headcount reductions and facility consolidations; segment recorded $18.4M total net restructuring and other charges, of which $17.8M was other restructuring costs ($17.5M cash).
2013-06-29restructuringin_progressnot specifiedCorporaterestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Corporate recorded $1.9M of net restructuring and other charges in first six months of 2013, all cash, for severance and abandoned facility costs; number of employees affected not disclosed.
2013-06-29restructuringannounced2013-08-022013-12-31not specifiednot specifiedUSD 60 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of August 2, 2013 the company identified restructuring actions expected to result in additional charges of approximately $60 million, primarily in the remainder of 2013; employee counts not disclosed. Restructuring actions charged in first six months of 2013 are expected to yield annual cost savings of about $50 million.
2013-06-29acquisition_additionannounced2013-04-142014-01-14not specifiednot specifiedother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Life Technologies Corporation at $76.00 per share (~$13.6 billion plus assumed net debt), expected to close in early 2014 subject to Life Technologies shareholder vote (scheduled 2013-08-21) and regulatory approvals; headcount to be added not disclosed in this filing.
2013-06-29restructuringin_progress80United States and EuropeAnalytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 80 employees in Q2 2013.
2013-06-29restructuringin_progress110Specialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 110 employees in Q2 2013.
2013-06-29restructuringin_progress150Laboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 150 employees in Q2 2013.
2013-06-29restructuringin_progressCorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs primarily for severance at corporate operations in Q2 2013; employee count not specified.
2013-06-29restructuringin_progress250United States and EuropeAnalytical TechnologiesUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 250 employees in the first six months of 2013.
2013-06-29restructuringin_progress185Specialty DiagnosticsUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 185 employees in the first six months of 2013.
2013-06-29restructuringin_progress220Laboratory Products and ServicesUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 220 employees in the first six months of 2013.
2013-06-29restructuringannounced2013-08-022013-12-31USD 60 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		As of August 2, 2013, company identified restructuring actions resulting in additional charges of approx $60 million, primarily in remainder of 2013.
2013-06-29restructuringin_progress Analytical TechnologiesUSD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Specialty DiagnosticsUSD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Laboratory Products And ServicesUSD 12,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress80 Employee Severance / Analytical TechnologiesUSD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress110 Employee Severance / Specialty DiagnosticsUSD 2,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress150 Employee Severance / Laboratory Products And ServicesUSD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Facility Closing / Analytical TechnologiesUSD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 1,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Other Restructuring / Analytical TechnologiesUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Other Restructuring / Specialty DiagnosticsUSD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Other Restructuring / Laboratory Products And ServicesUSD 1,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress CorporateUSD 1,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Pre2012 Restructuring PlansUSD 900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Restructuring Plans2012USD 7,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Restructuring Plans2013USD 35,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Employee Severance / Pre2012 Restructuring PlansUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Employee Severance / Restructuring Plans2012USD 2,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Employee Severance / Restructuring Plans2013USD 30,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Facility Closing / Pre2012 Restructuring PlansUSD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Facility Closing / Restructuring Plans2012USD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Facility Closing / Restructuring Plans2013USD 1,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Other Restructuring / Pre2012 Restructuring PlansUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Other Restructuring / Restructuring Plans2012USD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-06-29restructuringin_progress Other Restructuring / Restructuring Plans2013USD 3,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress170U.S. and EuropeAnalytical TechnologiesUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2013 net charges of $11.6M include $9.2M cash costs: $7.9M severance for approximately 170 employees, $0.7M abandoned facility costs, $0.6M other cash costs; plus $0.8M accelerated depreciation, $1.3M Life Technologies transaction costs, and $0.3M non-cash real estate writedown.
2013-03-30restructuringin_progress75Specialty DiagnosticsUSD 19 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2013 net charges of $18.9M include $12.2M cost-of-revenues charges primarily for sale of inventories revalued at acquisition date, and $6.7M cash restructuring costs: $6.5M severance for approximately 75 employees and $0.2M other.
2013-03-30restructuringin_progress70Laboratory Products and ServicesUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2013 net charges of $5.0M include $0.2M accelerated depreciation and $4.8M other restructuring costs, net, of which $5.0M were cash costs: $3.8M severance for approximately 70 employees, $0.5M abandoned facility costs, $0.7M retention/relocation/moving expenses; offset by $0.2M non-cash gain on sale of real estate.
2013-03-30restructuringin_progressCorporateUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2013 net charges of $0.5M, all cash costs, primarily severance at corporate operations and abandoned facility costs for a corporate facility.
2013-03-30restructuringannounced2013-05-032013-12-31USD 70 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 3, 2013, company identified restructuring actions expected to result in additional charges of approximately $70 million, primarily in the remainder of 2013; additional actions may be identified during 2013.
2013-03-30restructuringin_progress1702013-12-31United States and EuropeAnalytical TechnologiesUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 170 employees as part of headcount reductions and facility consolidations; segment total restructuring and other charges were $11.6M including $0.8M accelerated depreciation and $1.3M Life Technologies transaction costs.
2013-03-30restructuringin_progress752013-12-31Not specifiedSpecialty DiagnosticsUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 75 employees, all cash costs primarily for headcount reductions; segment total restructuring and other charges were $18.9M including $12.2M cost-of-revenue charges for acquisition-date inventory revaluation.
2013-03-30restructuringin_progress702013-12-31Not specifiedLaboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 70 employees from headcount reductions and facility consolidations; segment total restructuring and other charges were $5.0M net, including $0.2M accelerated depreciation and $0.2M gain on real estate sale.
2013-03-30restructuringin_progress2013-12-31Not specifiedCorporateUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All cash costs for severance at corporate operations and abandoned facility costs; employee count not disclosed.
2013-03-30restructuringannounced2013-05-032013-12-31Not specifiedNot specifiedUSD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 3, 2013 the company identified restructuring actions expected to result in approximately $70M of additional charges, primarily in the remainder of 2013; employee count not disclosed. Additional actions expected to be identified during 2013.
2013-03-30acquisition_additionannounced2013-04-142014-03-31GlobalNot specifiedsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Life Technologies Corporation for approximately $13.6 billion ($76.00/share) plus assumed net debt; expected to close early 2014. Headcount to be added not disclosed in this filing.
2013-03-30restructuringin_progress170United States and EuropeAnalytical TechnologiesUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 170 employees associated with headcount reductions and facility consolidations.
2013-03-30restructuringin_progress75Specialty DiagnosticsUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 75 employees primarily associated with headcount reductions.
2013-03-30restructuringin_progress70Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 70 employees associated with headcount reductions and facility consolidations.
2013-03-30restructuringannounced2013-05-032013-12-31USD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $70 million, primarily in the remainder of 2013.
2013-03-30restructuringin_progress CorporateUSD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Analytical TechnologiesUSD 9,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress170 Employee Severance / Analytical TechnologiesUSD 7,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Facility Closing / Analytical TechnologiesUSD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Other Restructuring / Analytical TechnologiesUSD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Specialty DiagnosticsUSD 6,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress75 Employee Severance / Specialty DiagnosticsUSD 6,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Other Restructuring / Specialty DiagnosticsUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Laboratory Products And ServicesUSD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress70 Employee Severance / Laboratory Products And ServicesUSD 3,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Other Restructuring / Laboratory Products And ServicesUSD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Pre2012 Restructuring PlansUSD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Restructuring Plans2012USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Restructuring Plans2013USD 19,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Employee Severance / Pre2012 Restructuring PlansUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Employee Severance / Restructuring Plans2012USD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Employee Severance / Restructuring Plans2013USD 18,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Facility Closing / Pre2012 Restructuring PlansUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Facility Closing / Restructuring Plans2012USD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Facility Closing / Restructuring Plans2013USD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Other Restructuring / Pre2012 Restructuring PlansUSD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Other Restructuring / Restructuring Plans2012USD 1,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2013-03-30restructuringin_progress Other Restructuring / Restructuring Plans2013USD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-12-31restructuringcompleted5902012U.S. and EuropeAnalytical TechnologiesUSD 42 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Charges incurred during fiscal 2012; no specific announcement date disclosed. Components: severance of $21.7 million for approximately 590 employees, abandoned facility costs of $9.5 million, other cash costs of $2.6 million, and $8.5 million non-cash expense primarily real estate writedowns from facility consolidations, plus $1.4 million accelerated depreciation in cost of revenues.
2012-12-31restructuringcompleted2402012Specialty DiagnosticsUSD 15 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Charges incurred during fiscal 2012. Severance of $11.3 million for approximately 240 employees, abandoned facility costs of $0.6 million, other cash costs of $2.4 million, and $0.7 million non-cash real estate writedowns. The segment's total restructuring-related charges of $81.5 million also include $52.8 million of acquisition inventory revaluation and $13.7 million of One Lambda transaction costs not tied to workforce reductions.
2012-12-31restructuringcompleted2902012Laboratory Products and ServicesUSD 24 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Charges incurred during fiscal 2012. Severance of $10.9 million for approximately 290 employees, abandoned facility costs of $3.2 million, other cash costs of $3.4 million, plus $6.3 million non-cash net (intangible impairment and asset writedowns, offset by a $5.9 million gain on pre-acquisition litigation).
2012-12-31restructuringcompleted2012CorporateUSD 1 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cash costs primarily for severance at corporate operations during 2012; affected employee count not disclosed. Partially offset by a $0.2 million net SG&A credit associated with product liability litigation.
2012-12-31restructuringannounced2013-02-272013USD 80 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Subsequent-event disclosure as of the February 27, 2013 filing date: restructuring actions identified that will result in additional charges of approximately $80 million in 2013, with further actions expected to be identified during 2013. Affected employee counts not disclosed. Also disclosed in MD&A.
2012-12-31divestiture_reductioncompleted2012-06-222012-10-22Laboratory Products and ServicesUSD 63 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Decision to pursue sale of the laboratory workstations business made June 22, 2012 to exit a non-core business; sale completed October 22, 2012 for nominal proceeds. After-tax loss on divestiture of $63 million (charge is divestiture loss, not severance). Business revenues were $147 million in 2012 before the sale. Headcount affected not disclosed.
2012-12-31acquisition_additioncompleted2012-09Specialty DiagnosticsUSD 885 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		One Lambda, a transplant diagnostics provider, acquired September 2012 for approximately $885 million net of cash acquired plus up to $25 million contingent consideration. Value shown is purchase price, not a severance charge. Headcount added not disclosed; One Lambda 2011 revenues were $182 million.
2012-12-31acquisition_additioncompleted2012-05Laboratory Products and ServicesUSD 175 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Doe & Ingalls, a specialty production chemicals channel and supply-chain services provider, acquired May 2012 for $175 million plus up to $3 million contingent consideration. Value shown is purchase price. Headcount added not disclosed; 2011 revenues approximately $110 million.
2012-12-31acquisition_additioncompleted2012Analytical Technologies; Specialty DiagnosticsUSD 25 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Aggregate consideration of $25 million (plus contingent consideration up to $15 million) for several 2012 tuck-ins: a maker of isotope identifiers, radiation detectors and spectroscopy systems; a miniature NMR spectrometer manufacturer; and a pre-eclampsia diagnostics business. Headcount added not disclosed.
2012-12-31restructuringin_progress590United States and EuropeAnalytical TechnologiesUSD 22 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 590 employees from headcount reductions and facility consolidations; segment recorded $43.6M total net restructuring and other charges in 2012, of which $33.8M cash.
2012-12-31restructuringin_progress240Not specifiedSpecialty DiagnosticsUSD 11 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 240 employees; segment recorded $81.5M total net charges in 2012, including $52.8M inventory revaluation and $13.7M One Lambda transaction costs.
2012-12-31restructuringin_progress290Not specifiedLaboratory Products and ServicesUSD 11 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 290 employees; segment recorded $24.3M total net charges in 2012, of which $17.5M cash.
2012-12-31restructuringin_progressNot specifiedCorporateUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash costs primarily for severance at corporate operations; affected employee count not disclosed.
2012-12-31restructuringin_progressNot specifiedMultiple segmentsUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash costs incurred in 2012 under the 2011 program (excludes non-cash charges); employee count for 2012 activity not disclosed. Program announced in a prior fiscal year.
2012-12-31restructuringin_progressNot specifiedMultiple segmentsUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash costs incurred in 2012 under pre-2011 programs (excludes non-cash charges); employee count for 2012 activity not disclosed. Abandoned-facility payments run through lease terms expiring 2018.
2012-12-31acquisition_additioncompletedNot specifiedSpecialty DiagnosticsUSD 885 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		One Lambda (transplant diagnostics) acquired September 2012 for ~$885M net of cash; 2011 revenues of $182M. Headcount added not disclosed; charge value is purchase price, not a severance charge.
2012-12-31acquisition_additioncompletedUnited States (North Carolina)Laboratory Products and ServicesUSD 175 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Doe & Ingalls acquired May 2012 for $175M plus up to $3M contingent consideration; 2011 revenues ~$110M. Headcount added not disclosed; charge value is purchase price.
2012-12-31acquisition_additioncompletedNot specifiedAnalytical Technologies and Specialty DiagnosticsUSD 25 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate consideration for three smaller 2012 acquisitions (radioactive isotope identifier maker, miniature NMR spectrometer maker, pre-eclampsia/eclampsia test technology) plus up to $15M contingent consideration. Headcount added not disclosed.
2012-12-31divestiture_reductioncompleted2012-06-222012-10-22Not specifiedLaboratory Products and Services — laboratory workstations businessdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale decision made June 22, 2012; sale completed October 22, 2012 for nominal proceeds, with an after-tax loss of $63M. Business had revenues of $147.1M in the 2012 period prior to sale. Headcount removed not disclosed.
2012-12-31restructuringannounced2013-02-27Not specifiedNot specifiedUSD 80 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of February 27, 2013 (filing date), additional restructuring actions identified that will result in ~$80M of charges, primarily in the first half of 2013; further actions expected to be identified during 2013. Employee count not disclosed.
2012-12-31restructuringcompleted5902012United States and EuropeAnalytical TechnologiesUSD 22 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 590 employees associated with headcount reductions and facility consolidations.
2012-12-31restructuringcompleted2402012GlobalSpecialty DiagnosticsUSD 11 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 240 employees associated with headcount reductions and facility consolidations.
2012-12-31restructuringcompleted2902012GlobalLaboratory Products and ServicesUSD 11 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 290 employees associated with headcount reductions and facility consolidations.
2012-12-31restructuringin_progress590 Employee Severance / Analytical TechnologiesUSD 21,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Facility Closing / Analytical TechnologiesUSD 9,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress240 Employee Severance / Specialty DiagnosticsUSD 11,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Facility Closing / Specialty DiagnosticsUSD 600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress290 Employee Severance / Laboratory Products And ServicesUSD 10,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 3,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Other Restructuring / Laboratory Products And ServicesUSD 3,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Specialty DiagnosticsUSD 14,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Analytical TechnologiesUSD 33,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Laboratory Products And ServicesUSD 17,500,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Employee Severance / CorporateUSD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Other Restructuring / Specialty DiagnosticsUSD 2,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Other Restructuring / Analytical TechnologiesUSD 2,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Employee Severance / Pre2011 Restructuring PlansUSD 1,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Facility Closing / Pre2011 Restructuring PlansUSD 4,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Other Restructuring / Pre2011 Restructuring PlansUSD 300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Pre2011 Restructuring PlansUSD 6,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Employee Severance / Restructuring Plans2011USD 800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Facility Closing / Restructuring Plans2011USD 2,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Other Restructuring / Restructuring Plans2011USD 1,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Restructuring Plans2011USD 5,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Employee Severance / Restructuring Plans2012USD 43,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Facility Closing / Restructuring Plans2012USD 6,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Restructuring Plans2012USD 57,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-12-31restructuringin_progress Other Restructuring / Restructuring Plans2012USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-09-29restructuringin_progress470U.S. and EuropeAnalytical TechnologiesUSD 16 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 470 employees tied to headcount reductions and facility consolidations; nine-month figure. Q3 alone was ~170 employees ($5.1 million severance).
2012-09-29restructuringin_progress220Specialty DiagnosticsUSD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 220 employees for headcount reductions and facility consolidations; nine-month figure. Q3 alone was ~100 employees ($1.5 million severance).
2012-09-29restructuringin_progress250Laboratory Products and ServicesUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 250 employees for headcount reductions and facility consolidations; nine-month figure. Q3 alone was ~140 employees ($4.1 million severance).
2012-09-29restructuringannounced2012-11-022013-06-30USD 60 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional restructuring actions identified as of November 2, 2012, expected to result in roughly $60 million of charges primarily in remainder of 2012 and first half of 2013; actions taken in 2012 expected to yield about $70 million of annual cost savings.
2012-09-29acquisition_additioncompleted2012-09-132012-09-13Specialty DiagnosticsUSD 884 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired transplant diagnostics provider for approximately $884 million net of cash; no employee headcount disclosed.
2012-09-29acquisition_additioncompleted2012-05-012012-05-01North CarolinaLaboratory Products and ServicesUSD 175 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired specialty production chemicals channel and supply-chain services provider for $175 million plus up to $3 million contingent consideration; no employee headcount disclosed.
2012-09-29divestiture_reductioncompleted2012-06-222012-10-22Laboratory Products and Services (laboratory workstations business)USD 58 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of laboratory workstations business completed October 2012 for nominal proceeds; after-tax divestiture loss charges of $58 million recorded in first nine months of 2012. No employee headcount disclosed.
2012-09-29restructuringin_progress1702013-12-31United States and EuropeAnalytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2012 cash severance for approximately 170 employees from headcount reductions and facility consolidations. Year-to-date through 2012-09-29 the segment recorded severance for approximately 470 employees ($15.8M cash). Accrued severance expected to be paid primarily through 2013.
2012-09-29restructuringin_progress1002013-12-31Specialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2012 cash severance for approximately 100 employees tied to headcount reductions and facility consolidations. Year-to-date through 2012-09-29 the segment recorded severance for approximately 220 employees ($9.9M cash). Geography not specified.
2012-09-29restructuringin_progress1402013-12-31United States and EuropeLaboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2012 cash severance for approximately 140 employees from headcount reductions and facility consolidations. Year-to-date through 2012-09-29 the segment recorded severance for approximately 250 employees ($7.7M cash).
2012-09-29restructuringannounced2012-11-022013-06-30USD 60 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of 2012-11-02 the company identified restructuring actions expected to generate additional charges of approximately $60 million, primarily in the remainder of 2012 and the first half of 2013, with further actions expected to be identified. No employee count disclosed.
2012-09-29divestiture_reductioncompleted2012-06-222012-10-22Laboratory Products and Services — laboratory workstations businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Senior management decided on 2012-06-22 to pursue a sale; the business was sold on 2012-10-22 for nominal proceeds. Headcount removed not disclosed. 2011 revenues approximately $180M with an operating loss of approximately $6M.
2012-09-29acquisition_additioncompleted2012-09-132012-09-13Specialty Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired One Lambda, a transplant diagnostics provider, for approximately $884M net of cash acquired plus up to $25M contingent consideration; $274M allocated to goodwill. 2011 revenues $182M. Headcount added not disclosed.
2012-09-29acquisition_additioncompleted2012-05-012012-05-01United StatesLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Doe & Ingalls Management, LLC, a North Carolina-based specialty production chemicals channel, for $175M plus up to $3M contingent consideration; $81M allocated to goodwill. 2011 revenues approximately $110M. Headcount added not disclosed.
2012-09-29restructuringin_progress170United States and EuropeAnalytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 170 employees associated with headcount reductions and facility consolidations.
2012-09-29restructuringin_progress100Specialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 100 employees associated with restructuring actions.
2012-09-29restructuringin_progress140Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 140 employees associated with headcount reductions and facility consolidations.
2012-09-29restructuringin_progress470United States and EuropeAnalytical TechnologiesUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD severance for approximately 470 employees associated with headcount reductions and facility consolidations.
2012-09-29restructuringin_progress220Specialty DiagnosticsUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD severance for approximately 220 employees associated with headcount reductions and facility consolidations.
2012-09-29restructuringin_progress250Laboratory Products and ServicesUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD severance for approximately 250 employees associated with headcount reductions and facility consolidations.
2012-09-29restructuringannounced2012-11-022013-06-30USD 60 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Subsequent event: Identified restructuring actions resulting in additional charges of approximately $60 million, primarily in the remainder of 2012 and the first half of 2013.
2012-09-29restructuringin_progress Analytical TechnologiesUSD 7,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Specialty DiagnosticsUSD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Laboratory Products And ServicesUSD 5,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress170 Employee Severance / Analytical TechnologiesUSD 5,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress100 Employee Severance / Specialty DiagnosticsUSD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress140 Employee Severance / Laboratory Products And ServicesUSD 4,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Facility Closing / Analytical TechnologiesUSD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Other Restructuring / Analytical TechnologiesUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Other Restructuring / Specialty DiagnosticsUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Other Restructuring / Laboratory Products And ServicesUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Facility Closing / Specialty DiagnosticsUSD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Employee Severance / CorporateUSD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Pre2011 Restructuring PlansUSD 2,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Restructuring Plans2011USD 4,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Restructuring Plans2012USD 41,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Employee Severance / Pre2011 Restructuring PlansUSD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Employee Severance / Restructuring Plans2011USD 1,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Employee Severance / Restructuring Plans2012USD 32,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Facility Closing / Pre2011 Restructuring PlansUSD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Facility Closing / Restructuring Plans2011USD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Facility Closing / Restructuring Plans2012USD 5,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Other Restructuring / Pre2011 Restructuring PlansUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Other Restructuring / Restructuring Plans2011USD 2,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-09-29restructuringin_progress Other Restructuring / Restructuring Plans2012USD 3,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress300U.S. and EuropeAnalytical TechnologiesUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		YTD severance for approximately 300 employees tied to headcount reductions and facility consolidations, including closure and consolidation of several U.S. and European facilities; segment total YTD net restructuring and other charges were $19.1 million.
2012-06-30restructuringin_progress120Specialty DiagnosticsUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		YTD severance for approximately 120 employees from headcount reductions and facility consolidations; segment total YTD net restructuring and other charges were $49.0 million, including $37.8 million of acquisition-inventory revaluation charges in cost of revenues.
2012-06-30restructuringin_progress110Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		YTD severance for approximately 110 employees from headcount reductions and facility consolidations; segment YTD net restructuring and other charges were $9.2 million.
2012-06-30restructuringannounced2012-08-032012-12-31USD 60 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 3, 2012, identified restructuring actions expected to result in additional charges of approximately $60 million, primarily in the remainder of 2012; 2012 actions initiated in the first six months are expected to yield annual cost savings of approximately $45 million.
2012-06-30acquisition_additioncompleted2012-05-012012-05-01North Carolina, U.S.Laboratory Products and ServicesUSD 175 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Doe & Ingalls Management, LLC for $175 million net of cash acquired plus up to $3 million contingent consideration; no employee headcount disclosed.
2012-06-30divestiture_reductionannounced2012-06-222013-06-30Laboratory Products and Services (laboratory workstations business)USD 51 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Decision to pursue sale of laboratory workstations business (2011 revenues ~$180 million); after-tax charge of $51 million recorded in Q2 2012 as estimated loss on planned divestiture; no employee headcount disclosed.
2012-06-30acquisition_additionannounced2012-07-162012-12-31Specialty DiagnosticsUSD 866 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Definitive agreement to acquire One Lambda (transplant diagnostics; 2011 revenues $182 million) for approximately $866 million in cash; total outlay could reach ~$925 million including contingent consideration and three-year employee retention obligations; no employee headcount disclosed.
2012-06-30restructuringin_progress300United States and EuropeAnalytical TechnologiesUSD 11 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2012. Severance for approximately 300 employees from headcount reductions and facility consolidations; includes $2.9M abandoned facility costs and $1.0M other cash costs. Also $3.6M non-cash fixed asset writedowns.
2012-06-30restructuringin_progress120Specialty DiagnosticsUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2012. Severance for approximately 120 employees from headcount reductions and facility consolidations; also $0.4M abandoned facility costs and $0.7M non-cash real estate writedowns.
2012-06-30restructuringin_progress110Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2012. Severance for approximately 110 employees from headcount reductions and facility consolidations; also $1.7M abandoned facility costs, $1.8M other cash costs, and $1.2M non-cash writedowns.
2012-06-30restructuringin_progressCorporateUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2012. $0.3M cash severance costs at corporate operations, offset by $7.6M gain from product liability insurance settlement. Employee count not disclosed.
2012-06-30restructuringannounced2012-08-032012-12-31USD 60 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of August 3, 2012, identified restructuring actions expected to result in approximately $60M in additional charges, primarily in remainder of 2012. Employee count not disclosed. Additional actions expected.
2012-06-30acquisition_additionannounced2012-07-162012-12-31Specialty Diagnosticssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire One Lambda (transplant diagnostics) for approximately $866M cash, up to ~$925M total including contingent consideration and retention agreements. 2011 revenues of $182M. Headcount not disclosed.
2012-06-30acquisition_additioncompleted2012-05-01United StatesLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired Doe & Ingalls Management, LLC for $175M net of cash acquired plus up to $3M contingent consideration. 2011 revenues ~$110M. Headcount not disclosed.
2012-06-30divestiture_reductionannounced2012-06-222013-06-30Laboratory Products and Services — laboratory workstations businessUSD 51 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision on June 22, 2012 to pursue sale of laboratory workstations business (2011 revenues ~$180M, operating loss ~$6M). After-tax charge of $51M recorded as estimated loss on planned divestiture. Headcount not disclosed.
2012-06-30restructuringin_progress200U.S. and EuropeAnalytical TechnologiesUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs for headcount reductions and facility consolidations.
2012-06-30restructuringin_progress60Specialty DiagnosticsUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs for headcount reductions and facility consolidations.
2012-06-30restructuringin_progress30Laboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs for headcount reductions and facility consolidations.
2012-06-30restructuringin_progress300U.S. and EuropeAnalytical TechnologiesUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD cash costs for headcount reductions and facility consolidations.
2012-06-30restructuringin_progress120Specialty DiagnosticsUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD cash costs for headcount reductions and facility consolidations.
2012-06-30restructuringin_progress110Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD cash costs for headcount reductions and facility consolidations.
2012-06-30restructuringannounced2012-08-032012-12-31USD 60 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approx $60M, primarily in remainder of 2012.
2012-06-30restructuringin_progress Analytical TechnologiesUSD 10,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Specialty DiagnosticsUSD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Laboratory Products And ServicesUSD 2,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress200 Analytical Technologies / Employee SeveranceUSD 7,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress60 Employee Severance / Specialty DiagnosticsUSD 6,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress30 Employee Severance / Laboratory Products And ServicesUSD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Analytical Technologies / Facility ClosingUSD 1,900,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Facility Closing / Specialty DiagnosticsUSD 100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Analytical Technologies / Other RestructuringUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Other Restructuring / Specialty DiagnosticsUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Laboratory Products And Services / Other RestructuringUSD 800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Corporate / Employee SeveranceUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Pre2011 Restructuring PlansUSD 2,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Restructuring Plans2011USD 3,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Restructuring Plans2012USD 27,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Employee Severance / Pre2011 Restructuring PlansUSD 1,400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Employee Severance / Restructuring Plans2011USD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Employee Severance / Restructuring Plans2012USD 21,800,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Facility Closing / Pre2011 Restructuring PlansUSD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Facility Closing / Restructuring Plans2011USD 700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Facility Closing / Restructuring Plans2012USD 3,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Other Restructuring / Pre2011 Restructuring PlansUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Other Restructuring / Restructuring Plans2011USD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30restructuringin_progress Other Restructuring / Restructuring Plans2012USD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress100Analytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2012 net charges of $4.6 million including $3.1 million severance for approximately 100 employees and $1.0 million abandoned facility costs; all cash costs.
2012-03-31restructuringin_progress50Specialty DiagnosticsUSD 29 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2012 net charges of $29.0 million, mostly $26.3 million cost-of-revenues charges for sale of inventories revalued at acquisition; $1.7 million severance for approximately 50 employees and $0.3 million abandoned facility costs.
2012-03-31restructuringin_progress80United StatesLaboratory Products and ServicesUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2012 net charges of $8.1 million tied to closure and consolidation of several U.S. facilities; $5.2 million severance for approximately 80 employees, $1.2 million abandoned facility costs, $1.2 million other cash costs.
2012-03-31restructuringannounced2012-05-042012-12-31USD 70 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 4, 2012, identified restructuring actions expected to result in approximately $70 million of additional charges, primarily in remainder of 2012; Q1-initiated actions expected to yield ~$25 million annual cost savings.
2012-03-31acquisition_additionannounced2012-05-01United States (North Carolina)Laboratory Products and ServicesUSD 175 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of Doe & Ingalls Management, LLC for ~$175 million net of cash plus up to $3 million contingent consideration; 2011 revenues ~$110 million. No headcount disclosed.
2012-03-31restructuringin_progress100Analytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash severance plus $1.0M abandoned facility costs; segment recorded $4.6M total net restructuring and other charges in Q1 2012, including accelerated depreciation at facilities closing due to real estate consolidation.
2012-03-31restructuringin_progress50Specialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash costs of $2.0M included $1.7M severance and $0.3M abandoned facility costs; segment also recorded $26.3M non-cash cost of revenues charge for inventory revalued at acquisition date and $0.7M real estate writedowns.
2012-03-31plant_closurein_progress80United StatesLaboratory Products and ServicesUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cash costs of $7.6M included $5.2M severance for about 80 employees, $1.2M abandoned facility costs, and $1.2M retention, relocation and moving expenses; plus $0.6M non-cash asset writedowns net of real estate sale gain.
2012-03-31restructuringin_progressCorporateUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee count not disclosed; corporate also recorded a $7.6M reduction to SG&A from a product liability insurance settlement.
2012-03-31restructuringannounced2012-05-042012-12-31USD 70 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charges expected primarily in the remainder of 2012; company expects to identify additional actions during the rest of 2012. Employee counts not disclosed. Also referenced in MD&A.
2012-03-31acquisition_additionannounced2012-05-01United StatesLaboratory Products and ServicesUSD 175 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		North Carolina-based specialty production chemicals and supply-chain services provider; purchase price plus up to $3M contingent consideration. Acquired headcount not disclosed; 2011 revenues of about $110 million.
2012-03-31restructuringin_progress100Analytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 100 employees associated with headcount reductions and facility consolidations.
2012-03-31restructuringin_progress50Specialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 50 employees associated with headcount reductions and facility consolidations.
2012-03-31restructuringin_progress80United StatesLaboratory Products and ServicesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 80 employees associated with closure and consolidation of several U.S. facilities.
2012-03-31restructuringin_progressCorporateUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs for severance at corporate operations; employee count not disclosed.
2012-03-31restructuringannounced2012-05-042012-12-31USD 70 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Company identified restructuring actions resulting in additional charges of approximately $70 million, primarily in the remainder of 2012. Employee count not disclosed.
2012-03-31restructuringin_progress100 Analytical Technologies / Employee SeveranceUSD 3,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Analytical Technologies / Facility ClosingUSD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress50 Employee Severance / Specialty DiagnosticsUSD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Facility Closing / Specialty DiagnosticsUSD 300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress80 Employee Severance / Laboratory Products And ServicesUSD 5,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 1,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Laboratory Products And Services / Other RestructuringUSD 1,200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Specialty DiagnosticsUSD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Analytical TechnologiesUSD 4,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Laboratory Products And ServicesUSD 7,600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Pre2011 Restructuring PlansUSD 2,100,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Restructuring Plans2011USD 4,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Restructuring Plans2012USD 8,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Employee Severance / Pre2011 Restructuring PlansUSD 1,500,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Employee Severance / Restructuring Plans2011USD 3,300,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Employee Severance / Restructuring Plans2012USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Facility Closing / Pre2011 Restructuring PlansUSD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Facility Closing / Restructuring Plans2011USD 400,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Facility Closing / Restructuring Plans2012USD 1,700,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Other Restructuring / Pre2011 Restructuring PlansUSD 200,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Other Restructuring / Restructuring Plans2011USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31restructuringin_progress Other Restructuring / Restructuring Plans2012USD 600,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-12-31restructuringin_progress4602011Analytical TechnologiesUSD 19 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for approximately 460 employees from headcount reductions and facility consolidations; segment's actions expected to deliver ~$30M of the ~$85M annual cost savings from 2011 restructuring. Total 2011 segment net restructuring and other charges were $119.3M, including $21.2M cash compensation from monetizing equity awards held by Dionex employees at acquisition and $5.4M non-cash impairments.
2011-12-31restructuringin_progress802011Finland and AustraliaSpecialty DiagnosticsUSD 7 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for approximately 80 employees tied to consolidating facilities of acquired businesses in Finland and Australia with existing facilities in those countries; segment expected to deliver ~$15M of annual cost savings from 2011 restructuring. Segment 2011 net restructuring and other charges totaled $71.4M.
2011-12-31restructuringin_progress9402011United States, Mexico, and six European countriesLaboratory Products and ServicesUSD 18 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for approximately 940 employees from U.S./Mexico facility consolidation and restructuring of a commercial organization across six European countries; segment expected to deliver ~$40M of annual cost savings from 2011 restructuring. Segment 2011 net restructuring and other charges totaled $38.9M.
2011-12-31restructuringin_progress2011CorporateUSD 2 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Corporate recorded $5.1M of restructuring and other charges in 2011, including $2.1M cash severance; employee count not disclosed. Also included $3.0M charge for product liability litigation.
2011-12-31restructuringannounced2012-02-29USD 60 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		As of the February 29, 2012 filing date, company identified restructuring actions expected to generate approximately $60M of additional charges, primarily in the first half of 2012, with ~$30M of additional annual savings upon completion. Headcount impact not disclosed.
2011-12-31acquisition_additioncompleted2010-12-13United States (Sunnyvale, California)Analytical Technologiesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Dionex acquisition completed May 2011 for $2.03B net of cash acquired; headcount added through the acquisition not disclosed. Note 14 separately discloses $21.2M of cash compensation from monetizing equity awards held by Dionex employees at the acquisition date.
2011-12-31acquisition_additioncompleted2011-05-19Sweden (headquartered)Specialty Diagnosticsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Phadia acquisition completed August 2011 for $3.54B net of cash acquired, including repayment of $2.14B of Phadia debt; headcount added through the acquisition not disclosed.
2011-12-31divestiture_reductioncompleted2011-04-04discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Athena Diagnostics sold for $740M in cash; classified as discontinued operations. Combined Athena/Lancaster sale generated a $304M after-tax gain. Headcount removed through the divestiture not disclosed.
2011-12-31divestiture_reductioncompleted2011-04-04discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Lancaster Laboratories sold for $180M in cash plus $20M escrowed proceeds due October 2012; classified as discontinued operations. Headcount removed through the divestiture not disclosed.
2011-12-31restructuringin_progress460GlobalAnalytical TechnologiesUSD 19 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 460 employees; segment also incurred $7.0M abandoned facility costs and $21.2M cash compensation from monetizing Dionex employee equity awards. Facility consolidations in the U.S. and Mexico.
2011-12-31restructuringin_progress80Finland; AustraliaSpecialty DiagnosticsUSD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 80 employees; consolidation of acquired-business facilities in Finland and Australia with existing facilities. Also $0.7M abandoned facility costs.
2011-12-31restructuringin_progress940United States; Mexico; Europe (six countries)Laboratory Products and ServicesUSD 18 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 940 employees; includes U.S./Mexico facility consolidation and restructuring of a commercial organization across six European countries. Also $4.2M abandoned facility costs.
2011-12-31restructuringin_progressGlobalCorporateUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Corporate cash costs for severance; employee count not disclosed. Segment also recorded $3.0M charge to SG&A related to product liability litigation.
2011-12-31acquisition_additioncompleted2011-05-192011-08-31Sweden (global operations)Specialty DiagnosticsUSD 3,538 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Phadia acquired August 2011 for $3.54B net of cash acquired; headcount added not disclosed. Charge value shown is total purchase price, not a restructuring charge.
2011-12-31acquisition_additioncompleted2010-12-132011-05-31United States (Sunnyvale, California)Analytical TechnologiesUSD 2,029 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Dionex acquired May 2011 for $2.03B net of cash acquired; headcount added not disclosed. Charge value shown is total purchase price, not a restructuring charge.
2011-12-31acquisition_additioncompletedUnited States; United Kingdom; SingaporeLaboratory Products and Services; Specialty DiagnosticsUSD 107 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate of five smaller 2011 acquisitions totaling $105M net of cash acquired (purchase price table shows $106.9M); headcount added not disclosed.
2011-12-31divestiture_reductioncompleted2011-04-042011-04-04United StatesSpecialty Diagnostics (Athena Diagnostics); Laboratory Products and Services (Lancaster Laboratories)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Athena Diagnostics sold for $740M and Lancaster Laboratories for $180M cash plus $20M escrow; combined 2010 revenues ~$226M and pre-tax income ~$59M. Employees removed through the sale not disclosed.
2011-12-31restructuringannounced2012-02-29GlobalNot specifiedUSD 60 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of February 29, 2012 (filing date), company identified restructuring actions expected to result in approximately $60M of additional charges in 2012, primarily in the first half; employee counts not disclosed. Additional actions expected to be identified during 2012.
2011-12-31restructuringcompleted4602011Analytical TechnologiesAnalytical TechnologiesUSD 19 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 460 employees in Analytical Technologies.
2011-12-31restructuringcompleted802011Finland and AustraliaSpecialty DiagnosticsUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 80 employees in Specialty Diagnostics, consolidating facilities in Finland and Australia.
2011-12-31restructuringcompleted9402011United States, Mexico, and EuropeLaboratory Products and ServicesUSD 18 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 940 employees in Laboratory Products and Services, including US/Mexico consolidation and European commercial restructuring.
2011-12-31restructuringcompleted2011CorporateCorporateUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Cash costs for severance at corporate operations.
2011-12-31acquisition_additioncompleted2011-08GlobalSpecialty Diagnosticsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Phadia group in August 2011.
2011-12-31acquisition_additioncompleted2011-05GlobalAnalytical Technologiesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Dionex Corporation in May 2011.
2011-12-31divestiture_reductioncompleted2011-04-04GlobalDiscontinued Operationsdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of Athena Diagnostics and Lancaster Laboratories businesses.
2011-12-31restructuringin_progress Analytical TechnologiesUSD 48,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Specialty DiagnosticsUSD 8,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Laboratory Products And ServicesUSD 25,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress460 Analytical Technologies / Employee SeveranceUSD 19,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress80 Employee Severance / Specialty DiagnosticsUSD 6,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress940 Employee Severance / Laboratory Products And ServicesUSD 18,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Analytical Technologies / Facility ClosingUSD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Facility Closing / Specialty DiagnosticsUSD 700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Facility Closing / Laboratory Products And ServicesUSD 4,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Analytical Technologies / Other RestructuringUSD 1,400,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Other Restructuring / Specialty DiagnosticsUSD 600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Laboratory Products And Services / Other RestructuringUSD 3,600,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Analytical Technologies / Dionex Monetized Equity AwardsUSD 21,200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Corporate / Employee SeveranceUSD 2,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Employee Severance / Pre2010 Restructuring PlansUSD 800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Facility Closing / Pre2010 Restructuring PlansUSD 2,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Other Restructuring / Pre2010 Restructuring PlansUSD 200,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Pre2010 Restructuring PlansUSD 3,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Employee Severance / Restructuring Plans2010USD 4,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Facility Closing / Restructuring Plans2010USD 100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Other Restructuring / Restructuring Plans2010USD 1,900,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Restructuring Plans2010USD 6,100,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Employee Severance / Restructuring Plans2011USD 41,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Facility Closing / Restructuring Plans2011USD 9,700,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Restructuring Plans2011USD 76,300,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-12-31restructuringin_progress Other Restructuring / Restructuring Plans2011USD 24,800,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2011-10-01restructuringin_progress2702011-01-02Finland and other locationsAnalytical TechnologiesUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Year-to-date severance for approximately 270 employees under 2011 restructuring plans; also includes $5.9M abandoned facility costs and $0.8M other cash costs. Q3 portion was $3.8M severance for ~180 employees.
2011-10-01restructuringin_progress502011-01-02United States and United KingdomSpecialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Year-to-date severance for approximately 50 employees; also $0.6M abandoned facility costs and $0.5M other cash costs, plus $1.1M non-cash real estate write-downs. Q3 portion was $0.4M severance for ~10 employees.
2011-10-01restructuringin_progress5702011-01-02Laboratory Products and ServicesUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Year-to-date severance for approximately 570 employees; also $1.6M abandoned facility costs and $1.7M other cash costs. Q3 portion was $4.0M severance for ~260 employees.
2011-10-01restructuringannounced2011-11-042012-12-31USD 40 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Company identified additional restructuring actions expected to result in charges of approximately $40 million, primarily in remainder of 2011 and beginning of 2012; headcount not disclosed.
2011-10-01restructuringin_progress180Finland and other locationsAnalytical TechnologiesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2011 severance for headcount reductions and facility consolidations; includes Finland manufacturing and sales facility consolidation. Part of broader 9M program totaling ~270 employees and $15.4M severance in this segment.
2011-10-01restructuringin_progress10United States and internationalSpecialty DiagnosticsUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2011 severance for approximately 10 employees; also includes $1.1M non-cash writedown of real estate held for sale. Part of broader 9M program totaling ~50 employees and $2.0M severance in this segment.
2011-10-01restructuringin_progress260United States and internationalLaboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2011 severance for approximately 260 employees; includes facility consolidations. Part of broader 9M program totaling ~570 employees and $13.3M severance in this segment.
2011-10-01restructuringannounced2011-11-04GlobalMultiple segmentsUSD 40 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: additional restructuring charges of approximately $40 million identified as of November 4, 2011, primarily in remainder of 2011 and beginning of 2012. Employee count not disclosed.
2011-10-01acquisition_additioncompleted2011-05-192011-08-31Sweden (headquarters), global operationsSpecialty Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Phadia acquisition completed August 2011 for $3.54 billion net of cash acquired. Headcount added not disclosed.
2011-10-01acquisition_additioncompleted2010-12-132011-05-31United States (Sunnyvale, CA), global operationsAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Dionex acquisition completed May 2011 for $2.03 billion net of cash acquired. Headcount added not disclosed.
2011-10-01divestiture_reductioncompleted2011-04-042011-04-04United StatesSpecialty Diagnostics (Athena Diagnostics)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Athena Diagnostics sold for $740 million cash. Headcount removed not disclosed.
2011-10-01divestiture_reductioncompleted2011-04-042011-04-04United StatesLaboratory Products and Services (Lancaster Laboratories)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Lancaster Laboratories sold for $180 million cash plus $20 million escrowed. Headcount removed not disclosed.
2011-10-01restructuringin_progress180Analytical TechnologiesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2011 severance for approximately 180 employees.
2011-10-01restructuringin_progress10Specialty DiagnosticsUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2011 severance for approximately 10 employees.
2011-10-01restructuringin_progress260Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2011 severance for approximately 260 employees.
2011-10-01restructuringin_progress270FinlandAnalytical TechnologiesUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2011 severance for approximately 270 employees associated with consolidation of manufacturing and sales facility in Finland.
2011-10-01restructuringin_progress50Specialty DiagnosticsUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2011 severance for approximately 50 employees.
2011-10-01restructuringin_progress570Laboratory Products and ServicesUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD 2011 severance for approximately 570 employees.
2011-10-01restructuringannounced2011-11-04USD 40 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of November 4, 2011, company identified restructuring actions resulting in additional charges of approximately $40 million, primarily in remainder of 2011 and beginning of 2012.
2011-10-01restructuringin_progress180 Analytical Technologies / Employee Severancerestructuring_footnote
f5-10q / no-ai-xblr
2011-10-01restructuringin_progress10 Employee Severance / Specialty Diagnosticsrestructuring_footnote
f5-10q / no-ai-xblr
2011-10-01restructuringin_progress260 Employee Severance / Laboratory Products And Servicesrestructuring_footnote
f5-10q / no-ai-xblr
2011-07-02restructuringin_progress120Finland (and other locations)Analytical TechnologiesUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approximately 120 employees in the Analytical Technologies segment; part of headcount reductions and facility consolidations including consolidation of a manufacturing and sales facility in Finland of an acquired business with an existing facility. Q2 portion was approximately 40 employees ($6.0 million severance).
2011-07-02restructuringin_progress310Australia (and other locations)Laboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Approximately 310 employees in the Laboratory Products and Services segment; includes consolidation of several facilities of an acquired business in Australia with an existing facility. Q2 portion was approximately 200 employees ($6.5 million severance).
2011-07-02plant_closurein_progressFinlandAnalytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Abandoned facility costs of $4.7 million in the first six months of 2011 for facility consolidations, including consolidation of a manufacturing and sales facility in Finland of an acquired business with an existing facility in that country.
2011-07-02plant_closurein_progressAustraliaLaboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Abandoned facility costs of $1.5 million in the first six months of 2011, including consolidation of several facilities of an acquired business in Australia with an existing facility in that country.
2011-07-02restructuringannounced2011-08-052011-12-31USD 40 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 5, 2011, the company identified restructuring actions expected to result in additional charges of approximately $40 million, primarily in the remainder of 2011; MD&A notes additional actions may be identified during the remainder of 2011. Actions initiated in the first six months of 2011 are expected to yield annual cost savings of approximately $40 million.
2011-07-02divestiture_reductioncompleted2011-04-042011-04-04Analytical Technologies (Athena Diagnostics); Laboratory Products and Services (Lancaster Laboratories)USD 304 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sold Athena Diagnostics for $740 million and Lancaster Laboratories for $180 million cash plus $20 million escrowed proceeds; after-tax gain of approximately $304 million. Headcount of divested businesses not disclosed.
2011-07-02acquisition_additioncompleted2011-05-01Sunnyvale, CaliforniaAnalytical TechnologiesUSD 2,030 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Dionex Corporation in May 2011 for $2.03 billion net of cash acquired; headcount added not disclosed.
2011-07-02restructuringin_progress1202011-12-31FinlandAnalytical TechnologiesUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2011-07-02: consolidation of an acquired business's manufacturing/sales facility in Finland with an existing facility; $13.2M severance for ~120 employees plus $4.7M abandoned facility costs. Second quarter alone disclosed $6.0M severance for ~40 employees across headcount reductions and facility consolidations, which may overlap with the six-month Finland figure. Severance expected to be paid primarily through 2011; abandoned-facility payments run through lease terms expiring 2018.
2011-07-02restructuringin_progress3102011-12-31Australia and other locationsLaboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2011-07-02: headcount reductions and facility consolidations, including consolidation of several facilities of an acquired business in Australia; $9.2M severance for ~310 employees plus $1.5M abandoned facility costs. Second quarter alone disclosed $6.5M severance for ~200 employees (subset of the six-month figure). Segment also recorded $3.0M non-cash costs, mainly a loss on sale of a heating equipment business.
2011-07-02restructuringin_progress2011-12-31CorporateUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2011-07-02: $0.6M of cash restructuring charges at corporate operations, all non-executive severance; employee count not disclosed.
2011-07-02restructuringannounced2011-08-052011-12-31USD 40 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of 2011-08-05 the company identified restructuring actions expected to generate additional charges of about $40M, primarily in the remainder of 2011; further actions expected to be identified. Employee counts not disclosed. Actions initiated in the first six months of 2011 are expected to yield annual cost savings of about $40M.
2011-07-02acquisition_additioncompleted2010-12-132011-05-31United States (Sunnyvale, California)Analytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Dionex Corporation acquired in May 2011 for $2.03B net of cash acquired; $1.32B allocated to goodwill. Headcount added not disclosed. Related restructuring included $21.6M of cash compensation for monetizing Dionex employee equity awards at acquisition date.
2011-07-02acquisition_additionannounced2011-05-19SwedenAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire the Phadia group for approximately €1.05B cash plus repayment of about €1.41B of Phadia debt (total ~$3.51B at announcement rates); closing subject to regulatory approvals. Headcount not disclosed; Phadia 2010 revenues €367M.
2011-07-02divestiture_reductioncompleted2011-04-042011-04-04Analytical Technologies — Athena Diagnosticsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Athena Diagnostics sold for $740M cash; results reported as discontinued operations. Headcount removed not disclosed.
2011-07-02divestiture_reductioncompleted2011-04-042011-04-04Laboratory Products and Services — Lancaster Laboratoriesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Lancaster Laboratories sold for $180M cash plus $20M escrowed proceeds due October 2012; results reported as discontinued operations. Combined after-tax gain on the two sales was ~$304M ($0.78 per diluted share). Headcount removed not disclosed.
2011-07-02acquisition_additioncompleted2011-07-31MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In July 2011 (after quarter end) the company acquired a provider of microbiology solutions for approximately $48M in cash; headcount not disclosed.
2011-07-02restructuringin_progress40Analytical TechnologiesAnalytical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 40 employees in Q2 2011.
2011-07-02restructuringin_progress120FinlandAnalytical TechnologiesUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 120 employees in YTD 2011 related to facility consolidation in Finland.
2011-07-02restructuringin_progress200Laboratory Products and ServicesLaboratory Products and ServicesUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 200 employees in Q2 2011.
2011-07-02restructuringin_progress310Laboratory Products and ServicesLaboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 310 employees in YTD 2011.
2011-07-02restructuringannounced2011-08-05GlobalCorporateUSD 40 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of August 5, 2011, company identified restructuring actions resulting in additional charges of approximately $40 million, primarily in remainder of 2011.
2011-04-02restructuringin_progress80Finland and other locationsAnalytical TechnologiesUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 80 employees as part of headcount reductions and facility consolidations, including consolidation of a manufacturing and sales facility in Finland with an existing facility in that country.
2011-04-02restructuringin_progress110Laboratory Products and ServicesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 110 employees associated with headcount reductions and facility consolidations in the segment.
2011-04-02restructuringin_progressCorporateUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Corporate recorded $0.2 million of cash severance charges in the first three months of 2011; affected-employee count not disclosed.
2011-04-02divestiture_reductioncompleted2011-04-04Athena Diagnostics (Analytical Technologies); Lancaster Laboratories (Laboratory Products and Services)other
f5-10q / GLM-5.3-flash-fp4-HTML		Company sold Athena Diagnostics for $740 million and Lancaster Laboratories for $180 million plus $20 million escrowed proceeds on April 4, 2011; both presented as discontinued operations. Headcount removed not disclosed.
2011-04-02restructuringin_progress80Finland and other locationsAnalytical TechnologiesUSD 7 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 80 employees; includes consolidation of a manufacturing and sales facility in Finland. Total segment restructuring and other charges were $15.5M, including $4.0M abandoned facility costs.
2011-04-02restructuringin_progress110Not specifiedLaboratory Products and ServicesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 110 employees; includes facility consolidations. Total segment restructuring and other charges were $5.6M, including $0.4M abandoned facility costs.
2011-04-02restructuringin_progressNot specifiedCorporateUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All cash costs for severance in Q1 2011; employee count not disclosed.
2011-04-02restructuringannounced2011-05-062011-12-31Not specifiedBoth segmentsUSD 35 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional restructuring actions identified as of May 6, 2011, expected primarily in remainder of 2011; employee count not disclosed. Company expects to identify further actions during 2011.
2011-04-02divestiture_reductioncompleted2011-04-042011-04-04United StatesAnalytical Technologies — Athena Diagnosticsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Athena Diagnostics sold for $740M cash on April 4, 2011 (subsequent event). Headcount not disclosed.
2011-04-02divestiture_reductioncompleted2011-04-042011-04-04United StatesLaboratory Products and Services — Lancaster Laboratoriesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Lancaster Laboratories sold for $180M cash plus $20M escrowed on April 4, 2011 (subsequent event). Headcount not disclosed.
2011-04-02acquisition_additioncompletedSingaporeLaboratory Products and ServicesUSD 2 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Operating assets of a Singapore-based distributor of laboratory equipment acquired for $2M in Q1 2011. Headcount not disclosed.
2011-04-02acquisition_additionannounced2010-12-132011-09-30United StatesAnalytical Technologies — Dionex CorporationUSD 2,100 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending tender offer at $118.50/share (~$2.1B); offer expires May 13, 2011. Special mandatory redemption of $2.2B senior notes if not consummated by September 30, 2011. Headcount not disclosed.
2011-04-02restructuringin_progress80FinlandAnalytical TechnologiesUSD 7 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 80 employees associated with headcount reductions and facility consolidations.
2011-04-02restructuringin_progress110Laboratory Products and ServicesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 110 employees associated with headcount reductions and facility consolidations.
2011-04-02restructuringin_progressCorporateUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs for severance at corporate operations; employee count not disclosed.
2010-12-31restructuringin_progress1702010Not specified by segment; 2010 plan-level actions included consolidating a Germany site into a U.S. site and an Iowa plant into Ohio and North Carolina plantsAnalytical Technologies — primarily manufacturing, sales and service functionsUSD 13 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for approximately 170 employees under actions initiated in 2010, which are expected to yield about $50M of annual cost savings beginning primarily in 2011 ($15M in this segment).
2010-12-31restructuringin_progress802010Not specified by segment; 2010 plan-level actions included consolidating a Germany site into a U.S. site and an Iowa plant into Ohio and North Carolina plantsLaboratory Products and Services — primarily manufacturing, administrative, sales and service functionsUSD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for approximately 80 employees under actions initiated in 2010; segment expected to contribute about $35M of the ~$50M annual cost savings beginning primarily in 2011. 2010-plan severance liability for both segments totaled $2.2M at year-end.
2010-12-31restructuringin_progress2009Analytical Technologies and Laboratory Products and ServicesUSD 19 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Current-year slice of plans initiated in 2009: $18.5M of cash costs incurred in 2010 (including $9.6M severance, $4.0M facility abandonment, $4.9M other) and $29.1M of payments; $10.6M liability remained at year-end. A 2010-specific affected-employee count is not disclosed.
2010-12-31restructuringin_progressUSD 2 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Current-year activity of pre-2009 plans: $2.1M costs incurred in 2010 ($0.2M severance, $1.8M facility abandonment, $0.1M other) and $5.0M payments; $3.4M liability remained at year-end.
2010-12-31restructuringannounced2011-02-24USD 35 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		As of February 24, 2011 the company identified restructuring actions expected to generate roughly $35M of additional charges in 2011, with further actions to be identified during 2011; affected-employee count not disclosed.
2010-12-31acquisition_additioncompleted2010-02United StatesAnalytical TechnologiesUSD 147 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Handheld spectroscopy instruments provider acquired for $147M net of cash plus up to $25M contingent consideration; 2009 revenue $45M. Headcount added not disclosed.
2010-12-31acquisition_additioncompleted2010-03FinlandAnalytical TechnologiesUSD 58 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Molecular biology tools provider acquired for $58M net of cash; 2009 revenue $20M. Headcount added not disclosed.
2010-12-31acquisition_additioncompleted2010-07Lithuania (principal operations)Analytical TechnologiesUSD 260 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Enzymes, reagents and kits manufacturer/distributor acquired for $260M net of cash; 2009 revenue approximately $55M. Headcount added not disclosed.
2010-12-31acquisition_additioncompleted2010Multiple (including India and Australia)Analytical Technologies and Laboratory Products and ServicesUSD 141 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Several tuck-ins: spectroscopy, chromatography/software, near-infrared and moisture analyzers, custom media, water purification and an India distributor (AT); an Australian laboratory chemicals/consumables/instruments provider (LPS); plus up to $7M contingent consideration. Headcount not disclosed.
2010-12-31acquisition_additionannounced2010-12-132011-09-30United States (Sunnyvale, California)Analytical TechnologiesUSD 2 (billions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Pending all-cash tender at $118.50 per share (~$2.1B); conditioned on majority tender and regulatory approvals. Senior notes issued February 2011 require special mandatory redemption at 101% if the deal is not consummated by September 30, 2011.
2010-12-31divestiture_reductionannounced2011-02Analytical Technologies — Athena Diagnostics (diagnostic testing, gene-based tests)USD 740 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		February 2011 agreement to sell for $740M cash; subject to regulatory approvals and closing conditions. Combined with Lancaster, the two businesses had 2010 revenues of ~$225M and operating income of ~$60M. Headcount affected not disclosed.
2010-12-31divestiture_reductionannounced2011-02Laboratory Products and Services — Lancaster Laboratories (contract analytical testing)USD 200 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		February 2011 agreement to sell for $200M cash; subject to regulatory approvals and closing conditions. The ~$225M revenue / ~$60M operating income figure covers Athena and Lancaster combined. Headcount affected not disclosed.
2010-12-31restructuringin_progress170United States and GermanyAnalytical TechnologiesUSD 13 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2010 severance for approximately 170 employees, primarily in manufacturing and sales/service, from headcount reductions and facility consolidations (Germany site consolidated with U.S. site; Iowa plant with Ohio and North Carolina plants). Segment total FY2010 restructuring and other charges were $61.9 million.
2010-12-31restructuringin_progress80United States and EuropeLaboratory Products and ServicesUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2010 severance for approximately 80 employees, primarily in manufacturing, administrative, and sales/service functions. Segment total FY2010 restructuring and other charges were $28.0 million.
2010-12-31restructuringin_progressGlobalMultipleUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2010 cash severance activity under restructuring plans initiated in 2009 (program announced prior to FY2010); employees affected during FY2010 under this program were not separately disclosed. Excludes non-cash items.
2010-12-31restructuringannounced2011-02-24GlobalMultipleUSD 35 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of February 24, 2011 the company identified restructuring actions expected to result in approximately $35 million of additional charges in 2011, primarily in the first half; additional actions expected to be identified during 2011. Headcount not disclosed.
2010-12-31acquisition_additioncompleted2010-02-01United StatesAnalytical Technologiesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ahura Scientific, Inc. (handheld spectroscopy instruments) for $147 million net of cash acquired plus up to $25 million contingent consideration; acquired 2009 revenue of $45 million. Headcount added not disclosed. Announcement month only (February 2010).
2010-12-31acquisition_additioncompleted2010-03-01FinlandAnalytical Technologiesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Finnzymes (molecular biology tools) for $58 million net of cash acquired; acquired 2009 revenue of $20 million. Headcount added not disclosed. Announcement month only (March 2010).
2010-12-31acquisition_additioncompleted2010-07-01LithuaniaAnalytical Technologiesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Fermentas International Inc. (enzymes, reagents, kits) for $260 million net of cash acquired; acquired 2009 revenue of approximately $55 million. Headcount added not disclosed. Announcement month only (July 2010).
2010-12-31acquisition_additioncompleted2010-12-31GlobalAnalytical Technologies and Laboratory Products and Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate of other smaller 2010 acquisitions (spectroscopy, chromatography software, near-infrared and microwave analyzers, custom media, water purification, India distributor, Australia distributor) totaling $141 million plus up to $7 million contingent consideration. Headcount added not disclosed. Date shown is fiscal-year placeholder; individual closing dates not stated.
2010-12-31divestiture_reductionannounced2011-02-01United StatesAnalytical Technologiessubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		February 2011 agreement to sell Athena Diagnostics for $740 million in cash, subject to regulatory approvals and closing conditions; 2010 revenues and operating income of the two businesses being sold aggregated approximately $225 million and $60 million. Headcount not disclosed. Announcement month only (February 2011).
2010-12-31divestiture_reductionannounced2011-02-01United StatesLaboratory Products and Servicessubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		February 2011 agreement to sell Lancaster Laboratories (contract testing laboratory) for $200 million in cash, subject to regulatory approvals and closing conditions. Headcount not disclosed. Announcement month only (February 2011).
2010-12-31restructuringcompleted1702010GlobalAnalytical TechnologiesUSD 13 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 170 employees primarily in manufacturing and sales and service functions.
2010-12-31restructuringcompleted802010GlobalLaboratory Products and ServicesUSD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 80 employees primarily in manufacturing, administrative, and sales and service functions.
2010-10-02restructuringin_progress110Analytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 110 employees as part of headcount reductions and facility consolidations to streamline operations; part of $5.0 million of other restructuring costs in the segment in Q3 2010.
2010-10-02restructuringin_progressLaboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance within $3.1 million of cash costs for headcount reductions and facility consolidations; employee count not disclosed.
2010-10-02restructuringin_progress40Analytical TechnologiesUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 40 employees; part of $4.5 million of other restructuring costs recorded in the second quarter of 2010.
2010-10-02restructuringin_progress65Analytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 65 employees; part of $8.0 million of cash restructuring costs recorded in the first quarter of 2010.
2010-10-02restructuringannounced2010-11-052011-12-31USD 28 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of November 5, 2010, identified restructuring actions expected to result in additional charges of approximately $28 million, primarily in the remainder of 2010 and in 2011.
2010-10-02restructuringin_progress110Not specifiedAnalytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2010 severance for approximately 110 employees; part of broader facility consolidation and headcount reduction program initiated in 2009.
2010-10-02restructuringin_progressNot specifiedLaboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2010 severance charge disclosed without employee count; part of facility consolidation and headcount reduction program.
2010-10-02restructuringannounced2010-11-05Not specifiedBoth segmentsUSD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of November 5, 2010, company identified restructuring actions expected to result in additional charges of approximately $28 million, primarily in remainder of 2010 and 2011. Employee count not disclosed.
2010-10-02acquisition_additioncompleted2010-02United StatesAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ahura Scientific acquired for $147M net of cash; headcount added not disclosed.
2010-10-02acquisition_additioncompleted2010-03FinlandAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Finnzymes acquired for $58M net of cash; headcount added not disclosed.
2010-10-02acquisition_additioncompleted2010-07LithuaniaAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fermentas International acquired for $260M net of cash; headcount added not disclosed.
2010-10-02acquisition_additioncompleted2010-06-30Not specifiedAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Four additional small acquisitions in first nine months of 2010 (aggregate $82M plus up to $7M contingent): tunable diode spectroscopy, liquid chromatography/proteomics, handheld near-infrared analyzers, microwave moisture analyzers. Headcount not disclosed; announcement date approximate (within first nine months of 2010).
2010-10-02restructuringin_progress110Analytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Third quarter 2010: Severance for approximately 110 employees associated with headcount reductions and facility consolidations.
2010-10-02restructuringin_progress40Analytical TechnologiesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Second quarter 2010: Severance for approximately 40 employees associated with headcount reductions and facility consolidations.
2010-10-02restructuringin_progress65Analytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		First quarter 2010: Severance for approximately 65 employees associated with headcount reductions and facility consolidations.
2010-10-02restructuringin_progressLaboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Third quarter 2010: Severance associated with headcount reductions and facility consolidations. Employee count not specified.
2010-10-02restructuringin_progressLaboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Second quarter 2010: Severance associated with headcount reductions and facility consolidations. Employee count not specified.
2010-10-02restructuringin_progressLaboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		First quarter 2010: Severance associated with headcount reductions and facility consolidations. Employee count not specified.
2010-10-02restructuringannounced2010-11-052011-12-31USD 28 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		As of November 5, 2010, company identified restructuring actions resulting in additional charges of approximately $28 million, primarily in remainder of 2010 and in 2011.
2010-07-03restructuringin_progress40Analytical TechnologiesUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 40 employees as part of headcount reductions and facility consolidations to streamline operations; part of $7.0 million total Q2 segment charges.
2010-07-03restructuringin_progress65Analytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 65 employees; part of $13.0 million Q1 segment restructuring charges including facility consolidations.
2010-07-03restructuringin_progressLaboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance within $4.6 million Q2 segment charges; employee count not disclosed.
2010-07-03restructuringin_progressLaboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance within $10.5 million Q1 segment charges; employee count not disclosed.
2010-07-03restructuringin_progress2010-12-31Company-wideUSD 23 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of August 4, 2010, identified restructuring actions expected to result in additional charges of approximately $23 million, primarily in remainder of 2010.
2010-07-03restructuringin_progress2010-12-31Germany, United Statesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of manufacturing and R&D operations at a site in Germany with an existing U.S. site.
2010-07-03restructuringin_progress2010-12-31Iowa, Ohio, North Carolina (United States)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of production operations at an Iowa plant with plants in Ohio and North Carolina.
2010-07-03acquisition_additioncompleted2010-02-01United StatesAnalytical TechnologiesUSD 147 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Ahura Scientific for $147 million net of cash plus contingent consideration; headcount added not disclosed.
2010-07-03acquisition_additioncompleted2010-03-01FinlandAnalytical TechnologiesUSD 58 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Finnzymes for $58 million net of cash; headcount added not disclosed.
2010-07-03acquisition_additionannounced2010-07-16LithuaniaAnalytical TechnologiesUSD 260 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired Fermentas International for $260 million net of cash, subject to post-closing adjustment; headcount added not disclosed.
2010-07-03restructuringin_progress402010-12-31International (segment-wide)Analytical TechnologiesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2010 severance for approximately 40 employees; segment also recorded $2.5M cost-of-revenues charges for inventory revaluation and accelerated depreciation at closing facilities, plus $0.3M abandoned facility and $0.5M other cash costs.
2010-07-03restructuringin_progress652010-12-31International (segment-wide)Analytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2010 severance for approximately 65 employees; segment recorded $13.0M net restructuring and other charges in Q1 2010 including $3.9M cost-of-revenues charges and $1.1M Finnzymes transaction costs.
2010-07-03restructuringin_progress2010-12-31United States (Iowa plant consolidated with Ohio and North Carolina plants)Laboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2010 cash restructuring costs; employee count not disclosed. Segment recorded $4.6M net charges in Q2 2010 including $1.2M accelerated depreciation, $1.2M abandoned facility and $1.7M other cash costs.
2010-07-03restructuringin_progress2010-12-31Germany and United States (German manufacturing and R&D site consolidated with existing U.S. site)Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2010 cash restructuring costs; employee count not disclosed. Segment recorded $10.5M net charges in Q1 2010 including a $5.8M non-cash patent infringement charge.
2010-07-03restructuringin_progress2010-12-31United StatesCorporateUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All cash costs recorded in each of Q1 and Q2 2010; employee count not disclosed.
2010-07-03restructuringannounced2010-08-042010-12-31Not specifiedBoth segmentsUSD 23 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of August 4, 2010 the company identified restructuring actions expected to result in additional charges of approximately $23 million, primarily in the remainder of 2010, with further actions expected; employee count not disclosed. 2009 and 1H2010 actions expected to yield annual cost savings of approximately $118 million.
2010-07-03acquisition_additioncompleted2010-022010-02United StatesAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ahura Scientific acquired for $147 million net of cash acquired plus up to $25 million contingent consideration ($20 million fair value at acquisition date); acquired headcount not disclosed. Target had 2009 revenues of $45 million.
2010-07-03acquisition_additioncompleted2010-032010-03FinlandAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Finnzymes acquired for $58 million net of cash acquired; acquired headcount not disclosed. Target had 2009 revenues of $20 million.
2010-07-03acquisition_additioncompleted2010-06-302010-06-30Not specifiedAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Four smaller 2010 acquisitions (tunable diode spectroscopy, proteomics liquid chromatography/software, miniature handheld NIR analyzers, microwave moisture analyzers) for aggregate consideration of $82 million plus up to $7 million contingent; acquired headcount not disclosed. Announcement dates not specified beyond first six months of 2010.
2010-07-03acquisition_additioncompleted2010-07-162010-07-16Lithuania (principal operations)Analytical Technologiessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fermentas International acquired for $260 million net of cash acquired, subject to post-closing adjustment; acquired headcount not disclosed. Target had 2009 revenues of approximately $55 million.
2010-07-03restructuringin_progress40Analytical TechnologiesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2010 severance for approximately 40 employees in Analytical Technologies segment.
2010-07-03restructuringin_progress65Analytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 2010 severance for approximately 65 employees in Analytical Technologies segment.
2010-07-03restructuringin_progressLaboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2010 severance in Laboratory Products and Services segment; employee count not disclosed.
2010-07-03restructuringin_progressLaboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 2010 severance in Laboratory Products and Services segment; employee count not disclosed.
2010-04-03restructuringin_progress652009-01-01Analytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 65 employees as part of headcount reductions and facility consolidations to streamline operations; part of 2009-initiated restructuring actions.
2010-04-03restructuringin_progress2009-01-01Analytical TechnologiesUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2010 net restructuring and other charges for the segment, including cost of revenue charges of $3.9M, SG&A charges of $1.1M, and $8.0M of net cash costs.
2010-04-03restructuringin_progress2009-01-01Laboratory Products and ServicesUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2010 net charges including $1.2M cost of revenue charges, $3.5M cash costs (severance, abandoned facilities, retention/relocation), and $5.8M non-cash costs primarily a patent infringement loss.
2010-04-03restructuringin_progress2009-01-01Germanyrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of manufacturing and R&D operations at a site in Germany with an existing site in the U.S.
2010-04-03plant_closurein_progress2009-01-01United Statesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of production operations at a plant in Iowa with plants in Ohio and North Carolina.
2010-04-03restructuringannounced2010-05-062010-12-31USD 27 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 6, 2010, identified restructuring actions expected to result in additional charges of approximately $27 million, primarily in the remainder of 2010.
2010-04-03restructuringin_progress65Not specifiedAnalytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 65 employees as part of headcount reductions and facility consolidations; segment total restructuring charges were $13.0M including $8.0M cash costs.
2010-04-03restructuringin_progressNot specifiedLaboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Headcount reductions and facility consolidations; $3.5M cash costs including $0.3M severance, $1.7M abandoned facility costs, $1.5M other cash costs. Employee count not disclosed. Segment total restructuring charges were $10.5M.
2010-04-03restructuringannounced2010-05-062010-12-31Not specifiedBoth segmentsUSD 27 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 6, 2010, company identified restructuring actions expected to result in additional charges of approximately $27 million, primarily in the remainder of 2010. Employee count not disclosed.
2010-04-03acquisition_additioncompleted2010-02-01United StatesAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Ahura Scientific, Inc. for $147M net of cash plus up to $25M contingent consideration. Headcount added not disclosed; target had $45M revenue in 2009.
2010-04-03acquisition_additioncompleted2010-03-01FinlandAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Finnzymes for $59M net of cash. Headcount added not disclosed; target had $20M revenue in 2009.
2010-04-03acquisition_additioncompleted2010-04-01Not specifiedNot specifiedMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In April 2010, company acquired a supplier of products for proteomics analysis for approximately $40M cash plus up to $2M contingent. Headcount added not disclosed.
2010-04-03restructuringin_progress65Analytical TechnologiesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 65 employees associated with headcount reductions and facility consolidations.
2010-04-03restructuringin_progressLaboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance associated with headcount reductions and facility consolidations; employee count not specified.
2010-04-03restructuringin_progressCorporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Recorded $0.1 million in cash restructuring charges; no employee count disclosed.
2009-12-31restructuringin_progress5202010-12-31Analytical Technologies (primarily manufacturing and sales and service functions)USD 31 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Approximately 520 employees under plans initiated in 2009; severance is part of $41.8M segment cash costs for headcount reductions and facility consolidations. Program-wide 2009 facility consolidations (not attributed by segment) included production moves at UK, Iowa, Netherlands, Germany and France sites into other locations. Segment net charges of $44.0M also reflected a litigation-settlement gain and a $2.5M pension termination benefits charge. Program-level guidance indicates remaining approved actions will be completed during 2010.
2009-12-31restructuringin_progress3702010-12-31Laboratory Products and Services (primarily manufacturing, administrative, and sales and service functions)USD 14 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Approximately 370 employees under plans initiated in 2009; severance is part of $17.9M segment cash costs for headcount reductions and facility consolidations. Segment net charges of $23.1M included a loss on an abandoned facility sold in July 2009. Remaining approved program actions expected to be completed during 2010.
2009-12-31restructuringin_progress2010-12-31United States (corporate office, Waltham, MA)CorporateUSD 2 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		$1.9M net charges at corporate office in 2009; $2.1M cash costs primarily abandoned facility costs and, to a lesser extent, severance, partially offset by a $0.2M gain on the sale of a previously written-down building. No employee count disclosed.
2009-12-31restructuringin_progressUSD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Residual 2009 activity under plans initiated in 2008 (original action headcount was disclosed in the prior-year 10-K and is not re-extracted here). 2009 costs included $2.1M of severance; payments totaled $9.7M and a $3.3M liability remained at December 31, 2009.
2009-12-31restructuringin_progressUSD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Residual 2009 activity under legacy plans begun before 2008. 2009 costs included $1.9M of severance and $2.4M of facility abandonment; payments totaled $12.5M and a $3.8M liability remained at December 31, 2009.
2009-12-31restructuringannounced2010-02-262010-12-31USD 38 (millions)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Subsequent-event disclosure: restructuring actions identified as of February 26, 2010 expected to result in approximately $38M of additional charges in 2010, primarily in the first half; the company expects to identify additional actions during 2010. No employee counts disclosed.
2009-12-31restructuringin_progress520Global (primarily manufacturing and sales/service functions)Analytical TechnologiesUSD 31 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2009 actions: severance for approximately 520 employees; segment also incurred $5.5M abandoned-facility and $4.9M other cash costs. Facility consolidations in UK, Iowa, Netherlands, Germany and France. Announcement date not disclosed; actions initiated during 2009.
2009-12-31restructuringin_progress370Global (primarily manufacturing, administrative and sales/service functions)Laboratory Products and ServicesUSD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2009 actions: severance for approximately 370 employees; segment also incurred $1.1M abandoned-facility and $2.9M other cash costs, plus $3.8M non-cash costs. Announcement date not disclosed; actions initiated during 2009.
2009-12-31restructuringannounced2010-02-26Not specifiedNot specifiedUSD 38 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of the 2010-02-26 filing date, additional restructuring actions identified that will result in approximately $38M of charges, primarily in the first half of 2010; employee counts not disclosed. Company also expected to identify further actions during 2010.
2009-12-31acquisition_additioncompleted2009-04-30AustraliaLaboratory Products and ServicesUSD 132 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Biolab completed April 2009 for AUD 180 million (USD $132 million net of cash acquired); acquired headcount not disclosed. Charge value shown is total purchase price allocation.
2009-12-31acquisition_additioncompleted2009-10-01Germany (Europe)Analytical TechnologiesUSD 482 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of B.R.A.H.M.S. AG completed October 2009 for 331 million Euros (approximately $482 million including $32 million of assumed debt); acquired headcount not disclosed. Charge value shown is total purchase price allocation.
2009-12-31divestiture_reductioncompleted2009-12-31Not specifiedNot specifieddiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Four small business units sold during 2009 with net cash proceeds of $4.4 million and gains of $0.6 million; associated headcount not disclosed.
2009-12-31restructuringcompleted5202009GlobalAnalytical TechnologiesUSD 31 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 520 employees primarily in manufacturing and sales and service functions.
2009-12-31restructuringcompleted3702009GlobalLaboratory Products and ServicesUSD 14 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 370 employees primarily in manufacturing, administrative, and sales and service functions.
2009-09-26restructuringin_progress80Analytical Technologies - primarily manufacturing functionsUSD 6 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 80 employees, part of $8.5 million of cash costs for headcount reductions and facility consolidations in Q3 2009
2009-09-26restructuringin_progress180Laboratory Products and Services - administrative, manufacturing, sales and service functionsUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 180 employees, part of $3.8 million of cash costs for headcount reductions and facility consolidations in Q3 2009
2009-09-26restructuringin_progress230Analytical Technologies - primarily manufacturing and sales and service functionsUSD 6 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 230 employees in Q1 2009, part of $8.4 million of cash costs for headcount reductions and facility consolidations
2009-09-26restructuringin_progress300Analytical Technologies - all functionsUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 300 employees in Q2 2009, part of $12.3 million of cash costs for headcount reductions and facility consolidations
2009-09-26restructuringin_progress330Laboratory Products and Services - primarily manufacturing and administrative functionsUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 330 employees in Q1 2009, part of $4.5 million of cash costs
2009-09-26restructuringin_progress60Laboratory Products and Services - administrative, manufacturing, sales and service functionsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 60 employees in Q2 2009, part of $2.5 million of cash costs
2009-09-26plant_closurein_progressUnited Kingdom, United States, GermanyAnalytical Technologies - production operationsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of production operations at a UK plant with plants in the US and Germany
2009-09-26plant_closurein_progressNetherlands, United Kingdom, United StatesAnalytical Technologies - production operationsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of operations at a Netherlands plant with plants in the UK and US
2009-09-26plant_closurecompletedFrance, GermanyLaboratory Products and Services - manufacturingrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Relocation of a manufacturing site in France to an existing site in Germany completed in 2009
2009-09-26plant_closurein_progressUnited States (Iowa, Ohio, North Carolina)Laboratory Products and Services - production operationsrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of production operations at an Iowa plant with plants in Ohio and North Carolina
2009-09-26restructuringannounced2009-10-302010-06-30USD 43 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of October 30, 2009, identified restructuring actions expected to result in additional charges of approximately $43 million, primarily in remainder of 2009 and first half of 2010
2009-09-26restructuringin_progress80GlobalAnalytical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2009 severance for about 80 employees, primarily manufacturing, as part of headcount reductions and facility consolidations; segment also recorded $0.7M accelerated depreciation and $0.5M asset write-downs.
2009-09-26restructuringin_progress180GlobalLaboratory Products and ServicesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2009 severance for about 180 employees, primarily administrative, manufacturing, and sales and service functions.
2009-09-26restructuringannounced2009-10-302010-06-30GlobalBoth segmentsUSD 43 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of October 30, 2009, identified restructuring actions expected to result in additional charges of about $43 million, primarily in remainder of 2009 and first half of 2010; employee counts not disclosed.
2009-09-26acquisition_additioncompleted2009-10-012009-10-01GermanyAnalytical Technologiessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of B.R.A.H.M.S. AG for EUR 330 million (about $480 million including $30 million assumed debt); headcount added not disclosed.
2009-09-26acquisition_additioncompleted2009-04-012009-04-01AustraliaLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Biolab for AUD 180 million (USD $132 million) net of cash acquired; headcount added not disclosed. Four smaller 2009 acquisitions (Malaysia/Singapore, Mexico, Spain, Sweden) totaling $17 million consideration also completed; headcount not disclosed.
2009-09-26divestiture_reductioncompletedGlobalNot specifiedbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Three small business units sold in first nine months of 2009 with $1.2 million aggregate gains; headcount removed not disclosed.
2009-09-26restructuringin_progress802009-07-01GlobalAnalytical Technologies - ManufacturingUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2009 severance for approx. 80 employees primarily in manufacturing functions.
2009-09-26restructuringin_progress1802009-07-01GlobalLaboratory Products and Services - Administrative, Manufacturing, Sales & ServiceUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q3 2009 severance for approx. 180 employees primarily in administrative, manufacturing, and sales and service functions.
2009-09-26restructuringcompleted3002009-04-01GlobalAnalytical Technologies - All FunctionsUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2009 severance for approx. 300 employees across all functions.
2009-09-26restructuringcompleted602009-04-01GlobalLaboratory Products and Services - Administrative, Manufacturing, Sales & ServiceUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q2 2009 severance for approx. 60 employees primarily in administrative, manufacturing, and sales and service functions.
2009-09-26restructuringcompleted2302009-01-01GlobalAnalytical Technologies - Manufacturing, Sales & ServiceUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 2009 severance for approx. 230 employees primarily in manufacturing and sales and service functions.
2009-09-26restructuringcompleted3302009-01-01GlobalLaboratory Products and Services - Manufacturing, AdministrativeUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Q1 2009 severance for approx. 330 employees primarily in manufacturing and administrative functions.
2009-06-27restructuringin_progress300Analytical Technologies — all functionsUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 300 employees across all functions, part of $12.3 million cash costs for headcount reductions and facility consolidations in response to economic downturn.
2009-06-27restructuringin_progress60Laboratory Products and Services — administrative, manufacturing, sales and serviceUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 60 employees primarily in administrative, manufacturing, and sales and service functions.
2009-06-27restructuringin_progress230Analytical Technologies — manufacturing, sales and serviceUSD 6 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 230 employees primarily in manufacturing and sales and service functions, recorded in the first quarter of 2009.
2009-06-27restructuringin_progress330Laboratory Products and Services — manufacturing and administrativeUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 330 employees primarily in manufacturing and administrative functions, recorded in the first quarter of 2009.
2009-06-27plant_closurein_progressUnited Kingdom, United States, GermanyAnalytical Technologiesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of production operations at a UK plant with plants in the US and Germany.
2009-06-27plant_closurein_progressNetherlands, United Kingdom, United StatesAnalytical Technologiesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of operations at a Netherlands plant with plants in the UK and US.
2009-06-27restructuringin_progressSwitzerland, Hungary, United StatesAnalytical Technologiesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Integration of Swiss operations with existing operations in Hungary and the US.
2009-06-27plant_closurecompletedFrance, GermanyLaboratory Products and Servicesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Completion of relocation of a manufacturing site in France to an existing site in Germany.
2009-06-27restructuringannounced2010-12-31USD 34 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of July 31, 2009, identified restructuring actions expected to result in additional charges of approximately $34 million, primarily in remainder of 2009 and early 2010.
2009-06-27restructuringin_progress3002009-06-27GlobalAnalytical TechnologiesUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2009 severance for approximately 300 employees across all functions; part of headcount reductions and facility consolidations.
2009-06-27restructuringin_progress602009-06-27GlobalLaboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2009 severance for approximately 60 employees in administrative, manufacturing, and sales/service functions.
2009-06-27restructuringin_progress2302009-03-28GlobalAnalytical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2009 severance for approximately 230 employees primarily in manufacturing and sales/service functions.
2009-06-27restructuringin_progress3302009-03-28GlobalLaboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2009 severance for approximately 330 employees primarily in manufacturing and administrative functions.
2009-06-27restructuringannounced2009-07-31GlobalAll segmentsUSD 34 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of July 31, 2009, additional restructuring charges of approximately $34 million identified, primarily for remainder of 2009 and early 2010; no employee count disclosed.
2009-06-27acquisition_additioncompleted2009-04-01AustraliaLaboratory Products and Servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Biolab acquired April 2009 for AUD 180 million (USD $130 million) net of cash; no headcount disclosed for acquired workforce.
2009-06-27divestiture_reductioncompleted2009-06-27GlobalMultipleother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Three small business units sold in first six months of 2009 with gains of $1.2 million; operating results not material; no headcount disclosed.
2009-06-27restructuringin_progress3002009-04-01GlobalAnalytical TechnologiesUSD 9 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 300 employees across all functions in Q2 2009.
2009-06-27restructuringin_progress602009-04-01GlobalLaboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 60 employees primarily in administrative, manufacturing, and sales and service functions in Q2 2009.
2009-06-27restructuringin_progress2302009-01-01GlobalAnalytical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 230 employees primarily in manufacturing and sales and service functions in Q1 2009.
2009-06-27restructuringin_progress3302009-01-01GlobalLaboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 330 employees primarily in manufacturing and administrative functions in Q1 2009.
2009-03-28restructuringin_progress230Analytical TechnologiesUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2009 net charges of $8.3 million; severance of $6.3 million for approximately 230 employees primarily in manufacturing and sales and service functions, plus $1.2 million abandoned-facility costs and $0.9 million other cash costs; $0.1 million non-cash income including $0.9 million gain on sale of a small business unit.
2009-03-28restructuringin_progress330Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2009 net charges of $4.4 million; severance of $3.6 million for approximately 330 employees primarily in manufacturing and administrative functions, plus $0.3 million abandoned-facility costs and $0.6 million other cash costs.
2009-03-28restructuringin_progressCorporateUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Corporate recorded $0.9 million of restructuring and other charges in Q1 2009, all cash charges, primarily abandoned facility costs and to a lesser extent severance.
2009-03-28restructuringannounced2009-05-012009-12-31USD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		As of May 1, 2009, identified restructuring actions expected to result in additional charges of approximately $22 million, primarily in the remainder of 2009. Annual cost savings from actions initiated in late 2008 and Q1 2009 expected to total approximately $50 million.
2009-03-28acquisition_additioncompletedSpainLaboratory Products and ServicesUSD 8 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired a Spain-based distributor of laboratory instrumentation and equipment for $8 million in Q1 2009; no headcount disclosed.
2009-03-28acquisition_additionannounced2009-04-302009-04-30AustraliaUSD 120 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Completed acquisition of Biolab, an Australia-based provider of analytical instruments, life science consumables and laboratory equipment, for AUD $175 million (approximately USD $120 million); no headcount disclosed.
2009-03-28divestiture_reductioncompletedAnalytical TechnologiesUSD 1 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sold a small business unit in Q1 2009, recording a $0.9 million gain in restructuring and other costs, net; net cash proceeds of $2.3 million; operating results not material; no headcount disclosed.
2009-03-28restructuringin_progress230Analytical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 230 employees, primarily in manufacturing and sales and service functions; also includes $1.2M abandoned-facility costs and $0.9M other cash costs. Net segment charge was $8.3M including a $0.9M gain on sale of a small business unit.
2009-03-28restructuringin_progress330Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 330 employees, primarily in manufacturing and administrative functions; also includes $0.3M abandoned-facility costs and $0.6M other cash costs. Net segment charge was $4.4M.
2009-03-28restructuringin_progressCorporateUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All cash charges, primarily for abandoned facility costs and, to a lesser extent, severance. Employee count not disclosed.
2009-03-28restructuringannounced2009-05-012009-12-31USD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		As of May 1, 2009, company identified restructuring actions expected to result in additional charges of approximately $22 million, primarily in the remainder of 2009. Employee count not disclosed.
2009-03-28acquisition_additioncompletedSpainLaboratory Products and ServicesUSD 8 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of a Spain-based distributor of laboratory instrumentation and equipment for $8 million. Headcount added not disclosed.
2009-03-28divestiture_reductioncompletedAnalytical Technologiesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Small business unit sold in Q1 2009; gain of $0.9M recorded in restructuring and other costs, net. Net cash proceeds $2.3M. Headcount removed not disclosed.
2009-03-28acquisition_additionannounced2009-04-302009-04-30AustraliaUSD 120 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: acquisition of Biolab, an Australia-based provider of analytical instruments, life science consumables and laboratory equipment, completed April 30, 2009 for AUD $175 million (approximately USD $120 million). Headcount added not disclosed.
2009-03-28restructuringin_progress230Analytical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 230 employees primarily in manufacturing and sales and service functions.
2009-03-28restructuringin_progress330Laboratory Products and ServicesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 330 employees primarily in manufacturing and administrative functions.
2008-12-31restructuringin_progress50020082009United States (Utah, New Mexico); Denmark; AustraliaAnalytical TechnologiesUSD 14 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Approximately 500 employees across all functions under 2008 restructuring plans. Facility consolidations: bioprocess production consolidated into a new Utah facility; manufacturing ceased at plants in New Mexico, Denmark and Australia with operations transferred to other sites. Total segment net charges were $42.3 million, also including a $7.0M intangible impairment, $5.0M litigation loss, $2.9M loss on sale of businesses, $2.6M in-process R&D charge and $1.0M asset write-downs. Estimated annual cost savings approximately $26 million. Severance and retention obligations expected to be paid primarily through 2009; abandoned-facility payments over lease terms expiring through 2013.
2008-12-31restructuringin_progress38020082009United States (California, New York); Mexico; France; GermanyLaboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Approximately 380 employees, primarily in manufacturing and administrative functions, under 2008 restructuring plans. Manufacturing of certain laboratory consumables moved from existing California and New York facilities to a new Mexico facility; move of a France manufacturing site to Germany continued. Total segment net charges were $9.7 million, including $0.8M of acquisition-inventory charges and $2.2M of non-cash income (mainly real-estate sale gain). Estimated annual cost savings approximately $8 million.
2008-12-31restructuringin_progress20082009United StatesCorporateUSD 3 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cash charges primarily for severance and, to a lesser extent, abandoned-facility costs; employee count not disclosed. Corporate also recorded a $19.2M gain on curtailment of part of a U.S. defined benefit pension plan, a $2.5M writedown of real estate held for sale and a $1.7M gain on sale of used equipment.
2008-12-31restructuringannounced2009-02-272009USD 7 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		As of the filing date, additional restructuring actions totaling approximately $7 million identified for 2009, with further actions expected to be identified during 2009; employee count not disclosed.
2008-12-31restructuringin_progress20072009USD 9 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Current-year activity only under plans initiated in 2007: costs incurred in 2008 of $9.1 million ($3.5M severance, $1.5M employee retention, $2.6M facility abandonment, $1.5M other). Payments in 2008 totaled $14.2 million; remaining accrual of $7.0 million at year-end 2008. Severance, retention and other costs expected to be paid primarily through 2009. Cumulative program activity reported in prior filings not included.
2008-12-31restructuringin_progress2013USD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Current-year activity only under plans initiated before 2007: costs incurred in 2008 of $4.4 million ($1.0M severance, $3.1M facility abandonment, $0.3M other). Payments in 2008 totaled $4.7 million; remaining accrual of $4.3 million at year-end 2008. Abandoned-facility payments extend over lease terms expiring through 2013. Cumulative program activity reported in prior filings not included.
2008-12-31restructuringin_progress500United States, Denmark, AustraliaAnalytical TechnologiesUSD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 500 employees across all functions; part of 2008 actions including facility consolidations in Utah, New Mexico, Denmark and Australia. Segment also recorded $6.0M abandoned-facility costs and $3.4M other cash costs within $23.1M total cash costs.
2008-12-31restructuringin_progress380United States, Mexico, France, GermanyLaboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 380 employees, primarily manufacturing and administrative functions; consolidations moved consumables production from California and New York to Mexico and a France site to Germany. Segment total cash costs were $11.1M.
2008-12-31restructuringin_progressUnited StatesCorporateUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash charges primarily for severance plus some abandoned-facility costs; headcount not disclosed. Corporate also recorded a $19.2M pension curtailment gain and a $2.5M real-estate write-down in the same period.
2008-12-31acquisition_additioncompletedUnited States and internationalAnalytical Technologies; Laboratory Products and ServicesUSD 190 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Eleven small acquisitions completed in 2008 (none individually above $50M purchase price); $190M cash net of cash acquired plus $8M assumed debt. Headcount added through these acquisitions is not disclosed; charge value shown is aggregate purchase consideration, not a workforce charge.
2008-12-31divestiture_reductioncompleted2008-02-29United KingdomAnalytical Technologies (GV Instruments product lines)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale completed February 2008 following UK Competition Commission divestiture remedy; $29M after-tax impairment was recorded in 2007, not the current fiscal year. Employees affected not disclosed.
2008-12-31restructuringannounced2009-02-27Not specifiedNot specifiedUSD 7 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		As of the February 27, 2009 filing date the company had identified actions totaling approximately $7 million for 2009 and expected to identify additional actions during 2009; headcount not disclosed. 2008 actions were generating about $34M of annualized savings ($26M Analytical Technologies, $8M Laboratory Products and Services).
2008-12-31restructuringcompleted5002008-01-012008-12-31GlobalAnalytical TechnologiesUSD 14 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 500 employees across all functions in Analytical Technologies segment.
2008-12-31restructuringcompleted3802008-01-012008-12-31GlobalLaboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 380 employees primarily in manufacturing and administrative functions in Laboratory Products and Services segment.
2008-09-27restructuringin_progress123Analytical TechnologiesUSD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2008 net charges included $5.5 million severance for 123 employees primarily in manufacturing and administrative functions, plus facility consolidation costs and $2.8 million in-process R&D expense.
2008-09-27restructuringin_progress56Laboratory Products and ServicesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2008 net charges included $2.0 million severance for 56 employees primarily in manufacturing and administrative functions, plus non-cash charges related to sale of real estate.
2008-09-27restructuringin_progress93Analytical TechnologiesUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2008 net charges included $1.8 million severance for 93 employees primarily in manufacturing, R&D functions, plus a $5.0 million litigation-related loss and $3.0 million loss on sale of a business.
2008-09-27restructuringin_progress176Laboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2008 net charges included $2.0 million severance for 176 employees primarily in manufacturing, offset by a $1.8 million gain on sale of real estate in Holland.
2008-09-27restructuringin_progress51Analytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2008 net charges included $1.2 million severance for 51 employees primarily in manufacturing, sales and service functions, partially offset by gains on sales of businesses.
2008-09-27restructuringin_progress11Laboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2008 net charges included $0.3 million severance for 11 employees across all functions, plus relocation expenses.
2008-09-27restructuringannounced2008-10-30Several businessesUSD 12 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Company expects a Q4 charge of approximately $12 million for severance under restructuring plans initiated through October 30, 2008; expected annual cost savings of approximately $26 million beginning Q4 2008 and Q1 2009.
2008-09-27restructuringin_progress123Analytical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2008 severance for 123 employees, primarily in manufacturing and administrative functions, as part of facility consolidations and streamlining; segment also recorded $4.2M abandoned-facility costs and $3.6M non-cash costs including $2.8M in-process R&D from an acquisition.
2008-09-27restructuringin_progress56Laboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2008 severance for 56 employees, primarily in manufacturing and administrative functions; segment also recorded $0.9M non-cash charges principally related to the sale of real estate.
2008-09-27restructuringannounced2008-10-30Multiple businessesUSD 12 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company expects a Q4 2008 severance charge of approximately $12 million for cost-reduction plans initiated through October 30, 2008; expected annual cost savings of approximately $26 million beginning in Q4 2008 and Q1 2009. Headcount affected not disclosed.
2008-09-27restructuringin_progress123Analytical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 123 employees primarily in manufacturing and administrative functions.
2008-09-27restructuringin_progress56Laboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 56 employees primarily in manufacturing and administrative functions.
2008-09-27restructuringannounced2008-10-30USD 12 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Company expects to record a charge in the fourth quarter for severance related to restructuring plans initiated through October 30, 2008.
2008-06-28restructuringin_progress93Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 93 employees primarily in manufacturing, research and development functions, part of facility consolidations and streamlining operations.
2008-06-28restructuringin_progress51Analytical TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 51 employees primarily in manufacturing, sales and service functions, part of facility consolidations and streamlining operations.
2008-06-28restructuringin_progress176Laboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 176 employees primarily in manufacturing.
2008-06-28restructuringin_progress11Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 11 employees across all functions.
2008-06-28plant_closurein_progressNew Mexico, California, DenmarkAnalytical Technologiesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Continuing actions initiated prior to 2008 to cease manufacturing at plants in New Mexico, California and Denmark and transfer operations to other sites.
2008-06-28plant_closurein_progressCalifornia, New York to MexicoLaboratory Products and Servicesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Moving manufacture of certain laboratory consumables from facilities in California and New York to a new facility in Mexico.
2008-06-28plant_closurein_progress2009-06-30France to GermanyLaboratory Products and Servicesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Phased move of a manufacturing site in France to Germany through mid-2009.
2008-06-28restructuringin_progress932009-12-31Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2008 severance for 93 employees, primarily in manufacturing and R&D, part of facility consolidation and streamlining actions. Severance expected paid primarily through 2009.
2008-06-28restructuringin_progress1762009-12-31Laboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2008 severance for 176 employees, primarily in manufacturing. Segment also recorded $0.2M abandoned-facility costs and $0.2M other cash costs, offset by a $1.8M gain on sale of real estate in Holland.
2008-06-28restructuringin_progress2009-12-31CorporateUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2008 corporate restructuring charges, most cash costs primarily for severance; employee count not disclosed.
2008-06-28restructuringin_progress512009-12-31Analytical TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2008 severance for 51 employees, primarily in manufacturing, sales and service functions; disclosed in the YTD restructuring rollforward.
2008-06-28restructuringin_progress112009-12-31Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2008 severance for 11 employees across all functions; disclosed in the YTD restructuring rollforward.
2008-06-28restructuringin_progress2009-12-31CorporateUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2008 corporate restructuring charges, all cash costs primarily for severance; employee count not disclosed.
2008-06-28plant_closurein_progressUnited States; DenmarkAnalytical Technologiesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Principal 2008 actions: consolidating bioprocess production into a new Utah facility and ceasing manufacturing at plants in New Mexico, California and Denmark. Headcount not separately disclosed.
2008-06-28plant_closurein_progress2009-06-30United States; France; Germany; MexicoLaboratory Products and Servicesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Principal 2008 actions: moving laboratory consumables manufacturing from California and New York to a new Mexico facility, and a phased move of a French manufacturing site to Germany through mid-2009. Headcount not separately disclosed.
2008-06-28restructuringin_progress932008-04-01United StatesAnalytical Technologies; Manufacturing, Research and DevelopmentUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 93 employees primarily in manufacturing, research and development functions in Q2 2008.
2008-06-28restructuringin_progress512008-01-01United StatesAnalytical Technologies; Manufacturing, Sales and ServiceUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 51 employees primarily in manufacturing, sales and service functions in Q1 2008.
2008-06-28restructuringin_progress1762008-04-01United StatesLaboratory Products and Services; ManufacturingUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 176 employees primarily in manufacturing in Q2 2008.
2008-06-28restructuringin_progress112008-01-01United StatesLaboratory Products and Services; All functionsUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 11 employees across all functions in Q1 2008.
2008-06-28restructuringin_progress2008-04-01United StatesCorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Corporate office restructuring charges in Q2 2008, primarily for severance. Employee count not disclosed.
2008-06-28restructuringin_progress2008-01-01United StatesCorporateUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Corporate office restructuring charges in Q1 2008, primarily for severance. Employee count not disclosed.
2008-03-29restructuringin_progress51Analytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 51 employees primarily in manufacturing, sales and service functions; also includes abandoned-facility costs and contract termination/relocation costs, partially offset by gains on prior business sales.
2008-03-29restructuringin_progress11Laboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 11 employees across all functions, plus abandoned-facility costs and relocation expenses.
2008-03-29restructuringin_progressCorporateUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		All cash costs, primarily severance at the corporate office; no employee count disclosed.
2008-03-29restructuringin_progress512009Not specifiedAnalytical TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 51 employees, mainly in manufacturing, sales and service, tied to facility consolidation and streamlining; segment recorded $2.6M total net restructuring and other charges in Q1 2008, including $0.3M accelerated depreciation. Announcement date not disclosed; plans initiated in prior periods.
2008-03-29restructuringin_progress112009Not specifiedLaboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 11 employees across all functions; segment recorded $1.1M total net restructuring and other charges in Q1 2008, all cash costs. Announcement date not disclosed; plans initiated in prior periods.
2008-03-29restructuringin_progress2009Not specifiedCorporateUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Corporate office recorded $1.8M of restructuring and other charges in Q1 2008, all cash and primarily severance; number of employees affected not disclosed.
2008-03-29restructuringin_progress51Analytical TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 51 employees primarily in manufacturing, sales and service functions.
2008-03-29restructuringin_progress11Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 11 employees across all functions.
2008-03-29restructuringin_progressCorporateUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs primarily for severance at corporate office; employee count not disclosed.
2007-12-31restructuringin_progress3852007United States (New Mexico, Pennsylvania); Australia; DenmarkAnalytical TechnologiesUSD 8 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for approximately 385 employees across all functions, part of $18M cash costs for facility consolidations; manufacturing ceased at plants in New Mexico, Pennsylvania, Australia and Denmark with operations moved to other sites. Segment total 2007 charges were $61M, including $41M of inventory-revaluation charges to cost of revenues. 2007-plan accruals of $13.4M remained at year-end; severance and other obligations payable primarily through 2009.
2007-12-31restructuringin_progress2302007Laboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for approximately 230 employees across all functions, within $13M of cash costs for facility consolidations, principally the planned move of a France manufacturing site to Germany. Segment 2007 charges totaled $23M, including $8M of inventory-revaluation charges, plus a $2M loss on sale of a small business.
2007-12-31plant_closurein_progress2007-102009-06FranceLaboratory Products and ServicesUSD 11 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		October 2007 decision to close an LPS manufacturing facility; operations consolidated with existing factories in phases through mid-2009. $11M charged in 2007; additional $7–9M expected between Q1 2008 and mid-2009, including $6–8M cash costs. Headcount not disclosed; action is included within LPS 2007 restructuring costs.
2007-12-31divestiture_reductioncompleted2007Laboratory Products and ServicesUSD 2 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Small business sold for nominal proceeds during 2007; $2M loss recorded within restructuring and other costs. No headcount impact disclosed.
2007-12-31divestiture_reductioncompleted2007-04United Kingdomdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Genevac Limited, a solvent evaporation technology manufacturer, divested as required by an FTC consent order tied to merger approval; sold April 2007 for net cash proceeds of $21M. Headcount not disclosed.
2007-12-31divestiture_reductioncompleted2007-07discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Systems Manufacturing Corporation (SMC), a provider of consoles, workstations and server enclosures, sold in July 2007 for cash proceeds of $2.5M. Headcount not disclosed.
2007-12-31divestiture_reductioncompleted2007-05-302008-02United KingdomAnalytical TechnologiesUSD 29 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		UK Competition Commission concluded the GVI acquisition lessened competition in Gas IRMS and TIMS markets and mandated divestiture of GVI or its Gas IRMS/TIMS assets. $29M after-tax impairment recorded in 2007; sale of the two principal product lines completed February 2008 (subsequent to fiscal year-end). Headcount not disclosed.
2007-12-31restructuringin_progress385United States, Australia, DenmarkAnalytical TechnologiesUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2007 severance for approximately 385 employees across all functions; facility consolidations at plants in New Mexico, Pennsylvania, Australia and Denmark; segment also recorded $41M cost-of-revenues charges and $2M non-cash asset write-downs
2007-12-31restructuringin_progress230France, GermanyLaboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2007 severance for approximately 230 employees; facility consolidations principally the planned move of a manufacturing site in France to Germany; segment also recorded $8M cost-of-revenues charges and a $2M loss on sale of a small business
2007-12-31plant_closurein_progress2007-10-012009-06-30FranceLaboratory Products and ServicesUSD 11 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision to close a manufacturing facility with operations consolidated into existing factories in a phased plan through mid-2009; $11M charged in FY2007 with $7-9M additional expected (cash $6-8M) through mid-2009; employee count not disclosed and may overlap with the Laboratory Products and Services severance action above
2007-12-31restructuringannounced2008-12-31USD 4 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Other restructuring actions identified by management to be undertaken during 2008; employee count not disclosed
2007-12-31acquisition_additioncompletedIndiaLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Qualigens Fine Chemicals (September 2007) for $59M purchase price; headcount added not disclosed
2007-12-31acquisition_additioncompleted2007-10-03United StatesLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Priority Solutions International (October 2007) for $165M net of cash acquired; headcount added not disclosed
2007-12-31acquisition_additioncompletedUnited StatesAnalytical Technologiesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of NanoDrop Technologies (October 2007) for $148M net of cash acquired; headcount added not disclosed
2007-12-31acquisition_additioncompletedEuropeLaboratory Products and Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of La-Pha-Pack (December 2007) for $46M net of cash acquired; headcount added not disclosed
2007-12-31divestiture_reductioncompleted2007-04-30United KingdomLaboratory Products and Servicesdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Genevac Limited in April 2007 for $21M net cash proceeds, required by FTC consent order; headcount removed not disclosed
2007-12-31divestiture_reductioncompleted2007-07-31United StatesLaboratory Products and Servicesdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Systems Manufacturing Corporation in July 2007 for $2.5M cash proceeds; headcount removed not disclosed
2007-12-31divestiture_reductionin_progress2007-05-302008-02-29United KingdomAnalytical TechnologiesUSD 29 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		UK Competition Commission ordered divestiture of GV Instruments' Gas IRMS and TIMS assets; $29M after-tax impairment recorded in FY2007 (primarily non-cash); sale completed February 2008 after fiscal year-end; headcount removed not disclosed
2007-12-31restructuringcompleted3852007Global (New Mexico, Pennsylvania, Australia, Denmark)Analytical TechnologiesUSD 8 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 385 employees across all functions associated with facility consolidations.
2007-12-31restructuringcompleted2302007France to GermanyLaboratory Products and ServicesUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 230 employees associated with planned move of manufacturing site in France to Germany.
2007-12-31plant_closurein_progress2007-102009-06FranceLaboratory Products and ServicesUSD 11 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Closure of Laboratory Products and Services manufacturing facility in France; operations consolidated with existing factories through mid-2009. $11 million charged in 2007.
2007-09-29restructuringin_progress115Analytical TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 115 employees primarily in sales, service and manufacturing functions, part of facility consolidations.
2007-09-29restructuringin_progress10Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 10 employees primarily in research and development functions.
2007-09-29restructuringin_progress2962007-12-31All functions; primarily related to Fisher mergerUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Principal acquisition expenses were severance for approximately 296 employees across all functions, primarily related to the Fisher merger; remaining severance accrual of $9.0 million at September 29, 2007, expected to be paid in 2007.
2007-09-29plant_closureannounced1152007-10-312009-06-30Chateau-Gontier, FranceLaboratory Products and ServicesUSD 17 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Phased closure of a manufacturing facility making centrifuges, incubators and biological safety cabinets; approximately 115 employees to be severed; total charges estimated at $16-18 million, including $15-17 million cash costs, to be recorded between Q4 2007 and mid-2009; production transferred to facilities in Germany and China.
2007-09-29restructuringin_progress115Not specifiedAnalytical TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2007 severance for approximately 115 employees, mainly in sales, service and manufacturing; part of facility consolidations. Specific announcement date not disclosed.
2007-09-29restructuringin_progress10Not specifiedLaboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2007 severance for 10 employees, primarily in research and development functions; segment also recorded a $1.5 million loss on sale of a small business.
2007-09-29plant_closureannounced1152007-10-312009-06-30France (Chateau-Gontier)Laboratory Products and ServicesUSD 16 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter decision to close the France manufacturing plant producing centrifuges, incubators and biological safety cabinets; work moving to Germany and China. Estimated charges $16-18 million (cash $15-17 million plus $1 million asset write-offs), recorded Q4 2007 through mid-2009.
2007-09-29restructuringin_progress1152007-07-01United StatesAnalytical Technologies; Sales, Service, ManufacturingUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 115 employees primarily in sales, service and manufacturing functions associated with facility consolidations in Q3 2007.
2007-09-29restructuringin_progress102007-07-01United StatesLaboratory Products and Services; Research and DevelopmentUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 10 employees primarily in research and development functions in Q3 2007.
2007-09-29plant_closureannounced1152007-10-312009-06-30FranceLaboratory Products and Services; ManufacturingUSD 16 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Decision to discontinue operations at Chateau-Gontier plant. Approximately 115 employees to be severed. Total charges estimated at $16-18 million, including $15-17 million cash costs.
2007-06-30restructuringin_progress215Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2007 severance for approximately 215 employees across all functions, part of facility consolidations; segment total Q2 charges were $16.1 million including $11.2 million to cost of revenues.
2007-06-30restructuringin_progress10Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2007 severance for 10 employees across all functions within facility consolidations; segment Q1 charges totaled $32.2 million.
2007-06-30restructuringin_progress35Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2007 severance for 35 employees primarily in sales, service and manufacturing functions.
2007-06-30restructuringin_progress10Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2007 severance for 10 employees primarily in sales and service functions.
2007-06-30plant_closureannouncedFranceLaboratory Products and ServicesUSD 17 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Contemplated closure of a manufacturing facility in France; estimated future charges of $16-18 million for real estate abandonment, moving costs, severance and asset write-offs, dependent on works council negotiations; operations to be consolidated with existing factories.
2007-06-30restructuringin_progressCorporateUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2007 corporate cash costs primarily for merger-related expenses and retention agreements with certain Fisher employees; retention accrued ratably generally through November 2007.
2007-06-30restructuringin_progress284restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Principal 2006-acquisition expenses were severance for approximately 284 employees across all functions and facility consolidation costs, primarily related to the Fisher merger; $11.6 million severance accrual remained at June 30, 2007.
2007-06-30divestiture_reductioncompleted2007-05-30United KingdomGVI (Gas IRMS and TIMS business)USD 27 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		UK Competition Commission required divestiture of GVI or its Gas IRMS and TIMS assets; non-cash after-tax impairment charge of $27 million recorded.
2007-06-30divestiture_reductioncompleted2007-04-03Genevac Limited (legacy Fisher business)other
f5-10q / GLM-5.3-flash-fp4-HTML		Genevac sold April 3, 2007 for net proceeds of $22 million cash, subject to post-closing adjustment; divestiture required by FTC consent order.
2007-06-30divestiture_reductioncompleted2007-07-01Systems Manufacturing Corporation (legacy Fisher business)other
f5-10q / GLM-5.3-flash-fp4-HTML		SMC sold in July 2007 for cash proceeds of $2.5 million; subsequent event after quarter end.
2007-06-30restructuringin_progress2842007-12-31All functionsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 284 employees across all functions, primarily from the November 2006 Fisher merger; costs charged to acquisition purchase price, severance expected paid in 2007
2007-06-30restructuringin_progress2152007-12-31Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Second quarter of 2007 severance for approximately 215 employees, part of facility consolidation cash costs
2007-06-30restructuringin_progress102007-12-31Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First quarter of 2007 severance for 10 employees across all functions, part of facility consolidation cash costs
2007-06-30restructuringin_progress352007-12-31Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Second quarter of 2007 severance for 35 employees, primarily in sales, service and manufacturing functions
2007-06-30restructuringin_progress102007-12-31Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First quarter of 2007 severance for 10 employees, primarily in sales and service functions
2007-06-30plant_closureannouncedFranceLaboratory Products and ServicesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Contemplated closure of a France manufacturing facility; estimated future charges of $16-18 million for real estate abandonment, moving, severance and asset write-offs, contingent on works council negotiations; headcount not disclosed
2007-06-30divestiture_reductionannounced2007-05-30United KingdomAnalytical TechnologiesUSD 27 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		UK Competition Commission required divestiture of GVI or its Gas IRMS and TIMS assets; non-cash after-tax impairment charge of $27 million recorded; headcount not disclosed
2007-06-30divestiture_reductioncompleted2007-04-03Laboratory Products and Servicesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Genevac Limited, a legacy Fisher solvent evaporation business, committed for disposal in 2006 following FTC consent order and sold April 3, 2007 for $22 million net cash proceeds; headcount not disclosed
2007-06-30divestiture_reductioncompletedLaboratory Products and Servicesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Systems Manufacturing Corporation, a legacy Fisher IT enclosure business, sold in July 2007 (after quarter end) for $2.5 million cash proceeds; headcount not disclosed
2007-06-30restructuringin_progress215Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 215 employees across all functions in Q2 2007.
2007-06-30restructuringin_progress10Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 10 employees across all functions in Q1 2007.
2007-06-30restructuringin_progress35Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 35 employees primarily in sales, service and manufacturing functions in Q2 2007.
2007-06-30restructuringin_progress10Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 10 employees primarily in sales and service functions in Q1 2007.
2007-06-30restructuringin_progress284All segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 284 employees across all functions related to 2006 acquisitions, primarily the Fisher merger.
2007-06-30plant_closureannouncedFranceLaboratory Products and ServicesUSD 17 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Contemplating closure of manufacturing facility; estimated future charges of $16-18 million for real estate abandonment, moving costs, severance and asset write-offs.
2007-03-31restructuringin_progress2522007-12-31All functions, primarily related to the Fisher mergerUSD 26 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance reserve for approximately 252 employees across all functions from 2006 acquisitions, principally Fisher; balance at March 31, 2007, expected to be paid primarily in 2007.
2007-03-31restructuringin_progress10Analytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cash costs principally for facility consolidations, including $2.0 million severance for 10 employees across all functions, plus abandoned-facility and relocation costs.
2007-03-31restructuringin_progress10Laboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cash costs including $0.3 million severance for 10 employees primarily in sales and service functions, plus abandoned-facility and relocation costs.
2007-03-31restructuringin_progressCorporateUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Cash costs primarily for merger-related expenses and retention agreements with certain Fisher employees, accrued ratably over required service periods.
2007-03-31restructuringannounced2007-11-30Fisher integration and existing businessesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plan for potential restructuring at Fisher or integrating businesses may include product-line rationalization, facility consolidation and staffing reductions; to be finalized within one year of the November 2006 merger.
2007-03-31divestiture_reductioncompleted2006-01-012007-04-03Genevac Limited (Fisher business)other
f5-10q / GLM-5.3-flash-fp4-HTML		Genevac, a solvent evaporation technology manufacturer, divested per FTC consent order; sold April 3, 2007 for approximately $22 million net proceeds. Headcount not disclosed.
2007-03-31otherannounced2007-03-222007-05-31United KingdomGV Instruments Limited (GVI)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		UK Competition Commission provisional findings may lead to required divestment of the GVI business; final report due May 31, 2007. Potential impairment charges if divestment required.
2007-03-31restructuringin_progress102007-12-31Analytical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2007 segment restructuring: $2.0M severance for 10 employees, plus facility consolidation and relocation cash costs; segment also recorded $29.1M non-cash cost-of-revenues charge for inventory revalued at acquisition dates. Severance expected to be paid in 2007.
2007-03-31restructuringin_progress102007-12-31Laboratory Products and ServicesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2007 segment restructuring: $0.3M severance for 10 employees primarily in sales and service functions, plus $0.2M abandoned-facility and $0.1M other cash costs; segment also recorded $7.3M non-cash cost-of-revenues charge for inventory revalued at acquisition dates.
2007-03-31restructuringin_progressCorporateUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		All cash costs, primarily merger-related expenses and retention agreements with certain Fisher employees; retention accrued ratably over qualifying service periods. No employee count disclosed.
2007-03-31restructuringin_progress2522007-12-31All functionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 252 employees across all functions for 2006 acquisitions, primarily the Fisher merger, plus facility consolidation costs. Accrued acquisition expenses totaled $35.1M at 2007-03-31 (severance $26.1M, abandoned facilities $6.6M, other $2.4M); severance and other costs expected to be paid in 2007.
2007-03-31acquisition_additioncompleted2007-01-15SwitzerlandAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Spectronex AG and Flux AG businesses for $24M net of cash acquired; $9M allocated to goodwill. No headcount of acquired employees disclosed.
2007-03-31acquisition_additioncompletedAnalytical Technologiesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2007 acquisition of a small manufacturer of electrostatic discharge products for aggregate consideration of $5M. No headcount disclosed.
2007-03-31divestiture_reductioncompleted2007-04-032007-04-03Genevac Limited (Fisher business)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: Genevac sold 2007-04-03 for net proceeds of approximately $22M cash, required by FTC consent order approving the Thermo Fisher merger. No employee count disclosed.
2007-03-31restructuringin_progress10Analytical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 10 employees across all functions in Analytical Technologies segment.
2007-03-31restructuringin_progress10Laboratory Products and ServicesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 10 employees primarily in sales and service functions in Laboratory Products and Services segment.
2007-03-31restructuringin_progress252All functionsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Principal acquisition expenses for 2006 acquisitions included severance for approximately 252 employees across all functions, primarily related to the merger with Fisher.
2006-12-31restructuringin_progress20920062007United Kingdom and Germany (facility consolidation); United States (New Mexico operations relocated to other U.S. and European plants)Analytical TechnologiesUSD 9 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2006 actions consolidated a U.K. facility into an existing German factory and moved New Mexico manufacturing to other plants; segment net charges totaled $73.5 million including $43.2 million of acquisition inventory step-up in cost of revenues and a $15 million Fisher in-process R&D charge; actions expected to yield roughly $6 million of annual cost savings.
2006-12-31restructuringin_progress12320062007Massachusetts, United States (plant closed; operations consolidated with existing factory)Laboratory Products and ServicesUSD 3 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plant closure in Massachusetts consolidated with an existing (Kendro) facility; segment 2006 net charges were $42 million, including $3 million accelerated depreciation, $32 million inventory revaluation and a $1 million asset write-down; roughly $5 million of annual cost savings expected.
2006-12-31restructuringin_progress20062007United States and Europe (administrative offices)CorporateUSD 8 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		All-cash charges primarily for pre-merger integration expenses and retention agreements with certain legacy Fisher employees; retention cost accrued ratably over the required service period.
2006-12-31restructuringin_progress21920062007Primarily United States (two facility abandonments); employee locations not specified2006 acquisitions, primarily the Fisher mergerUSD 26,750 (thousands)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Severance reserves established at acquisition (EITF 95-3) for roughly 219 employees across all functions, plus $3.1 million for abandoning two U.S. facilities; year-end balance of $30.4 million expected to be paid primarily through 2007.
2006-12-31acquisition_additioncompleted2006-05-082006-11-09GlobalBoth segments (Analytical Technologies and Laboratory Products and Services)USD 12,210 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Tax-free stock-for-stock merger completed November 9, 2006; preliminary aggregate consideration of approximately $12.21 billion; Fisher had 2005 revenues of $5.4 billion; Fisher standalone headcount not disclosed — combined company reported approximately 30,500 employees at year-end.
2006-12-31divestiture_reductionannounced2006Discontinued operations — solvent evaporation technology (legacy Fisher business)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		FTC consent order required divestiture of Genevac as a condition of merger approval; assets and liabilities not material at December 31, 2006; employee count not disclosed.
2006-12-31divestiture_reductionannounced2006Discontinued operations — consoles, workstations and server enclosures for IT/data centers (legacy Fisher business)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Reported within discontinued operations as a business held for disposal; headcount and financial detail not material at year-end 2006.
2006-12-31restructuringin_progress20052007Kendro integration at existing businesses (2005 restructuring plan)USD 8,126 (thousands)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Costs of $8.1 million incurred during 2006 under the Kendro-integration plan initiated in 2005, including $6.0 million of severance (employee count for the 2006 tranche not disclosed); cumulative expected expense approximately $16 million, of which $15 million recorded through December 31, 2006.
2006-12-31restructuringannounced20062007Existing businesses being integrated with Fisher; Fisher-integration plan pendingUSD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Actions totaling $5 million identified for 2007 at existing businesses; broader Fisher-integration plan (product-line rationalization, facility consolidation, staffing reductions) to be finalized within one year of the November 2006 merger, with Fisher-side costs charged to acquisition accounting rather than expense.
2006-12-31acquisition_additioncompleted2006-05-082006-11-09GlobalAll segmentsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger with Fisher Scientific International completed 2006-11-09; Fisher headcount added is not disclosed (Fisher 2005 revenues of $5.4 billion cited). Company total headcount rose to approximately 30,500 at year-end 2006.
2006-12-31restructuringin_progress2092006-01-01United Kingdom, Germany, United States (New Mexico)Analytical TechnologiesUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 209 employees across all functions; includes consolidating a U.K. facility into a German factory and moving New Mexico manufacturing to U.S. and European plants. Segment recorded $73 million net restructuring/other charges in 2006 including $43 million cost-of-revenue inventory revaluation.
2006-12-31plant_closurein_progress1232006-01-01United States (Massachusetts, North Carolina)Laboratory Products and ServicesUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of a Massachusetts plant with consolidation into an acquired Kendro facility in North Carolina; severance for 123 employees across all functions. Segment recorded $42 million net restructuring/other charges in 2006.
2006-12-31restructuringin_progress2192006-11-092007-11-09United States and internationalAll functions (Fisher integration)USD 27 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 219 employees plus plans to abandon two U.S. facilities, primarily Fisher-merger related; total 2006 acquisition reserves established were $31.1 million (severance $26.8M, facility abandonment $3.1M, other $1.3M), with $30.4 million accrued at year-end. Restructuring plans for Fisher to be finalized within one year of the merger.
2006-12-31restructuringin_progress2006-01-01United States and EuropeCorporate administrative officesUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		All cash costs for pre-merger integration expenses and retention agreements with certain Fisher employees; headcount affected not disclosed.
2006-12-31divestiture_reductionannounced2006-01-01GlobalGenevac Limited; Systems Manufacturing Corporationdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Company committed during 2006 to dispose of Genevac (required by FTC consent order for merger approval) and classified Systems Manufacturing Corporation as held for sale; assets, liabilities and headcount not material/disclosed at 2006-12-31.
2006-12-31restructuringannounced2006-12-312007-12-31United StatesExisting businesses being integrated with FisherUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Actions totaling $5 million identified for 2007 at existing businesses; additional Fisher-integration actions expected as plans are completed. Headcount affected not disclosed.
2006-12-31restructuringcompleted2092006United Kingdom, New Mexico, United States, EuropeAnalytical TechnologiesUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 209 employees associated with consolidation of UK facility into Germany and move of NM operations.
2006-12-31restructuringcompleted1232006Massachusetts, North CarolinaLaboratory Products and ServicesUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 123 employees associated with closing MA plant and consolidating with Kendro facility in NC.
2006-12-31restructuringcompleted182006United States, EuropeCorporaterestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 18 employees at US and European administrative offices.
2006-12-31acquisition_additioncompleted2006-11-09GlobalAll Segmentsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Merger with Fisher Scientific International Inc. completed November 9, 2006. Specific headcount added not disclosed in footnote, but total employee count increased to 30,500.
2006-12-31acquisition_additioncompleted2006-12-14MassachusettsAnalytical Technologiesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Cohesive Technologies Inc. Headcount not explicitly disclosed.
2006-12-31acquisition_additioncompleted2006-07-20United KingdomAnalytical Technologiesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of GV Instruments Limited. Headcount not explicitly disclosed.
2006-12-31acquisition_additioncompleted2006-06-30MassachusettsAnalytical Technologiesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of EGS Gauging, Inc. Headcount not explicitly disclosed.
2006-09-30restructuringin_progress262006-07-01Life and Laboratory Sciences — administrative functionsUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 26 employees, primarily in administrative functions, part of $1.0 million of other costs within $2.4 million of net restructuring charges in the segment for the quarter.
2006-09-30restructuringin_progress512006-07-01New Mexico manufacturing operations transferred to other U.S. and Europe facilitiesMeasurement and Control — manufacturing functionsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 51 employees, primarily in manufacturing functions, tied to transfer of manufacturing operations from New Mexico to other facilities in the U.S. and Europe.
2006-09-30plant_closurein_progress1122006-04-01Massachusetts (operations consolidated with acquired Kendro facility in North Carolina)Life and Laboratory Sciences — manufacturing functionsUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 112 employees, primarily in manufacturing functions, associated with closure of a Massachusetts plant and consolidation with a Kendro facility in North Carolina; recorded in Q2 2006.
2006-09-30restructuringin_progress812006-01-01United Kingdom facility consolidated into existing factory in GermanyLife and Laboratory Sciences — all functionsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 81 employees across all functions related to consolidation of a U.K. facility into an existing factory in Germany; recorded in Q1 2006.
2006-09-30restructuringin_progress72006-04-01Measurement and Control — sales and service functionsUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 7 employees, primarily in sales and service functions, within $1.4 million of cash cost-reduction charges recorded in Q2 2006.
2006-09-30restructuringin_progress72006-01-01Measurement and Control — sales and service functionsUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 7 employees, primarily in sales and service functions, within $1.3 million of cash cost-reduction charges recorded in Q1 2006.
2006-09-30acquisition_additioncompleted282006-07-202006-12-31United KingdomLife and Laboratory Sciences — all functions (GV Instruments Limited)USD 1 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Post-acquisition restructuring at GVI (acquired July 20, 2006 for $21.5 million net of cash): severance reserve of $536 thousand for 28 employees across all functions, expected to be paid in 2006.
2006-09-30plant_closurein_progress1122006-04-01Massachusetts, United StatesLife and Laboratory Sciences — manufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2006 severance for 112 manufacturing employees tied to closing a Massachusetts plant and consolidating with an acquired Kendro facility in North Carolina.
2006-09-30restructuringin_progress812006-01-01United Kingdom / GermanyLife and Laboratory Sciencesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2006 severance for 81 employees across all functions consolidating a U.K. facility into an existing factory in Germany.
2006-09-30restructuringin_progress262006-07-01United StatesLife and Laboratory Sciences — administrative functionsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2006 severance for 26 employees, primarily administrative, as part of cost reduction measures.
2006-09-30plant_closurein_progress512006-07-01New Mexico, United StatesMeasurement and Control — manufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2006 severance for 51 manufacturing employees transferring New Mexico operations to other plants in the U.S. and Europe.
2006-09-30restructuringin_progress72006-04-01United StatesMeasurement and Control — sales and servicerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2006 severance for 7 employees in sales and service functions plus revisions of prior estimates.
2006-09-30restructuringin_progress72006-01-01United StatesMeasurement and Control — sales and servicerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2006 severance for 7 employees in sales and service functions plus revisions of prior estimates.
2006-09-30acquisition_additioncompleted282006-07-20United KingdomLife and Laboratory Sciences — GV Instruments Limitedbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired GVI on 2006-07-20; accrued acquisition-related severance covers 28 employees across all functions, expected to be paid in 2006.
2006-09-30acquisition_additionin_progress1562005-05-012007-12-31United StatesLife and Laboratory Sciences — Kendro Laboratory Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Kendro acquired May 2005; accrued acquisition severance covers approximately 156 employees plus relocation and facility obligations, payable through 2007.
2006-09-30restructuringin_progress2006-01-012007-12-31GlobalConsolidated — Kendro integration and other actionsUSD 16 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Kendro integration restructuring expected to total approximately $16 million, of which approximately $13 million recorded through 2006-09-30; an additional $3 million expected through 2007 for actions not yet recordable.
2006-09-30restructuringin_progress262006-07-01Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 26 employees, primarily in administrative functions, part of cost reduction measures in Q3 2006.
2006-09-30restructuringin_progress512006-07-01Measurement and ControlUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 51 employees, primarily in manufacturing functions, related to transfer of operations from New Mexico to other facilities in Q3 2006.
2006-09-30acquisition_additioncompleted282006-07-20United KingdomLife and Laboratory SciencesUSD 0 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of GV Instruments Limited (GVI) on July 20, 2006. Accrued acquisition expenses consist of severance for 28 employees across all functions.
2006-07-01plant_closurein_progress1122006-12-31Massachusetts, United StatesLife and Laboratory Sciences - manufacturingUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2006 charge to close a Massachusetts plant and consolidate operations with an acquired Kendro facility in North Carolina; severance primarily in manufacturing functions. Additional charges of approximately $5 million expected in remainder of 2006.
2006-07-01restructuringin_progress7Measurement and Control - sales and service functionsUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2006 cash costs for cost reduction measures including severance for 7 employees primarily in sales and service functions, plus revisions of prior estimates.
2006-07-01restructuringin_progress81United Kingdom / GermanyLife and Laboratory Sciences - all functionsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2006 cash costs for consolidation of a U.K. facility into an existing factory in Germany; severance for 81 employees across all functions.
2006-07-01restructuringin_progress7Measurement and Control - sales and service functionsUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2006 cash costs for cost reduction measures including severance for 7 employees primarily in sales and service functions, plus revisions of prior estimates.
2006-07-01restructuringin_progress1562006-12-31Kendro acquisition integration - all functionsUSD 4 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Accrued acquisition expenses at July 1, 2006 include severance for approximately 156 employees across all functions at Kendro, plus relocation costs and facility obligations for a vacated Tennessee building; severance and other expected to be paid primarily through 2006.
2006-07-01restructuringin_progress1602006-12-31England / DenmarkJouan acquisition integration - all functionsbusiness_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Accrued acquisition expenses relate primarily to severance for approximately 160 employees at Jouan (acquired December 2003) and abandoned facilities in England and Denmark; severance expected to be paid primarily through 2006.
2006-07-01acquisition_additioncompleted2006-06-30Massachusetts, United StatesMeasurement and ControlUSD 26 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired EGS Gauging, Inc. for $26.3 million net of cash acquired; no employee headcount disclosed.
2006-07-01acquisition_additioncompleted2006-07-20United KingdomLife and Laboratory SciencesUSD 21 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired GV Instruments Limited for 11.6 million British pounds ($21.3 million); no employee headcount disclosed.
2006-07-01plant_closurein_progress1122006-04-022006-12-31United States (Massachusetts)Life and Laboratory Sciences (manufacturing)USD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2006 severance for 112 manufacturing employees; Massachusetts plant closing consolidated into acquired Kendro facility in North Carolina. Additional charges of approximately $5 million expected for this closure in remainder of 2006.
2006-07-01restructuringin_progress812006-01-012006-12-31United KingdomLife and Laboratory SciencesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2006 severance for 81 employees across all functions consolidating a U.K. facility into an existing factory in Germany; also included $0.4M net abandoned-facility costs.
2006-07-01restructuringin_progress72006-04-022006-12-31Not specifiedMeasurement and Control (sales and service)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2006 cost-reduction measures; segment recorded $1.4M of cash costs total including revisions of prior estimates, $0.3M net abandoned-facility costs, and $0.1M other cash costs.
2006-07-01restructuringin_progress72006-01-012006-12-31Not specifiedMeasurement and Control (sales and service)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2006 cost-reduction measures; segment recorded $1.3M of cash costs total including revisions of prior estimates.
2006-07-01restructuringin_progress1562005-05-012006-12-31United States (North Carolina and Tennessee)Life and Laboratory Sciences (Kendro Laboratory Products)USD 3 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition-related restructuring reserves for Kendro (acquired May 2005): severance for approximately 156 employees across all functions, relocation costs, and a vacated Tennessee building. Reserves established in 2006 shown as $3.2M severance; balance of Kendro integration charges (~$5M of ~$16M total) to be recorded primarily over remainder of 2006.
2006-07-01restructuringin_progress1602003-12-012014-12-31United Kingdom, DenmarkNot specified (Jouan acquisition)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Legacy acquisition-related accruals for Jouan (acquired Dec 2003): severance for approximately 160 employees plus abandoned facilities in England (leases through 2014) and a Denmark manufacturing closure (lease through 2007). Accrued balance at July 1, 2006 was $2.2M total.
2006-07-01acquisition_additioncompleted2006-06-302006-06-30United States (Massachusetts)Measurement and Controlbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		EGS Gauging, Inc. acquired for $26.3M net of cash acquired; EGS 2005 revenues were $25 million. No employee headcount disclosed. Balance sheet included; no results of operations or cash flows in the quarter.
2006-07-01acquisition_additionannounced2006-07-202006-07-20United KingdomLife and Laboratory Sciencessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		GV Instruments Limited acquired for £11.6M ($21.3M), subject to post-closing adjustment; GVI 2005 revenues were $19 million. No employee headcount disclosed.
2006-07-01acquisition_additionannounced2006-05-082006-12-31GlobalEnterprise (Thermo Fisher Scientific combination)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger with Fisher Scientific International announced May 8, 2006; expected to close Q4 2006. Fisher had 2005 revenues of $5.4B and $2.2B debt at June 30, 2006. Thermo holders to own ~39% of combined company. No headcount figures disclosed; substantially all Thermo equity awards would vest on closing.
2006-07-01restructuringin_progress1122006-04-022006-12-31Massachusetts, USALife and Laboratory SciencesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 112 employees primarily in manufacturing functions associated with closing a plant in Massachusetts and consolidating operations with an acquired Kendro facility in North Carolina. Total cash costs for this action were $3.2 million.
2006-07-01restructuringin_progress812006-01-012006-12-31United Kingdom / GermanyLife and Laboratory SciencesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 81 employees across all functions associated with consolidation of a U.K. facility into an existing factory in Germany. Recorded in Q1 2006.
2006-07-01restructuringin_progress72006-04-022006-12-31GlobalMeasurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 7 employees primarily in sales and service functions. Recorded in Q2 2006.
2006-07-01restructuringin_progress72006-01-012006-12-31GlobalMeasurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 7 employees primarily in sales and service functions. Recorded in Q1 2006.
2006-07-01acquisition_additioncompleted2006-06-302006-06-30Massachusetts, USAMeasurement and Controlbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of EGS Gauging, Inc. Employee count not disclosed.
2006-07-01acquisition_additioncompleted2006-07-202006-07-20United KingdomLife and Laboratory Sciencessubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of GV Instruments Limited. Employee count not disclosed.
2006-07-01restructuringin_progress1562005-05-012007-12-31GlobalLife and Laboratory SciencesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 156 employees across all functions at Kendro (acquired May 2005). Accrued balance at July 1, 2006 was $3.97 million. Payments expected through 2006.
2006-07-01restructuringin_progress1602003-12-012014-12-31Denmark / EnglandLife and Laboratory SciencesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 160 employees at Jouan (acquired Dec 2003). Accrued balance at July 1, 2006 was $0.133 million. Payments expected primarily through 2006.
2006-04-01restructuringin_progress81United Kingdom / GermanyLife and Laboratory SciencesUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2006 charges principally for consolidation of a U.K. facility into an existing factory in Germany; includes $2.2 million severance for 81 employees across all functions, $0.4 million abandoned-facility costs, and $0.3 million other cash costs primarily relocation.
2006-04-01restructuringin_progress7Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2006 cash costs for cost reduction measures including $1.1 million severance for 7 employees primarily in sales and service functions; segment also recorded a $0.8 million pre-tax gain on disposal of a product line.
2006-04-01restructuringannounced2006-042006-09-30Massachusetts / North CarolinaUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Plant closure in Massachusetts with consolidation into an acquired Kendro facility in North Carolina; ~$8 million of charges expected over Q2-Q3 2006, including $2.3 million severance, $3.2 million abandoned-facility costs, and $2.5 million fixed-asset write-off.
2006-04-01restructuringin_progress1562007-12-31Life and Laboratory Sciences (Kendro integration)USD 6 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Accrued acquisition expenses at April 1, 2006 of $6.1 million, primarily severance for approximately 156 employees across all functions at Kendro, relocation costs, and facility obligations for a building vacated in Tennessee; severance and other expected to be paid through 2006, facility costs through lease expiration in 2007.
2006-04-01restructuringin_progress1602014-12-31England / DenmarkUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Accrued acquisition expenses of $2.1 million for acquisitions completed prior to 2005, primarily severance for approximately 160 employees at Jouan (acquired December 2003) and abandoned facilities including three operating facilities in England (leases through 2014) and a Jouan manufacturing facility in Denmark (lease expiring 2007).
2006-04-01restructuringin_progress81United KingdomLife and Laboratory SciencesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Consolidation of a U.K. facility into an existing factory in Germany; $2.2M severance for 81 employees across all functions, part of $3.0M net segment charge in Q1 2006 (also includes $0.4M facility and $0.3M relocation cash costs)
2006-04-01restructuringin_progress7Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost-reduction measures; $1.1M severance for 7 employees, primarily sales and service functions; net segment charge $0.5M after a $0.8M gain on product-line disposal
2006-04-01plant_closureannounced2006-04Massachusetts, United StatesUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced April 2006: close a Massachusetts plant and consolidate with an acquired Kendro facility in North Carolina; $5.5M cash costs ($2.3M severance, $3.2M abandoned-facility) plus $2.5M fixed-asset write-off, principally over Q2-Q3 2006; employee count not disclosed
2006-04-01restructuringin_progress1562005-05United StatesLife and Laboratory SciencesUSD 4 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Kendro Laboratory Products acquisition (May 2005) integration: severance for ~156 employees plus relocation and vacated Tennessee facility obligations; $4.3M reserves established in Q1 2006, accrued acquisition expense balance $6.1M at 2006-04-01; total Kendro integration charges expected $15-20M, ~$8M recorded as of 2006-04-01
2006-04-01restructuringin_progress81United KingdomLife and Laboratory SciencesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of U.K. facility into existing factory in Germany.
2006-04-01restructuringin_progress7Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cost reduction measures, primarily in sales and service functions.
2006-04-01plant_closureannounced2006-04-01MassachusettsUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Announced closure of plant in Massachusetts and consolidation with Kendro facility in North Carolina. Includes $2.3M severance and $3.2M abandoned-facility costs.
2006-04-01restructuringin_progress156Life and Laboratory SciencesUSD 5 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued acquisition expenses for Kendro Laboratory Products division, primarily severance for 156 employees.
2005-12-31restructuringin_progress15120052006Life and Laboratory SciencesUSD 9 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for 151 employees across all functions, principally Kendro integration; segment also booked $1.6M abandoned-facility costs, offset by $7.8M gains on sale of six abandoned buildings. ~$9M of the ~$13M annual savings from 2005 actions attributed to this segment; company expects Kendro-integration charges at existing businesses to total $15-$20M, with ~$8M recorded at year-end 2005, and ~$2M further costs expected primarily in 2006.
2005-12-31restructuringin_progress9820052006Includes consolidation of two facilities in TexasMeasurement and ControlUSD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for 98 employees across all functions; also $4.4M abandoned-facility costs including 2005 consolidation of two Texas operating facilities; ~$4M of the ~$13M annual savings from 2005 actions attributed to this segment.
2005-12-31restructuringin_progress1820052006United States and EuropeCorporate (administrative offices)USD 2 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		$2.1M of cash costs at U.S. and European administrative offices, primarily severance for 18 employees.
2005-12-31restructuringin_progress7620052006-05Kendro Laboratory Products (2005 acquisitions)USD 4 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for approximately 76 employees across all functions, primarily related to Kendro; $4.0M reserve ($3.6M severance) established in cost of acquisitions under EITF 95-3, with $2.9M accrued at year-end; restructuring plans for acquisitions must be finalized within one year of the acquisition date.
2005-12-31acquisition_additioncompleted2005-05Life and Laboratory Sciences — Kendro Laboratory ProductsUSD 837 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired Kendro division of SPX Corporation for $836.6M net of cash acquired; Kendro 2004 revenues were $371M. No headcount disclosed for Kendro or the other 2005 acquisitions (Niton, R&P, Ionalytics).
2005-12-31divestiture_reductioncompleted2005-092005-09Life and Laboratory Sciences — point of care and rapid diagnostics businessdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Business sold in September 2005 for $53.1M cash, generating a $16.8M after-tax gain; 2005 revenues of the divested business through the sale date were $26.6M. Headcount of the divested business was not disclosed.
2005-12-31restructuringin_progress1512006-05Life and Laboratory SciencesUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 151 employees across all functions, principally tied to integrating Kendro with existing businesses. Company expects to finalize Kendro restructuring plans no later than one year from the May 2005 acquisition date.
2005-12-31restructuringin_progress98United StatesMeasurement and ControlUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 98 employees across all functions; segment also incurred abandoned-facility costs tied to consolidation of two operating facilities in Texas. Completion date not stated.
2005-12-31restructuringin_progress18United States and EuropeCorporateUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		All cash costs at U.S. and European administrative offices, primarily severance for 18 employees; charge is total restructuring and other charges, not severance alone.
2005-12-31restructuringin_progress76United StatesLife and Laboratory SciencesUSD 3,557 (thousands)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance reserves established for approximately 76 employees across all functions, primarily related to the Kendro acquisition; charged to cost of acquisition rather than expense. Total 2005 acquisition reserves established were $4,009 thousand including facility and other items.
2005-12-31acquisition_additioncompleted2005-05Life and Laboratory SciencesUSD 837 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Kendro Laboratory Products division of SPX Corporation acquired for $836.6 million net of cash acquired; acquired headcount not disclosed. Kendro 2004 revenues were $371 million.
2005-12-31acquisition_additioncompleted2005-03United StatesLife and Laboratory SciencesUSD 41 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Niton LLC acquired for $40.9 million net of cash acquired; acquired headcount not disclosed.
2005-12-31acquisition_additioncompleted2005-04United StatesMeasurement and ControlUSD 31 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Rupprecht and Patashnick Co., Inc. acquired for $31.0 million net of cash acquired; acquired headcount not disclosed.
2005-12-31acquisition_additioncompleted2005-08CanadaLife and Laboratory SciencesUSD 25 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Ionalytics Corporation acquired for $24.7 million net of cash acquired; acquired headcount not disclosed.
2005-12-31divestiture_reductioncompleted2005-09Life and Laboratory SciencesUSD 53 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Point of care and rapid diagnostics business sold for $53.1 million cash; removed headcount not disclosed. Business was not reclassified to discontinued operations due to immateriality.
2005-12-31divestiture_reductioncompletedUnited KingdomMeasurement and ControlUSD 6 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Small non-core U.K. business sold for $5.7 million net cash proceeds with a $0.3 million gain; removed headcount not disclosed.
2005-12-31restructuringcompleted1512005GlobalLife and Laboratory SciencesUSD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 151 employees across all functions, primarily associated with the integration of Kendro with existing businesses.
2005-12-31restructuringcompleted982005GlobalMeasurement and ControlUSD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 98 employees across all functions, primarily related to the consolidation of two facilities in Texas.
2005-12-31restructuringcompleted182005United States and EuropeCorporaterestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 18 employees in administrative functions at U.S. and European administrative offices.
2005-12-31acquisition_additioncompleted2005-05GlobalLife and Laboratory Sciencesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Kendro Laboratory Products division of SPX Corporation in May 2005. Specific headcount added not disclosed.
2005-12-31acquisition_additioncompleted2005-08CanadaLife and Laboratory Sciencesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Ionalytics Corporation in August 2005. Specific headcount added not disclosed.
2005-12-31acquisition_additioncompleted2005-04United StatesMeasurement and Controlbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Rupprecht and Patashnick Co., Inc. (R&P) in April 2005. Specific headcount added not disclosed.
2005-12-31acquisition_additioncompleted2005-03United StatesLife and Laboratory Sciencesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Niton LLC in March 2005. Specific headcount added not disclosed.
2005-10-01restructuringin_progress852005-07-012006-01-01GlobalLife and Laboratory SciencesUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 85 employees across all functions, primarily associated with the integration of Kendro.
2005-10-01restructuringin_progress782005-07-012006-01-01GlobalMeasurement and ControlUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 78 employees, primarily in sales and service functions, arising from cost reduction measures including facility consolidations.
2005-10-01restructuringin_progress222005-01-012005-12-31United StatesCorporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 22 employees at corporate offices. Costs incurred across Q1, Q2, and Q3 2005.
2005-10-01restructuringin_progress112005-04-032005-12-31GlobalLife and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 11 employees across all functions, principally associated with facility consolidations in Q2 2005.
2005-10-01restructuringin_progress312005-01-022005-12-31GlobalLife and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 31 employees across all functions, principally associated with facility consolidations in Q1 2005.
2005-10-01restructuringin_progress122005-04-032005-12-31GlobalMeasurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 12 employees, primarily in sales and service functions, associated with facility consolidations in Q2 2005.
2005-10-01restructuringin_progress82005-01-022005-12-31GlobalMeasurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 8 employees, primarily in sales and service functions, associated with facility consolidations in Q1 2005.
2005-10-01restructuringin_progress312005-05-092006-01-01GlobalLife and Laboratory Sciencesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued acquisition expenses for Kendro include severance for approximately 31 employees across all functions.
2005-07-02restructuringin_progressUSD 11 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2005 net restructuring and other costs of $11.1M included $1.0M of cash severance and abandoned facility costs for consolidated businesses, offset by a $1.3M gain on real estate sale; no employee count or segment name disclosed in available text.
2005-07-02restructuringin_progress112005-04-03Life and Laboratory SciencesAll functionsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 11 employees in Q2 2005.
2005-07-02restructuringin_progress122005-04-03Measurement and ControlSales and serviceUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 12 employees in Q2 2005.
2005-07-02restructuringin_progress152005-01-01CorporateCorporate officesrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 15 employees in H1 2005 (Q1 and Q2 combined).
2005-07-02restructuringin_progress312005-01-01Life and Laboratory SciencesAll functionsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 31 employees in Q1 2005.
2005-07-02restructuringin_progress82005-01-01Measurement and ControlSales and serviceUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 8 employees in Q1 2005.
2005-07-02restructuringin_progress142005-01-01Global2005 Restructuring Plansrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Terminations occurring to date in 2005 under 2005 plans.
2005-07-02restructuringin_progress712005-01-01Global2004 Restructuring Plansrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Terminations occurring to date in 2005 under 2004 plans.
2005-07-02restructuringin_progress122005-01-01Global2003 Restructuring Plansrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Terminations occurring to date in 2005 under 2003 plans.
2005-04-02restructuringin_progress31United States and GermanyLife and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 31 employees across all functions; part of $0.8M cash costs.
2005-04-02restructuringin_progress8EnglandMeasurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 8 employees primarily in sales and service functions.
2005-04-02restructuringin_progress12CorporateCorporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 12 employees at corporate offices; part of $0.5M cash costs.
2005-04-02restructuringin_progress48restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Terminations announced in 2005 under 2004 Restructuring Plans.
2005-04-02acquisition_additioncompleted2005-03-29MassachusettsLife and Laboratory SciencesUSD 41 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Niton LLC. Headcount not disclosed.
2005-04-02acquisition_additionannounced2005-01-012005-05-01USD 834 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Agreement to acquire Kendro Laboratory Products. Expected to close in May 2005. Headcount not disclosed.
2005-04-02acquisition_additioncompleted2005-04-26New YorkMeasurement and ControlUSD 33 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Rupprecht and Patashnick Co., Inc. (R&P). Headcount not disclosed.
2004-12-31restructuringcompleted1812004Life and Laboratory SciencesUSD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 181 employees across all functions in Life and Laboratory Sciences segment.
2004-12-31restructuringcompleted1062004Measurement and ControlUSD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 106 employees across all functions in Measurement and Control segment.
2004-12-31restructuringcompleted1692004CorporateUSD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 169 employees at U.S. and European administrative offices.
2004-12-31acquisition_additioncompleted2004-09Life and Laboratory Sciencesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of InnaPhase Corporation in September 2004. Employee count not disclosed.
2004-12-31acquisition_additioncompleted2004-04Life and Laboratory Sciencesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of US Counseling Services, Inc. in April 2004. Employee count not disclosed.
2004-12-31acquisition_additioncompleted2004-09ChinaMeasurement and Controlbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of manufacturer and distributor of air quality instruments in China in September 2004. Employee count not disclosed.
2004-10-02restructuringin_progress43Life and Laboratory SciencesUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2004 severance for 43 employees across all functions, part of $1.9 million cash costs including abandoned facilities and relocation.
2004-10-02restructuringin_progress71Measurement and ControlUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 2004 severance for 71 employees across all functions.
2004-10-02restructuringin_progress61Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2004 severance for 61 employees across all functions in connection with facility consolidations.
2004-10-02restructuringin_progress17Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2004 severance for 17 employees, primarily in sales and service functions.
2004-10-02restructuringin_progress20Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2004 severance for 20 employees across all functions in connection with facility consolidations.
2004-10-02restructuringin_progress7Measurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2004 severance for 7 employees, primarily in sales and service functions.
2004-10-02restructuringin_progress97restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Remaining terminations under 2003 restructuring plans at October 2, 2004: 162 remaining at year-end 2003, 128 announced in 2004, 176 terminations occurred, 17 plan adjustments.
2004-10-02restructuringin_progress54USD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2004 restructuring plans: 93 terminations announced, 39 occurred to date, 54 remaining at October 2, 2004; $3.1 million severance costs incurred in 2004.
2004-10-02acquisition_additioncompleted2004-09-13Life and Laboratory SciencesUSD 66 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of InnaPhase for $66.4 million cash; headcount not disclosed.
2004-10-02acquisition_additioncompleted2004-04-20Life and Laboratory SciencesUSD 79 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of USCS for $78.8 million cash; headcount not disclosed.
2004-10-02divestiture_reductioncompleted2004-06-012004-07-16Optical Technologies (Spectra-Physics)USD 41 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of Spectra-Physics to Newport Corporation for $300 million completed July 16, 2004; gain of $41.4 million net of tax; headcount not disclosed.
2004-10-02restructuringin_progress17620032004-12-31Multiple segments and corporateUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2003 Restructuring Plans. 176 terminations occurred YTD 2004; 128 announced in 2004; 97 remaining at 2004-10-02. Charge is cash components incurred in 2004 (severance, retention, facilities, other). Company expects 2003 and 2004 restructuring substantially complete in 2004.
2004-10-02restructuringin_progress3920042004-12-31Multiple segments and corporateUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2004 Restructuring Plans. 93 terminations announced in 2004; 39 occurred YTD 2004; 54 remaining at 2004-10-02. Charge is cash components incurred in 2004. Company expects to incur an additional $1.3 million of restructuring costs, primarily in 2004.
2004-10-02divestiture_reductioncompleted2004-062004-07-16GlobalOptical Technologies (Spectra-Physics)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Spectra-Physics to Newport Corporation completed 2004-07-16 for $300 million. No employee headcount associated with the divestiture is disclosed. A small New York manufacturing unit was retained and transferred to Life and Laboratory Sciences.
2004-10-02acquisition_additioncompleted2004-09-132004-09-13United StatesLife and Laboratory SciencesUSD 66 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of InnaPhase Corporation for $66.4 million cash including debt repayment. No employee headcount disclosed; InnaPhase had revenues of $17.7 million in 2004 prior to acquisition.
2004-10-02acquisition_additioncompleted2004-04-202004-04-20United StatesLife and Laboratory SciencesUSD 79 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of US Counseling Services, Inc. for $78.8 million cash including transaction costs. No employee headcount disclosed; USCS reported revenues of $57 million in 2003.
2004-10-02acquisition_additioncompleted2004-092004-09ChinaMeasurement and ControlUSD 4 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of a manufacturer and distributor of air quality instruments in China for $3.7 million cash. No employee headcount disclosed.
2004-10-02restructuringin_progress432004-07-04Life and Laboratory SciencesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 43 employees across all functions in Q3 2004.
2004-10-02restructuringin_progress712004-07-04Measurement and ControlUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 71 employees across all functions in Q3 2004.
2004-10-02restructuringin_progress2004-07-04U.S. and European corporate officesCorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs primarily for severance in Q3 2004; employee count not specified.
2004-10-02restructuringin_progress612004-04-04Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 61 employees across all functions in Q2 2004.
2004-10-02restructuringin_progress202004-01-03Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 20 employees across all functions in Q1 2004.
2004-10-02restructuringin_progress172004-04-04Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 17 employees, primarily in sales and service functions, in Q2 2004.
2004-10-02restructuringin_progress72004-01-03Measurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 7 employees primarily in sales and service functions in Q1 2004.
2004-10-02restructuringin_progress1602003-12-312005-12-31Global (Jouan SA)Life and Laboratory Sciencesrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 160 employees at Jouan across all functions; payments expected primarily through 2005.
2004-07-03restructuringin_progress612004-04-04Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 61 employees across all functions in Q2 2004.
2004-07-03restructuringin_progress172004-04-04Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 17 employees, primarily in sales and service functions in Q2 2004.
2004-07-03restructuringin_progress202004-01-04Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 20 employees across all functions in Q1 2004.
2004-07-03restructuringin_progress72004-01-04Measurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 7 employees primarily in sales and service functions in Q1 2004.
2004-07-03restructuringannounced2002004-07-03Several businessesUSD 5 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Headcount reductions approximating 200 employees announced for Q3 2004.
2004-07-03acquisition_additioncompleted2004-04-20Life and Laboratory SciencesUSD 79 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of US Counseling Services, Inc. Employee count not disclosed.
2004-07-03acquisition_additioncompleted1002003-12-31DenmarkLife and Laboratory Sciencesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Jouan SA. Severance accrued for approximately 100 employees.
2004-04-03restructuringin_progress762004-12-31Company-wide (2003 restructuring plans)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance actions under 2003 restructuring plans: 167 terminations remained at Dec 31, 2003; 27 announced in 2004; 118 occurred during Q1 2004; 76 remain at April 3, 2004. Company expects 2003 restructuring actions substantially completed in 2004.
2004-04-03restructuringin_progress2004-12-31Life and Laboratory SciencesUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2004 net charges of $3.8M: $2.4M to cost of revenues primarily for sale of inventories revalued at Jouan acquisition date; $1.0M cash costs including $0.6M severance for 20 employees across all functions; $0.4M loss on sale of two abandoned buildings.
2004-04-03restructuringin_progress7Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2004 net charges of $1.3M: $1.1M cash costs for facility consolidations including $0.4M severance for 7 employees primarily in sales and service functions; $0.1M equipment writedown; $0.1M cost-of-revenues charge for revalued acquisition inventories.
2004-04-03restructuringin_progressOptical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2004 net charges of $0.1M, primarily cash costs for facility consolidations recorded when incurred.
2004-04-03restructuringin_progressCorporateUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2004 corporate charges of $0.5M, all cash costs, primarily third-party advisory fees to simplify legal structure of non-U.S. subsidiaries.
2004-04-03acquisition_additioncompleted1002003-12-312007-12-31Denmark and other locationsLife and Laboratory Sciences (Jouan SA)USD 9 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Post-acquisition restructuring at Jouan: severance for approximately 100 employees across all functions and downsizing of a Denmark manufacturing facility to a smaller site (lease expires 2007). Accrued acquisition expenses of $9.0M at Dec 31, 2003, reduced to $8.0M at April 3, 2004.
2004-04-03acquisition_additionannounced2004-04-202004-04-20Life and Laboratory Sciences (US Counseling Services, Inc.)USD 78 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of USCS for approximately $78M cash ($75M net of cash acquired); USCS reported 2003 revenues of $57M. No headcount figure disclosed.
2004-04-03restructuringin_progress11820032004USD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Terminations occurring to date in 2004 under the 2003 restructuring plans (167 remaining at 2003-12-31, 27 announced during 2004, 76 remaining at 2004-04-03). Charge is total Q1 2004 restructuring and other costs, net, which includes about $2.5M of inventory revaluation at acquired businesses; accrued restructuring of $20.0M at quarter end; company expects roughly $2M of additional charges in 2004 and completion of the 2003 actions during 2004. Q1 severance charges covered 20 employees in Life and Laboratory Sciences and 7 in Measurement and Control. Ongoing 2001 and 2002 plan balances (facility lease obligations) continue without disclosed employee counts.
2004-04-03restructuringin_progress1002003-12-312004Life and Laboratory Sciences (Jouan SA)USD 4 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Approximately 100 Jouan employees across all functions slated for severance, plus downsizing of a Jouan manufacturing facility in Denmark (lease expiring 2007). Accrued acquisition expenses for 2003 acquisitions totaled $8.0M at 2004-04-03 ($3.9M severance, $3.9M abandonment of excess facilities, $0.2M other); severance expected to be paid primarily through 2004, facility amounts through 2007.
2004-04-03acquisition_additionannounced2004-04-20Life and Laboratory Sciencessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter acquisition of US Counseling Services, Inc. for approximately $78M in cash ($75M net of cash acquired), subject to post-closing adjustment; USCS reported 2003 revenues of $57M. Acquired headcount not disclosed.
2004-04-03restructuringin_progress20Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 20 employees across all functions; part of broader $3.8M net restructuring charge.
2004-04-03restructuringin_progress7Measurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 7 employees primarily in sales and service functions; part of broader $1.3M net restructuring charge.
2004-04-03restructuringin_progressOptical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Cash costs associated with facility consolidations; no specific headcount disclosed.
2004-04-03restructuringin_progressCorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Primarily third-party advisory fees to simplify legal structure; no specific headcount disclosed.
2004-04-03restructuringin_progress118Consolidatedrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Terminations occurring to date in 2004 under 2003 restructuring plans. 76 terminations remain.
2004-04-03acquisition_additioncompleted2003-12-31Life and Laboratory Sciencesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Jouan SA completed Dec 31, 2003. Accrued severance for approx 100 employees.
2004-04-03acquisition_additionannounced2004-04-20Life and Laboratory SciencesUSD 75 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of US Counseling Services, Inc. for approx $75M net of cash. Headcount not disclosed.
2003-12-31restructuringcompleted4152003United States, United Kingdom, Japan, EuropeLife and Laboratory SciencesUSD 10 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 415 employees across all functions in Life and Laboratory Sciences segment.
2003-12-31restructuringcompleted1642003Netherlands, France, Massachusetts, Wisconsin, GermanyMeasurement and ControlUSD 7 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 164 employees across all functions in Measurement and Control segment.
2003-12-31restructuringcompleted1222003United Kingdom, California, MassachusettsOptical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 122 employees across all functions in Optical Technologies segment.
2003-12-31restructuringcompleted162003EuropeCorporateUSD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 16 employees in administrative functions at corporate offices.
2003-12-31acquisition_additioncompleted1002003-12-31DenmarkLife and Laboratory Sciencesbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Approximately 100 employees at Jouan across all functions; closure of a Jouan manufacturing facility in Denmark.
2003-09-27restructuringin_progress712003-07-01GlobalLife and Laboratory SciencesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 71 employees across all functions in Q3 2003.
2003-09-27restructuringin_progress412003-07-01GlobalMeasurement and ControlUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 41 employees across all functions in Q3 2003.
2003-09-27restructuringin_progress232003-07-01GlobalOptical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 23 employees across all functions in Q3 2003.
2003-09-27restructuringin_progress62003-07-01FranceCorporateUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 6 administrative employees in Q3 2003.
2003-09-27restructuringin_progress2202003-04-01GlobalLife and Laboratory SciencesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 220 employees across all functions in Q2 2003.
2003-09-27restructuringin_progress252003-01-01GlobalLife and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 25 employees primarily in administrative, sales, and service functions in Q1 2003.
2003-09-27restructuringin_progress172003-04-01GlobalMeasurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 17 employees across all functions in Q2 2003.
2003-09-27restructuringin_progress462003-01-01GlobalMeasurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 46 employees across all functions in Q1 2003.
2003-09-27restructuringin_progress652003-04-01GlobalOptical TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 65 employees across all functions in Q2 2003.
2003-09-27restructuringin_progress212003-01-01GlobalOptical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 21 employees primarily in manufacturing functions in Q1 2003.
2003-09-27restructuringin_progress5392003-01-012004-12-31GlobalAll Segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Total terminations announced in 2003 restructuring plans. 425 occurred to date in 2003, with 114 remaining.
2003-06-28restructuringin_progress2202003-04-01Life and Laboratory SciencesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 220 employees across all functions in Q2 2003.
2003-06-28restructuringin_progress172003-04-01Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 17 employees across all functions in Q2 2003.
2003-06-28restructuringin_progress652003-04-01Optical TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 65 employees across all functions in Q2 2003.
2003-06-28restructuringin_progress252003-01-01Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 25 employees primarily in administrative, sales, and service functions in Q1 2003.
2003-06-28restructuringin_progress462003-01-01Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 46 employees across all functions in Q1 2003.
2003-06-28restructuringin_progress212003-01-01Optical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 21 employees primarily in manufacturing functions in Q1 2003.
2003-06-28restructuringin_progress3982003-01-012004-12-31Corporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2003 Restructuring Plans: 398 terminations announced, 306 occurring to date. Expected completion substantially in 2004.
2003-06-28restructuringin_progress1022002-01-01Acquired Businesses (Thermo CRS, RMP)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 102 employees at acquired businesses primarily in manufacturing, R&D, and sales/service.
2003-03-29restructuringin_progress252003-01-01Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 25 employees primarily in administrative, sales, and service functions.
2003-03-29restructuringin_progress462003-01-01Measurement and ControlUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 46 employees across all functions.
2003-03-29restructuringin_progress212003-01-01Optical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 21 employees primarily in manufacturing functions.
2003-03-29acquisition_additioncompleted2003-01-01Measurement and ControlUSD 3 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired product line of emission monitoring products for $2.6 million in cash.
2003-03-29restructuringin_progress1022002-01-012003-09-30USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Accrued acquisition expenses for 2002 acquisitions primarily for severance for approximately 102 employees.
2002-12-28restructuringcompleted2362002-01-012002-12-28GlobalLife and Laboratory SciencesUSD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 236 employees across all functions in Life and Laboratory Sciences segment.
2002-12-28restructuringcompleted3522002-01-012002-12-28GlobalMeasurement and ControlUSD 11 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 352 employees across all functions in Measurement and Control segment.
2002-12-28restructuringcompleted3152002-01-012002-12-28GlobalOptical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 315 employees across all functions in Optical Technologies segment.
2002-12-28restructuringcompleted1022002-01-012002-12-28GlobalAcquired BusinessesUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 102 employees at acquired businesses (CRS, RMP, Other) primarily in manufacturing, R&D, and sales/service.
2002-09-28restructuringin_progress1002002-07-01GlobalLife and Laboratory SciencesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 100 employees across all functions in Q3 2002.
2002-09-28restructuringin_progress2302002-07-01United StatesMeasurement and ControlUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 230 employees across all functions in Q3 2002.
2002-09-28restructuringin_progress782002-07-01GlobalOptical Technologiesrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 78 employees across all functions in Q3 2002.
2002-09-28restructuringin_progress122002-04-01GlobalLife and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 12 employees across all functions in Q2 2002.
2002-09-28restructuringin_progress1172002-04-01GlobalOptical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 117 employees across all functions in Q2 2002.
2002-09-28restructuringin_progress762002-01-01GlobalOptical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 76 employees across all functions in Q1 2002.
2002-09-28restructuringin_progress82002-01-01GlobalLife and Laboratory SciencesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 8 employees, primarily in administrative and sales functions, in Q1 2002.
2002-09-28restructuringin_progress32002-01-01GlobalCorporateUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 3 employees at corporate office in Q1 2002.
2002-09-28acquisition_additioncompleted982002-04-01GlobalLife and Laboratory Sciences / Measurement and ControlUSD 2 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 98 employees at acquired businesses (CRS and RMP) in manufacturing, R&D, and sales/service.
2002-06-29restructuringin_progress1,71420012002-12-31Company-wide (Life and Laboratory Sciences, Measurement and Control, Optical Technologies, Corporate)USD 49 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Terminations announced in 2001 under 2001 restructuring plans; 1,001 occurred in 2001, leaving 713 at December 29, 2001. Accrued balance for these plans was $48.7 million at year-end 2001 and $40.5 million at June 29, 2002. Company expects actions substantially completed by end of 2002; abandoned-facility payments continue through lease terms expiring up to 2012.
2002-06-29restructuringin_progress22120022002-12-31Company-wideUSD 18 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional terminations announced in 2002 under the 2001 restructuring plans; 679 terminations occurred in the first half of 2002, leaving 255 remaining at June 29, 2002. Costs incurred in 2002 under these plans were $17.9 million. Q2 2002 severance included 117 employees in Optical Technologies, 12 in Life and Laboratory Sciences, and severance in Measurement and Control.
2002-06-29restructuringin_progress11720022002-12-31Optical TechnologiesUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2002 net charges of $11.4 million included $3.2 million severance for 117 employees across all functions, $1.0 million abandoned-equipment leases, $0.7 million litigation settlement, and $5.5 million asset writedowns including $5.3 million abandoned telecom equipment. Telecom product initiatives suspended.
2002-06-29restructuringin_progress7620022002-12-31Optical Technologies (Spectra-Physics)USD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2002 charges of $8.3 million included $2.1 million severance for 76 employees across all functions and $4.5 million lease costs primarily for abandoned equipment at Spectra-Physics.
2002-06-29restructuringin_progress402002-042005-12-31Primarily Austria and CanadaLife and Laboratory Sciences (Thermo CRS)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Post-acquisition restructuring at Thermo CRS (acquired April 2002): severance for approximately 40 acquired employees primarily in manufacturing and R&D, and closure of a Thermo CRS manufacturing facility in Austria with lease expiring 2005; operations consolidated into existing Canadian facilities. Reserves of $1.269 million established; balance $1.123 million at June 29, 2002.
2002-06-29plant_closurein_progress20022005-12-31AustriaLife and Laboratory Sciences (Thermo CRS)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Closure of Thermo CRS manufacturing facility in Austria; lease expires 2005. Operations consolidated into existing facilities in Canada. Excess-facilities reserve of $509 thousand established as part of acquisition cost.
2002-06-29restructuringin_progress17519992002-12-311999 acquisitions (primarily Spectra-Physics AB)USD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 175 employees across all functions and abandoned facilities, primarily at Spectra-Physics AB; plans finalized in 1999 and 2000. Remaining severance balance $414 thousand at June 29, 2002; remaining pre-1999 acquisition accruals represent lease obligations for four facilities in England with leases expiring through 2014.
2002-06-29restructuringin_progress67920012002-12-31USD 18 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2001 Restructuring Plans: 679 terminations occurred YTD through June 29, 2002; 221 additional terminations announced in 2002; 255 remaining at quarter end. Charge reflects cash components of costs incurred in 2002 per roll-forward table. Company expects substantially complete by end of 2002. Segment-level severance counts disclosed for Q2 2002 (LLS: 12; Optical Technologies: 117) and Q1 2002 (LLS: 8; Optical Technologies: 76; Corporate: 3); Measurement & Control count not disclosed.
2002-06-29restructuringcompleted420002002-06-29USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2000 Restructuring Plans: 4 remaining terminations at December 29, 2001 all occurred in 2002; zero remaining at June 29, 2002. Charge reflects costs incurred in 2002 per roll-forward table.
2002-06-29acquisition_additioncompleted2002-042002-05CanadaLife and Laboratory SciencesUSD 1 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CRS Robotics acquisition (~$42M aggregate purchase price, ~$23.7M goodwill). Severance established for approximately 40 acquired employees, primarily in manufacturing and R&D. Includes closure of Thermo CRS manufacturing facility in Austria (lease expiring 2005), with operations to be consolidated into existing Canadian facilities. Charge covers total reserves established for all 2002 acquisitions (severance $739K, excess facilities $509K, other $21K). Total headcount added through acquisition not disclosed.
2002-06-29restructuringin_progress12Life and Laboratory SciencesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 12 employees across all functions in Q2 2002.
2002-06-29restructuringin_progress117Optical TechnologiesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 117 employees across all functions in Q2 2002.
2002-06-29restructuringin_progress3CorporateUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for three employees in Q1 2002.
2002-06-29restructuringin_progress8Life and Laboratory SciencesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for eight employees, primarily in administrative and sales functions, in Q1 2002.
2002-06-29restructuringin_progress76Optical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 76 employees across all functions in Q1 2002.
2002-06-29acquisition_additioncompleted40Life and Laboratory SciencesUSD 1 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 40 acquired employees, primarily in manufacturing and R&D, related to 2002 acquisitions.
2002-03-30restructuringin_progress1,6062001-01-012002-09-30Company-wideUSD 49 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Terminations announced in 2001 under 2001 restructuring plans; 1,001 occurred in 2001, 253 in Q1 2002, leaving 440 remaining at March 30, 2002. Company expects actions substantially completed by Q3 2002.
2002-03-30restructuringannounced882002-01-012002-09-30Company-widerestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional terminations announced in 2002 under the 2001 restructuring plans; part of the 440 remaining terminations at quarter-end.
2002-03-30restructuringin_progress762002-01-012002-09-30Optical Technologies — Spectra-PhysicsUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2002 charge includes $6.8M cash costs at Spectra-Physics: $4.5M abandoned-equipment lease costs, $2.1M severance for 76 employees across all functions, plus $0.7M asset writeoffs and $0.8M option-exchange charge.
2002-03-30restructuringin_progress82001-01-012002-09-30Life and Laboratory SciencesUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Net restructuring income of $0.3M: $1.5M gain on product-line sale offset by $1.2M cash costs including severance for eight employees (primarily administrative and sales) and $0.6M retention costs.
2002-03-30restructuringin_progress2001-01-012002-09-30Measurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Net restructuring income of $0.2M: $1.5M gains from dispute resolution and small-business sale offset by $1.1M cash costs including severance, retention, and a $0.2M building-impairment charge.
2002-03-30restructuringin_progress32002-01-012002-09-30CorporateUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		All cash costs: $0.6M third-party advisory fees for reorganization plan and $0.1M severance for three employees.
2002-03-30restructuringin_progress22000-01-012002-12-31Company-widerestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Two terminations occurred in Q1 2002 under 2000 restructuring plans; two terminations remained at March 30, 2002. Accrued severance balance of $0.9M at quarter-end.
2002-03-30acquisition_additioncompleted2002-02-012002-02-28Optical Technologies — Spectra-PhysicsUSD 21 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Short-form merger completed February 2002 made Spectra-Physics wholly owned; $21.3M cash spent to buy minority interest, $15.6M goodwill increase. Headcount not quantified.
2002-03-30restructuringin_progress2532002-09-30GlobalMultiple segments (Life and Laboratory Sciences, Measurement and Control, Optical Technologies, Corporate)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2001 restructuring plans: 253 terminations occurred in Q1 2002 (88 additional announced in 2002; 440 remaining at 2002-03-30). Charge is 2002 costs incurred of $9,112 thousand. Segment severance counts disclosed: 76 at Spectra-Physics (Optical Technologies), 8 (Life and Laboratory Sciences), 3 (Corporate); Measurement and Control severance not quantified by headcount. Program expected substantially complete by Q3 2002; further $6 million of costs expected from Q2 2002.
2002-03-30restructuringin_progress2GlobalMultiple segmentsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2000 restructuring plans: 2 remaining terminations occurred in 2002 (2 remaining at 2002-03-30). Charge is 2002 costs incurred of $548 thousand, all in 'Other'.
2002-03-30divestiture_reductioncompletedUnited StatesPower generation business (discontinued operations)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Last remaining component of former power generation business sold in March 2002; no headcount disclosed. Discontinued operations as a whole have aggregate annual revenues of approximately $90 million.
2002-03-30restructuringin_progress882002-01-012002-09-30GlobalVariousrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional terminations announced in 2002 under 2001 Restructuring Plans. Company expects actions to be substantially completed by Q3 2002.
2002-03-30restructuringin_progress762002-01-012002-09-30GlobalOptical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 76 employees across all functions at Spectra-Physics.
2002-03-30restructuringin_progress82001-01-012002-09-30GlobalLife and Laboratory SciencesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for eight employees, primarily with administrative and sales functions.
2002-03-30restructuringin_progress32001-01-012002-09-30GlobalCorporateUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for three employees at corporate office.
2001-12-29restructuringin_progress34220012002-09-30United States and EuropeLife SciencesUSD 30 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2001 restructuring plan (actions initiated in Q2 and Q4 2001). Includes $11.1M cash severance for 342 employees across all functions (128 terminated as of Dec 29, 2001), $4.4M cost-of-revenue charges for discontinued product lines, $6.7M asset writedowns, $3.4M in-process R&D writeoff, and $0.7M noncash severance. Facility consolidation: closure of 11 sales/service offices (10 Europe, 1 US) and 7 factories (5 Europe, 2 US). Expected annual cost reduction approximately $12M.
2001-12-29restructuringin_progress61420012002-09-30United States and EuropeOptical TechnologiesUSD 62 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2001 restructuring plan (actions initiated in Q2 and Q4 2001). Includes $7.6M severance for 614 employees, primarily in manufacturing positions (599 terminated as of Dec 29, 2001); $24.6M asset writedowns, principally telecom manufacturing equipment at Spectra-Physics; $11.8M cost-of-revenue charges, primarily excess telecom inventories at Spectra-Physics; $5.9M litigation loss. Facility consolidation: closure of 6 sales/service offices (4 Europe, 2 US), 3 US factories, and 2 European distribution facilities. Expected annual cost reduction approximately $24M.
2001-12-29restructuringin_progress62920012002-09-30United States, Europe, and CanadaMeasurement and ControlUSD 55 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2001 restructuring plan (actions initiated in Q2 and Q4 2001). Includes $19.4M severance for 629 employees across all functions (256 terminated as of Dec 29, 2001); $11.0M net loss on sale of ThermoMicroscopes (July 2001) and Pharos Marine (August 2001) businesses and related goodwill writedowns; $9.9M cost-of-revenue charges; $5.5M asset writedowns, partially offset by $1.1M gain on sale of a building. Facility consolidation: closure of 15 European sales/service offices and 16 factories (10 US, 5 Europe, 1 Canada). Expected annual cost reduction approximately $24M.
2001-12-29restructuringin_progress2120012002-09-30United States (corporate office)CorporateUSD 12 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2001 restructuring actions at the corporate office (initiated in Q2 and Q4 2001). Includes $5.9M reorganization-related investment banking, consulting, and legal fees; $3.5M employee-retention accruals earned ratably through 2001; $1.9M severance for 21 employees (18 terminated as of Dec 29, 2001); and $0.2M noncash severance. Expected annual cost reduction approximately $3M.
2001-12-29restructuringin_progress9120002001-06-30Multiple segmentsUSD 10 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Current-year tail activity under the 2000 restructuring plans (program originally announced in 2000): 91 terminations occurred during fiscal 2001, 16 additional terminations were announced in 2001, and 4 remained at Dec 29, 2001. Costs incurred in 2001 of $9.8M covered severance, employee retention, facility, and other exit costs. MD&A states 2000 restructuring actions were substantially completed by the end of Q2 2001.
2001-12-29restructuringannounced2002-03-152002-03-30Optical Technologies (integration of Spectra-Physics)USD 7 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Post-year-end announcement disclosed as of the March 15, 2002 filing date; integration plans for the formerly public Spectra-Physics subsidiary (merged into the company February 2002) were still being formed. Expected to include severance and abandonment of redundant manufacturing processes and related fixed assets and leased equipment, with associated charges of at least $7 million expected principally in Q1 2002.
2001-12-29restructuringin_progress1,0012001-04-012002-09-30GlobalAll segmentsUSD 159 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2001 restructuring plans: 1,606 terminations announced, 1,001 occurred in 2001, 605 remaining at year-end. Total 2001 restructuring and unusual charges of $158.8M including $26.1M to cost of revenues. Expected substantially complete by Q3 2002.
2001-12-29restructuringin_progress912000-07-012001-12-29GlobalAll segmentsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2000 restructuring plans: 91 additional terminations occurred in 2001 (from 249 announced in 2000). 4 remaining at year-end 2001.
2001-12-29divestiture_reductioncompleted2001-07-092001-08-08United StatesKadant Inc. (paper/recycling)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Kadant spun off as dividend to shareholders on August 8, 2001. Headcount not disclosed.
2001-12-29divestiture_reductioncompleted2001-10-112001-11-15United StatesViasys Healthcare Inc.discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Viasys Healthcare spun off as dividend to shareholders on November 15, 2001. Headcount not disclosed.
2001-12-29divestiture_reductioncompleted2001-06-012001-07-31GlobalPower generation businessdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Chief components of power generation business sold in June and July 2001 for $249M net proceeds. Headcount not disclosed.
2001-12-29divestiture_reductioncompleted2001-04-012001-08-31GlobalMeasurement and Control — Pharos Marine, ThermoMicroscopes, CAC and Mid Southrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Noncore businesses sold for net proceeds of approximately $46M. Aggregate revenues of $31.3M through dates of sale. Headcount not disclosed.
2001-12-29acquisition_additioncompleted2001-12-012002-02-25GlobalOptical Technologies — Spectra-Physicssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash tender offer completed December 2001; short-form merger completed February 2002 making Spectra-Physics a wholly owned subsidiary. Headcount not disclosed.
2001-12-29restructuringannounced2002-03-152002-03-31GlobalOptical Technologies — Spectra-Physics integrationUSD 7 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Plans being formed as of March 15, 2002 for integration of Spectra-Physics with other Optical Technologies businesses. Expected charges of at least $7M, principally in Q1 2002, for severance and abandonment of redundant manufacturing processes.
2001-12-29restructuringin_progress3422001-04-012002-09-30GlobalLife SciencesUSD 15 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 342 employees across all functions. 128 terminated as of year-end.
2001-12-29restructuringin_progress6142001-04-012002-09-30GlobalOptical TechnologiesUSD 8 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 614 employees, primarily manufacturing. 599 terminated as of year-end.
2001-12-29restructuringin_progress6292001-04-012002-09-30GlobalMeasurement and ControlUSD 19 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 629 employees across all functions. 256 terminated as of year-end.
2001-12-29restructuringin_progress212001-04-012002-09-30GlobalCorporateUSD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 21 employees. 18 terminated as of year-end.
2001-12-29restructuringin_progress162001-01-012002-09-30GlobalCorporaterestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Additional terminations announced in 2001 related to 2000 restructuring plans.
2001-09-29restructuringin_progress882001-06-302001-12-31Multiple (US, UK, Germany, Finland)Life SciencesUSD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2001 segment charges include $3.4M in-process R&D writeoff; severance for 88 employees across all functions; office closures in Florida and UK, German factory consolidation, Finland factory relocation; 76 of the employees severed as of 2001-09-29.
2001-09-29restructuringin_progress4132001-06-302001-12-31Multiple (US, Europe)Optical Technologies (incl. Spectra-Physics)USD 14 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2001 net charges include $7.0M provision for excess telecom inventories at Spectra-Physics and discontinued product lines; severance for 313 employees (Q2) plus 100 employees (Q3), primarily manufacturing; 326 severed as of 2001-09-29; sales office closures in New Jersey, France, Germany and European distribution consolidation.
2001-09-29restructuringin_progress1692001-06-302001-12-31Multiple (US, UK, Sweden)Measurement and ControlUSD 25 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2001 charges include $11.0M net loss on sale/writedown of ThermoMicroscopes and Pharos Marine, $4.5M inventory provisions, $1.9M asset writedowns; severance for 169 employees across all functions; 89 severed as of 2001-09-29.
2001-09-29restructuringin_progress52001-06-302001-12-31United StatesCorporateUSD 7 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 2001 corporate charges include severance for 5 employees (all terminated by 2001-06-30), investment banking/consulting/legal fees for the reorganization plan, and employee retention costs accrued ratably.
2001-09-29reduction_in_forceannounced5002001-09-29restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Company evaluating additional fourth-quarter 2001 restructuring actions including a plan to eliminate up to 500 positions; plans not finalized and expected cost not quantified.
2001-09-29divestiture_reductioncompleted2001-07-092001-08-08Kadant Inc. (discontinued operations)USD 197 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Spinoff of 91%-owned Kadant subsidiary completed August 8, 2001 as tax-free stock dividend; reduced net assets of discontinued operations and retained earnings by $197 million; headcount not disclosed.
2001-09-29divestiture_reductionannounced2001-10-112001-11-15Viasys Healthcare Inc. (discontinued operations)USD 300 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Board approved spinoff of wholly owned Viasys Healthcare subsidiary on October 11, 2001; distribution scheduled November 15, 2001; expected to reduce net assets of discontinued operations and retained earnings by approximately $300 million; headcount not disclosed.
2001-09-29restructuringin_progress882001-04-012001-12-31GlobalLife Sciencesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 88 employees across all functions; 76 had been severed as of 2001-09-29. Segment also recorded facility consolidations in Florida, UK, Germany, and Finland.
2001-09-29restructuringin_progress3132001-04-012001-12-31GlobalOptical Technologiesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 2001 action; severance for 313 employees, primarily manufacturing. Facility consolidations in New Jersey, France, Germany, and European distribution.
2001-09-29restructuringin_progress1002001-07-012001-12-31GlobalOptical Technologiesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2001 action; severance for 100 employees, primarily manufacturing positions. Combined with Q2 action, 326 of 413 announced had been severed as of 2001-09-29.
2001-09-29restructuringin_progress1692001-04-012001-12-31GlobalMeasurement and Controlrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 169 employees across all functions; 89 had been severed as of 2001-09-29. Facility consolidations in Sweden, UK, US.
2001-09-29restructuringcompleted52001-04-012001-06-30United StatesCorporaterestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 5 corporate employees, all terminated as of 2001-06-30.
2001-09-29restructuringannounced2001-09-292001-12-31GlobalMultiple segmentsMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Company evaluating additional restructuring actions in Q4 2001, including a plan to eliminate up to 500 positions; plans not finalized and cost not quantified.
2001-09-29divestiture_reductioncompleted2001-04-012001-08-31GlobalMeasurement and ControlMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Pharos Marine (Aug 2001), ThermoMicroscopes (Jul 2001), and CAC/Mid South businesses (Apr 2001) for net proceeds of $46 million; headcount removed not disclosed.
2001-09-29divestiture_reductioncompleted2001-07-092001-08-08GlobalKadant Inc. (91%-owned subsidiary)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spinoff of Kadant distributed to shareholders on 2001-08-08; headcount removed not disclosed.
2001-09-29divestiture_reductionannounced2001-10-112001-11-15GlobalViasys Healthcare Inc. (wholly owned subsidiary)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved spinoff of Viasys Healthcare on 2001-10-11; distribution planned for 2001-11-15. Subsequent-event disclosure; headcount removed not disclosed.
2001-09-29restructuringin_progress882001-04-012001-12-31GlobalLife SciencesUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 88 employees across all functions; 76 severed as of Sept 29, 2001.
2001-09-29restructuringin_progress1002001-07-012001-12-31GlobalOptical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 100 employees, primarily in manufacturing positions.
2001-09-29restructuringin_progress3132001-04-012001-12-31GlobalOptical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 313 employees, primarily in manufacturing positions; 326 severed as of Sept 29, 2001.
2001-09-29restructuringin_progress1692001-04-012001-12-31GlobalMeasurement and ControlUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 169 employees across all functions; 89 severed as of Sept 29, 2001.
2001-09-29restructuringin_progress52001-04-012001-06-30GlobalCorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 5 employees, all terminated as of June 30, 2001.
2001-09-29restructuringin_progress162001-01-012001-03-31GlobalMeasurement and Controlrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 16 employees terminated in Q1 2001 at quality control systems business.
2001-09-29restructuringannounced5002001-09-29GlobalCorporateMD&A
f5-10q / Qwen3.6-27B-Q8_0		Plan to eliminate up to 500 positions; plans not finalized nor costs quantified.
2001-06-30restructuringin_progress902001-042001-12-31US, UK, Germany, FinlandLife SciencesUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2001 charge includes $3.8M cash costs for severance for 90 employees and abandoned facilities, $2.2M asset writedowns, $1.8M inventory provisions; 66 of 90 employees severed as of June 30, 2001. Company expects 2001 restructuring actions substantially completed by end of 2001.
2001-06-30restructuringin_progress3112001-042001-12-31US, France, Germany, EuropeOptical Technologies (Spectra-Physics)USD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2001 net charge includes $7.0M provisions for excess telecommunication inventories, $3.6M cash costs for severance for 311 employees primarily in manufacturing, abandoned facilities and other exit costs, $0.6M asset writedowns, less $0.3M gain on facility sale; 167 of 311 employees severed as of June 30, 2001.
2001-06-30restructuringin_progress1662001-042001-12-31US, UK, SwedenMeasurement and ControlUSD 15 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2001 charge includes $7.4M cash costs for severance for 166 employees, abandoned facilities and other exit costs, $4.5M inventory provisions, $1.6M revision to ThermoMicroscopes disposal loss, $0.9M asset writedowns, $0.5M post-closing adjustment; 39 of 166 employees severed as of June 30, 2001.
2001-06-30restructuringin_progress52001-042001-12-31CorporateUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 2001 charge includes $1.4M severance for 5 employees (all terminated as of June 30, 2001), $0.9M reorganization advisory fees, $0.8M employee retention costs, $0.2M noncash severance.
2001-06-30restructuringin_progress2952001-042001-12-31Company-wide 2001 restructuring plansUSD 37 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		572 terminations announced in 2001 under 2001 restructuring plans; 277 occurred in 2001, leaving 295 remaining at June 30, 2001. Company expects additional $3.4M of restructuring costs in remainder of 2001 and annual cost reductions of $25 million beginning Q4 2001.
2001-06-30restructuringin_progress802000Company-wide 2000 restructuring plansrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		249 terminations announced in 2000; 168 occurred in 2000 and 63 in 2001, leaving 32 remaining at June 30, 2001 under 2000 plans; accrued severance balance of $2.7M at June 30, 2001. The 80 figure reflects remaining terminations at December 30, 2000 before 2001 activity.
2001-06-30divestiture_reductioncompleted2001-022001-06-30Power generation business (discontinued operations)USD 16 (millions)other
f5-10q / GLM-5.3-flash-fp4-HTML		Substantial portion of power generation business sold in June 2001 for $238 million cash; net-of-tax gain on disposition of $15.6 million. Headcount not disclosed.
2001-06-30divestiture_reductioncompleted2001-072001-07-31Measurement and Control — ThermoMicroscopesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Noncore scanning probe microscopes business sold in July 2001; $6.4M of charges recorded in first six months of 2001 to reduce carrying value to disposal value. Headcount not disclosed.
2001-06-30divestiture_reductioncompleted2001-07-092001-08-08Kadant Inc. (91%-owned subsidiary)USD 200 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Spinoff of Kadant completed August 8, 2001 as tax-free dividend to shareholders; reduces net assets of discontinued operations and retained earnings by approximately $200 million. Headcount not disclosed.
2001-06-30divestiture_reductionannounced2001-062001-12Viasys Healthcare Inc. (medical products business)other
f5-10q / GLM-5.3-flash-fp4-HTML		Previously announced spinoff of Viasys Healthcare expected to be completed during the fourth quarter of 2001. Headcount not disclosed.
2001-06-30restructuringin_progress902001-06-302001-12-31GlobalLife SciencesUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2001 plan severance for 90 employees; 66 severed as of June 30, 2001. Charge includes severance, abandoned facilities, asset writedowns, and inventory provisions. Announced during Q2 2001; exact date not disclosed.
2001-06-30restructuringin_progress3112001-06-302001-12-31GlobalOptical TechnologiesUSD 11 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2001 plan severance for 311 employees, primarily manufacturing; 167 severed as of June 30, 2001. Charge includes excess telecom inventory provisions, severance, facility closures, and exit costs. Announced during Q2 2001.
2001-06-30restructuringin_progress1662001-06-302001-12-31GlobalMeasurement and ControlUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2001 plan severance for 166 employees; 39 severed as of June 30, 2001. Charge includes severance, facility consolidations, ThermoMicroscopes goodwill writedown, and inventory provisions. Announced during Q2 2001.
2001-06-30restructuringin_progress52001-06-302001-12-31United StatesCorporateUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2001 plan severance for 5 employees, all terminated as of June 30, 2001. Charge includes severance, investment banking and consulting fees for reorganization plan, and employee retention costs. Announced during Q2 2001.
2001-06-30restructuringin_progress162001-06-302001-12-31GlobalMultiplerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional terminations announced in 2001 under pre-existing 2000 restructuring plans; 63 terminations occurred in 2001, 32 remaining at June 30, 2001.
2001-06-30divestiture_reductioncompleted2001-06-30GlobalPower generation business (discontinued operations)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Substantial portion of power generation business sold in June 2001 for $238 million; headcount removed not disclosed.
2001-06-30divestiture_reductioncompleted2001-04-01United StatesMeasurement and Control — CAC and Mid South businessesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CAC and Mid South oil and gas businesses sold in April 2001 for net proceeds of $38 million; headcount removed not disclosed.
2001-06-30divestiture_reductioncompleted2001-07-01GlobalMeasurement and Control — ThermoMicroscopesrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		ThermoMicroscopes sold in July 2001 (subsequent to quarter end); goodwill writedown of $6.4 million recorded in Q1–Q2 2001; headcount removed not disclosed.
2001-06-30divestiture_reductionannounced2001-07-092001-08-08GlobalKadant Inc. (91%-owned subsidiary spinoff)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Board approved Kadant spinoff July 9, 2001; distribution completed August 8, 2001. Approximately $200 million reduction in net assets and retained earnings; headcount impact not disclosed.
2001-06-30restructuringin_progress902001-04-012001-12-31Global (Florida, UK, Germany, Finland)Life SciencesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 90 employees; 66 severed as of June 30, 2001. Includes facility closures in Florida, UK, Germany, and Finland.
2001-06-30restructuringin_progress3112001-04-012001-12-31Global (New Jersey, France, Germany, Europe)Optical TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 311 employees, primarily manufacturing; 167 severed as of June 30, 2001. Includes closure of sales offices in NJ, France, Germany.
2001-06-30restructuringin_progress1662001-04-012001-12-31Global (Sweden, UK, US)Measurement and ControlUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 166 employees; 39 severed as of June 30, 2001. Includes closure of sales office in Sweden and consolidation in UK/US.
2001-06-30restructuringcompleted52001-04-012001-06-30United StatesCorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 5 corporate employees; all terminated as of June 30, 2001.
2001-06-30restructuringin_progress162001-01-012001-03-31United StatesMeasurement and Controlrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 16 employees in quality control systems business; terminated in Q1 2001.
2001-06-30restructuringin_progress1751999-01-012001-12-31Global (Sweden, Germany, France)Optical Technologies (Spectra-Physics)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approx. 175 employees from 1999 acquisitions; plans finalized in 1999/2000. Payments expected primarily through 2001.
2001-03-31restructuringin_progress612000-07-012001-06-30Company-wideUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring begun after new president/COO appointed July 2000; 61 terminations remained at March 31, 2001; program expected substantially complete by Q2 2001; Q1 2001 charge of $12.9 million including $2.0 million investment impairment.
2001-03-31reduction_in_forcein_progress162001-01-012001-12-31Measurement and Control — quality control systems businessUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 16 employees across all functions at the quality control systems business; part of 2001 additional terminations.
2001-03-31restructuringin_progress802000-07-012001-06-30Company-wideUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		80 terminations from the 2000 plan remained at December 30, 2000; severance accrual balance of $3.2 million at March 31, 2001 after 2001 activity.
2001-03-31restructuringin_progress2022000-072001-06-30Not specifiedConsolidated (Life Sciences, Optical Technologies, Measurement and Control, Corporate)USD 11 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program commenced after new president/COO appointed July 2000; headcount reductions, product line discontinuations, facility consolidation. Severance table: 249 terminations announced in 2000 (168 occurred) plus 16 announced in 2001 (34 occurred), 202 total occurring through 2001-03-31; 61 remaining terminations at quarter-end. Charge shown is Q1 2001 restructuring and other unusual costs, net, per income statement; includes noncash items. Includes 16 employees severed at Measurement and Control quality-control-systems unit. Company expects substantially complete by Q2 2001 and an additional $0.2 million of costs thereafter.
2001-03-31restructuringin_progress2001-06-30Not specifiedMeasurement and Control — scanning probe microscope business unit (held for sale)USD 5 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Goodwill writedown to estimated disposal value for noncore business unit held for sale; no employee count disclosed; expected sale in Q2 2001.
2001-03-31divestiture_reductionannounced2001-12-31Not specifiedMeasurement and Control — units held for sale or sold April 2001 (oil and gas wellhead safety/control businesses, scanning probe microscopes, data acquisition/oscilloscope/recorder unit)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cyclical and/or noncore units held for sale or sold in April 2001; divestitures expected complete in 2001. Aggregate Q1 2001 revenues $28.4 million and segment income $3.4 million before restructuring charges; no headcount disclosed.
2001-03-31divestiture_reductionin_progress2001-022001-12-31Not specifiedDiscontinued operations — power generation business (agreement to sell), Thermo Fibertek spinoff, Viasys Healthcare spinoffUSD 66 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell power generation business February 2001; $66.0 million after-tax charge for decline in Thoratec stock received for Thermo Cardiosystems. Remaining discontinued businesses expected sold by mid-2001; no headcount disclosed for any divested or spun-off business.
2001-03-31restructuringin_progress162001-01-012001-06-30Measurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 16 employees across all functions at the segment's business that manufactures and sells quality control systems.
2001-03-31restructuringin_progress2000-07-012001-06-30CorporateUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee retention costs accrued ratably over the period through which employees must work to qualify for a payment.
2000-12-30restructuringin_progress782000-072001-06-30Life Sciences — across all functionsUSD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		2000 restructuring plan commenced following July 2000 appointment of new president/COO. 31 of 78 employees terminated as of December 30, 2000. Segment recorded $16.3 million of restructuring and unusual costs, including $8.4 million cost-of-revenue charges for discontinued product lines and $1.4 million asset writedowns; facility closures in Spain, Belgium, Japan, Germany, and Colorado. Expected annualized savings of approximately $5 million per MD&A; program expected substantially complete by end of Q2 2001.
2000-12-30restructuringcompleted222000-07Optical Technologies — across all functionsUSD 0 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		All 22 severed employees terminated as of December 30, 2000. Segment recorded $6.5 million of restructuring and unusual costs, including $2.9 million cost-of-revenue charges, $1.5 million in-process R&D charge, $0.9 million asset writedowns, and closure of a California facility. Expected annualized savings of approximately $2 million per MD&A.
2000-12-30restructuringin_progress1282000-072001-06-30Measurement and Control — across all functionsUSD 3 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		101 of 128 employees terminated as of December 30, 2000. Segment recorded $91.9 million restructuring and unusual income, net, in 2000 (including $126.3 million gain on business sales); charges included $20.6 million asset writedowns for businesses held for sale, $8.0 million cost-of-revenue charges, and facility closures in Norway, New Zealand, Germany, and the UK. Expected annualized savings of approximately $4 million per MD&A.
2000-12-30restructuringin_progress212000-072001-06-30Corporate headquartersUSD 3 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		14 of 21 employees terminated as of December 30, 2000. Corporate recorded $20.5 million of restructuring and unusual costs, including $16.1 million of investment banking, consulting, and legal fees for the reorganization plan and $3.6 million of employee retention costs accrued ratably over required service periods. Expected annualized savings of approximately $2 million per MD&A.
2000-12-30divestiture_reductionin_progress2000-012001-06-30Discontinued operations — noncore businessesUSD 100 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		January 2000 reorganization plan to sell noncore businesses; nearly 30 operating units sold since December 1999 with annual revenues over $1 billion. Charge shown is the 2000 provision for loss on disposal of discontinued operations, net of $104 million tax benefit; $50 million provision recorded in 1999. Discontinued-operations sale proceeds were $390.1 million in 2000. Includes February 2001 sale of Thermo Cardiosystems to Thoratec for approximately 19.3 million Thoratec shares. Businesses held for sale at year-end 2000 had 2000 revenues of $102.3 million; additional businesses with $160 million annual revenues still being sold. Headcount reduction not quantified.
2000-12-30divestiture_reductionannounced2000-012001-12-31Thermo Fibertek (papermaking/recycling) and medical products companyItem_1_Business
f5-10k / GLM-5.3-flash-HTML		Planned spinoff of two businesses as a dividend to shareholders. Favorable IRS ruling received February 2001 requires spinoffs within one year of the ruling and public equity offerings within one year after each spinoff. Company expects to complete the spinoffs during the second half of 2001. Headcount not disclosed.
2000-12-30divestiture_reductionannounced2001-022001-06-30Power generation (Thermo Ecotek)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Definitive agreement to sell the power generation business entered February 2001; company expects to realize a gain on sale at closing. Business had 2000 income of $14.2 million, net of taxes and minority interest; many plants located in California. Company expects to substantially complete remaining discontinued-business sales by the middle of 2001. Headcount not disclosed.
2000-12-30divestiture_reductionannounced2001-022001-06-30Measurement and Control — scanning probe microscopes unitMD&A
f5-10k / GLM-5.3-flash-HTML		Unit designated held-for-sale in the first quarter of 2001; expected pretax charge of $4–5 million in Q1 2001 to reduce carrying value to estimated disposal value (range not reduced to a single figure). Segment divestitures expected primarily completed in the first half of 2001. Headcount not disclosed.
2000-12-30acquisition_additioncompleted2000Multiple segments (including Spectra-Physics)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Several acquisitions completed during 2000 for $15.8 million in cash, net of cash acquired, including the March 2000 compulsory acquisition of the remaining Spectra-Physics AB shares (aggregate Spectra-Physics purchase price approximately $351.5 million, including related expenses). Employee headcount added through acquisitions not disclosed.
2000-12-30restructuringin_progress782000-072001-06-30GlobalLife SciencesUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 78 employees; 31 terminated as of 2000-12-30. Total cash costs for segment were $6.5M including $4.0M severance. Part of broader 2000 restructuring program.
2000-12-30restructuringcompleted222000-072000-12-30GlobalOptical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 22 employees; all terminated as of 2000-12-30. Total cash costs for segment were $1.2M including $0.3M severance.
2000-12-30restructuringin_progress1282000-072001-06-30GlobalMeasurement and ControlUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 128 employees; 101 terminated as of 2000-12-30. Total cash costs for segment were $6.8M including $3.0M severance. Includes facility closures in Norway, New Zealand, Germany, and UK.
2000-12-30restructuringin_progress212000-072001-06-30United StatesCorporateUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 21 employees; 14 terminated as of 2000-12-30. Corporate restructuring also included $16.1M investment banking, consulting, and legal fees for reorganization plan.
2000-12-30restructuringin_progress2331998-012001-06-30GlobalMultiple segmentsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Combined 2000 and 1999 terminations under restructuring plans announced in 1998 and 1999; remainder not terminated due to attrition and sale of businesses. Filer does not split the 233 figure by year.
2000-12-30divestiture_reductionin_progress2000-012001-06-30GlobalDiscontinued operations — multiple businessesdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Since December 1999, nearly 30 operating units with annual revenues over $1B sold. Includes Spectra Precision (sold 2000-07-14), Nicolet Imaging Systems, Sierra Research and Technology, and others. No headcount disclosed for divested units.
2000-12-30restructuringin_progress782000-07-012001-06-30GlobalLife SciencesUSD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 78 employees across all functions. 31 terminated as of Dec 30, 2000. Completion expected by end of Q2 2001.
2000-12-30restructuringcompleted222000-07-012000-12-30GlobalOptical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 22 employees across all functions. All severed employees terminated as of Dec 30, 2000.
2000-12-30restructuringin_progress1282000-07-012001-06-30GlobalMeasurement and ControlUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 128 employees across all functions. 101 terminated as of Dec 30, 2000.
2000-12-30restructuringin_progress212000-07-012001-06-30GlobalCorporateUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 21 employees. 14 terminated as of Dec 30, 2000.
2000-09-30restructuringin_progress2942000-07-012001-06-30Company-wideUSD 58 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Company-wide restructuring commenced after new president/COO appointed in July 2000; includes headcount reductions, discontinued product lines, and facility consolidations. Plans call for termination of 294 employees; 139 terminated during first nine months of 2000. Additional $1.5 million of costs expected in Q4 2000 and thereafter; actions expected substantially complete by Q2 2001. Annualized savings of approximately $5M, $2M, $4M, and $2M expected in Life Sciences, Optical Technologies, Measurement and Control, and corporate office, respectively.
2000-09-30restructuringin_progress782000-07-012001-06-30Spain, Belgium, Japan, Germany, United States (Colorado)Life SciencesUSD 16 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $8.4M charges to cost of revenues for discontinued product lines, $6.4M cash costs including $4.0M severance for 78 employees across all functions, $1.1M ongoing lease costs through 2003, $0.8M lawsuit settlements, $0.5M other exit costs, and $1.4M asset writedowns. 31 employees terminated as of September 30, 2000. Closures include sales offices in Spain, Belgium, and Japan, consolidation of two German units, and relocation of a Colorado unit.
2000-09-30restructuringin_progress222000-07-012000-12-31California, United StatesOptical TechnologiesUSD 6 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $2.9M charges to cost of revenues for discontinued product lines, $1.5M in-process R&D charge on an acquisition, $0.9M asset writedowns, and $1.0M cash costs including $0.3M severance for 22 employees. All severed employees terminated as of September 30, 2000. Facility closure in California with lease payments through 2000.
2000-09-30restructuringin_progress1282000-07-012001-12-31Norway, New Zealand, Germany, United KingdomMeasurement and ControlUSD 84 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Net unusual income of $83.7M includes $115.4M gain on sale of two businesses (primarily Spectra Precision), offset by $16.6M asset writedowns for businesses held for sale, $8.0M cost-of-revenues charges, and $5.4M cash costs including $3.1M severance for 128 employees and $1.7M lease costs through 2001. 58 employees terminated as of September 30, 2000. Businesses held for sale include CAC Inc., Mid South Companies, Test and Measurement, and Pharos Marine.
2000-09-30restructuringin_progress192000-07-012002-01-31CorporateUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $2.9M severance for 19 employees, $1.3M investment banking/consulting/legal fees for reorganization plan, $1.0M employee retention costs accrued ratably, and $0.2M noncash costs.
2000-09-30divestiture_reductioncompleted2000-07-142000-07-14Measurement and Control — Spectra Precisionother
f5-10q / GLM-5.3-flash-fp4-HTML		Thermo Instrument sold Spectra Precision businesses to Trimble Navigation Limited for approximately $214 million cash plus $80 million seller debt. Headcount transferred not disclosed. Spectra Precision had an operating loss of $1.7 million in Q3 2000 prior to sale.
2000-09-30divestiture_reductioncompleted2000-03-312000-03-31Measurement and Control — Nicolet Imaging Systems and Sierra Research and Technologyrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		NIS and SRT sold in March 2000 for aggregate proceeds of $40.0 million with a $12.4 million gain in Q1 2000. Headcount transferred not disclosed.
2000-09-30restructuringin_progress1751999-12-312001-12-31Sweden, Germany, France, otherAcquisition-related (primarily Spectra-Physics AB)USD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 175 employees across all functions and abandoned facilities, primarily at Spectra-Physics AB (facilities in Sweden, Germany, France with obligations primarily through 2001). Balance of accrued acquisition expenses for 1999 acquisitions was $3.665 million at September 30, 2000.
2000-09-30restructuringin_progress452000-01-012001-12-31Power Generation (Thermo Ecotek)USD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2000 restructuring costs of $1.7 million included $1.0 million severance for 45 employees (12 terminated as of September 30, 2000), $0.6 million noncash charges from closing the gas marketing business, and $0.1 million retention costs. Additional $0.2 million of employee retention costs recorded in Q3 2000.
2000-09-30restructuringin_progress782000-072001-06-30Life SciencesUSD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance cash cost for 78 employees across all functions in Q3 2000; 31 employees terminated as of September 30, 2000. Component of the $58.1 million Q3 restructuring charge; program expected substantially complete by Q2 2001.
2000-09-30restructuringin_progress222000-072001-06-30Optical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 22 employees; all severed employees terminated as of September 30, 2000. Segment also closed a California facility (lease costs through 2000).
2000-09-30restructuringin_progress1282000-072001-06-30Measurement and ControlUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 128 employees across all functions; 58 employees terminated as of September 30, 2000. Segment also recorded $16.6 million of asset writedowns and facility consolidations (Norway, New Zealand, Germany, U.K.).
2000-09-30restructuringin_progress192000-072001-06-30CorporateUSD 3 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 19 corporate employees; number terminated as of September 30, 2000 not disclosed. Corporate charge also includes $1.3 million of reorganization advisory fees and $1.0 million of retention accruals.
2000-09-30restructuringin_progress1392001-06-30Company-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employees terminated during the nine months ended September 30, 2000 under 1998-2000 restructuring plans; the 2000 plans target termination of 294 additional employees. Overlaps the Q3 2000 segment-level severance actions listed separately (different metric: actual terminations YTD vs. Q3 severance-affected positions).
2000-09-30restructuringin_progress45Power Generation (Thermo Ecotek)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First-quarter 2000 restructuring tied to closure of Thermo Ecotek's gas marketing business; severance for 45 employees, 12 terminated as of September 30, 2000. Also included $0.6 million of noncash charges.
2000-09-30divestiture_reductioncompleted2000-07-14Measurement and Control (Spectra Precision)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Spectra Precision businesses to Trimble Navigation for approximately $214 million cash plus $80 million seller note; associated headcount not disclosed.
2000-09-30divestiture_reductioncompleted2000-03Measurement and Control (Nicolet Imaging Systems; Sierra Research and Technology)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sold for aggregate proceeds of $40.0 million; divested businesses had 1999 revenues of $28.3 million and operating income of $2.2 million. Headcount not disclosed.
2000-09-30divestiture_reductionannouncedMeasurement and Control (power electronics, test equipment, oil & gas wellhead products, Pharos Marine)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several noncore units held for sale (CAC Inc., Mid South Companies, Test and Measurement, Pharos Marine); 1999 revenues of $132.2 million and operating income of $2.9 million. Company expects divestitures completed by late 2000 or early 2001; headcount not disclosed.
2000-09-30restructuringin_progress782000-07-012001-06-30GlobalLife SciencesUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 78 employees across all functions; 31 terminated as of Sept 30, 2000.
2000-09-30restructuringcompleted222000-07-012000-09-30GlobalOptical TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 22 employees across all functions; all terminated as of Sept 30, 2000.
2000-09-30restructuringin_progress1282000-07-012001-06-30GlobalMeasurement and ControlUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 128 employees across all functions; 58 terminated as of Sept 30, 2000.
2000-09-30restructuringin_progress192000-07-012001-06-30United StatesCorporateUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 19 employees at corporate office.
2000-09-30restructuringin_progress452000-01-022000-12-31GlobalPower GenerationUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 45 employees; 12 terminated as of Sept 30, 2000. Part of Q1 2000 actions.
2000-09-30restructuringin_progress2942000-07-012001-06-30GlobalAll Segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Total plan for 2000 restructuring actions; 139 terminated during first nine months of 2000.
2000-07-01restructuringin_progress472000-01-02Continuing operationsUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2000 restructuring plans for continuing operations contemplated 47 terminations; 20 employees terminated during the first six months of 2000. Costs incurred in 2000 of $8.1 million include severance, employee retention, and other costs; excludes $1.2 million of noncash charges.
2000-07-01restructuringin_progress122000-07-012000-09-30Optical Technologies — spectroscopy businessesUSD 0 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Spectroscopy businesses reduced headcount by 32 permanent and 11 temporary employees in July 2000 to lower operating costs amid price competition; approximately $0.4 million of severance costs expected in Q3 2000.
2000-07-01restructuringin_progress452000-01-02Power Generation — Thermo EcotekUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First-quarter 2000 restructuring included $1.0 million of severance for 45 employees, of whom 8 were terminated in the first six months of 2000; also included $0.6 million of noncash charges for closing the gas marketing business.
2000-07-01restructuringin_progress7291998-01-01Company-wide (1998 and 1999 plans)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		1998 and 1999 restructuring plans included termination of 729 employees; 717 terminated as of January 1, 2000. Remaining severance balances at July 1, 2000: $230 thousand (1998 plans) and $1,206 thousand (1999 plans) for continuing operations.
2000-07-01divestiture_reductioncompleted2000-03-012000-03-31Optical Technologies — NIS and SRT subsidiariesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nicolet Imaging Systems and Sierra Research and Technology sold in March 2000 for aggregate proceeds of $40.0 million, generating $12.4 million of unusual income in Q1 2000; sold due to consolidation trend among test-equipment manufacturers.
2000-07-01divestiture_reductioncompleted2000-07-142000-07-14Measurement and Control — Spectra PrecisionUSD 2 (millions)subsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Spectra Precision businesses sold to Trimble Navigation Limited for approximately $214 million cash plus $80 million seller debt financing. Of total acquisition-expense reserves at July 1, 2000, $1.9 million related to Spectra Precision will not be paid as a result of the sale.
2000-07-01divestiture_reductionin_progress2000-01-022000-12-31Measurement and Control — power electronics and test equipment businessesMD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Power electronics and test equipment businesses held for sale as cyclical, noncore units; divestitures expected to be completed during the second half of 2000. 1999 restructuring charges were taken to adjust carrying value to estimated disposal value.
2000-07-01plant_closurecompleted2000-03-012000-06-01CaliforniaPower Generation — Thermo Ecotek Delano plantsMD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Delano facilities suspended operations in March 2000 after termination of fixed-price power-sales agreement effective December 31, 1999, deemed uneconomical in nonpeak periods; operations recommenced in June 2000.
2000-07-01plant_closurecompleted2000-01-022000-03-31Power Generation — Thermo Ecotek gas marketing businessUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Gas marketing business closed as a noncore business; Q1 2000 costs of $0.6 million included a $0.3 million write-off of cost in excess of net assets of acquired companies and $0.3 million of capitalized development costs, plus a $0.5 million Q2 charge for contract obligations.
2000-07-01restructuringin_progress2000-01-022002-01-31CorporateUSD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 2000 corporate restructuring and unusual costs of $4.9 million included $2.8 million of investment banking, consulting, and legal fees for the reorganization plan, a $1.2 million noncash charge primarily for modification of the former chairman's stock options, and $0.9 million of employee retention costs; Q2 included $1.9 million of similar fees and $0.1 million severance for 2 employees.
2000-07-01restructuringin_progress1999-01-012001-12-31Discontinued operationsUSD 3 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Discontinued operations incurred $3.2 million of restructuring costs in 2000 (severance, retention, facilities, other); accrued balances at July 1, 2000 of $21.1 million, with severance primarily payable in 2000, retention in 2000-2001, facility payments through 2014, and other costs primarily in 2000.
2000-07-01restructuringin_progress47Multiple segments and corporate headquartersUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2000 restructuring plans call for termination of 47 employees; 20 terminated during first six months of 2000. Total 2000 restructuring costs incurred of $8.079M comprise severance ($1.135M), employee retention ($2.277M), and other ($4.667M).
2000-07-01restructuringin_progress1752001-12-31Sweden, Germany, FranceSpectra-Physics AB (Optical Technologies)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 175 employees across all functions, primarily at Spectra-Physics AB (acquired February 1999). Company expects to pay severance through 2001; abandoned-facility payments over lease terms through 2014.
2000-07-01reduction_in_forceannounced322000-07Optical Technologies — spectroscopy businessesUSD 0 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		32 permanent employees reduced in July 2000 to lower operating costs; approximately $0.4M severance expected in Q3 2000. Announced after quarter-end.
2000-07-01reduction_in_forceannounced112000-07Optical Technologies — spectroscopy businessesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		11 temporary employees reduced in July 2000 alongside 32 permanent employees in the same action. Announced after quarter-end.
2000-07-01restructuringin_progress472000-01-01GlobalVariousrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring actions in 2000 included plans for termination of 47 employees. During the first six months of 2000, 20 employees were terminated.
2000-07-01restructuringcompleted322000-07-012000-07-01GlobalOptical TechnologiesUSD 0 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Spectroscopy businesses reduced headcount by 32 permanent employees in July 2000. Expected severance costs of $0.4 million in Q3 2000.
2000-07-01restructuringcompleted112000-07-012000-07-01GlobalOptical TechnologiesMD&A
f5-10q / Qwen3.6-27B-Q8_0		Spectroscopy businesses reduced headcount by 11 temporary employees in July 2000.
2000-07-01restructuringin_progress452000-01-01GlobalPower GenerationUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Power Generation segment incurred $1.0 million severance for 45 employees in Q1 2000. 8 of these were terminated in the first six months of 2000.
2000-07-01restructuringcompleted22000-01-01GlobalCorporateUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Corporate office recorded $0.1 million severance for 2 employees in Q2 2000.
2000-04-01restructuringin_progress482000-01-02Continuing operations (Measurement and Control, Power Generation, Corporate)USD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		2000 restructuring plans call for termination of 48 employees; 15 were terminated during Q1 2000. Costs include severance of $0.957M, employee retention of $1.234M, and other costs of $2.751M; excludes noncash charges of $0.6M (Power Generation) and $1.2M (corporate).
2000-04-01restructuringin_progress452000-01-02United StatesPower Generation (Thermo Ecotek)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 45 employees; 8 terminated in Q1 2000. Part of $1.7M restructuring costs that also include closure of gas marketing business and employee retention costs.
2000-04-01plant_closurecompleted2000-03-012000-03-31Delano, CaliforniaPower Generation (Thermo Ecotek)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Delano facilities suspended operations in March 2000 after termination of fixed-price power-sales agreement effective December 31, 1999; deemed uneconomical to operate at avoided-cost rates.
2000-04-01restructuringin_progress1999-01-02Continuing operationsUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance usage of $2.423M during Q1 2000 against a January 1, 2000 accrual of $10.512M; remaining balance $8.089M at April 1, 2000.
2000-04-01restructuringin_progress1998-01-02Continuing operationsUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance usage of $0.357M during Q1 2000; remaining accrual balance $1.206M at April 1, 2000.
2000-04-01restructuringin_progress1751999-02-222000-12-311999 acquisitions (primarily Spectra-Physics AB)USD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 175 employees across all functions; abandoned facilities primarily at Spectra-Physics AB (Sweden, Germany, France). Severance and other costs expected to be paid primarily in 2000.
2000-04-01divestiture_reductioncompleted2000-03-012000-03-31Optical Technologies (NIS and SRT subsidiaries)USD 12 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of Nicolet Imaging Systems and Sierra Research and Technology for aggregate proceeds of $40.0M resulted in $12.4M unusual income; no headcount disclosed.
2000-04-01divestiture_reductionin_progress2000-01-022000-06-30Measurement and Control (power electronics and test equipment business)USD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Employee retention costs of $0.2M for a business unit held for sale; remaining units expected to be sold during first half of 2000.
2000-04-01plant_closurecompleted2000-01-022000-03-31MainePower Generation (Thermo Ecotek Gorbell facility)USD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of Gorbell facility in Maine during Q1 2000 generated $2.0M gain; no headcount disclosed.
2000-04-01restructuringin_progress15Not specifiedMultiple segments and corporateUSD 4,942 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		2000 restructuring plans call for terminating 48 employees; 15 were terminated during Q1 2000. Cash restructuring costs incurred in 2000 totaled $4.9M across Measurement and Control ($0.2M), Power Generation ($1.1M), and corporate ($3.6M), excluding noncash charges and unusual income.
2000-04-01restructuringin_progress45United StatesPower Generation (Thermo Ecotek)USD 1,000 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 45 employees, 8 of whom were terminated in Q1 2000. Also includes $0.6M noncash charges for closure of gas marketing business and $0.1M retention costs. May overlap with the 15 total Q1 terminations disclosed in the General section.
2000-04-01restructuringin_progressNot specifiedCorporate headquartersUSD 4,865 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Corporate restructuring and unusual costs of $4.9M in Q1 2000: $2.8M investment banking/consulting/legal fees for reorganization plan, $1.2M noncash charge for stock option modification of former chairman, $0.9M employee retention costs accrued ratably.
2000-04-01restructuringin_progressNot specifiedMeasurement and Control (power electronics and test equipment business unit)USD 223 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee retention costs for a business unit being held for sale; sale expected to complete during first half of 2000. Headcount affected not disclosed.
2000-04-01acquisition_additionin_progress175Sweden, Germany, France (primarily)Optical Technologies / Measurement and Control (Spectra-Physics and other 1999 acquisitions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance accrual for approximately 175 employees across all functions, primarily at Spectra-Physics AB, plus abandoned facilities in Sweden, Germany, and France. Restructuring plans for Spectra-Physics finalized in 1999; other 1999 acquisitions unresolved at quarter-end.
2000-04-01divestiture_reductioncompletedNot specifiedOptical Technologies (Nicolet Imaging Systems and Sierra Research and Technology)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		NIS and SRT sold in March 2000 for aggregate proceeds of $40.0M; combined 1999 revenues $28.3M and operating income $2.2M. Headcount removed not disclosed.
2000-04-01plant_closurecompleted2000-03-31United States (California)Power Generation (Thermo Ecotek — Delano facilities)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Delano facilities suspended operations in March 2000 after termination of power-sales agreement effective 1999-12-31; 1999 revenues $60.5M and operating income $29.9M. Associated headcount not disclosed.
2000-04-01divestiture_reductionannounced2000-05-112000-06-30Not specifiedMeasurement and Control (Spectra Precision, Inc.)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Thermo Instrument agreed to sell Spectra Precision to Trimble Navigation for ~$200M cash plus $80M seller debt financing; closing expected end of Q2 2000 subject to regulatory approval and financing. Headcount not disclosed.
2000-04-01restructuringin_progressNot specifiedMultiple (1998 and 1999 restructuring plans — continuing operations)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Prior-year plans: 729 total terminations planned across 1998-1999; 717 completed as of 2000-01-01. Remaining accruals at 2000-04-01: 1998 plans $1.2M, 1999 plans $8.1M. Severance expected paid primarily in 2000; retention obligations in 2001 and Jan 2002.
2000-04-01restructuringin_progress482000-01-01GlobalCorporate and OtherUSD 5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2000 Restructuring Plans included termination of 48 employees; 15 terminated in Q1 2000. Corporate costs included $2.8M fees and $0.9M retention.
2000-04-01restructuringin_progress452000-01-01United StatesPower GenerationUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Power Generation segment recorded $1.0M severance for 45 employees, 8 terminated in Q1 2000.
2000-04-01restructuringin_progress1999-01-01GlobalOptical TechnologiesUSD -13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Unusual income of $12.5M from sale of NIS and SRT subsidiaries. Employee count not specified.
2000-04-01restructuringin_progress1999-01-01GlobalMeasurement and ControlUSD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee retention costs for business unit held for sale. Employee count not specified.
2000-04-01restructuringin_progress1999-01-01GlobalDiscontinued OperationsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs incurred in 2000 by discontinued operations. Employee count not specified.
2000-01-01restructuringin_progress225Continuing operations (multiple segments)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		225 employees terminated during fiscal 1999 under restructuring plans announced in 1998 and 1999. The 1998 program contemplated 729 terminations, with 500 completed by January 2, 1999; 1999 actions added plans for an additional 41 terminations. Severance reserves at January 1, 2000: $0.9 million (1998 plans) and $3.8 million (1999 plans); 1999 charges also included $2.3 million of reserve reversals.
2000-01-01reduction_in_forcein_progress71999Corporate headquartersUSD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Severance for seven senior-level employees, part of $5.8 million corporate restructuring costs that also included $0.9 million legal and advisory costs for the reorganization; accrued severance at year-end 1999 was principally at corporate headquarters with payments expected primarily in the first half of 2000. May overlap with the 225 terminations disclosed under the general restructuring narrative.
2000-01-01divestiture_reductionin_progress1999Measurement and Control — power electronics and test equipment businessUSD 30 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Restructuring and related costs of $32.4 million include a $1.4 million tax asset write-off and $0.9 million inventory provisions; restructuring costs include $28.5 million write-off of cost in excess of net assets and $1.6 million write-off of a subsidiary net investment. MD&A cites a $30.4 million restructuring charge; divestiture expected to be completed during the first half of 2000. No employee count disclosed.
2000-01-01plant_closurecompleted1999-05Gillette, Wyoming, United StatesPower Generation (Thermo Ecotek) — coal-beneficiation facilityUSD 68 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Plant ceased operation in May 1999 and investment held for sale/disposal; charge includes $63.3 million write-down to nominal salvage value, $4.4 million land reclamation and demolition, $0.3 million exit costs, offset by $1.5 million minority interest income. Disposal or salvage activities expected in 2000. No employee count disclosed.
2000-01-01restructuringcompleted1999-051999-12-31Delano, California, United StatesPower Generation (Thermo Ecotek) — Delano facilities power-sales agreementUSD 51 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Agreement reached May 1999 to terminate the fixed-rate power-sales agreement effective December 31, 1999; charge includes $47.5 million write-down of plant and assets, $2.4 million fuel-contract cancellation loss, and $1.1 million goodwill write-off. No workforce reduction disclosed.
2000-01-01plant_closurecompleted1999Athens, Maine, United StatesPower Generation (Thermo Ecotek) — Gorbell facilityUSD 14 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Unusual income (not a charge) of $13.5 million from termination of the power-sales agreement, representing proceeds net of facility closure costs including lease and fuel cancellation payments; facility had 1999 revenues of $7.7 million and operating income of $1.3 million before the termination. No workforce reduction disclosed.
2000-01-01restructuringin_progress31999Power Generation (Thermo Ecotek) — other restructuringUSD 3 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Bundled costs of $3.0 million: $1.5 million write-off of a power plant held for sale, $0.7 million abandoned assets, $0.4 million unrecouped development costs, $0.2 million severance for three employees, and $0.2 million other.
2000-01-01restructuringin_progress1751999Optical Technologies / Measurement and Control — Spectra-Physics acquisition integrationUSD 9 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Post-acquisition severance for approximately 175 employees across all functions, primarily at Spectra-Physics, plus abandoned facilities (Sweden, Germany, France) and other exit costs; total 1999 acquisition reserves of $15.1 million (severance $9.2 million, facilities $2.2 million, other $3.6 million). Plan finalized in 1999; severance payable primarily in 2000; facility obligations through 2000.
2000-01-01plant_closurein_progress3481999United StatesDiscontinued operations — Trex Medical (ThermoTrex)USD 11 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Consolidation of four domestic manufacturing facilities into two; restructuring and related costs of $27.3 million include $16.3 million inventory and warranty provisions, $3.7 million facility-closing costs (net of assumed sublease income), $3.6 million severance for 348 employees across all functions, $2.0 million leasehold/fixed-asset write-offs, and $1.6 million retention incentives accrued through facility closure dates.
2000-01-01divestiture_reductioncompleted1999Discontinued operations — ThermoLase (ThermoTrex)USD 61 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Sale of remaining nine day spas and The Greenhouse Spa stock plus exit of the hair-removal business; restructuring costs include $19.9 million loss on spa sales, $17.4 million leasehold/equipment write-offs, $11.7 million ongoing lease obligations (net of sublease income), $10.4 million termination of licensee/joint-venture obligations, and other items. Total restructuring and related costs of $67.9 million also include $2.3 million inventory provisions, $1.6 million receivable provisions, and a $3.4 million investment write-down. No employee count disclosed.
2000-01-01divestiture_reductionin_progress421999-05Discontinued operations — Thermo TerraTech (Thermo EuroTech used-oil processing; ThermoRetec soil-recycling; Randers Killam engineering businesses)USD 57 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Announced May 1999 plan to sell several businesses; restructuring and related costs of $58.3 million include a $1.1 million tax asset write-off and $0.7 million inventory provision; restructuring costs include $22.2 million goodwill write-down, $20.3 million fixed-asset write-downs, $4.6 million lease costs, $2.5 million land reclamation, $0.6 million severance for 42 employees, and other items. Randers division sold January 2000 for $0.5 million with a $2.2 million loss recorded in 1999.
2000-01-01restructuringin_progress1331999Discontinued operations — Thermo Power (ThermoLyte divestiture; Peek Malaysia/Croatia; outsourcing)USD 10 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Restructuring and related costs of $13.8 million include $3.0 million inventory provisions, $0.5 million outsourced warranty costs, and $0.2 million receivable provision; restructuring costs include $2.3 million severance for 133 employees across all functions, $4.1 million goodwill write-offs ($2.9 million ThermoLyte held for sale; $1.2 million Peek subsidiaries in Malaysia and Croatia), $1.9 million fixed-asset write-downs, and $1.6 million abandoned-facility lease costs.
2000-01-01restructuringin_progress241999Discontinued operations — Thermo FibertekUSD 2 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Restructuring costs of $1.3 million severance for 24 employees across all functions and $1.0 million distributor agreement terminations. Separately recorded $11.0 million gain on sale of the Thermo Wisconsin subsidiary (divestiture of a non-strategic graphics-arts unit) and impairment charges; no headcount disclosed for the divestiture.
2000-01-01restructuringin_progress1999Discontinued operations — Thermo ColemanUSD 17 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Exit of an information-technology products/services unit and a coherent laser radar business via sale or closure; includes $10.5 million goodwill write-off, $2.3 million fixed-asset write-down, $3.8 million inventory provisions, $0.4 million note receivable provision, and $0.3 million disposal loss; separately, $7.1 million gain on the sale of the LiveOnTheNet.com subsidiary. No employee count disclosed.
2000-01-01divestiture_reductionin_progress1999EnglandDiscontinued operations — Peter Brotherhood, Ltd. (industrial turbines and compressors)USD 8 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Business held for sale; fixed assets written down to estimated proceeds from sale. No employee count disclosed.
2000-01-01restructuringin_progress141999Discontinued operations — Thermo Trilogy (biopesticides)USD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Restructuring and related costs of $4.0 million include $3.5 million inventory provisions after a demand downturn, $0.4 million severance for 14 employees, and $0.1 million other costs.
2000-01-01restructuringannounced2000-01-31Company-widesubsequent_events
f5-10k / GLM-5.3-flash-HTML		Major reorganization announced January 31, 2000 (after fiscal year-end): spin off Thermo Fibertek and a new medical products company as dividends to shareholders, sell non-core businesses with aggregate revenues of more than $1 billion (discontinued operations employed 11,240 at year-end 1999), and take private all remaining majority-owned subsidiaries except Spectra-Physics Lasers. No workforce-reduction headcount disclosed.
2000-01-01restructuringin_progress22519992000GlobalContinuing operations — multiple segmentsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		225 employees terminated during FY1999 under restructuring plans announced in 1998 and 1999. 1998 plans targeted 729 total terminations (500 completed by Jan 2, 1999); 1999 plans added 41 more. Corporate segment separately disclosed severance for 7 senior-level employees ($4.9M), potentially included in the 225.
2000-01-01divestiture_reductionin_progress19992000-06-30GlobalMeasurement and Control — power electronics and test equipmentUSD 30 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision to sell cyclical, noncore power electronics and test equipment business; charge includes $28.5M goodwill write-down. Unaudited FY1999 revenues $28.2M, operating losses $0.5M, net assets $17.5M. Divestiture expected first half of 2000.
2000-01-01plant_closurein_progress1999-052000Wyoming, United StatesPower Generation — Thermo Ecotek coal-beneficiation facilityUSD 68 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Gillette, Wyoming coal-beneficiation plant ceased operations May 1999; $63.3M plant write-down to salvage value, $4.4M land reclamation and demolition. Facility held for sale or disposal in 2000.
2000-01-01restructuringin_progress3481999United StatesDiscontinued operations — Trex MedicalUSD 27 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 348 employees across all functions; consolidated four domestic manufacturing facilities into two. Charge includes $16.3M inventory and warranty provisions and $3.7M facility-closing costs.
2000-01-01plant_closurein_progress1999United StatesDiscontinued operations — ThermoLaseUSD 68 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed third domestic spa plus two additional spas; sold remaining nine day spas and destination spa. Charge includes $19.9M loss on spa business sales, $17.4M write-off of hair-removal assets, $11.7M ongoing lease obligations.
2000-01-01restructuringin_progress421999-05GlobalDiscontinued operations — Thermo TerraTechUSD 58 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 42 employees across all functions. Businesses proposed for sale include used-oil processing, soil-recycling facilities, and engineering/construction businesses. Charge includes $22.2M goodwill write-down and $20.3M fixed asset write-down.
2000-01-01restructuringin_progress1331999GlobalDiscontinued operations — Thermo PowerUSD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 133 employees across all functions. Actions include divesting ThermoLyte subsidiary, outsourcing manufacturing/warranty functions, and reducing staffing. Charge includes $4.1M goodwill write-down and $3.0M inventory provisions.
2000-01-01restructuringin_progress241999GlobalDiscontinued operations — Thermo FibertekUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 24 employees across all functions plus $1.0M to terminate distributor agreements.
2000-01-01restructuringin_progress1999GlobalDiscontinued operations — Thermo ColemanUSD 17 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Decision to exit IT products/services unit and coherent laser radar business through sale or closure. Charge includes $10.5M goodwill write-down, $3.8M inventory provisions, $2.3M fixed asset write-down.
2000-01-01restructuringin_progress141999GlobalDiscontinued operations — Thermo TrilogyUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for 14 employees plus $3.5M inventory provisions following downturn in biopesticide sales.
2000-01-01acquisition_additioncompleted1999-021999-02Global (Sweden-headquartered)Optical Technologies / Measurement and Control — Spectra-Physicsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Thermo Instrument acquired ~99% of Spectra-Physics AB for ~$351.5M including related expenses; acquired Spectra-Physics Lasers Inc. (SPLI) as part of transaction. Headcount added not disclosed. Spectra-Physics had 1998 revenues of ~$442M.
2000-01-01divestiture_reductionannounced2000-01-31GlobalMultiple — corporate reorganizationsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Major reorganization announced Jan 31, 2000 (after fiscal year end): spin off Thermo Fibertek and medical products company; sell non-core businesses with aggregate revenues >$1B; take private all remaining public subsidiaries except SPLI. Headcount impact not disclosed.
2000-01-01restructuringcompleted2251998-01-022000-01-01GlobalContinuing Operationsrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Terminations in connection with restructuring plans announced in 1998 and 1999. 500 employees terminated by Jan 2, 1999; additional 225 terminated in 1999.
2000-01-01restructuringcompleted1751999-02-012000-01-01GlobalAcquisitions (Spectra-Physics and others)USD 9 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for approximately 175 employees across all functions related to 1999 acquisitions.
2000-01-01restructuringcompleted3481999-01-022000-01-01United StatesTrex Medical (Discontinued Operations)USD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 348 employees across all functions at Trex Medical.
2000-01-01restructuringcompleted421999-05-012000-01-01GlobalThermo TerraTech (Discontinued Operations)USD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance costs for 42 employees across all functions.
2000-01-01restructuringcompleted1331999-01-022000-01-01GlobalThermo Power (Discontinued Operations)USD 2 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance costs for 133 employees across all functions.
2000-01-01restructuringcompleted241999-01-022000-01-01GlobalThermo Fibertek (Discontinued Operations)USD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance costs for 24 employees across all functions.
2000-01-01restructuringcompleted141999-01-022000-01-01GlobalThermo Trilogy (Discontinued Operations)USD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 14 employees.
2000-01-01restructuringcompleted71999-01-022000-01-01GlobalCorporate (Continuing Operations)USD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance costs for seven senior-level employees.
2000-01-01restructuringcompleted31999-01-022000-01-01GlobalPower Generation (Continuing Operations)USD 0 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for three employees at Thermo Ecotek.
1999-10-02restructuringin_progress5981999Company-wideUSD 54 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		1999 restructuring plans call for termination of an additional 598 employees; 490 employees were terminated in the first nine months of 1999 under 1998 and 1999 plans. Provision charged to expense of $54.5 million covers severance, facilities, and contract-termination/land-reclamation costs.
1999-10-02restructuringin_progress2651999-042000-03-31United StatesBiomedical and Emerging Technologies — Trex Medical CorporationUSD 6 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 265 employees across all functions as part of consolidation of four domestic units into two; Q3 1999 added $3.2 million of restructuring costs including employee retention incentives and facility-consolidation costs. Completion expected in Q1 2000.
1999-10-02restructuringcompleted1419981999-06-30United States and FranceBiomedical and Emerging Technologies — ThermoLase CorporationUSD 68 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Exit of spa business: sold The Greenhouse Spa and nine day spas in June 1999 and closed remaining spas; includes $19.9 million loss on spa sale, $17.4 million leasehold/equipment write-off, $11.7 million lease obligations, $10.0 million obligation-termination costs, and severance for approximately 14 employees.
1999-10-02restructuringin_progress721999-01United StatesBiomedical and Emerging Technologies — ThermoTrex CorporationUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		First-quarter 1999 charges of $3.5 million including severance for 72 employees across all functions and $2.4 million of inventory provisions at Trex Medical.
1999-10-02restructuringin_progress1999-04Biomedical and Emerging Technologies — ThermoTrex/ThermoLase goodwill write-offUSD 63 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Write-off of cost in excess of net assets of acquired companies, including $59.3 million from prior ThermoLase stock repurchases impaired by continuing losses and decision to exit its principal business; also reduced carrying value of Trex Communications held for sale.
1999-10-02restructuringin_progress1999-04Biomedical and Emerging Technologies — Thermo Coleman CorporationUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Exit of certain businesses through sale or closure: $10.5 million goodwill write-off, $2.3 million fixed-asset write-down, $3.8 million inventory provisions, and $0.4 million note-receivable provision; one unit disposed of in Q3 1999, another held for sale.
1999-10-02plant_closurecompleted171999-07Athens, Maine, United StatesEnergy and Environment — Thermo Ecotek Corporation (Gorbell facility)USD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Power-sales agreement for Gorbell facility terminated, generating $13.5 million net nonrecurring income; related restructuring costs of $1.9 million include $0.6 million severance for 17 employees, $0.7 million abandoned assets, and $0.4 million unrecouped development costs.
1999-10-02plant_closurecompleted1999-051999-05-31Gillette, Wyoming, United StatesEnergy and Environment — Thermo Ecotek coal-beneficiation facilityUSD 68 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Facility held for sale or disposal; charge includes $63.3 million plant write-down to nominal salvage value, $4.4 million land reclamation, and $0.3 million other exit costs. Facility closed in May 1999.
1999-10-02restructuringin_progress1999-051999-12-31Delano, California, United StatesEnergy and Environment — Thermo Ecotek Delano biomass facilitiesUSD 51 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement to terminate power-sales agreement effective December 31, 1999; charge includes $47.5 million asset write-down, $2.4 million fuel-contract cancellation loss, and $1.1 million goodwill write-off.
1999-10-02restructuringin_progress1999-07Woodland, California, United StatesEnergy and Environment — Thermo Ecotek Woodland plantUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		PG&E ceased paying fixed contract rates effective July 1, 1999; impairment of net investment in the Woodland facility recorded.
1999-10-02restructuringin_progress421999-052000-06-30United States and EuropeEnergy and Environment — Thermo TerraTech Inc.USD 56 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Planned sale of several businesses (used-oil processing, three soil-recycling facilities, Randers Killam units); charges include $22.2 million goodwill write-down, $20.2 million fixed-asset write-down, $4.6 million lease costs, and severance for 42 employees. Additional ~$3.0 million expected through H1 2000.
1999-10-02divestiture_reductionannounced1999-04Energy and Environment — Thermo Power Corporation (ThermoLyte)USD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Decision to divest ThermoLyte subsidiary, outsource certain manufacturing/warranty functions, and reduce staffing; includes $2.9 million goodwill write-down for ThermoLyte, $1.2 million Peek Malaysia/Croatia impairment, severance for approximately 63 employees, and $3.0 million inventory provisions. Additional ~$2.5 million expected through December 1999.
1999-10-02restructuringcompleted701999-01Energy and Environment — Thermo Power (Peek subsidiary)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 70 employees, lease costs for abandoned facilities, and asset write-down related to facility consolidation at Peek.
1999-10-02restructuringcompleted241999-01Recycling and Resource Recovery — Thermo Fibertek Inc.USD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 24 employees across all functions ($1.3 million) and $1.0 million to terminate distributor agreements.
1999-10-02divestiture_reductioncompleted1999-021999-02-28Recycling and Resource Recovery — Thermo Wisconsin, Inc. saleUSD 11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of Thermo Wisconsin subsidiary completed February 1999, generating an $11.1 million gain; reduced segment revenues by $13.7 million for the nine months.
1999-10-02divestiture_reductionin_progress1999-04United KingdomRecycling and Resource Recovery — Peter Brotherhood, Ltd.USD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Wholly owned subsidiary held for sale; fixed assets written down to estimated proceeds from sale.
1999-10-02restructuringin_progress1999-04Measurement and Detection — Thermedics Inc. power electronics and test equipment businessUSD 30 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Decision to sell power electronics and test equipment business; includes $28.5 million goodwill write-off, $1.6 million subsidiary investment write-off, $1.4 million deferred tax asset write-off, and $0.9 million inventory provisions.
1999-10-02restructuringin_progress1998Measurement and Detection — Thermo Instrument Systems Inc.USD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Restructuring actions commenced in 1998; 1999 costs of $1.5 million primarily for business relocation, facility-closure costs, and severance.
1999-10-02acquisition_additioncompleted1999-02Sweden; North America, Europe, Pacific RimMeasurement and Detection — Spectra-Physics ABUSD 351 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Thermo Instrument acquired approximately 99% of Spectra-Physics AB for approximately $351.0 million aggregate purchase price; headcount added not disclosed. Spectra-Physics had 1998 revenues of approximately $442 million.
1999-10-02restructuringcompleted721999-03-31United StatesBiomedical and Emerging TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		ThermoTrex recorded $1.1M in restructuring costs during Q1 1999 for severance covering 72 employees across all functions; $0.6M of the charge was recorded at Trex Medical. Announcement date approximated to quarter end as only the quarter is disclosed.
1999-10-02restructuringcompleted701999-03-31InternationalEnergy and EnvironmentUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Thermo Power recorded $0.4M in severance for approximately 70 employees at its Peek subsidiary during Q1 1999, alongside facility consolidation costs. Announcement date approximated to quarter end.
1999-10-02restructuringcompleted241999-03-31United StatesRecycling and Resource RecoveryUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Thermo Fibertek recorded $1.3M in severance for 24 employees across all functions during Q1 1999, plus $1.0M to terminate distributor agreements. Announcement date approximated to quarter end.
1999-10-02restructuringin_progress2651999-07-032000-03-31United StatesBiomedical and Emerging TechnologiesUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Trex Medical recorded $1.9M in severance for 265 employees across all functions as part of consolidating four domestic units into two. Completion expected in Q1 2000. Announcement date approximated to quarter end.
1999-10-02restructuringcompleted141999-07-03United StatesBiomedical and Emerging TechnologiesUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		ThermoLase recorded $0.2M in severance for approximately 14 employees as part of a broader $67.6M restructuring that included closing remaining spas and exiting the hair-removal business. Announcement date approximated to quarter end.
1999-10-02restructuringin_progress421999-052000-06-30InternationalEnergy and EnvironmentUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Thermo TerraTech announced in May 1999 plans to sell several businesses, recording $0.6M in severance for 42 employees as part of a $55.9M restructuring. Additional costs of approximately $3.0M expected through first half of 2000.
1999-10-02restructuringin_progress631999-07-031999-12-31InternationalEnergy and EnvironmentUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Thermo Power recorded $2.0M in severance for approximately 63 employees across all functions during Q2 1999, alongside decisions to divest ThermoLyte and outsource manufacturing. Completion expected by December 1999. Announcement date approximated to quarter end.
1999-10-02plant_closurein_progress1999-05Gillette, Wyoming, United StatesEnergy and EnvironmentUSD 68 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		In May 1999 Thermo Ecotek decided to cease operations and hold for sale or disposal its Gillette, Wyoming facility, recording a $68.0M charge including $63.3M to write down plant and equipment to nominal salvage value. Employee count not disclosed.
1999-10-02restructuringin_progress171999-10-02United StatesEnergy and EnvironmentUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Thermo Ecotek recorded $0.6M in severance for 17 employees during Q3 1999 as part of $1.9M in restructuring and nonrecurring costs, which also included abandoned assets and unrecouped development costs. Announcement date approximated to quarter end.
1999-10-02restructuringin_progress2651999-07-012000-03-31United StatesBiomedical and Emerging Technologies (Trex Medical)USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 265 employees across all functions recorded in Q2 1999; completion expected in Q1 2000.
1999-10-02restructuringin_progress171999-07-01United StatesEnergy and Environment (Thermo Ecotek)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 17 employees recorded in Q3 1999.
1999-10-02restructuringin_progress421999-05-012000-06-30GlobalEnergy and Environment (Thermo TerraTech)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 42 employees across all functions recorded in Q2 1999; additional costs expected through H1 2000.
1999-10-02restructuringin_progress631999-07-011999-12-31GlobalEnergy and Environment (Thermo Power)USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 63 employees across all functions recorded in Q2 1999; completion expected by Dec 1999.
1999-10-02restructuringin_progress701999-01-01GlobalEnergy and Environment (Thermo Power)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 70 employees recorded in Q1 1999.
1999-10-02restructuringin_progress241999-01-01GlobalRecycling and Resource Recovery (Thermo Fibertek)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 24 employees across all functions recorded in Q1 1999.
1999-10-02restructuringin_progress721999-01-01GlobalBiomedical and Emerging Technologies (ThermoTrex)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 72 employees across all functions recorded in Q1 1999.
1999-10-02restructuringin_progress141999-07-01GlobalBiomedical and Emerging Technologies (ThermoLase)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approximately 14 employees across all functions recorded in Q2 1999.
1999-10-02restructuringcompleted4901998-01-011999-10-02GlobalCorporate / Multiple Segmentsrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		490 employees terminated in first nine months of 1999 in connection with restructuring plans announced in 1998 and 1999.
1999-07-03restructuringin_progress1999-05-24Measurement and Detection - Thermedics Inc.USD 33 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Decision to sell power electronics and test equipment business; includes $28.5M goodwill write-off, $1.6M subsidiary investment write-off, $1.4M deferred tax asset write-off, $0.9M inventory provisions
1999-07-03restructuringin_progress1998-01-011999-09-30Measurement and Detection - Thermo Instrument Systems Inc.USD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Business relocation and facility-closure costs; $1.2M recorded in Q1 1999; additional $0.8M expected in Q3 1999
1999-07-03restructuringin_progress2651999-05-242000-03-31Biomedical and Emerging Technologies - Trex Medical CorporationUSD 18 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Facility consolidation and cost reductions; $1.9M severance for 265 employees; $12.0M inventory and warranty provisions including FDA denial of digital mammography 501(k); ~$5.0M additional costs expected
1999-07-03restructuringcompleted141999-05-24Biomedical and Emerging Technologies - ThermoLase CorporationUSD 68 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Exit of spa and hair-removal businesses; sold Greenhouse Spa and nine day spas, closed remaining spas; includes $19.9M loss on spa sale, $17.4M leasehold/equipment write-off, $11.7M lease obligations, $10.0M contract termination costs
1999-07-03restructuringin_progress1999-05-24Biomedical and Emerging Technologies - ThermoTrex Corporation / ThermoLase / Trex CommunicationsUSD 63 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Write-off of cost in excess of net assets of acquired companies: $59.3M from ThermoLase stock repurchases impaired by exit of principal business; balance reduces Trex Communications carrying value to expected sale proceeds
1999-07-03restructuringin_progress1999-05-24Biomedical and Emerging Technologies - Thermo Coleman CorporationUSD 17 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Exit of certain businesses through sale or closure; $10.5M goodwill write-off, $2.3M fixed-asset write-down, $3.8M inventory provisions, $0.4M note receivable provision
1999-07-03plant_closurein_progress1999-05-24Gillette, WyomingEnergy and Environment - Thermo Ecotek CorporationUSD 68 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Coal-beneficiation facility held for sale or disposal; $63.3M plant write-down to nominal salvage value, $4.4M land reclamation, $0.3M other exit costs
1999-07-03restructuringin_progress1999-05-241999-12-31Delano, CaliforniaEnergy and Environment - Thermo Ecotek CorporationUSD 51 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Agreement to terminate power-sales agreement effective December 31, 1999; $47.5M asset write-down, $2.4M fuel-contract cancellation loss, $1.1M goodwill write-off; subject to regulatory approval
1999-07-03restructuringin_progress1999-05-24Woodland, CaliforniaEnergy and Environment - Thermo Ecotek CorporationUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Impairment of net investment after PG&E ceased paying fixed contract rates effective July 1, 1999; company contests interpretation
1999-07-03restructuringin_progress421999-05-242000-06-30Energy and Environment - Thermo TerraTech Inc.USD 56 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Sale of several businesses including Thermo EuroTech used-oil processing, three ThermoRetec soil-recycling facilities, and Randers Killam businesses; $22.2M goodwill write-down, $20.2M fixed-asset write-down, $4.6M lease costs, $2.5M land reclamation; ~$3M additional costs expected through H1 2000
1999-07-03restructuringin_progress631999-05-241999-12-31Malaysia; CroatiaEnergy and Environment - Thermo Power CorporationUSD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Divestiture of ThermoLyte subsidiary, outsourcing of manufacturing/warranty functions, impairment at Peek subsidiaries in Malaysia and Croatia; $2.0M severance for 63 employees; ~$2.5M additional costs expected through December 1999
1999-07-03divestiture_reductionin_progress1999-05-24Recycling and Resource Recovery - Peter Brotherhood, Ltd.USD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Decision to hold Peter Brotherhood subsidiary for sale; fixed-asset write-down to estimated sale proceeds
1999-07-03restructuringcompleted721999-01-03Biomedical and Emerging Technologies - ThermoTrex Corporation (Q1 1999)USD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 1999 charges: $1.1M restructuring costs including severance for 72 employees, plus $2.4M inventory provisions at Trex Medical
1999-07-03restructuringcompleted701999-01-03Energy and Environment - Thermo Power Corporation (Peek subsidiary, Q1 1999)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 70 employees, lease costs for abandoned facilities, and asset write-down related to facility consolidation
1999-07-03restructuringcompleted241999-01-03Recycling and Resource Recovery - Thermo Fibertek Inc. (Q1 1999)USD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		$1.3M severance for 24 employees and $1.0M to terminate distributor agreements
1999-07-03restructuringin_progress5791999-01-03Company-wideUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		1999 restructuring plans include termination of an additional 579 employees; 373 employees terminated in first six months of 1999 under 1998 and 1999 plans; severance provision of $7.856M charged to expense in H1 1999
1999-07-03restructuringin_progress2651999-05-242000-03-31United StatesBiomedical and Emerging Technologies — Trex Medical CorporationUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 265 employees across all functions; facility consolidation. Trex Medical expects additional restructuring costs of approximately $5.0M, completion expected Q1 2000.
1999-07-03restructuringin_progress141999-05-24United StatesBiomedical and Emerging Technologies — ThermoLase CorporationUSD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 14 employees. ThermoLase also closed remaining spas, sold nine day spas and destination spa, and exited hair-removal business in Q2 1999.
1999-07-03restructuringin_progress421999-05-242000-06-30United States / EuropeEnergy and Environment — Thermo TerraTech Inc.USD 54 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 42 employees across all functions. Announced May 1999 plan to sell several businesses including used-oil processing, soil-recycling facilities, and Randers Killam divisions. Additional restructuring costs of approximately $3M expected through first half of 2000.
1999-07-03restructuringin_progress631999-05-241999-12-31United States / Malaysia / CroatiaEnergy and Environment — Thermo Power CorporationUSD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 63 employees across all functions. Includes decision to divest ThermoLyte subsidiary, outsource manufacturing and warranty functions, and write down impaired assets at Peek subsidiaries in Malaysia and Croatia. Additional restructuring costs of approximately $2.5M expected through December 1999.
1999-07-03plant_closurein_progress1999-05-24United States — Gillette, WyomingEnergy and Environment — Thermo Ecotek CorporationUSD 68 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision in May 1999 to cease operations and hold for sale or disposal the Gillette coal-beneficiation facility. Charge includes $63.3M plant write-down to nominal salvage value, $4.4M land reclamation, $0.3M other exit costs. Employee count not disclosed.
1999-07-03divestiture_reductionin_progress1999-05-24United StatesMeasurement and Detection — Thermedics Inc. power electronics and test equipment businessUSD 30 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to sell power electronics and test equipment business; $28.5M goodwill write-off to reduce carrying value to estimated sale proceeds. Employee count not disclosed.
1999-07-03divestiture_reductionannounced1999-05-24United KingdomRecycling and Resource Recovery — Peter Brotherhood, Ltd.USD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to hold Peter Brotherhood for sale; $8.4M fixed asset write-down to estimated sale proceeds. Employee count not disclosed.
1999-07-03restructuringin_progress241999-01-03United States / EuropeRecycling and Resource Recovery — Thermo Fibertek Inc.USD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 1999 action: severance for 24 employees across all functions ($1.3M) plus $1.0M to terminate distributor agreements.
1999-07-03restructuringin_progress701999-01-03United States / EuropeEnergy and Environment — Thermo Power Corporation (Peek subsidiary)USD 0 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 1999 action: severance for approximately 70 employees at Peek subsidiary across all functions.
1999-07-03restructuringin_progress721999-01-03United StatesBiomedical and Emerging Technologies — ThermoTrex CorporationUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 1999 action: severance for 72 employees across all functions, of which $0.6M recorded at Trex Medical.
1999-07-03acquisition_additioncompleted1999-02-01Sweden / North America / EuropeMeasurement and Detection — Spectra-Physics ABUSD 347 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of approximately 99% of Spectra-Physics AB for ~$347.2M aggregate purchase price. Spectra-Physics had 1998 revenues of ~$442M. Employee headcount added not disclosed.
1999-07-03restructuringin_progress2651999-04-012000-01-01United StatesBiomedical and Emerging Technologies (Trex Medical)USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 265 employees across all functions at Trex Medical. Completion expected in first quarter of 2000.
1999-07-03restructuringin_progress141999-04-01United StatesBiomedical and Emerging Technologies (ThermoLase)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for approximately 14 employees across all functions at ThermoLase.
1999-07-03restructuringin_progress421999-05-012000-06-30GlobalEnergy and Environment (Thermo TerraTech)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for 42 employees across all functions. Additional costs expected through first half of 2000.
1999-07-03restructuringin_progress631999-04-011999-12-31GlobalEnergy and Environment (Thermo Power)USD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for approximately 63 employees across all functions. Completion expected by December 1999.
1999-07-03restructuringcompleted701999-01-011999-03-31GlobalEnergy and Environment (Thermo Power)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for approximately 70 employees recorded in first quarter 1999.
1999-07-03restructuringcompleted241999-01-011999-03-31GlobalRecycling and Resource Recovery (Thermo Fibertek)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for 24 employees across all functions recorded in first quarter 1999.
1999-07-03restructuringcompleted721999-01-011999-03-31GlobalBiomedical and Emerging Technologies (ThermoTrex)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 72 employees across all functions recorded in first quarter 1999.
1999-07-03restructuringin_progress3731998-01-01GlobalCorporaterestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		373 employees terminated in connection with restructuring plans announced in 1998 and 1999 during the first six months of 1999.
1999-04-03restructuringin_progress38Thermo Fibertek Inc. (Recycling and Resource Recovery)USD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charge includes $1.3 million severance for 38 employees across all functions, none terminated as of quarter-end, plus $1.0 million to terminate distributor agreements.
1999-04-03restructuringin_progress81998-01-011999-09-30Thermo Instrument Systems Inc. (Measurement and Detection)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Actions commenced in 1998; Q1 1999 costs of $1.2 million cover business relocation, facility closure, severance for 8 employees, and other items. Additional ~$1.1 million expected through Q3 1999.
1999-04-03restructuringin_progress72ThermoTrex Corporation / Trex Medical Corporation (Biomedical and Emerging Technologies)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for 72 employees across all functions, all terminated during the quarter; $0.6 million recorded at Trex Medical.
1999-04-03restructuringannounced1999-05-01Trex Medical Corporation (Biomedical and Emerging Technologies)USD 11 (millions)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Plan to consolidate manufacturing facilities and reduce headcount; $6-7 million expected in Q2 1999, remainder over following quarters.
1999-04-03restructuringin_progress701999-09-30Thermo Power Corporation — Peek subsidiary (Energy and Environment)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 70 employees across all functions, abandoned-facility payments, and asset write-down related to facility consolidation; 20 employees terminated as of quarter-end.
1999-04-03restructuringin_progress8471998-01-01Certain subsidiariesrestructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		1998-announced plans for 847 terminations; 550 completed by January 2, 1999, and an additional 132 during Q1 1999. Accrued restructuring balance of $16.2 million at quarter-end.
1999-04-03divestiture_reductioncompleted1999-02-28Thermo Fibertek Inc. — Thermo Wisconsin, Inc. (Recycling and Resource Recovery)USD -11 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		February 1999 sale of Thermo Wisconsin subsidiary reduced quarterly revenues by $4.0 million; gain on sale of $11.1 million recorded.
1999-04-03acquisition_additioncompleted1999-01-07Sweden; North America, Europe, Pacific RimThermo Instrument Systems Inc. — Spectra-Physics AB (Measurement and Detection)USD 347 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquired ~99% of Spectra-Physics AB for ~$347.2 million including expenses; no headcount figure disclosed. Spectra-Physics had 1998 revenues of ~$442 million.
1999-04-03plant_closureannouncedThermoLase Corporation (Biomedical and Emerging Technologies)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		ThermoLase will not expand day spa operations, announced closure of two additional spas, and is assessing closing or selling others; ~$27 million of spa assets and lasers and ~$24 million of lease commitments at risk.
1999-04-03restructuringin_progress38Recycling and Resource RecoveryUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 38 employees across all functions; none terminated as of April 3, 1999. Also includes $1.0M to terminate distributor agreements.
1999-04-03restructuringin_progress81999-09-30Measurement and DetectionUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 8 employees plus relocation and facility-closure costs. Part of restructuring actions commenced in 1998. Additional $1.1M expected through Q3 1999.
1999-04-03restructuringcompleted721999-04-03Biomedical and Emerging TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for 72 employees across all functions; all terminated during the quarter. $0.6M recorded at Trex Medical Corporation.
1999-04-03restructuringin_progress701999-09-30Energy and EnvironmentUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 70 employees at Peek subsidiary; 20 employees terminated as of April 3, 1999. Includes abandoned-facility payments and asset write-down.
1999-04-03restructuringannounced1999-05-01Biomedical and Emerging TechnologiesUSD 11 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Trex Medical announced in May 1999 approximately $11M in additional restructuring for manufacturing consolidation and severance; ~$6-7M expected in Q2 1999. Employee count not disclosed.
1999-04-03acquisition_additioncompletedSwedenMeasurement and DetectionUSD 347 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Thermo Instrument acquired ~99% of Spectra-Physics AB for ~$347.2M. Spectra-Physics had 1998 revenues of ~$442M. Employee headcount not disclosed.
1999-04-03acquisition_additioncompletedUSD 26 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several other acquisitions during Q1 1999 for $26.4M net of cash acquired. Employee headcount not disclosed.
1999-04-03otherannounced1999-05-051999-09-30Energy and Environmentother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement May 5, 1999 for Company to acquire Thermo Power at $12.00/share; expected completion Q3 calendar 1999. Part of broader reorganization reducing majority-owned subsidiaries from 23 to 16.
1999-04-03restructuringin_progress381999-04-03Thermo Fibertek Inc.USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for 38 employees across all functions; none terminated as of April 3, 1999.
1999-04-03restructuringin_progress81999-04-031999-09-30Thermo Instrument Systems Inc.USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 8 employees; additional costs expected through Q3 1999.
1999-04-03restructuringcompleted721999-04-031999-04-03ThermoTrex Corporation (Trex Medical)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 72 employees across all functions; all terminated during the quarter.
1999-04-03restructuringin_progress701999-04-031999-09-30Thermo Power Corporation (Peek subsidiary)USD 0 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for approx. 70 employees; 20 terminated as of April 3, 1999.
1999-04-03restructuringin_progress1321998-12-31Various Subsidiariesrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Termination of 132 employees in Q1 1999 related to restructuring plans announced in 1998.
1999-04-03restructuringannounced1999-05-011999-12-31ThermoTrex Corporation (Trex Medical)USD 11 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Announced May 1999; consolidation of manufacturing facilities and severance. $6-7M expected in Q2.
1999-01-02restructuringin_progress7801999Measurement and Detection — Thermo Instrument Systems (all functions)USD 22 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Recorded during fiscal 1998; charge comprised $16.2 million severance for approximately 780 employees, $4.2 million facility-closing costs, $0.8 million goodwill write-off, and $0.4 million loss on a division sale. Approximately 500 employees had been terminated and $7.4 million of reserves expended by year-end. Total 1998 restructuring and related costs including $8.6 million inventory write-downs were $31.8 million, with $2.4 million of additional costs expected in early 1999.
1999-01-02plant_closurecompleted1998United StatesBiomedical and Emerging Technologies — ThermoLase spa services (Spa Thira)USD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Closure of three Spa Thira locations; charge included $2.4 million write-off of leasehold improvements and related spa assets and $2.2 million primarily for abandoned-facility payments. Item 1 confirms three of fifteen original spas (U.S.) were closed.
1999-01-02plant_closurein_progress1998Outside the United StatesBiomedical and Emerging Technologies — ThermoLase spa services (joint-venture spa)USD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Overseas closure of a spa operated under a joint-venture agreement, primarily to liquidate the joint venture and write off ThermoLase's remaining investment. MD&A indicates three of the four announced spa closures had been completed as of the filing, suggesting this component remained in process.
1999-01-02restructuringcompleted401998United States (California to Texas)Biomedical and Emerging Technologies — ThermoLase headquartersUSD 2 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Headquarters relocation from California to Texas; charge included $1.1 million severance for 40 terminated employees and $0.8 million write-off of fixed assets no longer of use.
1999-01-02plant_closurecompleted1998United StatesEnergy and Environment — Thermo TerraTech / ThermoRetec soil-remediation (soil-recycling facilities)USD 9 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Closure of two soil-recycling facilities in response to a severe downturn in ThermoRetec's soil-remediation business; costs included fixed-asset write-downs to disposal value, write-offs of intangibles including goodwill, and other closure costs. Two additional sites had been closed in 1997 (prior-year activity not extracted).
1999-01-02restructuringcompleted1998Energy and Environment — Thermo TerraTech (facility consolidation)USD 1 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Abandoned-facility payments relating to consolidation of the facilities of another business; part of $10.2 million total Thermo TerraTech restructuring costs in 1998.
1999-01-02divestiture_reductioncompleted1998Energy and Environment — Thermo Power, industrial and marine engines (Crusader Engines division)USD 1 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Loss on discontinuance and subsequent sale of the Crusader Engines division, sold in December 1998; driven by declining profitability and desire to focus on core traffic-control operations. Headcount affected not disclosed (division had approximately $23.0 million of 1998 revenues).
1999-01-02restructuringcompleted1998NetherlandsBiomedical and Emerging Technologies — SensorMedics (wholly owned)USD 1 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Primarily severance costs in connection with a reorganization of a subsidiary in the Netherlands; headcount not disclosed.
1999-01-02restructuringin_progress1998Businesses acquired during fiscal 1998USD 12 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Reserves established in 1998 at acquired businesses, primarily for severance ($7.3 million) and excess-facility costs ($3.9 million), per EITF 95-3; plans to be finalized within one year of acquisition, and completion of planned severances and facility abandonments for certain 1998 acquisitions remained unresolved at year-end. Headcount not disclosed.
1999-01-02divestiture_reductioncompleted1999-02United States (Wisconsin)Recycling and Resource Recovery — Thermo Fibertek (Thermo Wisconsin, Inc.)MD&A
f5-10k / GLM-5.3-flash-HTML		Subsequent to fiscal year-end, Thermo Wisconsin was sold in February 1999 for approximately $13.0 million in cash; the subsidiary had 1998 revenues of about $18.9 million. Headcount affected not disclosed.
1999-01-02restructuringin_progress7801998-01-011999-12-31United States and internationalMeasurement and DetectionUSD 22 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 780 employees across all functions; approximately 500 terminated by year-end 1998; $7.4M of reserves expended; additional $2.4M expected in early 1999
1999-01-02plant_closurecompleted1998-01-011998-12-31United StatesBiomedical and Emerging Technologies — ThermoLase spa operationsUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of three Spa Thira locations; includes $2.4M write-off of leasehold improvements and $2.2M abandoned-facility payments
1999-01-02plant_closurecompleted1998-01-011998-12-31United StatesBiomedical and Emerging Technologies — ThermoLase joint venture spaUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of another spa operated under a joint venture agreement, primarily to liquidate the JV and write off remaining investment
1999-01-02restructuringcompleted401998-01-011998-12-31United StatesBiomedical and Emerging Technologies — ThermoLase headquarters relocationUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Relocation of headquarters from California to Texas; $1.1M severance for 40 terminated employees and $0.8M fixed asset write-off
1999-01-02plant_closurecompleted1998-01-011998-12-31United StatesEnergy and Environment — ThermoRetec soil-recycling facilitiesUSD 9 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of two soil-recycling facilities; includes fixed asset write-down, intangible asset write-off, and other closure costs
1999-01-02restructuringcompleted1998-01-011998-12-31United StatesEnergy and Environment — Thermo TerraTech facility consolidationUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Abandoned-facility payments relating to consolidation of facilities of another business
1999-01-02divestiture_reductioncompleted1998-12-011998-12-31United StatesEnergy and Environment — Thermo Power Crusader Engines divisionUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divestiture of industrial and marine engine product lines; loss on discontinuance and subsequent sale
1999-01-02restructuringcompleted1998-01-011998-12-31NetherlandsBiomedical and Emerging Technologies — SensorMedics subsidiaryUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Primarily severance in connection with reorganization of a subsidiary in the Netherlands
1999-01-02restructuringin_progress1998-01-011999-12-31MultipleMultiple segments — acquisition-related restructuringUSD 12 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Reserves established in 1998 as part of acquisition-related restructuring: $7.3M severance, $3.9M abandonment of excess facilities, $0.9M other; plans to be finalized within one year of acquisition dates
1999-01-02acquisition_additionannounced1999-02-221999-03-01Sweden / North America / EuropeMeasurement and Detection — Thermo Instrument / Spectra-Physics ABUSD 355 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tender offer for Spectra-Physics AB completed February 1999; aggregate cost approximately $355M; headcount not disclosed
1999-01-02divestiture_reductioncompleted1999-02-011999-02-28United StatesRecycling and Resource Recovery — Thermo Wisconsin, Inc.MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Thermo Fibertek sold Thermo Wisconsin for approximately $13.0M in cash; Thermo Wisconsin had 1998 revenues of $18.9M and segment income of $2.7M; headcount not disclosed
1999-01-02restructuringin_progress7801998-01-031999-12-31GlobalMeasurement and Detection (Thermo Instrument)USD 22 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance costs for approximately 780 employees across all functions. Implementation expected to complete in 1999.
1999-01-02restructuringcompleted401998-01-031998-12-31United StatesBiomedical and Emerging Technologies (ThermoLase)USD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Severance for 40 terminated employees related to headquarters relocation from California to Texas.
1999-01-02restructuringin_progress1998-01-031998-12-31United StatesBiomedical and Emerging Technologies (SensorMedics)USD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring costs primarily for severance in connection with reorganization of a subsidiary in the Netherlands.
1998-10-03restructuringin_progress7601998-09-301999-06-30Thermo Instrument Systems Inc. — all functionsUSD 22 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for approximately 760 employees across all functions; 274 employees terminated and $1.7 million of reserves expended as of October 3, 1998. Additional $2.2 million of costs expected in Q4 1998 and Q1 1999.
1998-10-03plant_closurein_progress1998-09-301999-06-30Thermo Instrument Systems Inc. — facility closingsUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Facility-closing costs including $2.2 million of fixed-asset write-downs; also $0.4 million loss on sale of a division.
1998-10-03restructuringcompleted1998-07-05Thermo Instrument Systems Inc. — Epsilon Industrial arbitrationUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nonrecurring costs for resolution of arbitration claims by five former Epsilon Industrial employees.
1998-10-03plant_closurein_progress1998-09-30ThermoLase Corporation — closure of three Spa Thira locationsUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $4.6 million for closure of three spas (including $2.4 million leasehold-improvement and spa-asset write-offs) and $2.2 million primarily for abandoned-facility payments; remaining $1.4 million related to joint-venture liquidation.
1998-10-03plant_closurecompleted1998-09-30ThermoLase Corporation — closure of joint-venture spaUSD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Costs primarily to liquidate a joint-venture spa and write off the remaining investment.
1998-10-03restructuringcompleted401998-07-05California to TexasThermoLase Corporation — headquarters relocationUSD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes $1.2 million severance for 40 terminated employees and $0.8 million write-off of fixed assets; relocation of headquarters from California to Texas.
1998-10-03plant_closurein_progress1998-09-30ThermoRetec Corporation (Thermo TerraTech) — closure of two soil-recycling facilitiesUSD 9 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Includes fixed-asset write-down to disposal value, write-off of intangible assets including cost in excess of net assets of acquired companies, and other closure costs.
1998-10-03restructuringin_progress1998-09-30Thermo TerraTech Inc. — facility consolidationUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Abandoned-facility payments relating to consolidation of facilities of another business.
1998-10-03restructuringin_progress1998-09-30Thermo Power Corporation — discontinuance of engines businessUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Loss on discontinuance of the engines business.
1998-10-03restructuringcompleted1998-07-05NetherlandsSensorMedics Corporation — reorganization of Netherlands subsidiaryUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily severance in connection with reorganization of a subsidiary in the Netherlands; recorded in Q2 1998.
1998-10-03restructuringin_progress1998-09-30Biomedical Products segmentUSD 0 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Additional Biomedical Products segment restructuring costs recorded in Q3 1998.
1998-10-03restructuringannounced1998-08-122000-08-12Company-wide proposed reorganization of majority-owned public subsidiariesother
f5-10q / GLM-5.3-flash-fp4-HTML		Proposed reorganization would reduce the number of majority-owned public subsidiaries from 23 to 15; may take up to two years to complete. Workforce impact not quantified.
1998-10-03restructuringin_progress7601999-06-30Not specified (multiple locations)Instruments (Thermo Instrument Systems Inc.) — all functionsUSD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance for approximately 760 employees across all functions ($17.2M of the $21.9M restructuring charge); also includes $4.3M facility-closing costs and $0.4M loss on sale of a division. 274 employees terminated and $1.7M of reserves expended as of 1998-10-03. Additional $2.2M of costs expected in Q4 1998 and Q1 1999 (EITF 94-3 items). Announcement date not stated; Form 8-K on restructuring charges filed 1998-09-30.
1998-10-03plant_closurecompletedUnited StatesBiomedical Products (ThermoLase Corporation — Spa Thira locations)USD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure of three Spa Thira locations ($4.6M write-off of leasehold improvements and spa assets, $2.2M abandoned-facility payments) plus $3.6M to liquidate a spa joint venture; MD&A states four spas closed in total. Headcount affected not disclosed.
1998-10-03plant_closurecompletedUnited StatesIndustrial Outsourcing (ThermoRetec Corporation — two soil-recycling facilities)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure of two soil-recycling facilities; costs include write-down of fixed assets to disposal value and write-off of intangibles including goodwill. Headcount affected not disclosed.
1998-10-03restructuringcompletedUnited StatesIndustrial Outsourcing (Thermo TerraTech Inc. — facility consolidation)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Abandoned-facility payments relating to consolidation of facilities of another business. Headcount affected not disclosed.
1998-10-03restructuringcompletedUnited StatesAlternative Energy (Thermo Power Corporation — engines business)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Loss on discontinuance of the engines business. Headcount affected not disclosed.
1998-10-03restructuringcompletedNetherlandsBiomedical Products (SensorMedics Corporation — subsidiary reorganization)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Primarily severance for a reorganization of a Netherlands subsidiary; recorded in Q2 1998 (year-to-date action). Headcount affected not disclosed.
1998-10-03restructuringcompleted40United States (headquarters relocation from California to Texas)Biomedical Products (ThermoLase Corporation)USD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 1998 action: $1.2M severance for 40 terminated employees plus $0.8M write-off of fixed assets no longer of use.
1998-10-03restructuringin_progressUnited Kingdom / Europe (Fisons plc Scientific Instruments businesses)Instruments (Thermo Instrument Systems Inc.)USD 2 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing restructuring of businesses acquired from Fisons plc in 1996; $1.5M expended during the first nine months of 1998, primarily abandoned-facility and severance payments. Remaining reserve $10.0M at 1998-10-03. Headcount affected not disclosed.
1998-10-03restructuringannounced1998-08-12Global (corporate)Corporate — multiple majority-owned public subsidiariesother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Proposed reorganization announced 1998-08-12 that would reduce majority-owned public subsidiaries from 23 to 15; may take up to two years to complete. No headcount impact disclosed.
1998-10-03acquisition_additionin_progressNot specifiedMultiple segmentsUSD 178 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several acquisitions during the first nine months of 1998 for $177.7M cash net of cash acquired plus $11.5M subsidiary stock; headcount added not disclosed. Post-quarter: $27.8M expended on acquisitions since 1998-10-03, with ~$70M of agreements or nonbinding letters of intent as of 1998-11-11.
1998-10-03restructuringin_progress7601998-10-031999-06-30GlobalInstruments (Thermo Instrument Systems Inc.)USD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance costs for approx. 760 employees across all functions; implementation expected to complete in first half of 1999.
1998-10-03restructuringin_progress401998-07-05United StatesBiomedical Products (ThermoLase Corporation)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for 40 terminated employees recorded in second quarter 1998 related to headquarters relocation from California to Texas.
1998-07-04restructuringcompleted1998-06-30California to Texas relocationThermoLase Corporation (Biomedical Products)USD 2 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance and write-off of fixed assets in connection with actions including relocation of headquarters from California to Texas.
1998-07-04restructuringcompleted1998-06-30NetherlandsSensorMedics Corporation (Biomedical Products)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily severance in connection with a reorganization of a subsidiary in the Netherlands.
1998-07-04othercompleted51998-06-30United StatesEpsilon Industrial, Inc. (Thermo Instrument Systems)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nonrecurring costs from arbitration decision on claims by five former employees alleging breaches of pre-acquisition agreements.
1998-07-04restructuringannounced1998-07-041998-12-31ThermoSpectra Corporation (Instruments)MD&A
f5-10q / GLM-5.3-flash-fp4-HTML		ThermoSpectra expects additional restructuring activities during the remainder of 1998, which will result in additional charges.
1998-07-04restructuringin_progress1997-03-31Fisons Scientific Instruments Division (Thermo Instrument Systems)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Spent $1.2 million in first six months of 1998, primarily severance and abandoned-facility payments; remaining reserve $9.9 million at July 4, 1998.
1998-07-04otherannounced1998-08-122000-08-12Corporate-widesubsequent_events
f5-10q / GLM-5.3-flash-fp4-HTML		Proposed corporate reorganization to reduce majority-owned public subsidiaries from 23 to 15; may take up to two years; company does not expect significant restructuring charges.
1998-07-04restructuringin_progressUnited States (California to Texas)Biomedical Products — ThermoLase CorporationUSD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance and fixed-asset write-off tied to actions including relocation of headquarters from California to Texas; no employee count disclosed.
1998-07-04restructuringcompletedNetherlandsBiomedical Products — SensorMedics CorporationUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Primarily severance related to reorganization of a subsidiary in the Netherlands; no employee count disclosed.
1998-07-04othercompletedUnited StatesInstruments — Thermo Instrument Systems (Epsilon Industrial)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nonrecurring cost from arbitration award to five former Epsilon Industrial employees; no headcount reduction disclosed.
1998-07-04restructuringin_progressUnited KingdomInstruments — Thermo Instrument Systems (Fisons plc Scientific Instruments Division)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 1998 restructuring spend primarily for severance and abandoned-facility payments; remaining reserve of $9.9M at quarter end; no employee count disclosed.
1998-07-04restructuringannouncedUnited StatesInstruments — ThermoSpectra CorporationMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Filer states ThermoSpectra expects additional restructuring during remainder of 1998 resulting in additional charges; no employee count or charge amount disclosed.
1998-07-04restructuringcompletedCalifornia to TexasThermoLase CorporationUSD 2 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes severance and write-off of fixed assets in connection with headquarters relocation.
1998-07-04restructuringcompletedNetherlandsSensorMedics CorporationUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Primarily severance costs in connection with reorganization of a subsidiary.
1998-07-04othercompleted5Epsilon Industrial, Inc. (Thermo Instrument)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Nonrecurring costs related to arbitration settlement with five former employees for alleged breaches of agreements.
1998-07-04restructuringin_progressThermo Instrument (Scientific Instruments Division)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Expended $1.2 million for restructuring costs, primarily severance and abandoned-facility payments, from remaining reserve.
1998-04-04restructuringin_progress1997-03-01United KingdomIndustrial Outsourcing — Thermo Remediation soil-remediation business (Scientific Instruments Division of Fisons plc legacy operations)USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring of Fisons plc businesses acquired March 1996; plan finalized March 1997. Q1 1998 spend of $0.6M for severance and abandoned-facility payments; $10.5M reserve remaining at quarter-end. No employee count disclosed.
1998-04-04plant_closurecompleted1997-01-011997-12-31United StatesIndustrial Outsourcing — Thermo Remediation soil-remediation sitesUSD 8 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Two soil-remediation sites closed during 1997 following $7.8M restructuring charge in Q1 1997 to write down capital equipment and intangibles. No employee count disclosed; charge is prior-period.
1998-04-04restructuringin_progress1997-03Scientific Instruments DivisionUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Expended $0.6 million for ongoing severance and abandoned-facility payments related to restructuring finalized in March 1997.
1998-01-03restructuringin_progress1996Instruments — Thermo Instrument (acquired Fisons businesses)USD 46 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Restructuring of the Fisons businesses acquired in 1996, including reductions in staffing levels and abandonment of excess facilities. Plans were finalized in Q1 1997 under EITF 95-3. Of the $46.2M reserve for severance, excess facilities, and other exit costs, $14.3M was expended during fiscal 1997 ($19.0M in 1996), leaving $11.1M at January 3, 1998, primarily for ongoing severance and abandoned-facility payments. Affected headcount not disclosed.
1998-01-03plant_closurecompleted1997Industrial Outsourcing — Thermo Remediation (soil-remediation business)USD 8 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Two soil-remediation sites were closed during 1997 in response to a severe downturn in the soil-remediation business. The charge is a write-down of capital equipment and intangible assets, including cost in excess of net assets of acquired companies; affected headcount not disclosed.
1998-01-03restructuringcompleted1997Alternative-energy Systems — Peter BrotherhoodUSD 1 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Restructuring and other nonrecurring costs in 1997 related primarily to severance for employees terminated during 1997; number of employees not disclosed.
1998-01-03restructuringcompleted1997Instruments — ThermoSpectra (one business unit)USD 1 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Severance costs for employees terminated during 1997 at one ThermoSpectra business unit; headcount not disclosed.
1998-01-03restructuringcompleted1997Paper Recycling — Thermo Fibertek (consolidation of two subsidiaries into Thermo Black Clawson)USD 1 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Costs relate to consolidating the operations of two subsidiaries into the operations of Thermo Black Clawson; workforce impact not quantified.
1998-01-03plant_closurecompleted1997International (foreign sales offices)Biomedical Products — wholly owned businessesUSD 1 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Costs to close certain foreign sales offices at wholly owned businesses; headcount affected not disclosed.
1998-01-03restructuringin_progressUnited StatesIndustrial Outsourcing (Thermo Remediation)USD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Write-down of capital equipment and intangibles; closure of two soil-remediation sites during 1997 due to severe downturn in soil-remediation business
1998-01-03restructuringin_progressUnited StatesMultiple majority-owned subsidiaries and wholly owned businessesUSD 3 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Primarily severance costs at two majority-owned subsidiaries and wholly owned businesses during 1997
1998-01-03restructuringin_progressUnited StatesInstruments (Fisons businesses acquired 1996)USD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Expenditure during 1997 from $46.2M total restructuring reserve established for Fisons acquisition; primarily severance and abandoned-facility payments; remaining reserve $11.1M at year-end
1998-01-03acquisition_additioncompleted1997-03-01United KingdomInstruments (Life Sciences International PLC)USD 443 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Life Sciences International PLC for $442.8M aggregate purchase price; headcount added not disclosed
1998-01-03acquisition_additioncompletedMultipleMultiple segmentsUSD 406 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Several other 1997 acquisitions for aggregate $406.3M cash net of cash acquired; headcount added not disclosed
1998-01-03acquisition_additioncompleted1997-11-01United KingdomAlternative-energy Systems (Peek plc)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Thermo Power completed cash tender offer for Peek plc in November 1997; headcount added not disclosed
1998-01-03divestiture_reductioncompletedUnited StatesPaper Recycling (Thermo TerraTech thermal-processing equipment)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Thermal-processing equipment business sold in October 1997 for a nominal loss; headcount removed not disclosed
1998-01-03divestiture_reductioncompletedUnited StatesInstruments (ThermoSpectra)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Gain of $2.2M from sale of a business by ThermoSpectra during 1997; headcount removed not disclosed
1998-01-03restructuringcompleted1996-03-011998-01-03GlobalInstruments (Fisons businesses)USD 14 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring of Fisons businesses acquired in 1996. $14.3 million expended in 1997 for severance and abandoned-facility payments. Total reserve established was $46.2 million.
1998-01-03restructuringcompleted1997-01-011997-12-31GlobalIndustrial Outsourcing (Thermo Remediation)USD 8 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Write down of capital equipment and intangible assets due to downturn in soil-remediation business. Closure of two soil-remediation sites.
1998-01-03restructuringcompleted1997-01-011997-12-31GlobalVarious (Majority-owned subsidiaries and wholly owned businesses)USD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring and other nonrecurring costs, primarily severance, at two majority-owned subsidiaries and wholly owned businesses.
1998-01-03restructuringcompleted1997-01-011997-12-31GlobalBiomedical Products (ThermoTrex)USD 1 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Write-off of acquired technology relating to an acquisition at ThermoTrex.
1998-01-03restructuringcompleted1997-01-011997-12-31GlobalInstruments (ThermoSpectra)USD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Severance costs for employees terminated during 1997 at one of ThermoSpectra's business units.
1998-01-03restructuringcompleted1997-01-011997-12-31GlobalBiomedical Products (Wholly owned businesses)USD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Costs to close certain foreign sales offices at certain wholly owned businesses.
1998-01-03restructuringcompleted1997-01-011997-12-31GlobalPaper Recycling (Thermo Fibertek)USD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Restructuring costs relating to the consolidation of operations of two subsidiaries into Thermo Black Clawson.
1997-09-27restructuringcompleted1997-09-27Advanced Technologies (ThermoTrex)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Write-off of acquired technology in connection with an acquisition; no employee count disclosed.
1997-09-27restructuringcompleted1997-09-27Process Equipment (Thermo Fibertek / Thermo Black Clawson)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Consolidation of two subsidiaries into Thermo Black Clawson; severance for terminated employees and abandoned-facility payments.
1997-09-27plant_closurecompleted1997-03-31Environmental Services (Thermo Remediation soil-recycling)USD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Closure of two soil-remediation sites; write-down of capital equipment and intangibles including goodwill, plus write-down of other sites with insufficient future cash flows.
1997-09-27restructuringcompleted1997-06-30Alternative-energy Systems (Peter Brotherhood Ltd)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily severance for employees terminated during the second quarter of 1997.
1997-09-27restructuringcompleted1997-06-30Instruments (ThermoSpectra Corporation)USD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Primarily severance for employees terminated during the second quarter of 1997.
1997-09-27restructuringin_progress1996-03-31Instruments (Thermo Instrument — former Fisons Scientific Instruments Division)USD 13 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nine-month 1997 restructuring spend, primarily severance and abandoned-facility payments; additional $8.1 million reserve recorded in Q1 1997; $12.1 million reserve remaining at September 27, 1997.
1997-09-27acquisition_additioncompleted1997-03-31United KingdomInstruments (Life Sciences International PLC)USD 448 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Thermo Instrument acquired 95% then all of Life Sciences; purchase price net of $50.7 million cash acquired and includes repayment of $105.0 million bank debt; no headcount disclosed.
1997-09-27restructuringin_progressUnited KingdomProcess Equipment — Thermo Fibertek / Thermo Black ClawsonUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 1997 severance for terminated employees and abandoned-facility payments from consolidating two subsidiaries into Thermo Black Clawson (acquired May 1997). No employee count disclosed.
1997-09-27restructuringcompletedUnited KingdomAlternative-energy Systems — Peter Brotherhood Ltd.USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 1997 nonrecurring costs primarily for severance for employees terminated during the quarter. No employee count disclosed.
1997-09-27restructuringcompletedUnited StatesInstruments — ThermoSpectra CorporationUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 1997 nonrecurring costs primarily for severance for employees terminated during the quarter. No employee count disclosed.
1997-09-27plant_closurecompletedUnited StatesEnvironmental Services — Thermo Remediation Inc.USD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 1997 charge to write down capital equipment and intangible assets following closure of two soil-remediation sites due to downturn in soil-recycling business. No employee count disclosed.
1997-09-27restructuringin_progressUnited Kingdom / EuropeInstruments — Fisons Scientific Instruments Division (acquired March 1996)USD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD 1997 restructuring costs primarily for severance and abandoned-facility payments; remaining reserve of $12.1M at quarter-end. An additional $8.1M acquisition reserve recorded in Q1 1997. No employee count disclosed.
1997-09-27acquisition_additioncompleted1997-03-31United KingdomInstruments — Life Sciences International PLCUSD 448 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired 95% of Life Sciences International PLC in March 1997, then remaining shares; aggregate purchase price $448.3M net of cash. No headcount added disclosed.
1997-09-27acquisition_additioncompleted1997-05-31United StatesProcess Equipment — Thermo Black Clawsonbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Black Clawson recycled paper equipment business acquired May 1997; contributed $20.2M in Q3 sales. No headcount added disclosed.
1997-09-27restructuringcompleted1997-07-01Process EquipmentUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Thermo Fibertek recorded costs for severance and abandoned-facility payments related to consolidation of operations.
1997-09-27restructuringcompleted1997-07-01Advanced TechnologiesUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		ThermoTrex recorded nonrecurring costs to write off acquired technology.
1997-09-27restructuringcompleted1997-04-01Alternative-energy SystemsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Peter Brotherhood Ltd. recorded costs primarily for severance for employees terminated during the second quarter.
1997-09-27restructuringcompleted1997-04-01InstrumentsUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		ThermoSpectra Corporation recorded nonrecurring costs primarily for severance for employees terminated during the second quarter.
1997-09-27restructuringcompleted1997-01-01Environmental ServicesUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Thermo Remediation recorded costs to write down capital equipment and intangible assets due to downturn in soil-recycling business and closure of two sites.
1997-09-27restructuringcompleted1997-04-01InstrumentsUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Thermo Instrument expended costs for restructuring of businesses acquired from Fisons, primarily for severance and abandoned-facility payments.
1997-06-28restructuringcompletedAlternative-energy Systems — Peter Brotherhood LtdUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Nonrecurring costs primarily for severance for employees terminated during Q2 1997; headcount not disclosed.
1997-06-28restructuringcompletedInstruments — ThermoSpectra Corporation business unitUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Severance for employees terminated during Q2 1997; headcount not disclosed.
1997-06-28plant_closurecompletedEnvironmental Services — Thermo Remediation Inc. soil-recycling businessUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 1997 charge to write down capital equipment and intangibles, including goodwill, after closure of two soil-remediation sites; headcount not disclosed.
1997-06-28restructuringin_progress1996-03-01Instruments — businesses acquired from Fisons plc (Scientific Instruments division)USD 11 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Spent in H1 1997, primarily severance and abandoned-facility payments; remaining reserve of $15.4 million at June 28, 1997; headcount not disclosed.
1997-06-28restructuringin_progressInstruments — businesses acquired from Fisons plcUSD 8 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 1997 acquisition reserves, primarily facility abandonment and severance pay, recorded as increase to cost in excess of net assets of acquired companies.
1997-06-28plant_closurecompleted1997-03-28United StatesEnvironmental Services — Thermo Remediation Inc. soil remediationUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		First-quarter 1997 charge to write down capital equipment and intangibles after two soil-remediation sites were closed; also includes write-down for other open sites with insufficient future cash flows. No employee count disclosed.
1997-06-28restructuringin_progress1997-01-01United KingdomInstruments — Thermo Instrument (former Fisons Scientific Instruments businesses)USD 11 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring of businesses acquired from Fisons plc; costs during first six months 1997 primarily severance and abandoned-facility payments. An additional $8.1 million of acquisition reserves was recorded in Q1 1997 for facility abandonment and severance. Remaining reserve was $15.4 million at June 28, 1997. No employee count disclosed.
1997-06-28restructuringcompleted1997-04-01United KingdomAlternative-energy Systems — Peter Brotherhood Ltd.USD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nonrecurring cost recorded in the second quarter of 1997, primarily severance for employees terminated during the quarter. No employee count disclosed.
1997-06-28restructuringcompleted1997-04-01United StatesInstruments — ThermoSpectra CorporationUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nonrecurring cost recorded in the second quarter of 1997, primarily severance for employees terminated during the quarter at one business unit. No employee count disclosed.
1997-06-28acquisition_additioncompleted1997-03-01United KingdomInstruments — Life Sciences International PLCUSD 448 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Purchase price of $447.9 million net of cash acquired; excess of cost over fair value of net assets was $447.5 million. Headcount added through the acquisition was not disclosed.
1997-06-28restructuringcompletedPeter Brotherhood Ltd.USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for employees terminated during the second quarter.
1997-06-28restructuringcompletedThermoSpectra CorporationUSD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Severance for employees terminated during the second quarter.
1997-06-28restructuringcompletedThermo Remediation Inc.USD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Write-down of capital equipment and intangible assets; closure of two soil-remediation sites.
1997-06-28restructuringin_progressThermo Instrument Systems Inc. (Fisons businesses)USD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Expended for restructuring costs, primarily for severance and abandoned-facility payments.
1997-06-28restructuringcompletedThermo Instrument Systems Inc. (Fisons businesses)USD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Additional acquisition reserves recorded in Q1, primarily for abandonment of excess facilities and severance pay.
1997-03-29plant_closurein_progressUnited StatesEnvironmental Services — Thermo Remediation soil-remediationUSD 8 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Charge to write down capital equipment and intangible assets, including goodwill, due to severe downturn in soil-recycling business; two soil-remediation sites to be closed. No employee count disclosed.
1997-03-29restructuringin_progress1996-03-01United KingdomInstruments — Thermo Instrument Systems (Fisons Scientific Instruments division)USD 5 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q1 1997 restructuring costs primarily for severance and abandoned facility payments; additional $8.1 million of acquisition reserves recorded, remaining reserve $20.6 million at quarter-end. No employee count disclosed.
1997-03-29plant_closurein_progressUnited StatesEnvironmental Services — Thermo Remediation Inc.USD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Write-down of capital equipment and intangibles; closure of two soil-remediation sites due to downturn in soil-recycling business. No employee count disclosed.
1997-03-29restructuringin_progressUnited Kingdom / EuropeInstruments — Scientific Instruments division (acquired from Fisons plc)USD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 1997 severance and abandoned facility payments of $5.1M plus $8.1M additional acquisition reserves for excess facility abandonment and severance. Remaining reserve $20.6M at quarter-end. No employee count disclosed.
1997-03-29restructuringcompleted1997-03-29Environmental ServicesUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Thermo Remediation recorded $7.8 million to write-down capital equipment and intangible assets due to downturn in soil-recycling business, resulting in closure of two sites.
1997-03-29restructuringin_progress1997-03-29InstrumentsUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Thermo Instrument expended $5.1 million for severance and abandoned facilities and recorded $8.1 million in acquisition reserves for Fisons businesses restructuring.
1996-12-28restructuringin_progress1996-03-291997-03-29United Kingdom (acquired Fisons Scientific Instruments businesses)Instruments (Thermo Instrument Systems)USD 38 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Reserve established as part of Fisons acquisition cost for severance, excess facilities, and exit costs; about $19.0 million spent in 1996, mostly severance. Plan (staffing reductions, facility abandonments) still being finalized at year-end 1996; EITF 95-3 limits finalization to one year from the acquisition date.
1996-12-28restructuringcompleted1996-06Biomedical Products (SensorMedics)USD 11 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Costs recorded in 1996 primarily from SensorMedics' merger into the Company: merger-triggered employee compensation, banking and transaction fees, a pre-acquisition legal settlement, and severance for terminated employees. No employee count disclosed.
1996-12-28restructuringcompleted1996United KingdomAlternative-energy Systems (Peter Brotherhood Ltd.)USD 4 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		1996 charge recorded primarily for write-off of a nontrade receivable and severance costs at the wholly owned U.K. subsidiary. No employee count disclosed.
1996-12-28divestiture_reductioncompleted1996-07San Diego County, CaliforniaAlternative-energy Systems (waste-recycling facility)MD&A
f5-10k / GLM-5.3-flash-HTML		Waste-recycling facility sold in July 1996 to the County for a nominal amount plus buyer assumption of about $109.9 million of facility debt. Facility had ceased processing waste in 1995, when its net investment ($11.5 million) was written off; no 1996 charge and no headcount disclosed.
1996-12-28restructuringin_progress1996-03-291997-03-29InternationalInstrumentsUSD 38 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring of acquired Fisons Scientific Instruments Division; $19.0M expended in 1996 primarily for severance; plan expected to finalize within one year of acquisition.
1996-12-28restructuringcompleted1996-06-011996-12-31United StatesBiomedical ProductsUSD 11 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Costs from SensorMedics merger including severance for terminated employees, transaction costs, and settlement of pre-acquisition dispute.
1996-12-28restructuringcompleted1996-01-011996-12-31United KingdomAlternative-energy SystemsUSD 4 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Write-off of nontrade receivable and severance costs at Peter Brotherhood Ltd.
1996-12-28acquisition_additioncompleted1996-03-291996-03-29InternationalInstrumentsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of substantial portion of Fisons Scientific Instruments Division for approximately $188.9M cash plus $47.2M debt assumed; headcount not disclosed.
1996-12-28acquisition_additioncompleted1996-06-011996-06-01United StatesBiomedical Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired in exchange for 1,289,781 shares of Company common stock; pooling-of-interests method; headcount not disclosed.
1996-12-28divestiture_reductioncompleted1996-07-011996-07-01United StatesAlternative-energy SystemsMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Waste-recycling facility in San Diego County sold to San Diego County for nominal amount plus debt assumption; headcount not disclosed.
1996-12-28restructuringin_progress1996-03-291997-03-29GlobalInstrumentsUSD 38 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring of businesses acquired from Fisons plc. Reserves established for estimated severance, excess facilities, and other exit costs. Finalization of plan not to occur beyond one year from acquisition date.
1996-12-28restructuringcompleted1996-06-011996-12-30United StatesBiomedical ProductsUSD 11 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Costs recorded by SensorMedics primarily as a result of its merger with the Company, including employee compensation, investment banking fees, and severance costs for terminated employees.
1996-12-28restructuringcompleted1996-01-011996-12-28United KingdomAlternative-energy SystemsUSD 4 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Recorded by wholly owned Peter Brotherhood Ltd. subsidiary primarily for write-off of nontrade receivable and severance costs.
1996-09-28restructuringin_progressAlternative-energy Systems / Peter Brotherhood Ltd.USD 4 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 1996 charge primarily for write-off of a non-trade receivable and severance costs at wholly owned Peter Brotherhood subsidiary; no employee count disclosed.
1996-09-28restructuringcompletedBiomedical Products / SensorMedicsUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 1996 charge for settlement of a pre-acquisition legal dispute and severance costs for terminated employees at SensorMedics subsidiary.
1996-09-28plant_closurecompletedForeign operations relocated to U.S.Biomedical Products / Nicolet BiomedicalUSD 1 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q3 1996 costs to close and relocate a foreign business to the U.S. at wholly owned Nicolet Biomedical subsidiary.
1996-09-28restructuringin_progress1996-03-291997-03-29Instruments / Fisons Scientific Instruments DivisionUSD 35 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Reserves for estimated severance, excess facilities, and other exit costs from restructuring acquired Fisons businesses; $10 million expended in first nine months of 1996, primarily severance. Plan finalization required within one year of acquisition per EITF 95-3.
1996-09-28restructuringcompletedBiomedical Products / Thermedics' Corpak Inc.USD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 1996 write-off of cost in excess of net assets and certain intangible assets at Corpak; Thermedics no longer intends to invest in this business.
1996-09-28restructuringcompletedBiomedical Products / SensorMedicsUSD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Q2 1996 costs from SensorMedics merger with the Company, including employee compensation that became payable and investment banking/transaction fees.
1996-09-28divestiture_reductioncompleted1996-07-31Southern CaliforniaAlternative-energy Systems / waste-recycling facilityMD&A
f5-10q / GLM-5.3-flash-fp4-HTML		Waste-recycling facility sold to County of San Diego in July 1996; County assumed outstanding debt. No material additional gain or loss. Headcount not disclosed.
1996-09-28restructuringin_progressUnited KingdomAlternative-energy Systems — Peter Brotherhood Ltd.USD 4 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 1996 charge: non-trade receivable write-off plus severance; affected-employee count not disclosed.
1996-09-28restructuringin_progressUnited StatesBiomedical Products — SensorMedicsUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 1996: pre-acquisition legal settlement and severance for terminated employees; headcount not disclosed.
1996-09-28plant_closurein_progressForeign operations relocated to United StatesBiomedical Products — Nicolet BiomedicalUSD 1 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 1996 costs to close a foreign business and relocate it to the U.S.; headcount not disclosed.
1996-09-28restructuringin_progress1996-03-291997-03-29Global (Fisons Scientific Instruments Division businesses)InstrumentsUSD 35 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reserves for severance, excess facilities and exit costs; $10 million expended in first nine months of 1996; plan to be finalized within one year of acquisition; headcount not disclosed.
1996-09-28restructuringcompletedAdvanced Technologies — Thermedics' Corpak Inc.USD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 1996 write-off of goodwill and intangibles after decision to stop investing; headcount not disclosed.
1996-09-28othercompletedUnited StatesBiomedical Products — SensorMedics mergerUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q2 1996 merger-related employee compensation plus investment banking and transaction costs; headcount not disclosed.
1996-09-28acquisition_additioncompleted1996-03-29Global (analytical instruments businesses)Instrumentsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired most of Fisons Scientific Instruments Division for about GBP 123.7 million cash plus GBP 30.8 million debt assumed; headcount added not disclosed.
1996-09-28acquisition_additioncompleted1996-06United StatesBiomedical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pooling-of-interests acquisition of SensorMedics for 1,133,191 shares plus options and warrants; headcount added not disclosed.
1996-09-28divestiture_reductioncompleted1996-07United States (southern California)Alternative-energy Systems — waste-recycling facilityMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Facility sold to the County of San Diego, which assumed the related tax-exempt debt; headcount removed not disclosed.
1996-09-28acquisition_additionannouncedBiomedical Products — Thermo Cardiosystems Inc.MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Letter of intent to acquire an R&D company for $5.0 million; most of price expected to be expensed as acquired technology in development; headcount not disclosed.
1996-09-28restructuringin_progress1996-03-291997-03-29GlobalInstruments (Fisons acquisition)USD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reserves established for estimated severance, excess facilities, and other exit costs associated with the acquisition of Fisons Scientific Instruments Division. Finalization of plan expected within one year of acquisition date.
1996-09-28restructuringcompleted1996-07-011996-09-28United KingdomAlternative-energy Systems (Peter Brotherhood)USD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Includes write-off of non-trade receivable and severance costs.
1996-09-28restructuringcompleted1996-07-011996-09-28United StatesBiomedical Products (SensorMedics)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Settlement of pre-acquisition legal dispute and severance costs for terminated employees.
1996-09-28restructuringcompleted1996-07-011996-09-28Foreign to U.S.Biomedical Products (Nicolet Biomedical)USD 1 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs to close and relocate a foreign business to the U.S.
1996-09-28restructuringcompleted1996-04-011996-06-30United StatesBiomedical Products (Thermedics/Corpak)USD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Write-off of cost in excess of net assets and intangible assets; Thermedics no longer intends to further invest in this business.
1996-09-28restructuringcompleted1996-04-011996-06-30United StatesBiomedical Products (SensorMedics)USD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs incurred as a result of merger with the Company, including employee compensation payable and investment banking fees.
1996-09-28restructuringcompleted1996-01-011996-03-31GlobalInstruments (Fisons acquisition)USD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Write-off of acquired technology in connection with the acquisition of Fisons Scientific Instruments Division.
1996-06-29restructuringin_progress1996-03-291997-03-29Instruments (Scientific Instruments Division of Fisons plc)USD 34 (millions)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Reserves established for estimated severance, excess facilities, and other exit costs tied to the Fisons acquisition; $3 million expended in first six months of 1996; restructuring expected to be substantially complete within one year of acquisition. No employee count disclosed.
1996-06-29restructuringcompleted1996-06-29Biomedical Products (Thermedics' Corpak Inc. subsidiary)USD 13 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Write-off of cost in excess of net assets of acquired company and certain intangible assets at Corpak; Thermedics no longer intends to invest further in this business. No employee count disclosed.
1996-06-29restructuringcompleted1996-06-29SensorMedics CorporationUSD 10 (millions)restructuring_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Costs incurred by SensorMedics in connection with its merger with the Company, including employee compensation that became payable as a result of the merger and certain investment banking and transaction fees. No employee count disclosed.
1996-06-29acquisition_additioncompleted1996-03-29Instruments (Thermo Instrument Systems Inc.)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Acquisition of a substantial portion of the businesses comprising the Scientific Instruments Division of Fisons plc for approximately $187 million cash plus assumption of approximately $36 million of indebtedness; headcount added not disclosed.
1996-06-29acquisition_additioncompleted1996-06-29SensorMedics Corporation (pulmonary function and sleep disorder diagnosis)business_combinations_footnote
f5-10q / GLM-5.3-flash-fp4-HTML		Pooling-of-interests acquisition of SensorMedics in exchange for 1,133,191 shares of Company common stock plus 156,590 shares reserved for options and warrants; headcount added not disclosed.
1996-06-29restructuringin_progress1996-06-29United StatesBiomedical ProductsUSD 13 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Write-off of goodwill and intangibles at Thermedics' Corpak Inc. subsidiary; no employee count disclosed.
1996-06-29restructuringcompleted1996-06-29United StatesBiomedical ProductsUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		SensorMedics merger-related costs including employee compensation triggered by the merger, investment banking fees, and transaction costs; no employee count disclosed.
1996-06-29restructuringin_progress1996-03-291997-03-29United KingdomInstrumentUSD 34 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reserves for severance, excess facilities, and other exit costs related to Fisons Scientific Instruments Division acquisition; $3 million expended in first six months of 1996; no employee count disclosed.
1996-06-29acquisition_additioncompleted1996-06-29United StatesBiomedical Productsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		SensorMedics Corporation acquired via pooling-of-interests in June 1996 in exchange for 1,133,191 shares of Company common stock; no headcount disclosed.
1996-06-29acquisition_additioncompleted1996-03-29United KingdomInstrumentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Scientific Instruments Division of Fisons plc for approximately £123 million cash plus assumption of ~£24 million debt; no headcount disclosed.
1996-06-29restructuringin_progress1996-03-291997-03-29GlobalInstrumentsUSD 34 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reserves established for estimated severance, excess facilities, and other exit costs associated with the acquisition of Fisons Scientific Instruments Division. Completion expected over one-year period following acquisition.
1996-06-29restructuringcompleted1996-06-291996-06-29United StatesBiomedical ProductsUSD 10 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Costs incurred by SensorMedics as a result of its merger with the Company, including employee compensation payable as a result of the merger and investment banking fees.
1996-06-29restructuringcompleted1996-06-291996-06-29United StatesBiomedical ProductsUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Write-off of cost in excess of net assets and intangible assets at Thermedics' Corpak Inc. subsidiary due to decision to no longer further invest in this business.
1996-03-30acquisition_additioncompleted1996-03-291996-03-29United KingdomInstruments (Scientific Instruments Division of Fisons plc)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Thermo Instrument acquired most of Fisons' Scientific Instruments businesses for about GBP 123 million cash plus assumption of about GBP 24 million debt; no employee count disclosed. Results included from date of acquisition.
1996-03-30acquisition_additioncompletedMultiple (majority-owned subsidiaries)USD 89 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Several other first-quarter 1996 acquisitions by majority-owned subsidiaries for $88.9 million cash, subject to post-closing adjustments; no employee counts disclosed.
1996-03-30restructuringin_progress1996-03-291997-03-29United KingdomInstruments (acquired Fisons Scientific Instruments businesses)USD 61 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Reserves of $61 million for estimated severance, excess facilities and other exit costs; none expended in Q1 1996. Review and restructuring expected to be substantially completed within one year of acquisition; no employee counts disclosed.
1996-03-30restructuringin_progress1996-03-291997-03-30United KingdomInstrumentsUSD 61 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reserves established for estimated severance, excess facilities, and other exit costs associated with the acquisition of Fisons Scientific Instruments Division. Completion expected over one-year period following acquisition.
1995-12-30plant_closurecompleted1995Albuquerque, New Mexico, United StatesEnvironmental Services — metallurgical servicesUSD 2 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Decision to close metallurgical services division; facility was closed in the second quarter of 1995. $1.5 million charge primarily represents severance plus write-offs of goodwill and leasehold improvements; affected employee count not disclosed. MD&A separately attributes a $2.0 million metallurgical-services sales decline to this same closure.
1995-12-30plant_closurecompleted1994United States — East CoastAdvanced Technologies — ThermoTrex Corporation East Coast divisionUSD 1 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Multi-year closure. Fiscal 1995 charge of $1.0 million (current-year amount shown) includes $0.6 million intangible-asset write-off; fiscal 1994 had recorded $0.7 million, primarily severance and leasehold write-offs at the same division. Employee count not disclosed; completion not explicitly stated but inferred from the final-year asset write-off pattern.
1995-12-30plant_closurecompletedSan Diego County, California, United StatesAlternative-energy Systems — municipal solid waste-recycling facilityUSD 12 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Facility ceased processing waste during 1995 after San Diego County ceased waste deliveries and defaulted on payment obligations; $11.5 million write-off of net investment recorded in Q3 1995 per MD&A. Charge is an investment write-off, not severance; the filing discloses no workforce reductions, headcount impact, or severance tied to the shutdown.
1995-12-30restructuringcompletedUnited StatesAlternative-energy SystemsUSD 12 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Write-off of net investment in San Diego County waste-recycling facility due to customer default; no employee count disclosed
1995-12-30restructuringcompletedUnited StatesProcess EquipmentUSD 8 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		$5.0M goodwill write-off at Thermo TerraTech thermal-processing equipment business; $2.5M goodwill write-off at Napco subsidiary; no employee counts disclosed
1995-12-30restructuringcompletedUnited StatesEnvironmental ServicesUSD 2 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of metallurgical services division in Albuquerque, New Mexico; includes severance and goodwill write-off; no employee count disclosed
1995-12-30plant_closurecompletedUnited StatesAdvanced TechnologiesUSD 1 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closure of ThermoTrex East Coast division; includes $0.6M intangible asset write-off; no employee count disclosed
1995-12-30acquisition_additioncompletedUnited StatesAdvanced Technologiesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Coleman Research Corporation acquired March 1995 in pooling-of-interests transaction for 4,002,224 shares; headcount not disclosed
1995-12-30acquisition_additioncompletedUnited StatesBiomedical Productsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Bird Medical Technologies (August 1995) and Bennett X-Ray Corporation (September 1995) acquired; headcounts not disclosed
1995-12-30acquisition_additioncompletedUnited StatesInstrumentsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Gould Instrument Systems and Analytical Instrument Division of ATI acquired in 1995; headcounts not disclosed
1995-12-30acquisition_additioncompletedUnited StatesEnvironmental Servicesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Elson T. Killam Associates (February 1995), Lancaster Laboratories (May 1995), and Remediation Technologies (December 1995) acquired; headcounts not disclosed
1995-12-30acquisition_additionannounced1995-03-01United KingdomInstrumentssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of Fisons plc Scientific Instruments Division for approximately £150M (modified); antitrust clearance received February/March 1996; headcount not disclosed
1995-12-30restructuringcompleted1995-12-301995-12-30United StatesAlternative-energy SystemsUSD 12 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Write-off of net investment in waste-recycling facility in southern California due to customer defaults. Employee count not disclosed.
1995-12-30restructuringcompleted1995-12-301995-12-30United StatesProcess EquipmentUSD 5 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Write-off of cost in excess of net assets at Thermo TerraTech's thermal-processing equipment business. Employee count not disclosed.
1995-12-30restructuringcompleted1995-12-301995-12-30United StatesProcess EquipmentUSD 3 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Write-off of cost in excess of net assets at Napco subsidiary. Employee count not disclosed.
1995-12-30restructuringcompleted1995-12-301995-12-30United StatesEnvironmental ServicesUSD 2 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Closure of metallurgical services division in Albuquerque, New Mexico. Costs represent severance and write-offs. Employee count not disclosed.
1995-12-30restructuringcompleted1995-12-301995-12-30United StatesAdvanced TechnologiesUSD 1 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Closure of ThermoTrex's East Coast division. Costs include write-off of intangible assets. Employee count not disclosed.
1995-12-30restructuringcompletedUnited StatesAlternative-energy Systems; Process Equipment; Environmental Services; Advanced TechnologiesUSD 22 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY1995 charge of $21.9M comprises a $11.5M write-off of the net investment in a southern California waste-recycling facility, $5.0M and $2.5M goodwill write-offs (Thermo TerraTech thermal-processing business; Napco), and $2.9M other nonrecurring costs. No employee counts or severance amounts are disclosed; the filing does not state whether any of the $2.9M other costs relate to workforce reductions.
1995-09-30plant_closurecompleted1995-04-011995-06-30Albuquerque, New Mexico, United StatesEnvironmental Services — metallurgical services divisionUSD 2 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Decision to close the metallurgical services division; facility closed by end of June 1995. The $1.5 million charge primarily represents severance costs plus write-offs of goodwill and leasehold improvements; no employee count disclosed. Announcement date approximate (filing states only the decision and closure timing within Q2 1995).
1995-09-30restructuringin_progress1995-07-01Southern California, United StatesAlternative-energy Systems — Energy Systems division waste-recycling facilityUSD 12 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge represents the Company's net investment in a San Diego County waste-recycling facility written off in Q3 1995 amid customer payment defaults and contract termination discussions; no employee impact quantified. Announcement date approximate (recorded during the quarter).
1995-09-30acquisition_additioncompleted1995-03-151995-03-15United StatesAdvanced Technologies — systems integration and analytical servicesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired in exchange for 4,002,224 shares; accounted for as a pooling of interests with prior-period financials restated. Headcount added not disclosed.
1995-09-30acquisition_additioncompleted1995-01-01United StatesInstruments — Analytical Instruments Division of Baird CorporationMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition completed January 1995; contributed $21.9 million of Q3 segment sales together with the Gould acquisition. Headcount added not disclosed. Date stated only to month granularity.
1995-09-30acquisition_additioncompleted1995-05-01United StatesInstruments — Gould Instruments Systems, Inc.MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired May 1995. Headcount added not disclosed. Date stated only to month granularity.
1995-09-30acquisition_additioncompletedUnited StatesBiomedical Products — Bird Medical Technologies, Inc.MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired during Q3 1995; together with Bennett X-Ray contributed $6.8 million of Q3 segment sales. Exact date and headcount added not disclosed.
1995-09-30acquisition_additioncompletedUnited StatesBiomedical Products — Bennett X-Ray CorporationMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired during Q3 1995; together with Bird Medical contributed $6.8 million of Q3 segment sales. Exact date and headcount added not disclosed.
1995-09-30acquisition_additionannounced1995-03-011996-03-31United Kingdom / internationalInstruments — Scientific Instruments Division of Fisons plcMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition for approximately £202 million; FTC second request received April 1995 and agreement amended November 1, 1995 extending the termination date to March 31, 1996. Headcount to be added not disclosed.
1995-09-30plant_closurecompleted1995-06-30Albuquerque, New MexicoEnvironmental ServicesUSD 2 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Closure of metallurgical services division; costs include severance and write-offs.